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Abstract 
Background/Aims. A diagnosis of bipolar II disorder (BPII) is commonly accompanied by a 
need to make complex treatment decisions about medications and adjunctive psychological 
therapies, often for lifetime prophylactic use. As most research on treatment efficacy relates 
to bipolar I disorder, treatment decisions in BPII have less evidence to support available 
treatment options and are more finely balanced in terms of their benefit/side-effect profiles. 
Yet, there is currently no resource to support patients with BPII (and their families) to make 
evidence-based treatment decisions, which incorporate both patient and clinician preferences 
(i.e., shared decision-making, SDM). Patient decision-aids (DAs) are interventions designed 
to facilitate this process. This thesis project aimed to develop and evaluate the first known 
DA for patients considering BPII treatment options.  
 
Methods. The thesis comprised four phases: i) systematic review of the literature (n=13 
studies) on communication and decision-making about treatment in mental health, with a 
focus on bipolar disorders (Chapter 2); ii) qualitative interviews with patients with BPII 
(n=28), their families (n=13), and clinicians (n=20) (Chapters 3 – 5); iii) development of a 
DA according to International Patient Decision-Aid Standards (Chapter 6); iv) pilot of the 
DA to obtain evidence on its acceptability, feasibility, safety, and potential usefulness within 
a sample of potential end-users (30 patients with BPII, and 10 families; Chapter 7). 
 
Results. Phases i) and ii) identified key informational and decision-support priorities for 
patients with BPII and their families, as well as clinician-endorsed strategies for addressing 
barriers to treatment decision-making. These priorities and strategies then informed the 
content, format and delivery of the DA. Pilot data indicated that potential end-users strongly 
endorsed the DA, and provided preliminary evidence to support DA-related improvements in 
treatment decision-making.   
 
Conclusion. This innovative and comprehensive program of research culminated in the 
development and evaluation of a world-first DA for patients deciding on BPII treatment. The 
final DA has the potential to facilitate informed treatment decisions, which are both evidence-
based and consistent with patient preferences.  
 xiv 
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 2 
Chapter 1: Introduction 
 
1.1. Background to bipolar II disorder 
 
1.1.1. What is bipolar II disorder? 
Bipolar disorder is a chronic, relapsing and remitting psychiatric disorder that affects 
a person’ s mood, thinking, energy and behaviour [1]. It is characterised by a distinct 
pattern of ‘low’ states (depression) and ‘high’ states (hypomania or mania). Bipolar 
disorder comprises two main sub-types: bipolar I disorder (BPI) and bipolar II 
disorder (BPII). Although these sub-types were first recognised in 1974 [2], it was not 
until 1994 that BPII was formally recognised as a distinct diagnosis in the 4th edition 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV, [3]).  
 
According to current DSM-5 [1] criteria, a diagnosis of BPII requires the presence (or 
history) of a major depressive episode, along with at least one episode of hypomania. 
Depression in BPII has similar aetiology, course and psychosocial triggers [4] to 
unipolar depression. The diagnostic criteria are also the same (i.e., minimum two 
week period of depressed mood and/or diminished pleasure/interest in activities). 
However, some studies suggest that bipolar depression is more often characterised by 
melancholic (e.g., psychomotor slowing), atypical (e.g., increased appetite and/or 
hypersomnia), or psychotic features (e.g., excessive and unfounded guilt), reflecting a 
greater neurobiological contribution [5]. At the opposite pole, hypomania is 
characterised by a distinct, minimum four-day period of abnormally and persistently 
elevated, expansive or irritable mood, and increased energy and activity, which is 
uncharacteristic for the individual and observable by others [1].  
 
In DSM-5 [1], BPII is considered less severe and less impairing than BPI due to the 
reduced severity of the ‘highs’. ‘Highs’ in BPII (hypomania) include many similar 
symptoms to those in BPI but these are not sufficiently severe to require 
hospitalisation, do not include psychotic features, do not lead to any marked 
impairment in functioning, and are of shorter duration (four compared to seven day 
minimum duration) than those experienced in a manic episode [1]. However, clinical 
evidence challenges this view and suggests that BPII and BPI are associated with 
similar psychosocial impairments in functioning, since BPII is associated with more 
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frequent mood oscillation and shorter recovery time between episodes, greater 
predominance of depressive episodes [6], and higher risk of suicide [7]. Possible 
overlaps between BPI and BPII are also supported by a clinically-derived continuum 
model, the ‘bipolar spectrum’, whereby unipolar depression (i.e., Major Depressive 
Disorder; MDD) and bipolar disorder are positioned at opposing poles and degrees of 
bipolarity are possible, including depression with (hypo)manic features or mixed 
depression [8].  
 
Despite challenges to the diagnostic distinctiveness of BPI and BPII, a categorical 
approach persists in DSM-5 [1]. This categorisation is empirically supported on the 
basis of the possible presence or necessary absence of psychotic features in BPI and 
BPII, respectively [9]. In addition, DSM-5 has assigned bipolar disorder its own 
separate chapter, “Bipolar and related disorders”, thereby recognising its occurrence 
within a spectrum of disorders and distinguishing it from unipolar depression and 
other mood disorders.  
 
1.1.2. Prevalence, onset and course of bipolar II disorder 
According to the most recently published Australian National Survey of Mental 
Health and Wellbeing in 2007 [10], the 12-month prevalence rates of bipolar disorder 
(both BPI and BPII combined) are 1.8% for men and 1.7% for women. These 
aggregated prevalence rates are slightly higher than those reported in a 2011 
international community survey of eleven countries across the Americas, Europe and 
Asia (12-month prevalence = 0.4%, 0.3% for BPI and BPII, respectively) [11]. 
Community estimates are higher, and suggest that BPII is twice as common as BPI 
(5% vs. 2.4%; [16]). These rates should therefore be considered in the context of 
substantial inter-country variability [11], measurement differences, and possible 
changes to the ‘true’ prevalence of BPII [12]. Higher prevalence rates may also reflect 
broadening definitions of bipolar disorder (toward the concept of a ‘bipolar 
spectrum’), greater community awareness, and better detection and diagnosis [12].  
 
Age of onset in BPII is difficult to determine because studies tend to define onset as 
age at initial diagnosis and/or treatment, which may occur up to a decade after the 
initial onset of symptoms [13]. Reviews estimate the age of onset to be between 20.3 
and 26.0 years, with a slightly earlier onset for females [7]. Others report that bipolar 
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symptoms (usually depression) emerge earlier, between 15 and 19 years of age [14]. 
Delays in being assigned a diagnosis of BPII are common, with 30-60% of BPII 
patients reporting a previous (mis)diagnosis of MDD [13]. Reasons given for 
misdiagnosis include patients’ lack of insight into their own hypomanic episodes, 
poor screening by clinicians, and the fact that individuals with BPII more often seek 
treatment for depressive symptoms [6, 13].  
 
For most patients with BPII, depressive episodes predominate with relatively 
infrequent bouts of hypomania. A prospective longitudinal study on the long-term 
course of BPII [15] demonstrated that, for over a period of 20 years, patients with 
BPII experienced depressive symptoms approximately 39 times more often than 
hypomanic symptoms (59.1% versus 1.9% of follow-up weeks). Between episodes of 
depression and hypomania, these patients spent much of the time unwell, 
experiencing either syndromal or more commonly subsyndromal (below-threshold) 
symptoms (13.0% versus 40.9% of follow-up weeks). Furthermore, three-quarters of 
patients experienced relatively frequent shifts in mood - from depression to 
hypomania or vice-versa - at least once per year [15].  
 
Periods of depression and hypomania are not always enduring and clearly delineated. 
Patients with BPII can also experience symptoms of depression and hypomania 
concurrently (i.e., mixed affective states), as well as rapid cycling, which is defined as 
the occurrence of four or more mood episodes per year [7]. Both mixed states and 
rapid cycling are common in BPII (30 – 76%) and more marked in women [16, 17].  
 
1.1.3. Impact of bipolar II disorder on patients, their family, and society 
Due to its relatively early onset and chronic course, the impact of BPII on the 
patient’s life can cause considerable disability. Indeed, bipolar disorder (BPI and 
BPII) is a leading cause of global disease burden, accounting for the 6th highest 
number of disability adjusted life-years (DALY) amongst mental disorders [18]. 
Bipolar-related disability extends across psychosocial, physical, financial and 
occupational domains. Some of the negative psychosocial consequences of BPII 
include: impoverished interpersonal functioning, stigmatisation, isolation, reduced 
self-esteem and self-concept, hopelessness and demoralisation [19]. Other 
consequences include: lost income or compromised careers, relationship and 
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friendship breakdown, financial stress, alcohol or other substance abuse problems, 
unwanted sequelae of sexual disinhibition and promiscuity, as well as violent and 
suicidal behaviours [19]. Furthermore, high rates of comorbidity in BPII (>95%), in 
particular comorbid anxiety-related disorders [20], together with a protracted course 
of suboptimal treatment if the patient has previously been misdiagnosed [21], are also 
likely to worsen the impact of BPII.  
 
Certain features of the BPII course may differentially influence the severity of impact 
and associated disability. The most comprehensive longitudinal data on BPII-related 
disability (as separate from BPI) comes from a prospective 20-year follow-up study 
by Judd and colleagues [22]. Study findings revealed that increments in BPII 
depression severity (from asymptomatic to subsyndromal to syndromal) were 
associated with increasing psychosocial impairment in occupational role, 
interpersonal relationships, hobbies and interests, and overall satisfaction [22]. 
However, the converse was not observed for hypomania, where symptoms were 
associated with a non-significant trend towards enhanced psychosocial functioning 
[22]. Rapid cycling and mixed affective states have been found to be associated with 
disability and increased risk of suicide [23]. Even when patients with BPII were 
symptom-free, they had higher levels of psychosocial impairment (M=8.8/20, 
SEM=0.2) compared to healthy controls (M=7.4/20, SEM=0.04; p<0.05) [22]. In 
summary, the predominance of depressive episodes, subclinical symptoms between 
episodes, and high prevalence of both mixed symptoms and rapid cycling, create 
multiple, chronic sources of disability and impairment in patients with BPII.  
 
The impact of bipolar disorder on patients’ families has received limited attention in 
the academic literature. However, the impact on families may, to some extent, mirror 
the impact of BPII on the patients themselves. For the families of patients, serious 
mental illnesses engender both objective/practical burden (e.g., home-related role 
changes, reduced working hours and income) and subjective/psychosocial burden 
(e.g., distress and stigma) [24], with objective and subjective burden potentially 
negatively impacting on one another. For example, increased responsibilities at home 
may lead to a loss of social support and social isolation, while reduced participation in 
paid work and resulting financial hardship may trigger depression, anger and grief 
over loss of prior functioning and future goals [24].  
 6 
 
Among the family caregivers of patients with bipolar disorder, this ‘constellation’ of 
burden is not uncommon. A substantial proportion of families report reduced working 
hours (76%) and income (27%), along with ‘severe’ personal distress (64%) and 
‘major’ stress (71%) [25]. The negative impact of BPII may be further exacerbated 
when the patient lacks insight into their symptoms, is acutely unwell, or displays 
symptoms that are particularly distressing and burdensome, such as profound social 
withdrawal and sadness, or irritability and combativeness [26]. A stressful home 
environment can also impact negatively on the patient’s wellbeing and further 
exacerbate symptoms or trigger relapse [19]. This highlights the interplay between 
BPII symptoms, burden and distress both for the patient and their families.  
 
In addition to its ‘micro’ impact on the patient and their family, BPII also has a 
significant ‘macro’ impact on the broader community and society. The ‘direct’ costs 
of bipolar disorders (BPI and BPII) include pharmacotherapy, the use of psychiatric 
services, and hospitalisation whilst the ‘indirect’ costs include reduced employment 
and productivity, family/caregiver burden, and increased involvement in the social 
welfare and criminal justice systems [6]. Again owing to the early onset and life-long 
course of bipolar disorder, the direct and indirect costs of this condition can amount to 
significant economic burden. There are no estimates of costs related to BPII 
specifically, however, a comprehensive Australian study conducted in 2003 [27] 
calculated bipolar-related costs at $AU1.59 billion. Of these costs, $AU833 million 
(52%) was attributable to indirect costs made up largely of lost earnings due to BP 
illness ($464 million). The social and economic burden of bipolar disorder is most 
evident in work-related domains. A review has demonstrated that a diagnosis of 
bipolar disorder is associated with a 40% reduction in the likelihood of paid 
employment and a sevenfold increase in rates of absenteeism [28]. There is also the 
suggestion that these bipolar-related costs are underestimates given the delays to 
bipolar diagnosis, or misattribution of costs to (misdiagnosed) unipolar depression 
[6].  
 
1.1.4. Causes of bipolar II disorder  
The causes of BPII can be understood within a biopsychosocial model, which 
recognises the relative contributions of genetics and neurobiology, as well as 
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psychosocial factors, lifestyle and environment to the development of mental illness 
[29]. The strong heritability of bipolar disorder is evidenced by family studies which 
demonstrate that the lifetime risk is between 40-70% with an affected monozygotic 
twin, and 5-10% with an affected first degree relative, compared to 0.5-1.5% in 
individuals without any family history [30]. Moreover, individuals diagnosed with 
BPII are more likely to have a family member with BPII than BPI, and vice-versa [5]. 
Few studies have examined the neurobiology of BPII separately from BPI, but a 
review of findings implicates similar neurobiological changes in BPII as BPI [31]. 
These include structural and functional abnormalities in subcortical brain regions 
subserving emotion regulation, sleep and arousal (e.g., insula and thalamus), as well 
as the frontal brain regions involved in social decision-making and cognition (e.g., 
orbitofrontal cortex and medial frontal cortex), and the interconnections between 
these subcortical and cortical areas [31]. BPI and BPII also appear to share many 
neurochemical abnormalities. Those that are consistently documented include: 
decreased levels of brain-derived neurotrophic factor (BDNF) while symptomatic, 
decreased levels of N-acetylaspartate (NAA) and increased glutamate levels across 
several brain regions while both symptomatic and euthymic (i.e., symptom-free) [31]. 
 
Regarding psychosocial and environmental influences, research supports a link 
between stressful life events and subsequent episodes of depression and (hypo)mania. 
For example, stressful life events involving disruption to routines and sleep-wake 
cycles, and excessive focus on goal attainment tend to precede (hypo)manic episodes, 
while poor social supports and low self-esteem tend to precede depressive episodes 
[32]. Interestingly, the importance of these factors on symptom expression varies over 
time, such that, stressful life events are more likely to trigger initial rather than later 
episodes, and late onset rather than early onset bipolar disorder [33]. This pattern 
may, in part, be explained by the ‘kindling’ phenomenon, whereby the occurrence of 
a bipolar episode increases the likelihood of subsequent episodes occurring. Thus, 
over time, episodes become less linked to external (environmental) factors and 
eventually occur independently [34]. In sum, BPII, like BPI, has a primarily 
neurobiological basis but environmental and psychosocial stressors are implicated as 
important contributing factors to the onset of symptoms and relapse [31]. The 
interplay between biological and psychosocial factors in bipolar disorder informs the 
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basis of treatment approaches, which combine pharmacological and psychological 
treatments.  
 
1.1.5. Treatment and management of bipolar II disorder 
The treatment and management of BPII, as with BPI, focuses on two principal phases: 
the acute phase (the treatment of depressive and hypomanic symptoms) and the 
maintenance phase (the long-term preventative treatment of future episodes and 
relapse prevention, i.e., prophylaxis). Treatments vary according to which phase is 
being targeted. The treatment of BPII relies largely on assumptions and inferences 
from the treatment of BPI, as most of the research evidence from large well-designed 
trials is based on mixed or BPI-only patient samples. There are substantially fewer 
treatments with high-quality evidence to support their efficacy in BPII compared to 
BPI. It is still unknown, however, if treatment recommendations derived from 
efficacy findings in BPI are appropriate and generalisable to BPII [35]. As a result, 
most published clinical practice guidelines do not differentiate between BPI and BPII 
subtypes (e.g., [36, 37]) or provide only limited BPII specific recommendations [38]. 
One exception is the 2018 Canadian Network for Mood and Anxiety Treatments 
(CANMAT) guidelines [39], which provide a separate section with BPII treatment-
specific information. Despite an ongoing lack of consensus regarding the “best” 
treatment for BPII, a pluralist approach that incorporates both pharmacological and 
psychological treatments is advocated [19]. 
 
The management and prevention of depressive symptoms is often the focus of 
treatment in BPII. This is due to the fact that depression is the predominant mood 
state for most patients, is associated with high levels of disability, and leads more 
patients to seek treatment [40]. Accordingly, the main psychopharmacological 
treatments in BPII are antidepressant (e.g. selective serotonin reuptake inhibitors, 
SSRIs) and/or mood-stabilising (e.g. lithium, anti-epileptic, and second generation 
anti-psychotic) medications [41, 42]. However, there is limited evidence for the safety 
and efficacy of these medications in the treatment and prevention of BPII depression, 
compared to BPI and unipolar depression [43].  
 
Researchers argue that the evidence supporting the use/non-use of antidepressants 
and/or mood-stabilisers in the management of BPI may not apply to BPII [35]. For 
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example, antidepressant monotherapy is contraindicated in BPI [44], as it has been 
implicated in (hypo)manic ‘switching’ (i.e., triggering a shift from a depressive to a 
hypomanic state), and/or long-term mood destabilisation [23]. These concerns appear 
less warranted in BPII, given that the likelihood of switching is lower [37, 43], 
hypomania occurs much less frequently than depression [15], and hypomania is not as 
functionally debilitating or distressing as mania in BPI [40]. Findings from 
randomised controlled trials (RCT) have also demonstrated that antidepressant 
monotherapy was more effective than mood-stabiliser monotherapy in treating BPII 
depression, with no group differences on hypomanic symptoms [45]. Conversely, 
other evidence suggests some mood-stabiliser monotherapies may be as effective as 
antidepressant monotherapy at alleviating depressive symptoms, without the possible 
antidepressant-related increase in hypomanic symptoms [40].  
 
It is evident that pharmacological interventions play an important role in the treatment 
of BPII, however, its importance may vary from one patient to another. It is currently 
recommended [40, 46] that pharmacological treatment include consideration of the 
patient’s personal circumstances, preferences, and experience of the illness in order to 
improve outcomes. For example, antidepressant monotherapy may be sufficient if: 
hypomania causes no disruption or stress, symptoms are mild, the patient is unwilling 
to treat hypomania, and there is no presence or history of mixed affective states (e.g., 
depression with hypomanic features) or rapid cycling [46]. By contrast, mood-
stabilisers may be more appropriate than antidepressants in treating BPII depression 
in instances of: rapid cycling and frequent mood oscillations, proneness to 
hypomania, presence or history of depression with mixed (hypomanic) symptoms, 
poor response to antidepressant monotherapy, or loss of antidepressant efficacy over 
the long-term [40]. These recommendations, however, draw on an incomplete 
evidence base and attract differing expert opinions and clinical debate [35, 47].  
 
Although pharmacological treatments form the main approach to treatment in BPII, 
they may not be adequate in isolation. In the short term, poor adherence to medication 
is common due to unpleasant side-effects, alleviation of unwanted acute symptoms, 
and non-acceptance of the diagnosis [48]. In the longer-term, pharmacological 
treatments alone have limited effectiveness in preventing relapse; 37% of patients 
taking mood-stabilisers relapse after one year, and 73% after five years [49]. In 
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addition, patient prognoses and outcomes are significantly improved when 
pharmacological treatments are used in conjunction with psychological treatments 
[19, 50]. This said, evidence of benefit mainly relates to the maintenance phase of 
bipolar disorder (BPI and BPII), with limited evidence for the acute phases 
(depression and (hypo)mania) [36, 39]. Adjunctive psychological treatments may be 
particularly important in BPII, where the course and severity of illness is not fully 
explained by neurobiological factors and pharmacological treatments alone [19], and 
environmental and lifestyle stressors are known to play a contributing role [32]. As 
for pharmacological treatments, most of the evidence supporting the efficacy of 
adjunctive psychological treatments relates to BPI-only or mixed patient samples. 
This precludes the provision of BPII-specific outcomes or recommendations [36].  
 
The most empirically-supported adjunctive psychological treatments for the 
depressive and maintenance phases of bipolar disorder (both BPI and BPII) are: 
cognitive behavioural therapy (CBT) (Level I evidence1), group psycho-education 
(Level I), and family-focused therapy (Level II2)[36]. Interpersonal and social rhythm 
therapy (IPSRT) (Level III3) is also included in current guidelines [36], however, 
more recent meta-analytic findings did not support its efficacy [51]. Moreover, studies 
to support the efficacy of these treatments predominantly involve patients with BPI. A 
common component of these adjunctive treatments is psycho-education in order to 
enhance adherence to medication, interpersonal and occupational functioning,  
recognise and manage early warning signs and triggers and accept the diagnosis and 
acknowledge its impact on lifestyle [50]. A systematic review and meta-analysis of 55 
RCTs involving treatment which targeted these four components found a 30% 
reduction in the rate of relapse at post-treatment and 40% reduction at 1 to 2.5-year 
follow-ups [51]. Other review findings have shown reductions in symptom severity 
and improved functional outcomes, including psychosocial functioning and 
medication adherence, compared to treatment as usual [52]. Although most effective 
during the maintenance stage [14], different psychological treatments appear to have a 
                                                     
1 Meta-analysis with narrow confidence interval or replicated double-blind, RCT that includes a 
placebo or active control comparison (≥ 30 in each active treatment arm). 
2 Meta-analysis with wide confidence interval or one double-blind, RCT that includes a placebo or 
active control comparison (≥ 30 in each active treatment arm). 
3 One double-blind, RCT that includes a placebo or active control comparison (10 - 29 in each active 
treatment arm) or health system administrative data.  
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differential effect on depressive versus hypomanic symptoms. Specifically, treatments 
focusing on the regularisation of sleep-wake patterns and medication adherence may 
be more effective for hypomanic symptoms whereas treatments focusing on 
interpersonal behaviours, communication and problem-solving may be more effective 
for treating depressive symptoms [52]. Given the current lack of evidence to support 
the superiority of one psychological treatment over another, especially within the 
context of BPII, clinicians are encouraged to adopt a flexible approach. Such an 
approach draws on features from multiple treatment approaches, and can be tailored 
according to the patient’s individual needs and circumstances [19].  
 
In general, although there is Level I evidence for mood stabilisers in BPI [39], there is 
a paucity of trials that separate outcomes for BPII. Therefore, treatment 
recommendations are largely made on the basis of BPI, but relative benefit to harm of 
different medication options specifically for BPII is not well understood. Similarly, 
the evidence for adjunctive psychological interventions are based largely on patients 
with BPI and further depend on the target of intervention (i.e. depressive vs 
(hypo)manic phases)[51]. Hence, the decision as to which combinations of therapies 
are most suitable for an individual patient is challenging for clinicians and patients 
alike. 
 
1.2. Treatment decision-making  
 
1.2.1. What is treatment decision-making? 
During the course of a physical or mental illness, a patient is required to make 
numerous decisions regarding their treatment. A treatment decision implies a choice 
between one or more options, including the option to do nothing (e.g., wait-and-see). 
These treatment decisions may be made with their doctor and/or other treating 
clinician (e.g., psychiatrist or psychologist), and/or with significant others (e.g., 
family members or caregivers). Dyadic decision-making implies the involvement of 
two parties (e.g., patient-clinician) whereas triadic decision-making implies the 
involvement of three parties (e.g., patient-family-clinician) [53]. Some examples of 
treatment decisions may include, but are not limited to: whether or not to commence, 
change or cease treatment, whether to include an additional or adjunctive treatment, 
and deciding between different treatment options. Treatments may vary according to 
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the nature and type of illness and across the illness trajectory but may be 
pharmacological (e.g., medication-based), psychological (e.g., CBT) or involve a 
physical intervention (e.g., surgery, electroconvulsive therapy).  
 
Treatment decisions may be relatively simple, straightforward and routine, or 
complex. Based on audiotaped routine patient consultations with primary care 
physicians and surgeons, Braddock and colleagues [54] posited that healthcare 
decisions can be categorised as either basic (e.g., discussing laboratory test), 
intermediate (e.g., new medication) or complex (e.g., surgical procedure). 
Categorisation depends on: i) their impact on the patient’s life and/or functioning (i.e., 
minimal, moderate, large), ii) the amount of medical consensus (limited, moderate, 
complete), and iii) the nature of outcomes (uncertain, certain). A basic decision, for 
example, would entail minimal impact on the patient, complete medical consensus, 
and a single, clear outcome. By contrast, a complex decision would entail extensive 
consequences for the patient, be controversial within the medical community, and 
result in multiple, uncertain outcomes. In addition, the more complex a decision, the 
more patient involvement is needed and the more numerous the prerequisites for fully 
informed decision-making [54].  
 
Most decisions in outpatient clinical practice appear to be ‘intermediate’ decisions 
and lie somewhere between the basic and complex poles [54]. By this definition, most 
decisions about treatment are understood as having incomplete medical consensus and 
posing some potential risk to patients. This accords with a 2013 review of 3000 
treatments (including psychological, medical and surgical interventions), which 
demonstrated that only a third of these treatments had sufficient evidence to support 
likely (24%) or clear benefit (11%) [55]. The remaining two-thirds had insufficient 
evidence to support effectiveness (50%), involved a trade-off between benefits and 
harms (7%), were unlikely to be beneficial (5%) or likely to be harmful (3%) [55]. On 
the basis of these review findings, most treatment decisions involve some degree of 
‘equipoise’ (i.e., clinical uncertainty) and have no clear ‘best choice’. As a result, 
treatment decisions are generally considered to be ‘preference-sensitive’; such that 
more than one clinically-viable treatment option exists and patients (together with 
significant others, e.g., their families) may evaluate options differently depending on 
their personal values, preferences, and situation [56].  
 13 
 
1.2.2. Conceptual models of decision-making in healthcare 
From a healthcare perspective, treatment decision-making has been described in terms 
of three main conceptual models: the paternalistic model, the informed choice model, 
and the shared decision-making (SDM) model [57]. These models of treatment 
decision-making can be positioned along a continuum from clinician-led 
(paternalistic) to patient-led (informed choice) approaches, with SDM positioned in 
the ‘middle ground’ between the other two. These models posit that the process of 
treatment decision-making comprises three distinct stages: information 
transfer/exchange which refers to the information that is shared by the clinician and 
the patient; deliberation which refers to the weighing-up of the benefits and risks 
associated with treatment options and; decision on treatment to implement (including 
the option to postpone or not pursue treatment) [58]. According to these models, the 
decision-making stages can occur in a sequential or concurrent fashion, or as a 
dynamic, iterative process whereby members of the decision-making dyadic/triad 
move back and forth between the stages [58]. Where these models differ is in their 
underlying assumptions about the relative involvement of the clinician and the 
patient, the relative importance given to clinician knowledge of treatment options 
versus patient preferences, and who assumes authority as the primary decision-maker 
[58, 59]. More broadly, these models also reflect a gradual shift in societal views and 
attitudes, the influence of Western bioethics, and changing legal and professional 
guidelines on patient rights and input in their healthcare.  
 
Up until the 1980s, the paternalistic model was the most prevalent approach to 
treatment decision-making in Western clinical practice settings. In this model, the 
clinician takes on a dominant role and the patient a passive role, whereby the 
clinician’s medical knowledge and expertise are of a primary focus when making a 
treatment decision. Thus, it is the clinician who makes the decision with minimal 
patient involvement beyond providing consent. According to this approach, the 
clinician needs to only provide the most relevant medical information and encourages 
the patient to consent to the treatment option that they consider the best for the patient 
[57]. Within the paternalistic approach, the clinician is regarded as the ‘guardian’ of 
the patient’s values and interests [57]. It is assumed therefore that clinician and 
patient preferences regarding treatment are always perfectly aligned. According to 
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this approach, the ‘best’ treatment option in the clinician’s view will also be the ‘best’ 
treatment option in the patient’s view. There is, as a result, no need for any discussion 
of patient preferences.  
 
Paternalistic models of treatment decision-making have since been challenged on 
medical, legal, and ethical grounds. Firstly, in medicine there are often multiple, more 
or less equivalent treatment options with differing benefit-risk profiles or a lack of 
medical consensus supporting a single ‘best’ treatment option. Secondly, patients 
have a recognised legal and ethical right to be informed about all treatment options 
and retain decision-making authority [58, 60]. The extent to which the paternalistic 
approach persists in current clinical practice varies. This said, there are situations that 
may favour or necessitate this approach to treatment decision-making. For example, 
when patients prefer to defer decision-making to their clinician, lack decisional 
capacity or competence, or are acutely ill and require emergency intervention [60, 
61].  
 
The informed choice model represents a diametric shift away from clinician-led styles 
of decision-making and sees decision-making authority transferred from the clinician 
to the patient [57]. This model is also regarded as a response to the supposed 
shortcomings and flawed assumptions of the paternalistic model. In this model, the 
clinician’s role is to simply disclose to patients information about all available 
treatment options, along with their associated benefits and risks. The clinician then 
allows patients to make a treatment decision independently, based on this information 
together with their values and preferences [59]. As in the paternalistic model, the 
informed choice model delegates decision-making authority to one party only (the 
patient as opposed to the clinician). It also posits that the final treatment choice 
considers only one party’s treatment preferences (those of the patient as opposed to 
the clinician) [60].  
 
In contrast to the two aforementioned models, SDM models [58, 60] advocate that 
clinicians and patients work in partnership in the decision-making process. This 
process may also involve significant others, such as the patient’s family. Thus, the 
final treatment choice is mutually agreed upon, involves input from both the clinician 
and patient, and considers both their treatment preferences. SDM is optimal when 
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there is some degree of medical uncertainty, that is, the existence of two or more 
viable treatment options [62]. However, SDM is also applicable to situations where 
there is strong evidence to support one treatment option over others, but this option 
poses a significant impact on a patient’s quality-of-life or carries high risk (e.g., some 
surgeries, where SDM is used in conjunction with fully informed consent) [62]. In 
these situations, Charles and colleagues who established the first and most commonly 
used model of SDM, outline four essential elements: i) there are at least two parties 
(i.e., patient and clinician) who are involved; ii) both share information; iii) both 
express treatment preferences; and iv) both come to a consensus on a treatment 
decision to implement [58, 60]. Though initially developed in the acute-care context, 
this model of SDM has also been applied to chronic illness but with an increased 
emphasis on the patient-clinician relationship, and the possibility of deferring and/or 
reviewing treatment decisions [63].  
 
In any case, SDM maintains that the clinician and patient are viewed as experts in 
their own right; the clinician is considered an expert by way of their medical 
knowledge and clinical experience, whereas the patient is considered an expert of 
their own lives, values and personal experience of the illness. This is important as 
differences in patient and clinician perspectives of treatment effects (positive and 
negative) can arise, and influence the likelihood of the patient implementing the 
decision over time (e.g., continuing to take medication) [64]. Both forms of expertise 
are also regarded as necessary for “good quality” treatment decisions that are, by 
definition, well informed, evidence-based, and congruent with personal values [65]. 
 
A somewhat problematic assumption of SDM, however, is that it assumes that 
patients want the same level of decision-making control as their clinician. This is 
shown to not always be the case; patient (and clinician) preferences for involvement 
vary [66], and large scale surveys reveal that some patients moderately (23%) or 
strongly (14%) prefer their clinician to make the final decision [67]. The elicitation of 
patient preferences for involvement is an often-cited recommendation in the literature 
[68], yet it is among the most frequently neglected aspects of SDM in clinical practice 
[69, 70]. Moreover, SDM continues to be conceptualised and operationalised in 
different ways, with one systematic review identifying 161 definitions of SDM [71]. 
Indeed, ‘pure’ step-wise SDM approaches with equal involvement of both parties at 
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each decision-making stage may be unfeasible in clinical practice [66], whilst 
‘hybrid’ approaches that vary in their degree of patient-clinician collaboration appear 
more common [72, 73]. Thus, the mutual acknowledgment and two-way exchange of 
different, but equally valuable patient and clinician perspectives form a central tenet 
of SDM, and differentiate this approach from other approaches to treatment decision-
making. SDM is also at the crux of patient-centred care [59], and is associated with 
improvements on a number of patient outcomes, such as: satisfaction with 
care/service delivery, reduced symptoms, improved treatment adherence [74].  
 
Despite its widespread support and link to improved patient outcomes, there are 
ongoing challenges to SDM in routine clinical practice. In marked contrast to earlier 
models of healthcare decision-making, SDM involves active clinician-patient 
involvement and a two-way exchange of information, enabling final decisions that 
integrate the informed preferences of both the patient and the clinician (and others, 
e.g. family). As such, the successful implementation of SDM hinges on effective 
clinician-patient(-family) communication about patient involvement preferences and 
treatment preferences. Yet, eliciting and negotiating patient preferences remains 
suboptimal in clinical practice.  
 
1.2.3. Communication and decision-making about treatment in physical health 
conditions 
The 1980s and 1990s saw a growing interest in and endorsement of SDM and/or 
collaborative decision-making approaches in the management of physical health 
conditions. This stemmed from increasing recognition of patient choice and autonomy 
[66], along with concurrent advances in treatment which resulted in more numerous 
options and thus more ‘preference-sensitive’ decisions necessitating patient 
involvement [75]. Consistent with this, a large body of empirical research has focused 
on patient involvement and the implementation of SDM approaches in physical 
illness, primarily cancer [66]. Overall, studies demonstrate that most (but not all) 
patients prefer to be involved in treatment decision-making, especially receiving 
information about available treatment options [76-78]. This said, some mixed findings 
emerge with regards to the time of study publication (i.e., more recent studies show a 
trend towards greater involvement preferences [78]), or the decision-making stage, for 
example, stronger preferences for involvement in the decision-making process (e.g., 
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information sharing and discussion of treatment options) versus making the final 
decision [77]. Patient characteristics may also influence involvement preferences; 
more highly educated patients, healthier patients and women are more likely to desire 
active involvement in decision-making [67, 79] whereas older patients and those with 
more severe illnesses are less likely [76].  
 
Of concern, studies using patient-report [79, 80] and/or observer ratings [69, 70] of 
consultation behaviours reveal that around a third (34%, [80]) to over half (~58%, 
[79]) of oncology patients do not experience their preferred level of decision-making 
involvement. Of note though, these studies are limited by their focus on dyadic 
interactions involving only the clinician and patient. Thus, they fail to acknowledge 
the involvement of others, such as family members, who assume numerous supporting 
roles and also influence decisional outcomes in treatment decision-making in, for 
example, the cancer setting [53, 81]. These study findings are also predicated on the 
notion that patients understand and know what is meant by terms such as 
‘preferences’, ‘decisions’, and ‘options’, which may in fact be unfamiliar or, as in the 
case of decision-making, take place without patients being aware of them [82]. In 
spite of these limitations, it appears that current SDM practice is suboptimal and has 
not accounted for, nor responded fully to patient preferences for involvement in their 
treatment.  
 
1.3. Treatment decision-making in mental health conditions 
 
1.3.1. Communication and decision-making about treatment in mental health 
conditions 
Many mental health conditions, such as unipolar depression, schizophrenia, and 
bipolar disorder, show a similar chronic pattern to major physical health conditions, 
including diabetes, coronary heart disease, hypertension, and some cancers. In this 
way, these mental health conditions are characterised by multiple, complex causal and 
risk factors, a prolonged course of illness, and at least some degree of functional 
impairment or disability [83]. The long-term management of these chronic mental 
health conditions also relies on the successful implementation of informed, evidence-
based decisions about treatments, such as consistent adherence to medications and/or 
psychosocial strategies. Barriers to ongoing treatment adherence may be similar for 
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both chronic mental health and physical health conditions, such as treatment being a 
reminder of illness and perceived as being unnecessary due to non-acceptance of 
illness, and intermittent use of medication to treat certain symptoms only when 
present and distressing [64]. Moreover, the chronicity of many mental health 
conditions may place particular importance on effective communication and 
establishing a strong therapeutic alliance, as these may impact on patient involvement 
and long-term treatment outcomes [84].  
 
As in physical health conditions, paternalistic approaches to decision-making were 
also prevalent in mental health conditions. In fact the uptake of SDM approaches in 
mental health conditions represents an even more recent shift [74, 85]. Consistent 
with SDM, involving patients as active and informed participants is now recognised 
as applicable to most treatment decisions in mental healthcare [61, 86, 87]. 
Accordingly, mental healthcare professionals are increasingly encouraged to adopt a 
SDM approach in treatment decision-making, both to meet many patients’ 
information and involvement preferences, but also out of an ethical obligation to 
ensure patient autonomy and informed decision-making [88, 89]. SDM also aligns 
with the recovery approach to care in chronic illness, where affected individuals have 
a responsibility to actively self-manage their illness over the long-term [64]. 
Supporting this, a systematic review of SDM-based treatment programs concluded 
that they appear particularly beneficial with regards to patient satisfaction, well-being 
(e.g., depression, anxiety, quality of life), and treatment adherence in the context of 
chronic illnesses, including mental illnesses, which involve the implementation of 
long-term decisions [90].  
 
Another important factor favouring the adoption of a SDM approach is that many 
treatment decisions in mental health are ‘preference-sensitive’ [61]. These preference-
sensitive decisions necessarily require at least some patient involvement, in order to 
elicit patient preferences for treatment options when multiple viable options exist. 
However, there are psychiatry-specific situations in which a more paternalistic or 
directive approach to decision-making may be needed (e.g., suicidal or acutely 
psychotic patients [61]).  
 
 19 
Although many clinicians endorse SDM, and most patients want to be actively 
involved in treatment decision-making, SDM may prove especially challenging in the 
mental health setting [85, 91, 92]. Some clinicians have the perception that: i) they 
already apply SDM principles, ii) SDM permits patients to make decisions that 
disregard clinician advice, iii) fully-informing patients of treatment side-effects will 
discourage adherence, and/or iv) that all psychiatric patients lack decisional capacity 
[93, 94]. Some patients may also be reluctant to engage in SDM due to a perceived 
lack of skills or knowledge; feeling they are already involved in SDM, feel 
stigmatised, lack insight, or feel unmotivated to review their treatment decisions 
following coercion or pressure in the past [61, 95, 96]. In addition to these clinician 
and patient-reported barriers, another challenge is to “balance advocacy for an active 
patient role with individual patients’ preference for participation” (p. 865, [97]). In 
accordance with this, it is important that clinicians do not assume, but rather elicit and 
clarify patient preferences, as these may vary not only across patients but also within 
patients and from time to time. [73, 86].  
 
1.3.2. Involvement of patients  
By comparison with general medical conditions, research on treatment decision-
making in mental healthcare is still its infancy. To date, most studies have focussed 
on patients with unipolar depression or schizophrenia. These studies have drawn on a 
range of different methodologies, making use of both quantitative approaches, such as 
self-report questionnaires and/or observer ratings of consultations, and qualitative 
approaches, such as interviews exploring patient and/or clinician perceptions of 
communication and decision-making. Quantitative studies indicate that people with a 
mental illness are highly information-seeking, they generally want and expect 
comprehensive information about their care [98]. These patients prefer to be involved 
and take an active role in treatment decision-making [98, 99], sometimes to a greater 
extent than patients with physical health conditions (see [98]). To illustrate this, one 
mixed sample study showed that patients with depression were more likely to report 
preferring an active role than patients with diabetes, heart disease, and hypertension 
[100]. Similarly, about three-quarters (77%) of patients with severe mental illness 
preferred a shared or autonomous role in decision-making, which is greater than (45% 
[80] and 47% [79]) or comparable to (~72% see [76]) the proportion of patients with 
cancer using the same self-report measure. Despite consistent evidence for strong 
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involvement preferences, psychiatric patients, like other patients [77], do not always 
desire full control over the final treatment decision [87]. There is also the suggestion 
that psychiatric patients, like oncology patients, often fail to achieve their preferred 
level of participation in decision-making [99]. However, unlike some oncology 
patient samples [79, 80, 101], these patients tend to experience less (rather than more) 
involvement in decision-making than they prefer. These patients’ preference for 
greater decision-making involvement may be explained by research suggesting that 
psychiatric patients may receive SDM less often than primary care patients [91]. 
 
Although a number of studies report patient perceptions of decision-making, only a 
few studies provide observer reports of decision-making in the psychiatric setting [84, 
91]. Three naturalistic studies used a standardised SDM measure (previously 
validated in the general medical context) to rate psychiatrist behaviours during initial 
consultations with psychiatric outpatients [102, 103], and physician/GP behaviours 
with primary care patients with depression [104]. They found that both psychiatrist 
and GPs generally made limited attempts to involve patients in decision-making 
(M=14.6/100 [104]; M=26.7/100 [103]; M=43/100 [102]), and SDM was poorly 
enacted with regards to offering options, eliciting patient’s preferred level of 
involvement, and assessing patient’s preferred way of receiving information to assist 
decision-making [103, 104]. Interestingly, one study [102] found that the 
psychiatrists’ failure to elicit patient preference for information and involvement were 
not related to patient dissatisfaction in these skill areas, which may be explained by 
other research showing that not all aspects of SDM predict satisfaction [105]. 
Although limited by a paucity of studies integrating both observer and patient reports, 
these consistent findings of low psychiatric patient involvement align with observer 
ratings of doctor-patient consultations in general medicine [69] and oncology [70].  
 
Taken together, there is a lack of concordance between patient preferences for 
involvement, experienced levels of involvement, and observed SDM in mental health 
clinical practice. In light of these findings, endorsing more active patient roles, and 
advocating SDM approaches appear well justified for patients who are not 
experiencing acute psychiatric symptoms. Lending further support to this, increased 
patient involvement and SDM also promote improved patient outcomes, such as 
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greater patient satisfaction with care [106, 107], treatment adherence [108], 
amelioration of depressive symptoms [109], and reduced suicidal ideation [110].  
 
The more important priority, however, appears to be an adoption of a more flexible 
and tailored approach based on greater awareness of patient preferences for 
involvement [72, 73]. Findings from a qualitative analysis of psychiatric visits [111] 
found that although clinicians’ behaviours were not necessarily reflective of SDM 
criteria, they still demonstrated an orientation towards patient-centred care. 
Specifically, while patient-initiated decisions tended to result in higher rates of 
disagreement (in contrast to SDM), the final decision was more in keeping with 
patient preferences and involved greater negotiation and discussion of options [111]. 
Further, patient perceptions of involvement do not always translate to decisions that 
are well informed and supported, and in line with their values. In a qualitative study 
with 40 patients with depression, 85% reported they felt involved in the treatment 
decision-making process, and yet more than three-quarters indicated ambivalence and 
some degree of decisional conflict (e.g., poor values clarity, feeling overwhelmed, 
and confused) [96]. These findings suggest that a more active role in decision-making 
does not necessarily result in good quality decision-making, unless there is 
appropriate decisional support and an explicit exploration of patient ideas, concerns 
and expectations [96]. These considerations may be especially pertinent in the mental 
health context, as mental illness can be associated with feelings of disempowerment, 
along with a reduced sense of confidence and autonomy [112]. Furthermore, other 
mental-health related symptoms (e.g., poor concentration and memory, fatigue, lack 
of motivation) may compromise active patient involvement in decision-making, and 
necessitate the involvement of family as a form of decision support.  
 
1.3.3. Involvement of the family  
In the literature on treatment decision-making in mental health, there is a notable 
paucity of studies investigating the role of family members and their involvement. 
This contrasts with common research findings that patients seldom make purely 
autonomous decisions but rather draw on the support and input of close others 
(including family and friends) [81, 113, 114]. The academic literature on cancer and 
other physical health conditions reports that family members frequently attend 
consultations (64-84%, [115, 116]), assume numerous supporting roles, facilitate 
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more informed and autonomous decisions, as well as influence decisional outcomes in 
treatment decision-making [53, 81]. These supporting roles included providing 
practical (e.g., transporting patients to appointments), emotional (e.g., comforting the 
patient, and companionship), and informational support (e.g., asking questions, 
clarifying aspects of the patient’s history, ensuring patient understanding), with the 
latter particularly appreciated by patients [53]. Meanwhile, a qualitative study of 
mothers who were primary caregivers for a child with depression (aged 15-24 years), 
found that that their involvement was mainly restricted to practical support (e.g., 
driving their child to appointments) [72]. As such, these mothers often felt removed 
from clinical encounters involving treatment decision-making, and/or did not receive 
the information they wanted about their child from clinicians [72]. Given that 
adolescence coincides with a need to actively assert ones independence from parents, 
these findings may not generalise to family involvement in the adult mental health 
context.  
 
In other mental health literature conducted in adults, family members of patients with 
a serious mental illness appear to provide both emotional and instrumental support 
[24]. Indeed, as early as 2001, the World Health Organisation’s report of Mental 
Health acknowledged the mutual benefits of clinicians developing an early 
partnership with family members in a patient’s mental healthcare, in terms of 
information sharing, effective treatment management and fostering the therapeutic 
alliance ([117] page 58): 
 
 “Through such a joint engagement, information on a wide range of 
issues related to the illness can be discussed, family reactions 
explored, and a treatment plan formulated. Families, in turn, 
benefit from learning a process of problem solving in order to 
manage the illness most effectively… 
 
 “The mutual sharing of knowledge, the professional knowledge of 
mental health workers (i.e., clinicians), and the knowledge gained 
by families and consumers through their lived experiences is vital 
for the development of trust. Without trust, an effective treatment 
alliance is often not possible.” 
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Echoing these statements from the World Health Organisation, a more recent review 
acknowledged the importance of involving families in terms of effective treatment 
goals and planning, as they can provide important information that is not readily 
available to health professionals such as specific stressors or triggers, current health 
and wellbeing, past experience with illness and coping skills [24]. Importantly, there 
is RCT evidence that family involvement leads to improved patient outcomes [14], 
possibly because people with stronger support networks are more likely to adhere to 
treatment and better manage their mental illness [118].  
 
In addition to the benefits of family involvement, a majority of patients with a serious 
mental illness also want their family involved in their care (78%, [119]). However, 
patient preferences for family involvement, as for their own involvement, are highly 
variable [119], and do not concord with actual involvement [24]. For example, only 
31-40% of patients reported that their families had had contact with their treatment 
provider, with a further 40% reporting that their families had never had contact [24]. 
Furthermore, there may be additional barriers impeding family involvement in mental 
health compared to physical health conditions, such as concerns over privacy and 
stigma [119]. Given the profound psychosocial and practical burden that serious 
mental illness can have on the patient’s family [24, 25, 120], the involvement of 
family in treatment decisions appears justified on ethical and legal grounds [81, 112, 
121]. Variation in the type and extent of family involvement – both patient 
preferences and actual experience – points to a need to explicitly elicit patient 
preferences for these. This is consistent with patient-centred care, as well as literature 
recommendations in physical health conditions [81].  
 
1.4. Interventions to support treatment decision-making 
Decision-support interventions, such as patient decision-aids (DAs), are tools 
designed to facilitate SDM, by preparing patients to make informed, values-based 
decisions about treatment, screening tests, and other aspects of healthcare [122]. DAs 
come in a variety of formats (e.g., booklets, websites, video), and aim to: i) inform 
patients about the evidence-based healthcare options available; ii) encourage patients 
to actively participate in the decision-making process; and iii) guide patients through 
a deliberative process of considering what is important and matters to them, so that 
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they can make evidence-based, healthcare choices that are consistent with their values 
and preferences [123]. At a minimum, DAs presents non-directive information on the 
decision to be undertaken, the options available, and their related outcomes, including 
their benefits, side-effects/risks, and uncertainties, based on a comprehensive review 
of the evidence [122, 124]. Information is presented via a combination of text-based 
and graphical formats, and uses lay language [123].  
 
A 2017 Cochrane review of 105 DA RCTs for treatment or screening decisions [75] 
confirmed that DAs are associated with a number of improved patient outcomes, such 
as: greater knowledge of options, more accurate risk perceptions and better match 
between care choices and informed patient preferences. Specifically, DAs appeared to 
enhance patient-clinician communication by increasing the extent to which clinicians 
were seen to involve patients in decision-making and achieve informed decision-
making, patient-clinician agreement regarding satisfaction with the decision and 
decision-making process, and patient-clinician discussion about the decision [75]. 
Patient participation in decision-making was also improved across reviewed studies 
with patients receiving a DA compared to usual care reporting greater involvement, a 
more active (patient-controlled) role in decision-making, and reduced clinician 
control over decision-making [75]. While these review findings are promising, it is 
important to consider that the included studies used different measures to assess 
patient decision-making involvement, included different comparison groups (e.g., 
usual care or simple DA), and were conducted in a diverse range of patient 
populations (e.g., cancer, diabetes, pregnant women). Despite these considerations, 
there is consistent evidence to suggest that DAs encourage people to be more 
involved and to become active participants in their own treatment decision-making. 
The ability of DAs to improve concordance with patient preferences for involvement 
remains an unknown yet important outcome.  
 
In contrast to the large body of research on the applicability and usefulness of DAs in 
physical health conditions, research in mental health conditions is scant [125]. An 
earlier 2010 Cochrane review on interventions to facilitate SDM for people with 
mental health conditions identified two separate RCT studies; the first involving a DA 
for inpatients with schizophrenia [126], and the second for a primary care sample of 
patients with physician diagnosed depression [127]. Meanwhile, the 2017 Cochrane 
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review of DA RCTs in physical and mental health conditions published through to 
April 2015 [75] identified two additional studies: one in primary care patients 
deciding on antidepressants [128] and another in military veterans diagnosed with 
post-traumatic stress disorder [129]. Consistent with findings in physical health 
conditions, those patients randomised to receive the mental health DA were more 
knowledgeable about treatment options and outcomes, and felt (or were rated) as 
more involved in the decision-making process compared to those receiving usual care 
[126-128]. Mixed findings were reported with regards to uptake and adherence to 
evidence-based treatments, and improvements to mental health symptomatology.  
 
Consistent DA-related improvements in patient knowledge and perceived decision-
making involvement align with Charles et al. [66], who identify patient knowledge 
and involvement as the key components of DAs (p. 249): 
 
 “…advocated as a tool to help physicians involve patients in the 
treatment decision-making process, i.e., to promote and facilitate 
shared treatment decision-making and to create more informed 
patients.” 
 
Moreover, Charles et al. [66] argue against the use of DAs to promote patient 
outcomes that go beyond the intended purpose and scope of a DA. Some ‘unintended’ 
uses of DAs, which still lack adequate empirical support, include decreasing uptake of 
invasive treatment options (e.g., elective survey). These deviate from the initial aim of 
a DA, which is to provide patients with non-directional and unbiased information 
about the available evidence-based treatment options and their associated benefits and 
risks [66]. Nevertheless, findings from these DA RCTs in mental health are promising 
and suggest positive effects comparable with those documented in non-mental health 
conditions [86].  
 
There appears to be a role for DAs to facilitate SDM about treatment options in BPII. 
Treatment decision-making in this setting is complex with an array of 
pharmacological and psychological treatments that have varying benefit-risk profiles, 
and divergent treatment guidelines that lack consensus or specificity to BPII (see 
section 1.1.5.). Moreover, as a chronic illness, patient engagement and self-
 26 
management is needed to prevent future relapses, in line with the recovery approach 
to care [64].  
 
Even after having made a treatment decision, a significant proportion of patients 
expressed poor values clarification, feeling uninformed, and other manifestations of 
decisional conflict [130], which was not alleviated by available sources of 
informational support. Taken together, these findings suggest a need for improving 
patient involvement that is more in line with their elicited preferences, as well as 
facilitating decision-making that is based on a deliberative exploration of the patients’ 
informed values. DAs are capable of fulfilling these objectives [75], but so far none 
have been specifically designed for BPII.  
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1.5. Significance and aims of this thesis  
To date, no known studies have explored the perceptions and experiences of treatment 
decision-making in either BPI or BPII from the perspectives of patients, family 
members and clinicians. It is clear however, that treatment decisions for BPII are 
complex and necessitate patient involvement that is well informed and supported. The 
following thesis chapters present an innovative and timely research program, 
strengthened by its combination of both qualitative and quantitative research methods, 
and its applied clinical focus. This PhD research program was committed to exploring 
an under-researched area of inquiry in mental health, and developing an evidence-
based decision-support resource that is informed by the views and lived experiences 
of key stakeholders, including family members whose role, though important, has 
been largely under-recognised. Research on decision-support resources to facilitate 
SDM is firmly established in medical healthcare, but is still in its infancy in mental 
healthcare. The development of such resources is fundamental for providing optimal 
care about BPII treatment and management, and has potential ramifications for patient 
quality of life, illness-related burden and treatment adherence. 
 
The overall aim of this multi-stage project is to explore and improve the process of 
decision-making about the treatment and ongoing management of BPII. More 
specifically, this project will:  
 
(i) Explore patient, family, and clinician perspectives on BPII treatment decision-
making in relation to: information and involvement preferences; perceived 
barriers, facilitators and modifiers, challenges and related strategies; unmet 
decisional support and informational needs; 
(ii) Develop a decision-support resource/ DA to facilitate SDM in this setting, The 
development of a DA will be informed by the unmet informational and 
decisional-support needs identified in (i); 
(iii) Conduct a pilot study to obtain evidence on the DA’s acceptability, safety, 
feasibility, and potential usefulness in this setting.  
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1.6. Structure of this thesis 
The following chapter, Chapter 2, presents a systematic review of the current 
empirical literature on communication and decision-making about treatment with a 
focus on patients with bipolar disorder. In line with aim (i) (see section 1.5), Chapters 
3 – 5 provide an in-depth qualitative investigation of treatment decision-making in 
bipolar II disorder (BPII) from the perspectives of patients, their families, and 
experienced treating clinicians. Chapter 6 outlines the rationale for, and development 
of a decision-aid (DA) for treatment decision-making in BPII, thus aligning with aim 
(ii) (see section 1.5). Following this, Chapter 7 reports on findings from a pilot study 
of the DA in a sample of potential end-users (as per aim (iii), see section 1.5). Finally, 
Chapter 8 concludes with a summary of the key findings and implications of the 
thesis as a whole. Chapters 2, 3, 4, 5, and 7 are reproductions of peer-reviewed 
journal articles; they retain all their published content with slight formatting changes 
as appropriate. Minor inconsistencies in headings and subheadings reflect journal-
specific requirements and/or feedback from peer-reviewers. Chapter 6 is an 
unpublished thesis chapter. As a thesis in the style of a “thesis with publications”, 
each chapter is prefaced by a brief paragraph summarising the publication and 
contextualising it within the overall scope of the thesis. 
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Chapter 2: Communication and decision-making in mental health: A systematic 
review focusing on bipolar disorder 
 
This chapter is reformatted from the published manuscript:  
Fisher A, Manicavasagar V, Kiln F, Juraskova, I. Communication and decision-
making in mental health: A systematic review focusing on bipolar disorder. 
Patient Education and Counseling. 2016;99(7):1106-20. 
https://doi.org/10.1016/j.pec.2016.02.011 
 
 
This chapter presents a systematic review of empirical studies of clinician-patient(-
family) communication and decision-making about treatment in mental health 
samples which included patients with bipolar II disorder (BPII). Review findings 
informed preliminary recommendations for clinicians working in this setting, and 
were used to guide the subsequent qualitative phases of the PhD research program. 
Supplementary materials related to this chapter are provided in Appendix C.  
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2.1. Abstract 
Objectives. To systematically review studies of communication and decision-making 
in mental health-based samples including patients with bipolar disorder (BP). 
 
Methods. Qualitative systematic review of studies using PsychINFO, MEDLINE, 
SCOPUS, CINAHL, and EMBASE (January 2000–March 2015). One author assessed 
study eligibility, verified by two co-authors. Data were independently extracted by 
two authors, and cross-checked by another co-author. Eligible studies were assessed 
using a validated quality appraisal by two independent raters.  
 
Results. Of 519 articles retrieved, 13 studies were included (i.e., 10 quantitative/1 
qualitative/1 mixed-methods). All were cross-sectional; twelve were rated 
good/strong quality (>70%). Four inter-related themes emerged: 1) patient 
characteristics and 2) patient preferences, 3) quality of patient-clinician interactions, 
and 4) influence of shared decision-making (SDM)/ patient-centred approach on 
patient outcomes. Overall BP patients, like others, have unmet decision-making 
needs, and desire greater involvement. Clinician consultation behaviour influenced 
patient involvement; interpersonal aspects (e.g., empathy, listening well) fostered 
therapeutic relationships and more positive patient outcomes, including: improved 
treatment adherence, patient satisfaction with care, and reduced suicidal ideation. 
 
Conclusions. This review reveals a paucity of studies reporting Bipolar-specific 
findings. To inform targeted BP interventions, greater elucidation of unmet decision-
making needs is needed. 
 
Practice Implications. Eliciting patient preferences and developing a collaborative 
therapeutic alliance may be particularly important in BP, and promote improved 
patient outcomes.  
 
Keywords. Bipolar disorder, treatment, decision-making, communication, patient 
involvement, patient outcomes 
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2.2. Introduction 
Bipolar disorder (BP) is a chronic, relapsing and remitting disorder of mood, thinking, 
and behaviour characterised by “lows” (depression) and “highs” (hypo/mania). 
Current diagnostic classifications recognise two subtypes, BPI and BPII; BPII is 
considered the less severe due its absence of impairment and psychotic features 
during “highs” [1]. By contrast, empirical evidence suggests comparable overall 
impairment across subtypes [2]. 
 
Pharmacological treatments represent the primary therapy for the acute treatment and 
long-term prophylactic management of BP [3]. Indeed, pharmacotherapy decisions in 
BP may be especially challenging, due to an incomplete evidence base [4], and high 
potential side-effect and quality-of-life burden of options [3, 5]. Further, treatment 
adherence–a well-documented problem among BP patients [6]-depends on the 
subjective value that BP patients assign to treatment efficacy versus side-effect 
burden [4].  
 
Given medical uncertainty underlies BP treatment decisions, and the potential link 
between patient involvement and outcomes, patients should participate in treatment 
decisions. Patient involvement is particularly important in BP, as patients are 
responsible for actively self-managing their illness to prevent further relapse and/or 
recurrence [3, 7]. To this end, mental healthcare professionals are increasingly 
encouraged to practice shared decision-making (SDM) in patient treatment and 
management. SDM is well-suited to treatment decisions that are sensitive to patient 
values and preferences, as in BP [8]. Key elements include: providing patients with 
treatment option information, checking patient understanding of options and 
involvement preferences, and incorporating both patient and clinician perspectives 
and preferences into final decisions [9].  
 
A prominently-cited model of SDM by Charles and colleagues [10, 11] recognises 
three decision-making stages: information exchange (providing information about 
treatment options), deliberation (discussing treatment preferences), and deciding on 
the treatment to implement (selecting a specific treatment option from the range of 
presented options). Each stage may involve the clinician, the patient and/or others 
(e.g., family or friends). Then, depending on patient’s level of involvement, patients 
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may assume a passive, collaborative, or active role resulting in more clinician-led, 
shared, or more patient-led decision-making, respectively. Although mostly applied 
model to the acute care context, Charles et al.’s model is also applicable chronic 
illnesses that require ongoing decision-making and patient self-management, as with 
BP [12]. Of note, a systematic review highlighted that Charles et al.’s model [10, 11] 
emphasised more SDM elements than other prominently-cited models [13]. Based on 
this, it provides a comprehensive and integrative model of SDM [13]. 
 
Although informative, existing reviews of communication and treatment decision-
making in mental health have methodological limitations (e.g., single database, [14]), 
been limited in scope (e.g., only RCTs, [15]) and have focused almost exclusively on 
unipolar depression and/or schizophrenia [16, 17]. Thus, findings may not generalise 
to BP. Firstly, BP patients might be expected to differ from others (e.g., 
schizophrenia) in terms of their preferences and experience of involvement in 
treatment decision-making [14], given the fluctuating nature of BP symptoms and 
associated disability together with periods of wellness. Secondly, treatment decision-
making in BP may be more complex than in unipolar depression, as treatment 
addresses two distinct, though sometimes co-occurring sets of symptoms, depression 
and (hypo)mania [18]. Finally, a collaborative approach to illness management is 
perhaps of greater importance in BP than in other mood-based disorders (e.g., 
unipolar depression), given that long-term treatment relies heavily on patient self-
management to prevent illness (prophylaxis) rather than the treat of illness symptoms 
as they occur [19].  
 
To date, no known systematic reviews have focused on studies comprising BP patient 
samples. To address this gap, this qualitative systematic review aimed to synthesise 
quantitative and qualitative studies exploring communication and decision-making 
outcomes in mental health-based samples including BP patients. Where possible, the 
review aimed to draw preliminary comparisons between patient groups to elucidate 
any differences (and/or similarities) between BP and other mental health conditions. 
The review’s scope was restricted to cognitively competent adult patients receiving 
voluntary mental healthcare.  
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2.3. Methods 
 
2.3.1. Search strategy 
 To minimise the potential for publication bias a comprehensive, systematic approach 
was employed; electronic searches were conducted using multiple scientific literature 
databases (PsychINFO, MEDLINE, SCOPUS, CINAHL, EMBASE), manual 
searches of included article reference lists, and follow-up searches of articles related 
to published conference abstracts. Search results were limited to English-language 
articles published January 2000 to end March 2015, to capture the current clinical 
findings. Quantitative, qualitative, or mixed methodologies were all eligible. For a 
comprehensive list of search terms see Box 2.1.  
Notes:  
 “two word phrase” = two adjacent words to be considered as a single phrase  
OR = any of the search terms appearing at this level may be included 
 AND = at least one search term at each level must be included 
AND NOT = none of the subsequent search terms (i.e., Level 5) may be included.  
* = include all possible word endings (e.g., collaborat* = collaboration, collaborate, collaborative etc.) 
a = Dependent on mapped subject heading for database.  
Box 2.1. Database search terms 
 
Level 1 
patient OR client OR consumer OR “patient involvement” OR “patient participation” 
AND  
Level 2 
consultation OR “medical encounter” OR “medical visit” OR “medical setting” OR “psychiatric 
setting” OR clinician OR psychiatrist OR psychologist OR “health professional” OR doctor OR 
physician 
AND  
Level 3 
Bipolar* OR “Bipolar disorder”a OR “Bipolar affective disorder”a OR “Bipolar mood disorder”a 
AND  
Level 4 
communicat* OR  decision* OR “decision making” OR collaborat* 
AND NOT  
Level 5 
pediatric* OR paediatric* OR alzheimer* OR dementia OR cancer OR oncolog* 
Additional limits: English language only, published January 2000 – present. 
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Initially returned articles were independently title-screened by two authors (AF, FK) 
for irrelevant or review papers, conference abstracts, and duplicates. In cases of 
ambiguity, abstracts were consulted. All abstracts and full-texts were then 
independently screened for eligibility by the same two authors (AF, FK) according to 
specified criteria (Box 2.2). Additional articles were identified by a manual search of 
references lists and screened for eligibility according to the same criteria (Box 2.2). 
Discrepancies were discussed and resolved. One author assessed final study eligibility 
(AF), verified by two co-authors (IJ, FK).  
 
Box 2.2. Eligibility criteria   
Types of studies: Quantitative or qualitative (primary and secondary analyses of data 
sets) studies including: 
– Interviews/focus groups 
– Surveys 
– Consultation audit-studies (audio- or video-taped consultations, 
consultation observation) 
Exclusion: Review papers, editorials, commentary/discussion 
papers, papers published in languages other than English, papers not 
available in full text 
 
Types of participants: Communication/decision-making must have included one of the 
following participants: 
– Adult patients (>18 years) with a diagnosis of Bipolar Disorder (I 
or II) 
Exclusion: Studies where patients not able to fully engage in the 
consultation (e.g. impaired decisional capacity; acutely psychotic), 
studies where BP patient sample not clearly defined, or comprise ≤ 
10% total patient sample. 
– Adult companions involved in the consultation (including spouse, 
family members, friends) 
Exclusion: Studies where the companion had a unique responsibility 
(e.g. paid caregiver, proxy) 
– Treating clinicians/ health professionals 
 
Types of settings: Any type of medical setting (including but not limited to: psychiatric, 
allied health, hospital, clinic, primary care, community mental health 
centre, inpatient, outpatient) 
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2.3.2. Data extraction 
Both inductive and deductive techniques were used for data extraction. Main study 
aims and findings were recorded by the first author, who then organised studies 
according to key topics. A preliminary list of common themes was then created and 
later refined via iterative discussions with a co-author (IJ). Studies were then 
organised deductively according to a standard format (design, method, sample, 
measures, results and summary). Two authors (AF, FK) independently extracted all 
data, which were later cross-checked for accuracy by another co-author (IJ).  
 
2.3.3. Quality assessment  
Study quality was assessed according to standardised criteria for quantitative and 
qualitative studies [20], which are provided in Appendix C. This assessment tool has 
been used to rate study quality in previous systematic reviews of medical decision-
making [21] and includes an extensive manual for quality scoring with definitions and 
detailed instructions. Two authors (AF, FK) independently rated the quality of all 
eligible studies. On each criterion, studies were rated from 2 to 0, depending on 
whether the criterion was satisfactorily met (“yes”=2), partially met (“partial”=1), or 
not met (“no”=0). Krippendorff’s alpha, used to estimate inter-rater reliability, was 
0.85 (95% C.I.=0.73-0.94, based on 1000 bootstrapped samples), indicating excellent 
agreement [22]. Based on its summary score 4, each study was allocated a quality 
percentage (0-100%), which corresponded to limited (<50%), adequate (50-70%), 
good (71-80%), or strong quality (>80%) [23].  
  
                                                     
4
 Total sum = [number of “yes”] + [number of “partials”*1]; total possible sum [quantitative studies] = 
28 – [number of “N/A”*2] or total possible sum [qualitative studies] = 20; summary score: total sum/ 
total possible sum. 
Types of communication: Any form of clinician-patient communication and/or decision-making 
(including behaviours, attitudes, perceptions, self-report)  
Exclusion: Studies where communication and/or decision-making 
mentioned only in passing, and primarily in relation to other 
concepts (e.g., aspect of therapeutic relationship/alliance, clinician-
related qualities) 
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2.4. Results 
The search returned 513 articles. Manual reference searches yielded an additional 5 
articles, along with 1 additional citing article. Of these, 97 duplicates and 387 
irrelevant articles were removed (see Figure 2.1). Thirty-five abstracts were screened 
for eligibility, based on which 15 articles were excluded. Full-text screening of the 
remaining 20 articles excluded a further 7 articles, leaving 13 studies for final 
inclusion (see Figure 2.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. PRISMA Flow diagram of study selection.   
Records identified through 
database searching 
(n=513) 
Manual search (n=6) 
 
 
 
 
 
 
Duplicates excluded 
(n=97) 
Records after duplicates removed 
(n=422) 
Abstracts screened 
(n=35) 
Records excluded 
(n= 87) 
 
Example reasons: 
 
- Treatment efficacy 
studies (e.g., RCTs) 
- Conducted outside 
treatment setting (e.g., 
chat rooms) 
- Focused on clinician 
decision-making (e.g., 
algorithms) 
Full-text articles assessed 
for eligibility 
(n=20) 
Full-text articles excluded, 
with reasons 
(n=7) 
 
-Poorly defined or 
inadequate BP patient 
sample (≤10%, n=5) 
 
- Focused on aspects of 
care other than 
communication and/or 
decision-making (n=3)* 
 
* One study ineligible on 
both criteria. 
Studies included in 
systematic review 
(n=13) 
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2.4.1. Study characteristics 
Table 2.1 summarises eligible study characteristics, including: quality rating, 
proportion of BP patients, use of (non-)validated measures, and main results. All 
studies were cross-sectional and conducted in outpatient settings. Most studies were 
published since 2010 (n=9/13) and from the United States (n=8). Analyses tended to 
be retrospective or secondary analyses of data from larger studies (n=8). All studies 
except one [24] were rated good (n=2) or strong (n=10) quality (M=85.8%) [23].  
 
As seen in Table 2.1, most studies included a mixed psychiatric patient sample 
(n=11). The proportion of BP patients (across subtypes) ranged 12%-98% of the total 
sample; only two studies had BP-only samples [25, 26]. Diagnosis-specific findings 
were often not reported (n=8); no differentiation was made between BPI/II subtypes. 
Patient samples were heterogeneous with respect to age and gender: patient age 
ranged (M=36-54.3 years); some samples were gender-balanced, others had a female 
(n=5,62-66%) or male majority (n=3,76-89%). Predominant methods were patient-
report questionnaires and observer consultation-ratings, less common methods were 
semi-structured patient interviews [27, 28], focus group [26] or audit of consultation 
notes [24]. In consultation-based studies, clinicians were either psychiatrists or nurse 
practitioners, or trainee GPs [24]. All consultation studies coded only dyadic 
(clinician-patient) interactions. Patients in two qualitative studies alluded to 
(potential) family involvement in decision-making [27, 28].  
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Table 2.1. Tabulated summary of included study findings (N=13) 
Authors 
 
Year 
Country 
Theme(s) 
 
Quality 
rating 
Approach, Design & 
Method 
Sample & Setting Measures specific to 
results 
Key: (+)/(-)= 
validated/ 
unvalidated 
measure 
 
Results Summary 
Quantitative 
studies 
 
      
De las Cuervas et 
al.,  
 
2014a 
 
Spain 
 
 
Patient preferences 
 
Influence of SDM/ 
patient-centred 
approach on 
patient outcomes 
85% 
a, k 
Design: Cross-
sectional 
Method: Socio-
demographic survey 
& self-report 
questionnaires 
 
Bipolar sample: 
n=118 bipolar 
patients (12.2% total) 
Overall sample: 
N=967 patients (M 
age = 49.6 years; 
62.9% females) 
Response Rate: 79% 
Setting: Community 
mental health 
services 
Mental health 
discipline: 
Psychiatry 
(+) Morisky 
Medication 
Adherence Scale 
(MMAS-8) 
(+) Control 
Preferences Scale 
(CPS, administered 
twice) 
- 64.3% patients preferred shared 
decisional control; 28.6% a passive 
approach; 6.7% an active approach. 
- Experienced roles were passive 
(78.1%); collaborative (21.6%); and 
active (0.3%). 
- Preferred and experienced roles 
were concordant for half patients; 
mismatch resulted from preferring a 
more active role than experienced. 
- Self-reported adherence higher for 
patients with concordant 
preferred/experience decision-making 
roles than for patients with discordant 
- Psychiatric outpatients prefer 
shared/collaborative approaches 
to discussion making. 
- Almost half of patients do not 
experience their preferred level of 
decision-making control in 
consultations with their 
psychiatrists; most of these 
patients experience less 
involvement than preferred. 
- Achieving a preferred level of 
involvement (be it active, passive 
or collaborative) is associated 
 52 
 Provider type: 
Psychiatrist  
decision-making roles (p<.001); this 
pattern did not differ for different 
levels of involvement.  
with increased medication 
adherence. 
De las Cuervas et 
al.,  
 
2014b 
 
Spain 
 
 
Patient 
characteristics 
 
Patient preferences 
90% 
a, j  
Design: Cross-
sectional 
Method: Socio-
demographic survey 
and self-report 
questionnaires 
 
Bipolar sample: 
n=67 patients (13.2% 
total)  
Overall sample: 
N=507 patients (M 
age = 48.4 years; 
62.1% females) 
Response Rate: 76% 
Setting: Community 
mental health 
services 
Mental health 
discipline:  
Psychiatry 
Provider type: 
Psychiatrist 
 
(+) Control 
Preferences Scale 
(CPS, administered 
twice) 
(+) Multidimensional 
Health Locus of 
Control (MHLC) 
(+) General Perceived 
Self-Efficacy Scale  
- 63.5% patients preferred shared 
decisional control; 34.7% a passive 
approach; 1.8% an active approach. 
- Experienced roles were passive 
(86%) or collaborative (14%). 
- Older age, lower self-efficacy, 
positive external HLC, and negative 
internal HLC predicted stronger 
preferences for more passive 
decision-making styles. 
- Being older age, male, and having 
low self-efficacy, predicted  
experiencing a passive decision-
making style. 
- 47% patients reported concordance 
between preferred and experienced 
role; 52% preferred a more active 
role than experienced; 1% more 
passive. 
- Consistent role mismatch across all 
disorders; patients with personality 
disorders preferred more 
active/collaborative role (70%) than 
- Psychiatric outpatients prefer 
shared/collaborative approaches 
to discussion making. 
- About half of patients do not 
experience their preferred level of 
decision-making control in 
consultations with their 
psychiatrists; most of these 
patients experience less 
involvement than preferred. 
- Socio-demographic and 
attitudinal characteristics of 
patients influence  preference and 
experience of more 
active/collaborative or more 
passive decision-making styles. 
- Some differences in preferred 
and experience roles emerge for 
different psychiatric disorders; 
Bipolar disorder does not appear 
to differ from other psychiatric 
disorders in this respect.  
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others; patients with schizophrenia 
and personality disorders experienced 
more passive role (90%) than others. 
Frankel et al.,*  
 
2013 
 
USA 
 
 
Quality of patient-
clinician 
interactions 
75% 
a, e, f, 
h, m 
Design: Cross-
sectional 
Method: Audiotaped 
psychiatric visits 
 
Bipolar sample: 
n=28 patients (23% 
total) 
Overall sample: 
N=124 patients (M 
age = 43.2 years; 
51% males); n=8 
prescribers (5 
psychiatrists, 3 nurse 
practitioners). 
Response Rate: 97% 
Setting: Community 
mental health centre 
Mental health 
discipline: 
Psychiatry 
Provider type: 
Psychiatrist and NP 
(-) Purpose-designed 
coding system for 
agenda setting; 
identified 10 essential 
and 9 non-essential 
elements (rated 
present or absent/ 
partial/complete). 
- A majority of encounters showed 
>= 1 essential element; 10% 
encounters showed no essential 
elements; no encounters showed >= 6 
essential elements. 
- Commonly absent elements were 
orienting the patient to the visit 
(96.8% absent), eliciting a statement 
of patient concerns (66.1%), and 
elicit full breadth of concerns at 
beginning of visit (89.5%). 
- Approximately half of visits showed 
partial (27.4%) or complete (26.6%) 
rapport building. 
- Overall, prescribers showed 
quite poor involvement of patients 
in agenda setting; mostly 
commonly missing elements 
related to patient-centredness and 
partnership building.  
- Prescribers are inconsistent in 
their rapport building during 
consultations.   
Fukui et al.,* 
 
2013 
 
USA 
100% Design: Cross-
sectional 
Method: Audiotaped 
psychiatric visits 
 
Bipolar sample: 
n=18 patients (14.1% 
total) 
Overall sample: 
N=128 patients (M 
(-) Shared Decision-
making (SDM) scale 
adapted from (+) 
Informed Decision-
making Scale. 
- Mean rated SDM was 9.7 out of 18 
- Mean rated patient initiation score 
was 1.8 out of 9. 
- 46% of consultations involved a 
“basic” decision; 54% involved an 
- Overall, clinicians’ exhibited 
low levels of SDM, and patients 
exhibited low levels of active 
involvement. 
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Quality of patient-
clinician 
interactions 
age = 43.4; 50.8% 
females); n=8 
providers (5 
psychiatrists, 3 nurse 
practitioners). 
Response Rate: 69% 
Setting: 3 
community mental 
health centres 
Mental health 
discipline: 
Psychiatry 
Provider type: 
Psychiatrist and NP 
“intermediate” or “complex” 
decision.  
- 79% consultations achieved patient-
clinician agreement; 21% included 
some disagreement. 
- More complex decisions (B=2.467, 
p<.001) and more patient initiation 
(B=0.767, p<.001) predicted more 
SDM; accounted for 37.6% variance.  
- Eliciting patient preferences 
(B=0.767, p<.001, OR=3.97) 
predicted greater patient-clinician 
agreement; accounted for 52.5% 
variance.  
- Clinicians successfully involved 
patients more in decisions with 
less medical consensus and 
decisions which posed greater 
potential risk to the patient. 
- Eliciting patient preferences 
may be a key way of increasing 
patient-clinician agreement in 
making a decision.  
- N.B. Consultations comprised 
predominantly progress-check 
visits and 25% did not involve 
any clinical decisions. 
Ilgen et al.,*  
 
2009 
 
USA 
 
 
Influence of SDM/ 
patient-centred 
approach on 
patient outcomes 
 
90% 
e, j 
Design: Cross-
sectional 
Method: Socio-
demographic survey 
and self-report 
questionnaires. 
 
Bipolar sample: 
N=423 patients (98% 
of total, M age = 49.0 
years, 76% male; 
n=164 BPI, n=45 BP 
NOS, n=4 BPII) 
Response Rate: N/A 
Setting: Veterans 
receiving inpatient 
and outpatient mental 
health treatment 
(+) Health Care 
Climate 
Questionnaire 
(HCCQ) 
(+) Patient Health 
Questionnaire (PHQ-
9) suicide ideation 
item 
(+) Morisky 
Medication 
Adherence scale 
(MMAS-8). 
- Patients reporting a lower 
medication adherence and a less 
collaborative therapeutic relationship 
were more likely to report suicidal 
ideation (p’s <.001) 
- Patients reporting a collaborative 
therapeutic relationship were less 
likely to report suicidal ideation in 
the two weeks prior (OR = 0.97, 
p<.001) 
- In addition to medication 
adherence, establishing a 
therapeutic relationship that 
patient perceive as collaborative 
may act as a buffer against 
suicidal ideation amongst patients 
with BP.  
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Mental health 
discipline: 
Psychiatry  
Provider type: NS 
Klingaman et al.,*  
 
2015 
 
USA 
 
 
Patient preferences 
 
Influence of SDM/ 
patient-centred 
approach on 
patient outcomes 
 
73.2% 
e, g, l 
Design: Cross-
sectional 
Method: Self-report 
questionnaires 
 
Bipolar sample: 
n=76 patients (32% 
total) 
Overall sample: 
N=239 veterans with 
serious mental illness 
(M age = 54.0 years, 
89% male) 
Response Rate: N/A 
Setting:  Veterans 
receiving inpatient 
and outpatient mental 
health treatment 
Mental health 
discipline: 
Psychiatry 
Provider type: 
Psychiatrist and NP 
(-) Purpose-designed 
questionnaire based 
on (+) validated 
measure of patient 
satisfaction 
(+) Behaviour and 
Symptom 
Identification Scale 
(BASIS-24) 
(+) Scale to Assess 
Therapeutic 
Relationship (STAR-
P) 
(-) 3-item scale of 
shared decision-
making (SDM) 
preferences. 
- A large majority of patients (75.7-
93.4%) preferred their clinician to 
offer them options and ask their 
opinion about mental health 
treatments. 
- Positive collaboration (B=.15, 
p<.01) and positive clinician input 
(B=.18, p<.001) predicted greater 
patient satisfaction during visits. 
Unsupportive clinician input did not. 
- Preferences for a more 
shared/collaborative approach to 
decision-making (B=-.06, p<.05) 
predicted lower patient satisfaction.  
- Most people with serious mental 
illness, desire involvement in 
treatment decision-making, 
though preferences may be 
stronger for particular aspects of 
decision-making. 
- Patients who prefer a SDM 
approach report lower satisfaction 
with visits which may hint at a 
potential mismatch between 
preferred and experienced roles in 
decision-making in this context.  
- Patient satisfaction is enhanced 
by their perceptions of a positive 
and collaborative therapeutic 
relationship.  
Llewellyn-Jones et 
al.,  
 
2001 
61.1% 
a, b, e, 
f, h, j 
Design: Cross-
sectional 
Method: Audit of 
consultation notes 
Bipolar sample: 
n=24 patients (12% 
total) 
(-) Routine clinical 
practice question “Do 
you have any 
questions you would 
- Most common questions in patients 
with BP included reductions in 
medication (12.5%) and fitness to 
drive (12.5%), similar to patients 
- Similar to patients with 
schizophrenia and unipolar 
depression, patients with BP tend 
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UK 
 
 
Quality of patient-
clinician 
interactions 
 Overall sample: 
N=200 patients 
(mostly with 
schizophrenia [32%] 
or unipolar 
depression [26%]) 
seen by consultant 
psychiatrist (78%) or 
trainee GP (22%). 
Response Rate: N/A 
Setting: Outpatient 
clinics  
Mental health 
discipline: 
Psychiatry 
Provider type: 
Psychiatrist or GP 
like to ask?” Patient 
replies and case note 
diagnoses recorded.  
with schizophrenia (19% asked about 
stopping medication, 9% asked about 
reducing medication), unipolar 
depression patients (7.7% asked 
about medication termination).  
- 50% of patients with BP had no 
questions, comparable to of 
schizophrenia patients (57%) and 
unipolar depression patients (40%). 
21% of patients with anxiety and 
33% with personality disorders had 
no questions. 
  
to ask questions related to 
medication.  
- Questions about medication 
reflect a desire to stop or reduce 
medication.  
- Patients with BP, similar to 
patients with schizophrenia, ask 
less questions of their clinician 
than patients with other mental 
disorders (i.e., depression, 
anxiety, personality disorders).  
- Low rate of question asking may 
reflect difficulties in discussing 
symptoms and medication issues, 
or barriers to participation during 
psychiatric visits.  
Park et al.,* 
 
2014 
 
USA 
 
 
Patient 
characteristics 
95% 
h 
Design: Cross-
sectional  
Method: Self-report 
questionnaires 
 
Bipolar sample: 
n=63 patients (26% 
total) 
Overall sample: 
N=239 patients (M 
age = 54.3 years, 
89% male) and N=21 
prescribers (13 
psychiatrists, 8 NPs). 
(-) 3-item scale of 
shared decision-
making (SDM) 
preferences. 
(+) Behaviour and 
Symptom 
Identification Scale 
(BASIS-24) 
- 85% of patients indicated  
preference  for choices and to be 
asked their opinions about their 
mental health treatment by their 
clinician. 
- 61% of patients  showed preference 
to rely on their clinician’s knowledge 
rather than obtaining information 
- Patient preferences for SDM 
appear to  depend on the stage of 
the decision-making process; 
patients almost uniformly endorse 
their clinician offering options 
and asking their opinions about 
mental health treatments.  
- Preferences for SDM appear to 
be strong among patients with 
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Patient preferences 
Response Rate: N/A 
Setting: Two 
outpatient mental 
health clinics 
Mental health 
discipline: 
Psychiatry 
Provider type: 
Psychiatrist or NP 
 
(+) Scale to Assess 
Therapeutic 
Relationship (STAR-
P) 
 
 
about their mental illness on their 
own. 
- 64% of patients would prefer their 
clinician to make the final decisions 
about their mental health treatment. 
- Preference for clinician knowledge 
and clinician-led decisions were 
positively correlated (r=.54, p<.001). 
- Patients were more likely to prefer 
seeking mental health information on 
their own if they were employed 
(B=.76, p=.007), had tertiary 
education (B=.66, p=.004), and had a 
diagnosis of BP (B=.60, p=.054), 
depression (B=.82, p=.01), or PTSD 
(B=.92, p=.03,versus schizophrenia).  
- Patients were more likely to prefer 
relying on their clinician’s knowledge 
if they were Caucasian (B=-.86, 
p<.001), or reported a stronger 
therapeutic relationship (B=-.06, 
p=.002).  
higher education, and a diagnosis 
of BP, depression or PTSD 
compared to schizophrenia.  
- Patients preferring a more 
paternalistic/passive decision-
making style report a stronger 
therapeutic relationship which 
may be attributable to greater 
concordance between preferred 
and experienced roles in decision-
making participation. 
Salyers et al.,*  
 
2012 
 
97.5% 
f 
Design: Cross-
sectional 
Method: Audiotaped 
consultations 
Bipolar sample: 
n=37 patients (22% 
total) 
(-) Shared decision-
making scale/coding 
system (SDM-18) 
adapted from (+) 
- Clinical decisions (in 75% of 
consultations)  included; stopping 
(8%) or adding (18%) a medication, 
changing time/administration (18%) 
- Important aspects of SDM are 
commonly absent during 
psychiatric visits; even though 
clinicians demonstrate a more 
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USA 
 
 
Quality of patient-
clinician 
interactions 
 Overall sample: 
N=170 patients (M 
age = 43.6 years, 
52% males) and N=8 
providers (5 
psychiatrists, 3 NPs).  
Response Rate: N/A 
Setting: Community 
mental health centres 
Mental health 
discipline: 
Psychiatry 
Provider type: 
Psychiatrist and NP 
 
 
Elements of Informed 
Decision-making 
Scale. 
or dosage (18%) of current  
medication (18%), deciding not to 
change medication when alternative 
offered (40%), deciding on non 
medication alternative (49%).  
- 46% decisions were “basic”; 52% 
intermediate; and 2% complex. 
- Reciprocal/complete discussion was 
most common in consumer’s goal 
and context of decision (92%), 
clinical nature of decision (63%), 
alternatives (58%, most commonly 
nonmedication), consumer’s 
preference (56%).  
- Most commonly absent was 
discussion of patient’s desire for 
others’ input (90%), and patient’s 
understanding (52%).  
- Most SDM elements were initiated 
by clinician, except for discussion of 
patient QoL (66%). 
- 79% decisions were made in full 
patient-clinician agreement; 15% 
patients and 6% clinicians agreed 
reluctantly. 
SDM approach for more complex 
decisions, the minimum required 
levels of SDM are not achieved in 
a substantial proportion of visits.  
- Most SDM is initiated by 
clinicians rather than patients, and 
a majority of decisions are made 
in full clinician-patient 
agreement.  
- Although SDM is associated 
with longer consultation times, 
this was attributable to the greater 
complexity of decisions requiring 
SDM rather than SDM per se.  
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- After controlling for decisional 
complexity, no relationship between 
SDM and visit length.  
- Minimum required SDM was 
achieved in 61% basic and 46% of 
intermediate/complex decisions. 
- More SDM behaviours were 
observed in intermediate/complex 
decisions than basic decisions 
(p<.001). 
Stacey et al.,  
 
2008 
 
Canada 
 
 
Patient preferences 
 
Influence of SDM/ 
patient-centred 
approach on 
patient outcomes 
 
82.5% 
a, e, j, k 
Design: Cross-
sectional 
Method: Semi-
structured interviews 
and self-report 
questionnaires. 
 
Bipolar sample: 
n=25 patients (26.5% 
total) 
Overall sample: 
N=94 patients 
(Median age = 40 
years, 66% females) 
Response Rate: 91% 
Setting: Psychiatric 
hospital outpatient 
services and 
community hospital 
Mental health 
discipline: 
Psychiatry  
Provider type: NS 
(-) Population Needs 
Assessment Tool 
based on Ottawa 
Decision Support 
Framework. 
(+) Decisional 
Conflict Scale 
(+) Control 
Preferences Scale, 
modified 
- Most common treatment decisions 
involved taking medications (n=35) 
- 40/67 patients were uncertain about 
a recent treatment decision, often 
resulting in “wavering between 
choices” (57% versus 9% when 
certain), difficulties in decision-
making commonly manifested as 
feeling distressed/upset (70%) or 
worrying (69%).  
- Uncertain patients were more likely 
to feel uniformed, have unclear 
values, feel less supported (p<.001), 
to report lacking motivation (p=.012) 
or skills/ability to make decision 
(p=.026), and have greater supportive 
- Over half of patients who have 
made a recent treatment decision 
remain uncertain; often due to 
feeling uniformed, unclear about 
values, or lacking support.  
-  More than 90%  patients with 
depression and bipolar disorder 
wish to make treatment decisions 
either alone or collaboratively 
with their clinician, over half 
prefer to involve family and/or 
friends.  
- Family involvement, if it occurs, 
is usually perceived as supportive, 
and patients do not feel pressured 
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 family involvement (28/66 vs 4/27 
certain).  
- Patients preferred to discuss 
decision with psychiatrist (89%), 
friends (62%), and family (45%); 
preferred support resources were 
pamphlets (82%) and developed by 
health professionals (95%). 
 
either by them or by their 
clinician.  
- This patient group are generally 
information seeking, although 
greater exposure to information 
about outcomes associated with 
options may contribute to 
uncertainty.  
 
- Pamphlets developed by 
healthcare professionals appear to 
be the preferred information 
support resource.  
Sylvia et al.,* 
 
2013 
 
USA 
 
 
Influence of SDM/ 
patient-centred 
approach on 
patient outcomes 
 
88.6% 
b, j, m 
Design: Cross-
sectional 
Method: Self-report 
questionnaires 
 
Bipolar sample: 
N=3337 patients 
(71.1% BPI, 28.9% 
BPII) 
Response Rate: N/A 
Setting: Outpatient 
clinics specialised in 
BP treatment 
Mental health 
discipline: 
Psychiatry 
Provider type: 
Psychiatrist 
(-) Purpose-designed 
scale of medication 
adherence, Affective 
Disorders Evaluation 
(+) Helping Alliance 
Questionnaire, patient 
version 
(+) Care Satisfaction 
Questionnaire. 
 
- After controlling for clinical factors 
associated with poor adherence, 
patient perceptions of a therapeutic 
relationship that was strong (e.g., 
feeling understood), positive (e.g., 
having good relationship), and 
collaborative (e.g., jointly working on 
problems) positively predicted a 
higher likelihood of medication 
adherence (OR’s <1.0, p’s<.05).  
- Higher levels of patient satisfaction 
with care (e.g., feeling respected, 
helped, and being attended to on 
- Feeling liked and liking the 
clinician, having a positive and 
meaningful relationship,  
involving collaborative problem 
solving appear to contribute to 
medication adherence.  
- Patient perceptions of clinician 
respect, helpfulness and 
efficiency also contribute to 
medication adherence.  
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time) positively predicted a higher 
likelihood of medication adherence 
(p’s<.05). 
Qualitative 
studies 
 
      
Bilderbeck et al.,  
 
2014 
 
UK 
 
 
Quality of patient-
clinician 
interactions 
92.5% 
d, p 
Design: Cross-
sectional  
Method: Semi-
structured interviews 
post-assessment and 
at 6 months’ follow-
up. 
 
Bipolar sample: n=5 
patients (18% total) 
Overall sample: 
N=28 patients (M age 
= 36 years, 64% 
female). 
Response Rate: N/A 
Setting: Community 
mental health teams, 
a specialist mood 
disorders clinic, and 
outpatient therapeutic 
service 
Mental health 
discipline: 
Psychiatry 
Provider type: 
Psychiatrist or other 
 
 
(-) Qualitative semi-
structured interview 
topic schedule 
exploring patient 
experience of 
assessment by 
clinical staff in 
secondary psychiatric 
care. Specific topics 
included: 
expectations, 
suggestions for 
improvement, and 
feelings about the 
outcomes of their 
assessment.  Follow-
up interviews 
inquired about 
longer-term 
perceptions of 
- Five broad themes emerged: (i) 
wanting an explanation and help; (ii) 
wanting consistent and continuous 
care; (iii) struggling to communicate 
and be understood (e.g. feeling 
unable to answer questions or 
communicate internal mood states); 
(iv) wanting to feel involved and 
informed in diagnosis and treatment 
decisions; (v) wanting to be 
acknowledged but often feeling 
dismissed and discredited by 
clinicians time constraints and 
inflexibility.  
- Many patients felt family and/or 
friends could facilitate 
communication with clinician and 
that stigma was neglected from 
discussion. 
  
- Patients identified several 
communication barriers and 
difficulties during clinical 
assessments, which were in part 
due to the nature of their 
symptoms. Family and friends 
may play supporting or 
facilitative roles in this setting.  
- Patients are not as involved and 
informed about their diagnosis 
and treatment decisions as they 
would like and feel necessary.  
- Specific clinician behaviours are 
considered important by patients, 
and their absence may result in 
feelings of abandonment, 
frustration or being 
dismissed/discredited. These 
include being empathetic and 
listening, acknowledging patient 
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assessment and 
diagnosis. 
problems and concerns, and being 
flexible about treatment options.  
Mixed methods 
studies 
 
      
Sajatovic et al.,*  
 
2005 
 
USA 
 
 
Quality of patient-
clinician 
interactions 
85% 
e, j, n, 
p 
Design: Cross-
sectional  
Method: Self-report 
questionnaire and 
focus groups. 
 
Bipolar sample: 
N=52 patients (85% 
BPI, 15% BPII, M 
age = 43.8 years, 
73% females) 
Response Rate: N/A 
Setting: Community 
mental health centre 
Mental health 
discipline: 
Psychiatry 
Provider type: NS  
 
 
(+) Drug Attitude 
Inventory 
(-) Open-ended focus 
group question 
eliciting essential 
qualities for an 
effective patient-
provider relationship.  
- On average, 87.5% of patients 
adhered to psychotropic medication 
and 84.7% to scheduled clinic visits.  
- Essential qualities for an effective 
patient-provider relationship included 
patient-centred, provider-centred, and 
interactional qualities.  
- Patient-centred qualities included 
willingness to disclose information; 
and help and/or information-seeking 
behaviours. 
- Crucial provider-centred qualities 
included being a good-listener and 
responding to clients’ feelings, 
allowing patients to talk and be 
heard, and admitting limits of one’s 
knowledge. Patient concerns related 
to a lack of discussion of alternative 
therapies and failure to acknowledge 
medication side effects. 
- These patient identified 
elements of an effective patient-
provider relationship that may 
have contributed to their high 
levels of treatment adherence.  
- An effective relationship relies 
on patient and clinician qualities/ 
behaviours, as well as aspects of 
the interaction itself.  
- Patients described themselves as 
needing to be open with 
information and assertive, while 
clinicians were described as 
needing to be a good-listener, 
sensitive, and flexible.  
- The extent to which decision-
making is collaborative depends 
on severity of symptoms, and 
being informed, and patients 
appreciate the circumstances in 
which illness management may 
 63 
Notes: * = Secondary analysis of data drawn from separate study.  
Score of 1 or 0 on the Standard Quality Assessment Criteria for Evaluating Primary Research Papers (Kmet et al., 2004) (Item number from quantitative [QN] and qualitative 
[QL] studies quality rating checklist) 
Provider types include; NP = Nurse Practitioner, GP = General Practitioner, NS = Not Specified, Other = various . 
 
a Question description [QN 1; QL 1]; b Study design [QN 2; QL 2]; c Study context description [QL 3]; d Theoretical/empirical connection [QL 4]; e Sampling strategy [QN 
3; QL 5]; f Subject characteristics reported [QN 4]; g Data collection methods [QN 5, 6, 7, ; QL 6]; h Means of assessment reported [QN 8]; i Sample size [QN 9]; j Data 
analysis [QN 10; QL7]; k Estimate of variance reported [QN 11]; l Controlled for confounding [QN 12]; m Results reported in sufficient detail [QN 13]; n Verification 
procedure to establish credibility [QL 8]; o Conclusions supported by the results [QN 14; QL 9]; p Reflexivity of the account [QL 10]. 
- Interactional qualities included 
flexibility in consultation length, 
variability in the desired amount of 
involvement based on bipolar 
symptoms and disability, and belief 
that “giving more weight” to clinician 
opinions and “trusting” clinicians in 
making decisions was important for 
illness management when they felt 
insufficiently informed or too 
symptomatic to do so. 
benefit from a more clinician-led 
approach to decision-making.  
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2.4.2. Primary themes 
Four primary themes emerged: i) patient characteristics, i.e., individual beliefs about 
self, clinical and/or demographic characteristics pertinent to decision-making; ii) 
patient preferences for decision-making style and involvement, and patient 
decisional-support needs; iii) quality of patient-clinician interactions, i.e., in-
consultation behaviours within a SDM/patient-centred approach, the therapeutic 
alliance, and patient-/clinician-related qualities that facilitate or impede this process; 
iv) influence of SDM/patient-centred approach on patient outcomes, e.g., care 
satisfaction, uncertainty, treatment adherence, and suicidal ideation, and associations 
with SDM/patient-centredness. 
 
2.4.3. Theme 1: Patient characteristics 
Two studies examined the predictors of patient socio-demographic characteristics on 
preferences for, and experience of, decision-making roles and involvement [29, 30], 
with inconsistent findings. These discrepancies may be due to one study assessing 
general involvement preferences using a single-item measure [29] and the other 
separate involvement preferences for the decision-making stages using a multi-item 
measure [30]. Older age and being male predicted stronger preferences for, and 
greater likelihood of experiencing, less involvement in decision-making in general 
[29]. When decision-making stages were assessed separately, being Caucasian 
predicted preferences for less involvement (i.e., relying on clinician’s knowledge; 
[30], whereas higher education predicted preferences for greater involvement (i.e. 
independent information gathering, and patients making decisions on their own; [30].  
 
In addition to socio-demographic variables, patient diagnosis was also found to 
influence preferences and/or experience of decision-making. However, findings were 
inconsistent regarding whether patients with BP differed from other psychiatric 
patients in their preferences for, or experience of decision-making involvement (yes 
[30], no [29]). When differences were seen, BP patients showed a trend towards 
preferring more independent information-gathering (p=.054), but not for actually 
making the decision on their own [30]. As with non-modifiable (socio-demographic 
and diagnostic) patient characteristics, a negative relationship with modifiable patient 
characteristics was also found (low self-efficacy, external health locus of control) 
[29]. 
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2.4.4. Theme 2: Patient preferences 
Patient preferences for involvement and decision-making style were quantitatively 
assessed in five studies [28-32]. In studies examining decision-making preferences as 
a single construct, a majority of patients reported preferring an active or collaborative 
decision-making role [28, 29, 31]. Specifically, patients -including BP patients- 
preferred sharing decision-making with their clinician (38.3-64.3%) or making the 
final decision alone (1.8-52.1%). A minority of the patients in these studies reported 
preferring a passive role (8.5-34.7%). Qualitative studies revealed that patients’ 
desired involvement level varied according to their current BP symptoms and 
disability. Differences in BP symptoms and disability did not relate to differences in 
BP subtype, as these were also reported within patient samples comprising a single 
subtype (BPII) [27]. Rather, such variability related to within-individual changes over 
time. Thus, “trusting clinicians” and “giving more weight” to clinician opinions were 
important for illness management when patients felt insufficiently informed or too 
symptomatic to do so [26]. 
 
When looking at decision-making preferences as a multi-dimensional construct, there 
was greater variability in patient preferences for theirs’ versus the clinicians’ 
involvement [30, 32]. Most patients wanted to be informed and asked their opinion of 
treatment options (75.7-93.4% [30, 32]), but preferred to rely on their clinician for 
giving professional advice (versus independent information-gathering, 61%) and 
making the final treatment decision (64%) [30]. Variability was also seen in terms of 
whom patients with BP and depression wished to involve in treatment discussions, 
and where they wished to source information about treatment options from. Most 
patients preferred discussions with their treating clinician (i.e., psychiatrist, 89%), but 
around half also preferred to have treatment discussions with friends (62%) and 
family (45%) [28]. Preferred information-support resources were those developed by 
health professionals (95%), and in pamphlet format (89%), yet some also preferred 
CD-Roms (44%), and information provided by pharmaceutical companies (21%) [28].  
 
In two studies assessing both patient preferences and self-reported experience of 
decision-making involvement [29, 31] over half of participants (52%) reported a 
mismatch between preferred and actual levels of involvement. This discordance 
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between preferred/experienced roles was significant for all psychiatric diagnoses 
including BP (X2(2)=7.83; p<0.005), underlined by patients wanting greater in 
decision-making than they experienced [29, 31]. This latter finding was echoed in 
qualitative studies, where patients reported wanting to feel informed about diagnosis 
and be involved in treatment decisions, but that this was seldom realised in practice 
[27].  
 
2.4.5. Theme 3: Quality of patient-clinician interactions 
Six studies investigated the quality of patient-clinician interactions; with two studies 
using semi-structured patient interviews [26, 27] and four studies coding consultation 
behaviours [24, 33-35]. These latter studies used either purpose-designed coding 
systems [24, 33] or a previously validated coding system adapted to the mental health 
setting [34, 35]. Consultation studies tended to focus on clinician behaviours [33-35] 
rather than patient behaviours [24, 34, 35]. Consultation studies usually pooled 
findings across the heterogeneous clinician types (e.g., psychiatrists and nurse 
practitioners, psychiatrists and GPs) [24, 33, 35], which precluded clinician 
comparisons. One study compared clinician types (psychiatrists and nurse 
practitioners) and found no differences on SDM outcomes [34]. Consultations were 
usually evaluated in terms of observed patient involvement, and shared and/or 
informed decision-making. Across patients with BP, schizophrenia and depression, a 
large proportion of treatment discussion and decision-making related to medication 
[24, 28, 35], such as stopping, reducing, continuing or changing medication, or 
deciding on a non-medication alternative (e.g. join support group, attend counselling). 
In BP patients alone, 12.5% of all consultation questions related to reductions in 
current medication [24]. Observed patient involvement during consultations was low 
across agenda setting and decision-making [33, 34]. Patients also initiated very few 
decision-making behaviours [34, 35], with rates of question-asking particularly low 
amongst BP patients (50%), compared to some patient groups (unipolar depression, 
anxiety, or personality disorders, 60-79%) but not all (schizophrenia, 43%) [24].  
 
While, in general, clinicians’ involvement of patients was relatively poor, they varied 
in the extent to which they practised SDM. More commonly, clinicians engaged 
patients in discussions about treatment goals and preferences, and treatment 
alternatives [35]. Less commonly, clinicians engaged in partnership-building or 
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patient-centredness [33], checked patient preferences for others’ involvement (e.g., 
family) and understanding of information [35]. Indeed, minimum SDM requirements 
were achieved in less than half of immediate/complex decisions (46%) [35]. 
Immediate/complex decisions also formed the majority of treatment decisions in the 
community mental health setting (54%) [33, 35]. Immediate/complex decisions were 
defined as having a moderate-to-extensive impact on the patient (e.g., side effects 
and/or risk), involving some degree of medical uncertainty, and potentially posing a 
risk to patients.  
 
Despite an overall low patient involvement and suboptimal SDM engagement, a 
number of consultation-related factors lead to higher SDM levels. Greater SDM was 
associated with more complex decisions [34, 35] and a greater number of patient-
initiated SDM behaviours [34]. Interestingly, greater SDM was not associated with 
longer consultation times, after controlling for level of decisional complexity [35]. 
Although patient-clinician agreement on the final treatment decision was common 
(79%) [34, 35], agreement was more likely when the clinician elicited patient 
treatment preferences [34], which accounted for a large proportion of variance in 
agreement (52%) [34]. No specific findings per psychiatric group were reported in 
either study. Together these findings suggest a role of both patients and clinicians in 
initiating and facilitating SDM, which is also moderated by the complexity of 
decisions being made.  
 
In a similar vein, patient-related, clinician-related, and interactional qualities were all 
identified as influencing effective patient-clinician communication. BP patients felt 
they needed to be open and share information with clinicians, and be proactive in their 
health- and/or information-seeking [26]. However, patients also reported barriers to 
communication [27], such as difficulties recalling information, and feeling pressured 
to accurately answer clinicians’ “ambiguous” questions [27]. Family members and/or 
friends were identified as means for overcoming these communication barriers [27], 
and family involvement in treatment discussions was perceived as mostly supportive 
[28].  
 
Several clinician interpersonal behaviours, both positive and negative, were identified 
by patients in two qualitative studies [27] [26] and in one consultation study [33]. To 
 68 
build rapport, BP patients said clinicians needed to be a good listener, allow patients 
time to talk and be heard, show empathy and sensitivity to their patients’ feelings, and 
admit the limits of their clinical knowledge [26, 27]. By contrast, barriers to rapport-
building included patients being pressured by time constraints, patients feeling 
unheard, dismissed or discredited by clinicians who did not acknowledge their 
problems, clinicians being inflexible with treatment options, or prescribing 
medication over engaging in a meaningful discussion of patient problems [27]. 
Indeed, rapport-building was commonly absent from psychiatric consultations, with 
only half of psychiatrists and nurse practitioners demonstrating either partial (27.4%) 
or complete (26.6%) rapport-building [33]. 
 
2.4.6. Theme 4: Influence of SDM/patient-centred approach on patient outcomes 
Five studies examined the influence of SDM/ patient-centred approaches on various 
patient-reported outcomes. Outcomes of interest included: medication adherence in 
BP and mixed patient samples [25, 31, 36], suicidal ideation in BP [36], care 
satisfaction in BP and mixed patient samples [25, 32], and decisional uncertainty 
about treatment choices in BP and unipolar depression [28].  
 
Although not always tested directly, a supportive therapeutic relationship and patient 
satisfaction with care were commonly associated with more positive patient 
outcomes. Namely, patients who perceived their therapeutic relationship as strong 
(e.g., feeling understood), positive (e.g., having a good relationship), and 
collaborative (e.g., jointly resolving problems), were more likely to indicate improved 
medication adherence [25], reduced suicidal ideation [36], and greater patient 
satisfaction with psychiatric visits [32]. In the two studies involving BP patients only, 
these associations were evident even after controlling for clinical factors associated 
with poorer BP outcomes (e.g., rapid cycling, earlier onset of illness, medication non-
adherence) [25, 36]. By contrast, uncertainty regarding chosen treatment was 
associated with feeling less supported in decision-making [28]. Decisional uncertainty 
was not alleviated by information-seeking, as information-seeking rates were higher 
among uncertain patients [28].  
 
Across studies, patients who were satisfied with their care and decision-making, and 
experienced their preferred involvement level, reported more positive outcomes. In 
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two studies, patient satisfaction with care in BP [25] and satisfaction with treatment 
decision-making [28] were associated with better medication adherence and lower 
decisional uncertainty, respectively. Similarly, patients reported better medication 
adherence when they experienced their preferred decision-making style, whether 
passive, active or collaborative [31]. Lower care satisfaction was found when patients 
preferred shared/collaborative decision-making [32].  
 
2.5. Discussion and conclusion 
This is the first known systematic review of empirical studies focusing on 
communication and decision-making among individuals with BP. Derived from 
studies of good to strong quality [23], the review findings centre around four inter-
related themes mapping onto three sequential aspects decision-making: decision 
antecedents (patient characteristics and patient preferences), decision process 
(quality of patient-clinician interactions), and decision outcomes (influence of SDM/ 
patient-centred approach on patient outcomes). These three aspects have been 
previously identified in a systematic review of SDM measures within the general 
medicine and psychiatric settings [37]. Of note, these aspects of decision-making 
provide a broader context to Charles et al.’s model [10, 11] of SDM as they highlight: 
i) the patient characteristics and preferences that likely shape the purported decision-
making stages (information exchange, deliberation, and final decision-making), ii) the 
extent to which patients are/feel involved during these stages and where shortcomings 
exist, and iii) how clinician SDM behaviours and patient perceptions of involvement 
during these stages may relate to outcomes. Findings also build on a recent systematic 
review of decision-making needs in mental health [14]. However, Tlach et al.’s 
review did not include any studies of BP patients and was limited to four studies 
identifying decision topics (medication and non-medication treatments, general 
treatment issues and treatment setting, lifestyle, working and living conditions). 
 
2.5.1. Patient characteristics and preferences for SDM 
Our review findings point to increasing interest in the applicability of SDM and 
patient-centredness in the mental health setting. By and large, study findings were 
reported across mixed patient samples precluding BP specific conclusions. When 
patient outcomes were reported separately for the different psychiatric diagnoses, BP 
patients differed from other patient groups in some studies [24, 30] but not all [29]. 
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Compared to patients with schizophrenia, BP patients reported a trend towards 
wanting greater involvement in decision-making (i.e., more independent information-
gathering) [30]. Yet, compared to patients with depression, anxiety and personality 
disorders, BP patients exhibited fewer involvement behaviours during consultations 
(i.e., less question-asking) [24]. These differences should be interpreted with some 
caution given that they derive from studies of heterogeneous quality (adequate: [24]; 
strong: [29, 30]). However, findings align with a recently published cross-sectional 
survey of patients with BP or depression [38]. In this survey, BP patients were more 
information seeking than patients with depression; actual decision-making 
involvement also differed across groups, however, involvement preferences did not 
[38]. Thus, it is unlikely that diagnostic factors alone are predictive of either 
individual patient involvement preferences or actual involvement, but may play a 
contributing role. Although not specific to BP, it is important to recognise that BP has 
a relatively early onset, is chronic and marked by periods of fluctuating 
symptomatology severity. By contrast, other psychiatric disorders may be more 
situationally-focused with later onset (e.g., unipolar depression). The chronic, 
relapsing and remitting nature of BP, accompanied by periods of euthymia may 
predispose BP patients to want greater involvement in treatment decision-making 
compared to other patients. However, the disability and diminished insight associated 
with acute BP symptoms may impair these patients’ ability to actively participate in 
consultations.  
 
As in the medical setting [39, 40], psychiatric patient preferences for involvement 
show a mixed relationship with demographics (e.g., age, education;[29, 30]), clinical 
factors (e.g., BP symptom severity;[41]), and individual-based beliefs (e.g., health 
locus of control and self-efficacy;[29]). Of note, this relationship appears to be less 
consistent with socio-demographic characteristics but more consistent with symptom 
severity, again paralleling the medical setting [39, 40]. Therefore, mental health 
professionals would be remiss to assume patient involvement preferences based on 
socio-demographic characteristics. Poorer mental health status may be a better proxy 
of a patient’s involvement preferences. When experiencing more severe symptoms, 
BP patients are likely to prefer more clinician-led decision-making. However, given 
that patients with depression report strong information preferences regardless of 
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symptom severity [42], eliciting preferences with each patient remains a necessary 
step. 
 
Similarly to medical conditions [43], psychiatric patients – including those with BP – 
wish to be informed and involved in treatment decision-making [27-29, 31]. This said, 
patient preferences varied across the decision-making stages. Patients almost 
universally want to be offered and informed about treatment options (the information 
exchange and deliberation stages)[11] yet a smaller proportion of patients wanted to 
make the final decision about treatment themselves. One explanation for variability in 
patient involvement preferences may be differences in the measures used (i.e., single 
item versus multi-item measures) [39]. Alternatively, this variability may reflect 
patients perceiving greater benefit in “the process of involvement” (i.e., information 
exchange and deliberation) than in “actual decisional responsibility” (i.e., who makes 
the final decision on treatment to implement) [44]. Based on these findings, clinicians 
cannot assume that BP patients desire active involvement throughout the whole 
decision-making process [44], and thus need to check their preferences at different 
stages.  
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2.5.2. Patient experience of SDM and its influence on outcomes 
Despite strong patient preferences for involvement in consultations, it appears that 
patients with BP are often less involved than they desire [27, 29, 31]. These findings 
are corroborated by studies showing overall poor patient involvement by clinicians, 
and suboptimal SDM in more complex treatment decisions (according to criteria by 
Braddock et al. [45]). Discordance between patients’ preferred and actual 
involvement levels, may be explained by clinicians’ failure to elicit patient 
involvement preferences [35]. Further, mismatch between preferred and experienced 
roles [29, 31], may also explain why preferring SDM predicted lower patient 
satisfaction with psychiatric consultations [32], while preferring clinician-led 
decisions predicted a stronger therapeutic relationship [30]. Reviews of patients with 
schizophrenia and depression also report achieving less involvement than desired [16, 
46, 47]. Among general medical patients, some report less involvement than desired 
[48], with others reporting greater involvement than desired [49]. These discrepant 
findings may point to psychiatric patients having stronger involvement preferences 
than patients in general medicine. More likely, however, is that patients tend to 
experience less involvement in psychiatric consultations than in general medical 
consultations [50].  
 
Interestingly, observer ratings of patient-clinician consultation interactions revealed 
two categories of patient involvement: instrumental and interpersonal. The 
instrumental aspects of patient involvement and SDM comprised clinicians’ 
functional behaviours: presenting treatment options, eliciting patient treatment goals 
and preferences [33, 35]. Meanwhile, the interpersonal aspects of patient involvement 
included patients feeling heard and acknowledged, and being responded to with 
sensitivity and empathy [26, 27]. Both instrumental and interpersonal aspects were 
valued and considered important by patients, including those with BP [26]. These 
findings fit with an expanded definition of patient involvement [51], which 
encompasses more objective aspects of “being” involved as well as more subjective 
aspects of “feeling” involved. “Feeling” aspects of patient involvement are argued to 
be less tangible and unable to be externally observed, yet both “being” and “feeling” 
involved likely contribute to patient’s self-reported involvement post-consultation 
[44, 51]. The notion that both “being” and “feeling” involved contribute to patient’s 
own evaluations involvement [44, 51], also accords with relational understandings of 
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patient autonomy [52]. Relational autonomy proposes that relational aspects of the 
clinician-patient interaction may foster (e.g., clinician listening to patients) or impair 
(e.g., clinician dismissing patients’ concerns) a patient’s sense of autonomy [52]. 
Thus, to enhance patient involvement clinicians should address not only the 
functional aspects of their behaviour but also their interpersonal manner with patients.  
 
A strong, positive and collaborative therapeutic alliance was associated with several 
positive BP patient outcomes, including reduced suicide risk, better medication 
adherence, and patient satisfaction in care [25, 32]. Of note, the therapeutic alliance 
appeared “buffer” against clinical factors associated with poorer BP outcomes. Patient 
satisfaction with care and achievement of preferred involvement levels also appear 
related to better medication adherence in BP [25, 26]. Indeed, patient satisfaction and 
achievement of involvement preferences may be indicative of a strong therapeutic 
alliance [32], based on mutual trust, respect and understanding of treatment goals 
[53]. These findings echo others showing the importance of the therapeutic alliance in 
chronic mental health conditions, such as BP, both to promote patient engagement 
and treatment adherence [8, 19]. Therefore developing a strong therapeutic alliance 
appears to be a priority for both BP patients and their treating clinicians.  
 
2.5.3. Limitations  
Although findings from the small number of reviewed studies are informative and 
based on good quality research, they are limited in several ways. Firstly, most studies 
utilised mixed patient samples and did not report psychiatric disorder-specific 
findings. This is likely due to most reviewed studies employing convenience 
sampling, which often resulted in a smaller proportion of BP patients compared to 
other patient groups and precluded group comparisons. Further, in studies that did 
report BP-specific findings, no differentiation was made between the BP subtypes (I 
and II). The presence of psychotic features in BPI but not BPII may interfere with BPI 
patients’ ability to make decisions and report their preferences for, and perceptions of 
involvement in decision-making. Thus, definitive conclusions cannot be drawn 
regarding individuals with BP, and future BP-specific studies would benefit from 
distinguishing between BPI and BPII patients whose capacity for decision-making 
involvement may differ. Although the present review should be treated as exploratory, 
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it nevertheless highlights areas of potential clinical interest and future research 
directions.  
 
Secondly, only patients receiving voluntary mental healthcare were included in the 
current review. Although this inclusion criterion was applied to ensure that findings 
reflected cognitively competent patients with decisional capacity, this also limits the 
generalisability of findings. Thirdly, retained studies included a variety of clinicians, 
including psychiatrists, nurse practitioners, and GPs without any psychiatric 
speciality. This heterogeneity in provider types reflects the nature of mental health 
practice but may also influence clinician-patient communication and patient 
involvement in decision-making. Fourthly, a number of studies comprised samples 
that were “older aged” or non-gender-balanced; therefore the current findings may not 
be representative of the broader adult population with BP, or mental illness more 
generally. Fifthly, the reviewed studies were mostly descriptive surveys and cross-
sectional design. Patient-reported preferences or outcomes may vary over time and 
differ from those depicted at the time point studied. Finally, all studies captured only 
one perspective of the communication and decision-making process, either the 
patient’s or trained observer’s, but not the clinician’s. As clinicians, patients, and 
family members are all involved and exert influence on the decision-making process 
to some extent [54], examining one party’s perspective or behaviour is unlikely to 
provide a complete picture of events. Therefore, there is a need to investigate the 
viewpoints and experiences of all stakeholder groups, in order to address unmet 
decisional-support needs and inform clinical recommendations. 
 
2.5.4. Conclusion 
This systematic review highlighted a paucity of studies on communication and 
treatment decision-making in BP. Nevertheless, it provides a valuable synthesis of the 
existing high-quality literature, with a focused discussion of quantitative and 
qualitative findings as they relate to BP patients. To date, this patient group has been 
largely neglected in the literature, which has mostly focused on other psychiatric 
populations. Preliminary clinical recommendations are proposed, however further 
research is needed to discern BP-specific decision-support needs and involvement 
preferences.  
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2.5.5. Practice implications 
Although BP-specific findings are limited, findings from the reviewed studies have a 
number of implications for clinical practice in the psychiatric setting. The good to 
strong quality of most of the reviewed studies also lends credibility and confidence to 
preliminary clinical recommendations (summarised in Table 2.2). Findings highlight 
that BP patients tend to prefer an active-collaborative decision-making role, and 
desire greater levels of involvement than what they are currently experiencing. This 
said, a BP diagnosis by itself is unlikely to explain the involvement preferences of 
individual patients. Thus, to optimise patients’ decision-making involvement, 
clinicians are advised to check and tailor their involvement of patients on the basis of 
individual patient preferences. Although, more research is needed to delineate the 
involvement preferences of BP patient specifically, targeted BP interventions to 
enhance and tailor involvement appear warranted. Patient decision-aids (DAs) may be 
potentially useful in the BP setting, as these are evidence-based interventions 
designed to increase patient involvement and promote more informed, values-based 
treatment decisions [55]. While decision-aid use in mental health is still scant, there is 
promising evidence supporting their efficacy in depression and schizophrenia [15, 55, 
56] 
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Table 2.2. Preliminary clinical recommendations based on reviewed studies 
1. To optimise patient involvement in treatment decision-making, clinicians should tailor the 
level of involvement to patient preferences. 
2. Targeted SDM interventions, such as decision-aids, may be useful for BP patients to facilitate 
their treatment decision-making involvement.  
3. Interpersonal and rapport-building aspects of clinician behaviour appear particularly important 
with BP patients. Clinician behaviours which may strengthen the collaborative relationship 
with BP patients include: being a good listener, showing sensitivity to patient’s feelings, 
allowing patients time to talk and be heard, admitting limits to one’s knowledge (e.g., in cases 
of medical uncertainty, other clinical expertise).  
4. Clinicians are advised to assess each patient’s involvement preferences:  
(i) at different stages of the decision-making process;  
(ii) in response to changing BP symptom severity; and  
(iii) on a case-by-case basis and not generalise preferences across patients. 
5. Clinicians should not assume a patient’s desired level of involvement in treatment decisions 
based socio-demographic characteristics (e.g., age, education level, ethnicity). 
6. Clinicians should raise the subject of family involvement with patients and elicit their 
preferences for this.  
 
In addition to patient DAs that enhance the functional aspects of SDM (i.e., patient 
knowledge, clarification of values and preferences), a clinician’s interpersonal 
behaviours may also enhance patient autonomy and perceived involvement. In BP 
patients especially, these behaviours likely foster the therapeutic alliance and in turn 
more positive patient outcomes. Improving the interpersonal aspects of patient-
clinician interactions may prove particularly challenging, however. Limited evidence 
supports the positive effects of SDM interventions on interpersonal rapport [57]. This 
said, interventions targeting both patients and clinicians lead to greater improvements 
in SDM compared to those targeting only patients or only clinicians [57]. This may 
also be the case for interventions to promote the interpersonal aspects of patient 
involvement. 
 
Before clinicians set out to engage patients more in decision-making, it is important 
that they first assess patient involvement preferences. Specifically, patient preferences 
for involvement should be assessed at different stages of the decision-making process, 
and in response to changing BP symptom severity, but not based on socio-
demographic characteristics (e.g., age, education level, ethnicity). Finally, BP patients 
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acknowledge that family members facilitate effective consultation communication; a 
majority of patients also wished to engage family and friends in treatment discussions. 
Therefore clinicians should raise the subject of family involvement with BP patients 
and elicit their preferences for this. This strategy has been proposed by a review of 
family involvement in medical consultations, where family attendance tends to be 
more common (16-86%) [21] than in mental health consultations (31-40%) [58]. Even 
though family appear less likely to attend mental health consultations, clinicians may 
discuss with patients their preferences for family involvement, and any potential 
barriers to involving family to the extent patients prefer. Indeed, identified barriers to 
family involvement [21] may be particularly salient in the BP setting (e.g., perceived 
stigma and lack of understanding, concerns about privacy and confidentiality, and 
discussion of sensitive topics). If the patient does wish to involve their family, it is 
therefore important to discuss and address any potential benefits of family 
involvement in relation to their treatment goals [58].  
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Chapter 3: A qualitative exploration of patient and family views and experiences 
of treatment decision-making in bipolar II disorder. 
 
This chapter is reformatted from the published manuscript:  
Fisher A, Manicavasagar V, Sharpe L, Laidsaar-Powell R, Juraskova, I. A qualitative 
exploration of patient and family views and experiences of treatment decision-making 
in bipolar II disorder. Journal of Mental Health. 2018;27(1):66-79. 
https://doi.org/10.1080/09638237.2016.1276533  
 
 
This chapter reports on a qualitative study, which sought to explore the views and 
experiences of treatment decision-making among patients with bipolar II disorder 
(BPII) and their families. Findings elucidated key informational and decisional-
support priorities and unmet needs in this setting; these were used to inform the 
content, format, and delivery of the decision-aid (DA, see Chapter 6). Ethics approval 
letters are provided in Appendices B1 and B2; supplementary materials related to this 
study are provided in Appendix D. 
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3.1. Abstract 
Background. Treatment decision-making in bipolar II disorder (BPII) is challenging, 
yet the decision-support needs of patients and family remain unknown.   
 
Aim. To explore patient and family perspectives of treatment decision-making in 
BPII.  
 
Method. Semi-structured, qualitative interviews were conducted with 28 patients with 
BPII-diagnosis and 13 family members with experience in treatment decision-making 
in the outpatient setting. Interviews were audiotaped, transcribed verbatim and 
analysed thematically using framework methods. Participant demographics, clinical 
characteristics, and preferences for patient decision-making involvement were 
assessed. 
 
Results. Four inter-related themes emerged: 1) Attitudes and response to diagnosis 
and treatment; 2) Influences on decision-making; 3) The nature and flow of decision-
making; 4) Decision support and challenges. Views differed according to patient 
involvement preferences, time-since-diagnosis, and patients’ current mood symptoms. 
 
Conclusions. This is the first known study to provide in-depth patient and family 
insights into the key factors influencing BPII treatment decision-making, and 
potential improvements and challenges to this process. Findings will inform the 
development of BPII treatment decision-making resources that better meet the 
informational and decision-support priorities of end users. 
 
Declaration of interest. This research was partly funded by a Postgraduate Research 
Grant awarded to the first author by the University of Sydney. No conflicts of interest 
declared. 
 
Keywords. Bipolar II disorder, treatment decision-making, patient involvement, 
qualitative, barriers, facilitators, qualitative.   
 87 
3.2.  Introduction 
While shared decision-making (SDM) in mental health is increasingly encouraged [1] 
there is evidence that in many psychiatric illnesses, patients do not achieve their 
desired level of involvement in treatment decision-making [2, 3].  
 
One disorder with a relative paucity of evidence on patient involvement in treatment 
decision-making is bipolar II disorder (BPII) [4], a chronic and relapsing psychiatric 
condition involving depressive and hypomanic episodes [5]. Further, there are 
particular challenges for BPII patients that may make their treatment decisions unique 
and more complicated than in other mental health conditions. These include: a more 
limited evidence-base to support treatment choices [6], more finely balanced 
decisions due to high potential side-effects of mood-stabilisers [7] absence of 
debilitating psychotic symptoms [5], and that hypomanic symptoms may enhance 
rather than impair perceived psychosocial functioning [8]. Thus, BPII patients may 
require additional support to make evidence-informed treatment decisions that 
integrate their preferences [7]. Patients’ family members facilitate medical decision-
making, by providing emotional, informational, practical, decisional support and/or 
advocacy to the patient [9]. Yet, little is known about family involvement the mental 
health setting, and specifically bipolar disorder [10].  
 
This study explored: i) the nature of clinician-patient-family decision-making about 
BPII treatment; ii) unmet patient/family needs for information and decision-support; 
and iii) decision-making barriers and facilitators. 
 
3.3.  Materials and methods 
 
3.3.1. Participants  
Patients: Adults, aged 18-65 years, diagnosed with bipolar II disorder (BPII) who 
were currently making or had recently made (i.e., within the past 12 months) a non-
/medication-related treatment decision were eligible. Participants were referrals to: i) 
a clinical service specialising in mood and bipolar disorders in metropolitan Sydney, 
or ii) the clinical service’s BPII psycho-education group. BPII diagnosis was based on 
a “consensus diagnostic decision” between at least two assessing psychiatrists with 
expertise in mood and bipolar disorders [11]. To establish BPII diagnosis, all patients 
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were clinically assessed by an intake psychiatrist who made a lifetime clinical 
diagnosis of BPII applying clinician-judged criteria. These criteria took into account 
DSM-5 symptom criteria [5] but did not impose the minimum duration criterion for 
hypomania (4 days). This criterion is largely arbitrary and not of clinical significance 
[11, 12]. Approximately a third of patients were also assessed by a second 
independent psychiatrist. Prior to clinical assessment, patients also completed the 27-
item Mood Swings Questionnaire [13], which has sensitivities and specificities of 70-
82% and 78-98% in tertiary patient referral samples [14, 15]. 
 
Family members: Adults, aged 18-65 years, whose family member had: i) an adult 
BPII diagnosis (18+ years), and who had ii) attended at least one consultation 
involving treatment decision-making, and/or had iii) experience helping their family 
member make treatment decisions outside consultations were also invited to 
participate. Family were identified through patients; however, patient participation 
was not a pre-requisite. 
 
All participants required English proficiency and informed consent capacity. Patient 
exclusion criteria also included: i) comorbid substance abuse disorder and ii) 
concurrent neurological/major psychiatric condition. Recruitment continued until data 
saturation (i.e., no new information after three consecutive interviews) [16]. Ethical 
approval for all aspects of the study was obtained. 
 
3.3.2. Procedure 
A clinic research assistant introduced the study to eligible patients following their 
clinical assessment, and passed on contact details of interested patients to the study 
coordinator (AF), who had no pre-existing relationship with the patients. Patients 
attending the psycho-education group responded to an expression-of-interest flyer at 
meetings. Eligible family members were identified through patients who were then 
contacted by AF.  
 
AF telephoned interested patients to explain the nature and purpose of the study, i.e., 
to investigate patient and family views and experiences of decision-making about 
treatment for BPII. At this time, AF also obtained verbal consent to post/email a study 
pack containing: an information sheet, written consent form, family expression-of-
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interest form, and pre-interview questionnaire. Upon receiving the completed 
questionnaire and written consent form, a one-off telephone interview was arranged. 
The same procedure was followed for interested family. Post-interview, patients 
completed a verbally-administered mood measure.  
 
3.3.3. Qualitative data collection  
The researcher conducting the interviews (AF) was trained in conducting semi-
structured qualitative interviews by two experienced qualitative health psychology 
researchers (IJ, RL-P) and received ongoing supervision and advice in response any 
issues that arose in interviews (e.g., establishing when and how to prompt for further 
information).   
 
Purpose-designed, semi-structured interview protocols (Appendix D) were informed 
by SDM models [17-19], the Ottawa decisional support framework [20] and similar 
qualitative studies in mental health (depression) [21] and medical populations 
(cancer) [22]. Parallel interview protocols were developed for patients and family 
members. During the interview, participants were asked about general aspects of BPII 
treatment decision-making (e.g., patient and family involvement, clinician 
behaviours), followed by a more focused discussion of a consultation involving an 
actual treatment decision with reference to key decision-making stages, such as 
information exchange (sharing of decision-relevant clinical and personal information), 
deliberation (expressing and discussing treatment preferences), and making a final 
decision (reaching an agreement on treatment to follow) [17, 18].  
 
3.3.4. Quantitative measures 
Preferences for involvement in decision-making were assessed using adapted, parallel 
versions of the Control Preferences Scale (CPS) [23-25]. The CPS has been 
previously validated in outpatients with a mental illness, including bipolar disorder 
[26-28]. 
 
Patients’ current mood state and symptomatology were assessed using the Internal 
States Scale (ISS) [29]. This 17-item self-rating scale comprises four subscales: 
‘Activation’, ‘Wellbeing’, ‘Depression Index’, and ‘Perceived Conflict’, all rated on a 
Likert-type scale from 0 (‘rarely in the past 24 hours’) to 100 (‘very much so in the 
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past 24 hours’). Scores on the Activation and Wellbeing Subscales are used to 
determine current mood states, as follows: hypomania (Activation: ≥155; Wellbeing: 
≥125), Mixed state (Activation: ≥155, Wellbeing <125), Euthymia (Activation: <155, 
Wellbeing: ≥125), Depression (Activation: <155; Wellbeing:<125) [30]. 
The Activation and Depression Index subscales correlate highly and specifically to 
clinician ratings of hypomanic (r=0.60) and depressive (r=0.84) symptoms, 
respectively [29]. 
 
Demographic and clinical characteristics were collected using a purpose-designed 
self-report questionnaire.  
 
3.3.5. Data analysis 
Questionnaire data were analysed using SPSS version 22. Frequency analyses 
analysed all categorical variables (e.g., highest level of education obtained), whilst 
descriptive analyses analysed all continuous variables (e.g., age diagnosed with BPII). 
Interviews were audio-recorded and professionally transcribed verbatim. Interview 
data were then analysed thematically [31] using framework methods as outlined in 
Ritchie et al [32]:  
1) Familiarisation with the data: AF conducted all interviews, cross-checked each 
transcript against the audio-recording, and read each transcript several times;  
2) Creating a thematic framework: a preliminary thematic framework was based on 
independent analyses of 20% of transcripts by IJ and RL-P. Data were independently 
organised according to concepts, themes, and subthemes. Different interpretations of 
the data were discussed together with LS until consensus was reached on the main 
framework themes;  
3) Indexing: with the assistance of NVivo11, AF coded all transcripts according to the 
framework, with new themes and revisions discussed with IJ;  
4) Charting: themes and supporting quotes from each transcript were transferred by 
AF to the framework matrix with participants as rows and themes as columns. At this 
stage, MS Excel was utilised as a computerised qualitative data analysis tool [33];  
5) Mapping and Interpretation: the framework was examined within and across 
themes and participants to identify patterns, and relationships. In line with the 
flexibility afforded by thematic analysis [31, 34], analyses were guided by both 
deductive (literature-based) and inductive (data-driven) approaches, within a realism 
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paradigm [35]. To ensure methodological rigour, a proportion of the transcripts (20%) 
were cross-coded by another co-author (RL-P) and discrepancies discussed and 
resolved before proceeding with coding the entire dataset. Secondly, the thematic map 
was developed in consultation with two co-authors (IJ, RL-P), who have expertise in 
treatment decision-making and qualitative analysis. In addition, a subsample of 
participants (n=6 patients, n=2 family) who had agreed to provide feedback, were sent 
a summary of findings and provided feedback on the research team’s interpretations 
of the data (i.e., member checking) [36].  
 
3.4.  Results 
 
3.4.1. Participant characteristics 
Twenty-eight of the 40 patient participants (70%) and 13/20 family participants (65%) 
who agreed to be contacted, completed both the questionnaire and interview. Patient 
and family interviews lasted M=35 minutes (SD=10.16) and M=33 minutes 
(SD=15.47), respectively.  
 
A majority of patients (64%) had been diagnosed within the past 12 months. Many 
family members (54%) were the patient’s spouse/partner, who had been diagnosed 
over 12 months ago (85%). Most patients (78.6%) and family (61.5%) reported 
having recently decided on treatment, or having an established treatment plan. Most 
patients (71.4%) and family (84.6%) also indicated that relapse prevention/mood 
stability was their main treatment goal (Tables 3.1 & 3.2). 
 
Regarding involvement preferences, a similarly large majority of patients and family 
preferred patient/family-led or SDM in both clinician-patient-family (86% patients, 
85% family) and clinician-patient (82% patients, 92% family) scenarios. At interview, 
patients variously reported euthymia (32%), hypomania (32%), depression (18%) or 
mixed-state (18%; Table 3.2).  
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Table 3.1. Socio-demographic characteristics of patients (n=28) and families (n=13) 
 Patients 
M (SD) 
Family 
M (SD) 
Age 41.61 (13.06) 48.38 (13.47) 
 n (%) n (%) 
Gender (female) 19 (67.9) 10 (76.9) 
Relationship to patient   
   Spouse/partner -- 7 (53.9) 
   Mother -- 3 (23.1) 
   Sister -- 2 (15.4) 
   Friend -- 1 (7.7) 
Highest qualification   
   Year 12/ HSC or below  5 (17.9) 2 (15.4) 
   TAFE certificate/ diploma 8 (28.6) 3 (23.1) 
   University degree 11 (39.3) 6 (46.2) 
   Postgraduate degree 4 (14.3) 2 (15.4) 
Current employment    
   Working full-time 12 (42.9) 7 (53.8) 
   Working part-time 6 (21.4) 2 (15.4) 
   Not employed/ Retired/ 
Home-duties  
5 (17.9) 3 (23.1) 
   Studying 3 (10.7) -- 
   Other (e.g., PT work, study) 2 (7.1) 1 (7.7) 
Country of birth    
   Australia 20 (71.4) 10 (76.9) 
   Other (e.g., UK, Netherlands) 8 (28.6) 3 (23.1) 
Language spoken at home   
   English  26 (92.9) 12 (92.3) 
   Other (e.g., Dutch, Turkish) 2 (7.1) 1 (7.7) 
Present marital status   
   Single or dating 12 (42.9) 2 (15.4) 
   Married/ living with partner 10 (35.7) 9 (69.2) 
   Separated or divorced 6 (21.4) 2 (15.4) 
Current living arrangement    
   By yourself/ independently 9 (32.1) 2 (15.4) 
   With partner (and/or 
children) 
14 (50) 10 (76.9) 
   With other family members 3 (10.7) -- 
   With non family members 2 (7.1) 1 (7.7) 
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Table 3.2. Patient clinical characteristics for patients (n=28) and families (n=13)  
 Patient 
M (SD) 
Family 
M (SD) 
Age first diagnosed BPII 39.21 (13.59) 34.69 (13.59) 
 n (%) n (%) 
Time since BPII diagnosis   
   < 1 month 9 (32.1) -- 
   1 - 12 months 6 (32.1) 5 (38.5) 
   1 - 5 years 2 (7.1) 1 (7.7) 
   5 + years  8 (28.6) 7 (53.9) 
Pre-BPII diagnoses   
   No 4 (14.3) 8 (30.8) 
   Depression 11 (39.3) 7 (53.8) 
   Anxiety 1 (3.6) -- 
   Depression and anxiety 12 (42.9) 1 (7.7) 
   Yes, other (e.g., Personality disorder) 2 (7.1) 1 (7.7) 
Episodes since BPII diagnosis *   
   More than once per month 15 (53.6) 5 (38.5) 
   4 or more times per year 5 (17.9) 3 (23.1) 
   About 2-3 times per year 7 (25.0) 2 (15.4) 
   Less than once per year 1 (3.6) 2 (15.4) 
Episode type since BPII diagnosis   
   Mainly hypomanic episodes 15 (53.6) 1 (7.7) 
   Mainly depressive episodes 12 (42.9) 6 (46.2) 
   Equal depression/ hypomanic -- 3 (23.1) 
   Mainly euthymic/ subdromal 1 (3.6) 2 (15.4) 
Clinicians seen for BPII a   
   Psychiatrist 28 (100) 13 (100) 
   Psychologist 20 (71.4) 12 (92.3) 
   GP 25 (89.3) 12 (92.3) 
   Counsellor 8 (28.6) 5 (38.5) 
 
Any children 
 
 
 
 
   No 18 (64.3) 5 (38.5) 
   Yes 10 (35.7) 8 (61.5) 
Patient/Family dyads   
   No 19 (67.9) 5 (41.7) 
   Yes 9 (32.1) 8 (61.5) 
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   Mental healthcare nurse 7 (25.0) 6 (46.2) 
Current stage BPII treatment    
   Considering/ yet to decide on treatment 4 (14.3) 3 (23.1) 
   Recently decided 10 (35.7) 8 (61.5) 
   Established plan to continue 12 (42.9) -- 
   Established plan to change 2 (7.1) 1 (7.7) 
   Other (e.g., no plan in place) -- 1 (7.7) 
Current medication    
   None 3 (10.7) 1 (7.7) 
   Mood-stabiliser only (incl. anticonvulsants) 10 (35.7) 4 (30.8) 
   Antitypical antipsychotic 1 (3.6) -- 
   Mood-stabiliser plus atypical antipsychotic 3 (10.7) 3 (23.1) 
   Mood-stabiliser plus antidepressant 5 (17.9) 3 (23.1) 
   Atypical antipsychotic plus antidepressant 1 (3.6) 1 (7.7) 
   Combination of all three types 5 (17.9) 1 (7.7) 
Psychological interventions  
   Yes (e.g., CBT, Mindfulness) 
 
20 (71.4) 
 
12 (92.3) 
Goal of BPII treatment*   
   Treat current depression 3 (10.7) 1 (7.7) 
   Treat current hypomania -- -- 
   Prevent relapse long-term 20 (71.4) 11 (84.6) 
   Other (e.g., treat depression and prevent 
relapse) 
5 (17.9) -- 
Other chronic medical condition   
Yes (e.g., Hypothyroidism, diabetes) 11 (39.3) 7 (53.8) 
Family attended consultation   
   Yes 16 (57.1) 11 (84.6) 
Usual attendance in consultation   
   Usually patient alone 24 (85.7) 8 (61.5) 
   Mix alone and accompanied 4 (14.3) 5 (38.5) 
Patient involvement preferences, triadic 
(based on CPS) 
  
   Patient-led alone 4 (14.3) 1 (7.7) 
   Patient-led with family/clinician 14 (50.0) 6 (46.2) 
   Patient/family-led with clinician 3 (10.7) 1 (7.7) 
   Patient/family/clinician shared 2 (7.1) 3 (23.1) 
   Family-led with patient/clinician -- -- 
   Clinician-led with patient/family  4 (14.3) 2 (15.4) 
   Clinician-led alone -- -- 
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Patient involvement preferences, 
(based on CPS) 
 
 
 
 
   Patient-led alone -- -- 
   Patient-led with clinician 13 (46.4) 6 (46.2) 
   Patient/clinician shared  10 (35.7) 6 (46.2) 
   Clinician-led with patient 5 (17.9) 1 (7.7) 
   Clinician-led alone -- -- 
Mood state at time of interview (based on 
ISS) 
  
   Depressed 5 (17.9) -- 
   Hypomanic 9 (32.1) -- 
   Mixed state 5 (17.9) -- 
   Euthymic/ subsyndromal 9 (32.1) -- 
* = remaining family members indicating “don’t know” 
 
3.4.2. Qualitative findings 
Qualitative analyses yielded four inter-related themes, comprising several subthemes 
(Figure 3.1): 1) Attitudes and response to diagnosis and treatment; 2) Influences on 
decision-making; 3) The nature and flow of decision-making; and 4) Decision support 
and challenges. Overall, family and patient participants expressed concordant views, 
and most themes were similarly represented among patient and family participants. 
The use of the term “participants”, without qualification, denotes instances where 
views were expressed to a similar extent by both patients and family; the use of 
“patients” or “family” denotes instances where views were expressed only by that 
group. Illustrative quotes are presented in Tables 3.3 – 3.4. 
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Figure 3.1. Diagrammatic summary of themes and subthemes based on BPII patient 
and family data. The three overlapping circles highlight the overlapping and non-
linear nature of the themes, which do not conform to any hierarchy. 
 
3.4.3. Theme 1: Attitudes and response to diagnosis and treatment 
Theme 1 comprised attitudes towards treatment options and treatment approaches, 
which influenced participant engagement with treatment decision-making in this 
setting (Table 3.3). Attitudes appear at the peripheries of Figure 3.1, as they are often 
presented from the outset of decision-making, or are determined by pre-existing 
treatment characteristics (e.g., multimodal approaches, clinical uncertainty). 
Theme 3: Nature & flow 
of decision-making 
Decision-making 
 as an ongoing,  
iterative process  
Continuity of care 
Patient & family  
involvement  
Clinician  
decision-making 
styles 
Theme 4: Decision-making  
support & challenges 
Theme 1: Attitudes & response to  
diagnosis & treatment 
Theme 2: Influences on  
decision-making 
Relational 
(therapeutic 
relationship) Relational 
(family) 
Systemic 
& practical  
Informational 
Multimodal treatment  
 characterised by  
trial-&-error 
“Trading off” 
benefits & costs 
Pre-existing  
beliefs 
Clinical factors 
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Table 3.3. Illustrative patient and family quotations for Theme 1: Attitudes and response to diagnosis and treatment and Theme 2: Influences on 
decision-making. 
Subtheme Illustrative patient quotations Illustrative family quotations 
1.1. Multimodal treatment 
characterised by trial-and-error 
 
 
I guess it's this holistic approach to managing ...it was about the 
medication, the counselling options, the maintaining exercise and 
meditation, and the fish oil.  
(Multimodal approach, Patient 109) 
 
... I could actually be on the same merry-go-round here … So that 
made me feel a bit less positive about it….hearing [from the 
psychiatrist]... if plan A fails then we can go to plan B and plan B 
fails we can go to plan C... feeling a bit less sure about the process 
(Uncertainties of treatment, Patient 109) 
 
During the initial period immediately after diagnosis there 
was a lot of trying different medications to see which ones 
would work…. It felt like guesswork even on the part of the 
professionals. We'll try this one, we'll try that one. It's that 
sense of trial and error  
(Trial-and-error, Family 218) 
 
1.2. Attitudes and response to 
treatment 
 
 “…it's better to be a bit dopey and overweight rather than being 
depressed 90% of the time...So you've got to weight up their pros, the 
benefits and costs and things.” (Trading off benefits versus costs, 
Patient 117) 
 
With one medication in particular I found it really successful [in 
stabilising mood] but it was a really difficult decision because it's 
made me put on a significant amount of weight....my life just became 
completely unmanageable and that was the trade-off.  ..... I decided 
to eventually just come off that medication completely  
(Trading off benefits versus costs, Patient 134) 
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2.1. Clinical 
 
…. when you're depressed or even when you're [hypo]manic, 
sometimes I experience a high level of confusion and an inability to 
think logically... when you're presented with options... it's not 
possible to think through the solutions. (Impact of symptoms, Patient 
106) 
 
I have bipolar too... [so I] have a good understanding...what 
she [my partner] is going through so we can talk about it. 
When you’re seeing the psychiatrist... [I encourage her to] ask 
definite questions which they are then obliged to answer, 
[which] is the one thing I’ve learnt. (Family history of mental 
illness, Family 207) 
 
2.2. Pre-existing beliefs about self. 
 
I’m independent… I make all the other decisions in life on my own so 
it's just something you have to do.  
(Patient 111) 
 
I'm not very proactive so it's good to given suggestions and then 
being made to decide on them because if it was left to me I probably 
wouldn't do anything. (Patient 122) 
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Multimodal treatment characterised by trial-and-error 
Participants reported mostly medication-based decisions (starting new/adjunctive 
medication, change medication type/dose) but also psychological-based decisions 
(CBT) and lifestyle modifications (e.g., exercise). Accordingly, most participants 
noted that treatment needed to be “holistic” and involve multiple clinicians 
(psychiatrists/GPs/psychologists) (Patient 109; Table 3.3).  
 
Patients and family noted that medication options carried inherent uncertainty. This 
uncertainty often made treatment decisions more difficult and based on “trial-and-
error” (Family 218; Table 3.3). For some participants, this uncertainty and “hit and 
miss” process engendered feelings of frustration, confusion, hopelessness, and 
perceived discrediting of clinician expertise (Patient 109; Table 3.3).  
 
Attitudes and response to treatment 
Patient and family participants expressed varying attitudes to treatment options 
(medication/psychological-based), which strongly influenced patient willingness or 
reluctance to start/continue treatment. Of note, patients respondents without current 
mood symptoms (euthymic) were more likely to express positive (n=5) compared to 
negative medication attitudes (n=3), which contrasted with patient respondents with 
current depressive or hypomanic/mixed state symptoms who expressed more negative 
(n=7) than positive medication attitudes (n=1). Positive medication attitudes were also 
more salient amongst patients previously treated with antidepressants for depression 
and/or anxiety, who felt mood-stabilisers would deliver greater benefits. 
 
Several participants reported “trading-off” treatment benefits and costs. 
Approximately half of patients assigned greater value to the perceived medication 
benefits (mood stability) and believed these outweighed the costs (side-effects). This 
view was only expressed by patients and supported their willingness to start/continue 
medication (Patient 117; Table 3.3). The remaining half of participants, including 
patients with currently depressed mood and family, felt medication costs (burdensome 
side-effects) outweighed benefits (Patient 134; Table 3.3).  
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3.4.4. Theme 2: Influences on decision-making 
Theme 2 comprised pre-existing patient and family characteristics, which participants 
believed made treatment decisions more or less difficult (Table 3.3). Again, these 
characteristics appear at the peripheries of Figure 3.1 as they are already present when 
patients/family start considering treatment options.  
 
Clinical 
Persistent treatment resistance/non-response appeared to make decision-making more 
difficult for some patients (futility) but easier for others, especially those with a 
previous diagnosis of depression and/or anxiety. These latter participants found the 
decision to commence mood-stabilisers easier given years of incomplete 
antidepressant response, and more strongly endorsed the potential benefits of mood-
stabilisers. Overall, a family history of mental illness had a positive influence on 
treatment decision-making (empathy) (Family 207; Table 3.3).  
 
Participants reported that it was best to time decision-making while euthymic, noting 
that depressive and hypomanic symptoms had a negative impact on their decision-
making engagement (Patient 106; Table 3.3). Depressive symptoms reportedly 
diminished patient’s ability and desire to be the primary decision-maker, and resulted 
in patients deferring decisional responsibility to clinicians and/or family. Patients 
were mostly happy to do this, but still wanted to be involved to some degree. When 
hypomanic, meaningful patient engagement was also difficult (irrational/impulsive 
decision-making). 
 
Pre-existing beliefs about self 
Patient personality traits and beliefs about oneself influenced decision-making in 
various ways. Patients viewing themselves as independent often preferred, and 
reported more active decision-making involvement (Patient 111; Table 3.3). By 
contrast, patients viewing themselves as more dependent were more inclined to defer 
decisional responsibility to the clinician (Patient 122; Table 3.3). 
 
3.4.5. Theme 3: Nature and flow of decision-making 
Theme 3 described how the decision-making process unfolds both within and outside 
consultations, highlighting the relative contributions of the clinician, the patient, and 
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the family, and their interplay (Table 3.4). This theme is at the core of decision-
making in this setting (Figure 3.1), because it characterises how decisions are made 
within current clinical practice.  
 
Decision-making as an ongoing process requiring continuity-of-care 
Medication-related decision-making was often described as fluid, and subject to 
ongoing review in response to persistent mood instability and/or unpleasant side-
effects (Family 206; Table 3.4). Patients appeared to like revisiting decisions at 
follow-up consultations with their psychiatrist/GP (Patient 137; Table 3.4). A few 
participants were “comfortable” they made the “right” medication decision, which 
mainly stemmed from a positive treatment response. 
 
Consistent with this ongoing decision-making process, many participants also 
appreciated the need for continuity-of-care. More participants reported that they 
received good continuity-of-care than not, which usually existed alongside an 
ongoing, healthy therapeutic relationship with a GP/psychiatrist (Patient 140; Table 
3.4). In contrast, inadequate continuity-of-care reportedly led to patients feeling 
unsupported and lacking knowledge to manage their illness (Patient 111; Table 3.4).  
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Table 3.4. Illustrative patient and family quotations for Theme 3: Nature and flow of decision-making and Theme 4: Decision-making support 
and challenges. 
Subtheme Illustrative patient quotations Illustrative family quotations 
3.1 Decision-making as an ongoing 
process requiring continuity-of-care 
 
I go and see him [GP] every week to two weeks. We’ll decide, 
“Yes, okay we can up the dose a little bit now,” we’re doing it 
very slowly. He’ll ask me whether there’s any side effects...Then 
we make decisions whether to increase the dose. It’s good. 
(Patient 137) 
 
For the last four years that I’ve been seeing him [Psychiatrist], 
things have been going a lot better because I feel like it’s more 
individualised treatment.  
(Good continuity-of-care, Patient 140) 
 
… there's never been any ongoing "are you taking it, how are you 
going with it". So there's probably something missing there....if a 
GP has prescribed you some medication there should be some 
sort of follow up.  
(Poor continuity-of-care, Patient 111) 
 
…it's like a progressive thing. We're looking at, there's a 
sense of... medication trying... see how it works for you, 
what, how.  
(Family 206) 
 
3.2. Clinician decision-making styles 
 
I know when I first started lithium back in 2010, the doctor said I 
needed to take it and I said no. He said... they’d start me on that. 
I felt more like they were telling me what I had to do.  
(Clinician-led decision-making, Patient 140) 
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…. the decision was made in co-operation...if there was a lack of 
respect [for] my decision from the doctor’s perspective [GP]... 
the doctor didn't do that...the doctor was happy to trust my 
judgement  
(Shared decision-making, Patient 124) 
 
When I went to see the psychiatrist, and that was just a once-off, 
there wasn’t a lot of discussion about what any alternative 
treatments might be. It was pretty much that this is the drug of 
choice for bipolar II.  
(Clinician-led information exchange, Patient 137) 
 
I told him [Psychiatrist] exactly how I felt about gaining weight 
and some of the drugs making me more aggressive or really flat. 
He listened to that and he told me why he suggested the drug he 
did  
(Shared deliberation, Patient 133) 
 
3.4. Patient involvement and autonomy 
 
I'll always talk to other people and see what they think but 
ultimately I'll always make the decision myself  
(Patient as ultimate decision-maker, Patient 117) 
 
I’ve been involved in increasing it [medication], so I’ve chosen 
when to take more….and [my psychiatrist] he’s said that I know 
myself and what I want to do, and that’s fine…..I have a lot of 
I just saw his [patient] role was to make the decision 
himself and mine was to support it.  
(Patient as ultimate decision-maker, Family 206) 
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insight into my mood and I said to my psychiatrist that I thought I 
needed to be back on antidepressants.  
(Patient as ultimate decision-maker, Patient 140) 
 
3.5. Family involvement 
 
…If I talk to them [family] about it [medication] they say if 
something sounds like the right thing….Sometimes I will discuss it 
with my husband… (Family involvement outside consultations, 
Patient 128) 
 
… If there's a need for another person to put a point of view 
across, where I'm not able to do it, she [wife] will come along.. 
(Factors influencing family involvement, Patient 120) 
 
.... I sort of chimed in to mostly try to describe her 
behaviour for the doctor’s [Psychiatrist's] benefit, to give 
him a bit more of an idea about how [my sister] she’d 
been….she was trying to describe some of her behaviours I 
felt that they weren’t very accurate. I would discuss them a 
little bit as well.... to provide a slightly more accurate 
description of her health...  
(Family involvement in consultations, Family 225) 
4.1. Relational (family) 
 
My ex-partner will often ask me questions about the decisions I'm 
making, to clarify in my own head what's going on. Like she just 
wants to know that I'm clear about why I'm doing what I want to 
do….there are times when I'm almost incapable of making 
decisions and it's been helpful for me to have someone that I trust 
from a personal point of view.  
(Benefits of family involvement for patients, Patient 106) 
 
...to come along and participate in some of the consults 
[with the psychologist]…I could see the quality of that 
clinician….I understand it better, then I can support 
[patient name] in that [form of treatment].... it sort of gives 
me credence to want to support that decision, to put that 
money into that area.  
(Benefits of family involvement for family, Family 206). 
 
4.2. Relational (Therapeutic 
relationship) 
 
….. [My GP has] just always given me the time to talk...being 
very compassionate... responsive to my saying that I didn't feel 
like the antidepressants that I was on were working....being sort 
of interested in that process.  
(Collaborative therapeutic relationship, Patient 109) 
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…Sometimes I don't feel that they [clinicians] really listen to you 
as an individual. They've got their set routine that they go 
through with people and that's it... [not] really listening and 
assessing me....They didn't take the time to really talk to me and 
find out whether there were other underlying issues.  
(Non-supportive therapeutic relationship, Patient 125)  
 
....when I mentioned [antipsychotic brand name] Seroquel the GP 
didn't really seem to know it that well so he actually had to look 
up information on it.... it just made me a little uneasy that I'm not 
getting the best possible treatment here.  
(Limitations to clinician expertise, Patient 112) 
 
4.3. Informational  
 
[Accessing information] to feel more in control as opposed to 
having a situation that is totally foreign. Getting information like 
that just puts me in a better position to, to be decisive....that 
applies to any medicine that I take.  
(Supporting role of information, Patient 120) 
 
So, fitting my medication in with my lifestyle and considering that 
as well. I think giving people those ideas of what they need to 
consider in making treatment decisions. That would be helpful. 
(Potential benefits of decision-support tool, Patient 140) 
While I was able to read research papers, I didn't 
understand a lot of what I was reading even though I've got 
tertiary qualifications, but they're not in a medical science 
area so some of the language in that was quite foreign.  
(Unmet information needs, Family 218) 
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Clinician decision-making styles 
Regardless of involvement preferences, many participants reported engaging in 
predominantly clinician-led decision-making and being “told what to do” about 
medication (Patient 140; Table 3.4). This lack of patient agency usually occurred 
when they were symptomatic with reduced decisional capacity.  
 
Participants reported that they experienced shared decision-making (SDM) less often 
than clinician-led decision-making. SDM appeared more common within a 
longstanding therapeutic relationship, among participants who preferred patient-
led/SDM, and when patients’ family had attended consultations (Patient 124; Table 
3.4).  
 
Both pre-/post-consultations, most patients and some family reported being proactive 
in information seeking, mostly using online sources (Google, leading mood disorder 
organisations) to supplement clinician-provided information. A few patients appeared 
to avoid information-seeking as a self-protective strategy (being “put off” by negative 
medication information).  
 
Within consultations, most patients and family described clinician-led information 
exchange, whereby psychiatrists/GPs provided information (benefit/side-effect 
profiles, safety information) about their “recommended” medication option. Several 
participants noted minimal discussion of options; often only one treatment was 
presented by their treating clinician without any alternatives (Patient 137; Table 3.4).  
 
In-consultation discussion about treatment preferences was reportedly mostly 
clinician-led, with clinicians expressing their treatment preference with limited 
discussion of patient treatment preferences. Some patients reported volunteering their 
treatment preferences to clinicians (Patient 133; Table 3.4). One patient-family dyad 
described a more collaborative “weighing-up the pros and cons” (Patient 133 and 
husband).  
 
Notably, clinician-led information exchange and deliberation was reported by all 
recently-diagnosed (<1 year) participants, and by all participants preferring clinician-
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led decision-making, however it was also commonly reported by participants 
preferring patient-led/SDM.  
 
Post-decision, a few participants preferring patient-led/SDM reportedly ignored 
clinician advice (discontinued prescribed medication), particularly when it was 
inconsistent with their treatment preferences, or to “take charge” over their illness. 
 
Patient involvement and autonomy 
Almost all (patient/family) participants felt that the patient should be the ultimate 
decision-maker, but acknowledged that both clinician and patient expertise should 
inform treatment decision-making (Patient 117; Family 206; Table 3.4). Most patients 
also felt that their decision-making autonomy was supported and respected (Patient 
140; Table 3.4).  
 
Reasons given for active patient involvement included treatment decisions being 
“about them” and “their brain”, having lived illness experience, the possibility of 
adverse medication effects, and because BPII required ongoing management.  
 
Family involvement 
Family involvement typically occurred outside consultations, ranging from patients 
informing family about a decided-upon treatment (minimal), to always deliberating 
options with their family pre-decision (active). Absent or dominant family 
involvement was less-commonly reported. Both patients and family noted that family 
primarily acted as a sounding-board (talking through patient treatment 
preferences/feelings/concerns), which was a role more often assumed by 
partners/spouses than other family (e.g., parent, sibling). Family also provided 
reassurance post-decision, or encouraged treatment seeking/adherence in response to 
adverse effects or worsening symptoms (Patient 128; Table 3.4). These two roles 
were more commonly reported by patients, and by family, respectively. 
 
Family attendance at consultations tended to be intermittent, which is supported by 
patients’ self-report (57% had family attend). Some participants reported that 
clinicians sometimes initiated family involvement (inviting family into consultation). 
Within consultations, family roles were mostly as information support (giving the 
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clinician patient information), and as a monitor of patient accuracy 
(clarifying/elaborating on patient accounts) (Family 225; Table 3.4). This latter role 
was expressed only by family members themselves.  
 
Family involvement was mainly influenced by: pre-existing relationship dynamics 
(estranged, close-knit), family respect for patient autonomy and confidentiality, and 
strength of the therapeutic relationship. Consultation-related factors included: 
patient’s need for additional informational support (due to disabling symptoms), at 
important treatment milestones (shortly post-diagnosis), and when treatment options 
directly impacted on the family (financially) (Patient 120; Table 3.4). Most of these 
factors were mentioned by both patients and family, however, patients more 
commonly referred to pre-existing relationship dynamics (with their family and 
clinician).  
 
Participants, both patients and family, often linked their support for patient autonomy 
to family expressing their treatment preferences indirectly and without coercion (i.e., 
“suggesting”, “encouraging” options without “steering”, “pushing”, “enforcing”). 
 
3.4.6. Theme 4: Decision-making support and challenges 
Theme 4 outlined factors influencing how decision-making unfolded. This theme also 
elucidated a number of (unmet) decision-support needs spanning relational, 
informational, and systemic domains. (Table 3.4). This theme is more proximal to the 
core of decision-making (Figure 3.1) as challenges and supports were present “in real 
time”, as decision-making occurred.  
 
Relational (family) 
Outside consultations, both patients and family noted that family involvement 
benefited decision-making by: reassuring patients when concerned or uncertain about 
medication efficacy, facilitating more realistic expectations (delayed benefits), and 
providing encouragement in light of adverse medication effects. Patients, in 
particular, also valued their family acting as a sounding-board because this 
consolidated and clarified patient treatment preferences (Patient 106; Table 3.4).  
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Within consultations, family involvement served two primary decision-making 
benefits: providing clinicians a more detailed and/or accurate account of patient 
symptoms, and enhancing the family’s own understanding of BPII and the rationale 
for various treatments. When family were party to discussion about the rationale 
behind recommended treatments, they could more easily participate in post-
consultation deliberations (Family 206; Table 3.4). These views were similarly 
represented in patient and family accounts.  
 
Primary barriers to family involvement included a lack of knowledge/understanding 
of BPII and treatment options, as well as perceived family burden and worry, which 
was only noted by patients. According to both patients and family, maintaining open 
lines of communication with family reportedly facilitated discussion of patient 
treatment concerns as well as adverse treatment effects impacting on family (reduced 
libido).  
 
Relational (Therapeutic relationship) 
Participants valued a therapeutic relationship that was based on trust, collaboration, 
empathy and respect for patient treatment preferences (Patient 109; Table 3.4). The 
absence of these clinician qualities led to negative patient-clinician interactions 
(Patient 125; Table 3.4). Some participants linked the therapeutic relationship to 
various outcomes, including: patient satisfaction with care, greater patient confidence 
in starting/changing/continuing treatments, more open communication and, in turn, 
improved clinician understanding of the patient's treatment preferences. Patients 
especially appreciated having a good therapeutic relationship when unwell, because 
they felt more confident to defer decisional responsibility to clinicians. 
 
Patients and family reported mixed perceptions of clinician expertise (both clinical 
knowledge and knowledge of the patient). Several patients reported GPs lacking the 
“expected” expertise of BPII and medication options, which undermined the GP’s 
credibility in the patients’ eyes (Patient 112; Table 3.4). Perceived good 
GP/psychiatrist expertise in BPII instilled greater patient trust in the clinician, and 
willingness to follow treatment advice.  
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Informational  
Patient stories (e.g., online chat-rooms/forums) reportedly fostered greater 
patient/family understanding of symptoms, complemented more medical/clinically-
based information, and validated patients’ lived experience of the illness. A few 
participants felt that personal accounts of the illness were not credible (“rubbish”), 
were negatively-biased (“discouraging”), or had a negative psychological impact 
(felt “wary” about medication).  
 
Accessing information reportedly benefited patients’ decision-making, by: patients 
feeling more in control and confident in decision-making, and dispelling medication 
fears by understanding the expected benefits/side-effects (Patient 120; Table 3.4). 
These views were predominantly expressed by participants preferring patient-
led/SDM. Two recently diagnosed patients noted that medication-based information 
better prepared them for consultations (“knowing what to say”, “which questions to 
ask”), and communicating their medication preferences.  
 
Regarding content, participants reported preferences for evidence-based, unbiased 
lay information on a broad range of medication and psychological options, medication 
effects and rationale for use. Patients and family also endorsed personalised 
information, which acknowledged that treatment choice was sensitive to patient 
circumstances.  
 
Regarding format, all patients and family preferred written as opposed to verbal 
information. Most participants expressed a preference for hardcopy information (e.g., 
booklet/factsheet) as opposed to online information. Participants believed hardcopy 
information allowed patients privacy, could be taken home, and provided a tangible 
point-of-reference for patients to refer to outside consultations, and was more reliable 
than internet-provided information.  
 
Commonly-cited unmet information needs, included a lack of comprehensiveness 
regarding the full range of available treatment options, easy-to-understand medical 
information, and a consolidated point-of-reference to supplement consultations 
(Family 218; Table 3.4).  
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To better support unmet information needs, participants were specifically asked about 
the development of a future decision-support resource. Potential participant-reported 
benefits included incorporation of patient values into treatment decisions, 
consideration of how medication “fits into their life” and “tailor it to their lifestyle” 
(Patient 140; Table 3.4), and the ability to actively weigh-up options, enhance patient 
question-asking in consultations, and clinician understanding of medication effects on 
the patient and their life. These potential benefits were mainly reported by participants 
with a recent BPII diagnosis (<1 year) and/or preferences for patient-led/SDM.  
 
Systemic and practical 
Several participants highlighted difficulties in accessing psychiatrists and 
psychologists due to high costs, residing outside metropolitan areas, and limited 
government-subsidies. Limitations to mental health service access and affordability 
negatively impacted on patients’ continuity-of-care (infrequent appointments) and 
formation of therapeutic relationships.  
 
Inadequate consultation times with GPs/psychiatrists reportedly led to treatment 
decision-making that seemed overly “prescriptive”, precluding a meaningful, patient-
centred discussion of medication options (Patient 109; Table 3.4). Scheduling longer 
and follow-up consultations reportedly allowed patients to better consider options, 
and made them more likely to adhere to treatment (Patient 131; Table 3.4). 
 
3.5.  Discussion  
This is the first known study to provide in-depth exploration of patient/family 
perspectives on BPII treatment decision-making. As depicted in Figure 1, decision-
making about BPII treatment is essentially an ongoing, iterative process supported by 
good continuity-of-care, and a balance between clinician-patient(-family) 
involvement. Integral to decision-making are various challenges and supports, which 
manifest as decision-making occurs. Additionally, patients/family have pre-existing 
characteristics and treatment attitudes, which predispose them to certain treatment 
preferences and having more/less decision-making involvement.  
 
Patient autonomy and involvement in treatment decision-making is highly valued in 
this setting. Yet, patient reports of actual involvement suggest lower-than-preferred 
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involvement, as previously reported [37]. In general, it appears that clinician-led 
decision-making is the “default” in this setting, irrespective of patient involvement 
preferences. In addition to patient symptoms, time constraints, failure to establish a 
strong therapeutic relationship, and limited patient knowledge about illness/treatment 
may all explain clinician-led decision-making [38], especially among recently-
diagnosed patients. While clinician-led decision-making meets some patients’ 
involvement preferences, it does not meet most patients’ preferences [39]. Given that 
patients preferring shared or patient-led decision-making are most likely to be 
disadvantaged by current clinician-led decision-making styles, there is a particular 
need for SDM interventions in the BPII treatment setting.  
 
Discussion and integration of patient attitudes and preferences for treatment appears 
crucial in this setting. Specifically, patients varied in the value they ascribed to 
medication side-effects versus therapeutic benefits. Whereas some participants 
prioritised medication benefits, a similar proportion prioritised medication side-effects 
when making a decision. This “trading-off” of benefits/costs then impacted on 
patient’s un/willingness to commence and/or continue medication. Of note, the 
various mood states participants were experiencing also appeared to influence 
medication attitudes, with euthymic patients expressing more positive attitudes 
compared to those experiencing hypomanic or depressive symptoms, thus reinforcing 
the particular need to regularly discuss treatment preferences in this population. 
Further, when treatment choice did not match patient preferences, this undermined 
treatment adherence, which is consistent with studies examining the preferences of 
outpatients with depression [40]. 
 
This link between patient preferred treatment choice and adherence to treatment was 
especially the case amongst patients preferring patient-led and/or SDM, who are more 
likely to want their treatment preferences considered. A collaborative/SDM approach 
may optimise BPII treatment decision-making, by facilitating discussion and 
consideration of what matters most to patients, which may differ from clinician 
priorities [41]. SDM interventions may be useful for better involving these 
patients/family in making specific and deliberative treatment decisions [42, 43]. 
Decision-aids (DAs), for example, are one empirically-supported SDM intervention 
which provide patients/family with evidence-based, non-directional information about 
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available treatment options and outcomes. Importantly, DAs also include values 
clarification exercises which are designed specifically to assist patients/family to 
consider their preferences and deliberate on the varying benefits/costs of the different 
treatment options [43]. 
 
Almost uniformly, patients and family strongly endorsed patient involvement and 
autonomy in treatment decision-making. Similar to a qualitative study in depression 
[44], relational, informational, and systematic factors all appeared to underlie patient 
perceptions of autonomy and patient-centred care, and other decision-making 
outcomes. When present, a positive, trusting and collaborative therapeutic 
relationship appeared to enable patients to achieve their involvement and treatment 
preferences. Importantly, perceived clinician expertise and trust made patients 
comfortable to defer decisional control when experiencing reduced decisional 
capacity. By contrast, when the therapeutic relationship was precarious, patients 
tended to reported poorer outcomes, including reduced decision-making autonomy, 
less preference-based decisions, and poorer adherence. A strong, collaborative 
therapeutic relationship appears particularly important in chronic mental illnesses like 
BPII [45] where treatment decision-making is subject to ongoing review and rests on 
good continuity-of-care.  
 
Other relational factors, such as family involvement also supported treatment 
decision-making within/outside consultations. Significantly, patients preferring 
patient-led and/or SDM were more likely to achieve their involvement preferences if 
a family member had attended consultations. Two forms of family involvement may 
explain why family attendance was related to patients’ achieving their involvement 
preferences. Firstly, family provided clinicians with comprehensive and personalised 
knowledge of the patient’s circumstances (information-support). Secondly, family 
who attended consultations were better equipped to help patients clarify their 
understanding of, and preferences for treatment (sounding-board). Thus, family 
attendance at consultations may improve patient and clinician understanding of 
patient preferences, and ensure treatment decisions consider these. This explanation 
aligns with “shared mind” [46], whereby family can enhance patient autonomy in 
decision-making by facilitating “shared knowledge” (knowing the patient-as-a-
person) and “shared deliberation” (mutual construction of preferences). This said, 
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there were a number of reported barriers to family involvement in this setting (e.g., 
patient confidentiality, perceived family burden and distress), and thus is it essential 
that any family involvement occurs in line with patient preferences [4]. Providing 
patients with private opportunities to discuss distressing topics, even when family is 
present, is key, and clinicians could achieve this by inviting family into consultations 
partway through [9]. 
 
Participants identified several unmet informational needs and decision-support 
priorities, which are consistent with previous surveys in bipolar [39] and have 
important implications for clinical practice. Specifically, it is important that clinicians 
understand patient preferences for involvement in decision-making, and integrate 
patient preferences into treatment choice. To better engage patients with BPII in the 
decision-making process, clinicians could discuss with patients: i) both their own 
recommended treatment option/s as well as alternative, evidence-based treatment 
options, and ii) patient attitudes towards and preferences for treatment options. 
Seeking to maintain an ongoing relationship with these patients, where feasible, is 
also crucial to enabling patients with BPII to adopt a more active role in their 
treatment decision-making and choose treatments that are consistent with their 
preferences. Encouraging family involvement, to the extent desired by patients, can 
also facilitate the decision-making process especially when sharing information and 
deliberating on options. To effectively implement these improvements in clinical 
practice, SDM interventions, such as question-prompt lists, decision-aids, are likely to 
be helpful [43, 47], as they have been shown to improve patient knowledge of 
available treatment options and outcomes and perceived decision-making 
involvement in depression and schizophrenia [48]. Moreover, these informational and 
decision-support priorities are not unexpected, given that both patients and family 
endorsed “multimodal” treatment approaches, proactive information-seeking, and 
viewed patients as the ultimate decision-maker. These views are commonly endorsed 
in mental health [39, 49], making these findings relevant not only to potential 
decision-support interventions for BPII but for other mental health conditions too.  
 
Study limitations include the “opt-in” recruitment and potential self-selection bias; 
findings may reflect the views of more interested patients and family. Secondly, 
approximately half of participants did not have their family participate in the study. 
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Thus, patient-reported experiences of family involvement and decision-making may 
not correspond with family views, and vice-versa.  
 
In accordance with broader patient perspectives of patient-centred care in bipolar 
disorder [50], BPII patients and family appreciate treatment decision-making that is 
well-informed, respects patient preferences and needs, and involves patients. Yet, 
patient preferences for information, decision-making, and treatment choice appear not 
fully met. The present findings point to a number of potential avenues for future 
research. These include: systematically comparing and contrasting patient and family 
views with those of other key stakeholders in the decision-making process (e.g., 
treating clinicians), and ascertaining the extent to which patient mood states and other 
patient-/family-related characteristics influence attitudes towards and uptake of 
effective treatment options. This information is needed to discern how clinician 
perceptions may facilitate or impede effective decision-making in this setting, as well 
as to identify when and whom to best target with BPII-specific decision-making 
interventions. Findings will also inform the development and evaluation of a patient 
treatment decision-aid to enhance patient/family knowledge and involvement, and 
optimise clinician-patient(-family) collaboration in treatment decision-making. 
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Chapter 4: A qualitative exploration of clinician views and experiences of  
treatment decision-making in bipolar II disorder. 
 
This chapter is reformatted from the published manuscript:  
Fisher A, Manicavasagar V, Sharpe L, Laidsaar-Powell R, Juraskova, I. A qualitative 
exploration of clinician views and experiences of treatment decision-making in 
bipolar II disorder. Community Mental Health Journal. 2017;53(8):958-971. 
https://doi.org/10.1007/s10597-016-0077-4 
 
 
This chapter reports on a qualitative study, which sought to explore the views and 
experiences of treatment decision-making among clinicians with experience working 
with patients with bipolar II disorder (BPII). Findings elucidated key informational 
and decisional-support priorities and unmet needs in this setting; these were used to 
inform the content, format, and delivery of the decision-aid (DA, see Chapter 6). 
Ethics approval letters are provided in Appendices B1 and B2; supplementary 
materials related to this study are provided in Appendix E.  
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4.1. Abstract 
Aim. This study qualitatively explored clinicians’ views and experiences of treatment 
decision-making in BPII.  
 
Methods. Semi-structured interviews were conducted with 20 practising clinicians 
(n=10 clinical psychologists, n=6 GPs, n=4 psychiatrists) with experience in treating 
adult outpatients with BPII. Interviews were audiotaped, transcribed verbatim and 
thematically analysed using framework methods. Professional experience, and 
preferences for patient involvement in decision-making were also assessed.  
 
Results. Qualitative analyses yielded four inter-related themes: 1) (non-)acceptance of 
diagnosis and treatment; 2) types of decisions; 3) treatment uncertainty and balancing 
act; and 4) decision-making in consultations. Clinician preferences for treatment, 
professional experience, and self-reported preferences for patient/family involvement 
seemed to influence decision-making.  
 
Discussion. This study is the first to explore clinician views and experiences of 
treatment decision-making in BPII. Findings demonstrate how clinician-related 
factors may shape treatment decision-making, and suggest potential problems such as 
patient perceptions of lower-than-preferred involvement.  
 
Keywords. Bipolar II disorder, treatment decision-making, qualitative, clinician 
attitudes, patient involvement, family involvement. 
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4.2. Introduction 
Bipolar disorder is a chronic, relapsing and remitting psychiatric disorder 
characterised by episodes of depression (‘lows’) and hypo/mania (‘highs’) [1]. 
Effective long-term management relies heavily on patient self-management and 
warrants collaborative approaches to decision-making about treatment [2]. Shared 
treatment decision-making (SDM) involves both the clinician and the patient (and 
others’) working together to make a treatment decision based on their relative 
expertise and preferences for treatment options [3, 4]. SDM is increasingly recognised 
as important and applicable to many treatment decisions in mental health [5], where 
more than one treatment option is feasible and final treatment choice is sensitive to 
patient preferences. 
 
Compared to bipolar I disorder, treatment choices in bipolar II disorder (BPII) are 
more variable with regards to clinical evidence and patient preferences. This is 
because much of the high-quality research on treatment efficacy has been evaluated in 
patients with bipolar I disorder, leading to a paucity of published BPII-specific 
treatment recommendations (e.g. [6]). Further, there is an ongoing lack of clinical 
consensus over the use of antidepressants (with/out mood-stabilising medications) in 
treating BPII depression, [7, 8] the far more predominant mood state [9, 10]. Lastly, 
as individuals with BPII do not experience psychotic features during their hypomania, 
the perceived benefits of mood-stabilising medication may be outweighed by 
potential side-effects [11].  
 
The application of SDM continues to present a challenge to mental health, especially 
to the treatment and management of bipolar disorder. In a systematic review of 
bipolar disorder, patient-reported involvement did not match their stated preferences 
[12]. Further, observed levels of SDM and patient involvement often did not meet 
minimum a priori criteria for informed decision-making [13] when options involved 
some degree of medical uncertainty, and potentially posed a risk to patients. However, 
the review identified no studies investigating clinician perceptions of how treatment 
options are discussed and treatment decisions made [12]. Limited existing qualitative 
studies of clinician views have focused on treatment decision-making in 
schizophrenia (e.g., [14]) and unipolar depression [15]. However, these disorders are 
distinctly different to BPII and patient preferences for, and actual involvement in their 
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own treatment decisions can be expected to be different to those with schizophrenia 
[16] and depression [17]. There is a need to better understand SDM in bipolar 
disorder and especially the role of clinicians in this process.  
 
Clinician views may be used to supplement independent observer ratings of SDM in 
consultations [18] as these ratings do not capture the full scope of decision-making 
behaviours (e.g., partnership building) that influence patient-reported involvement 
and decision quality. Evidence indicates that patients evaluate similar clinician SDM 
behaviours (e.g., clinician-provided information and deliberation of treatment option) 
in different ways (i.e., perceiving SDM versus patient-led decision-making) [19]. 
Discrepancies can arise between patient-reported and observed SDM [19], and 
between patient and clinician perceptions of patient involvement in decision-making 
[20]. Thus, an examination of clinician views may highlight aspects of treatment 
decision-making that are not readily captured by consultation ratings and explain 
discrepant patient and clinician views, clarify the underlying reasons for clinician 
behaviours, or patients experiencing less involvement than desired. 
 
The present study aimed to qualitatively explore clinicians’ views and experiences of 
treatment decision-making with BPII patients in an outpatient setting. Specifically, 
this study aimed to elucidate: i) the nature of BPII treatment decision-making; ii) 
factors that appear to shape the decision-making process; and iii) the respective roles 
and involvement of the clinician, patient, family (and others) in decision-making.  
 
4.3. Methods 
 
4.3.1. Participants 
Participants were 20 practising clinicians with experience in treating adults with 
bipolar II disorder (BPII). Clinicians were both medical practitioners (i.e., 
psychiatrists, general practitioners [GPs]) and clinical psychologists, and worked in 
various clinical practice settings, including general and specialist care clinic and 
government-subsidised and private practice settings. Clinicians were recruited 
through: i) the Black Dog Institute (BDI), a clinical service specialising in the 
assessment and treatment of mood and bipolar disorders in the Sydney metropolitan 
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area; ii) BDI-organised professional development workshops; and iii) e-newsletters to 
clinicians signed-up to BDI mailing-lists.  
 
Purposive sampling was used to obtain maximum variation on characteristics likely to 
influence views and/or experiences of treatment decision-making – i.e. years of 
clinical practice, professional specialty (psychiatry, general practice, clinical 
psychology), and level of BPII patient contact. Recruitment continued until data 
saturation, a concept used to describe the point at which three consecutive interviews 
fail to reveal any new information or insights [21]. Ethical approval was obtained for 
all aspects of the study from The University of Sydney Human Research Ethics 
Committee and the Black Dog Institute Research Advisory Committee. 
 
4.3.2. Procedure 
Expression-of-interest flyers were provided at BDI staff meetings, professional 
development workshops, and disseminated via clinician emailing-lists. Interested 
clinicians were invited to contact the researcher at the University of Sydney (AF), 
who explained the rationale for the study and obtained verbal consent to post/email a 
study pack to potential participants. The study pack contained an information sheet 
and consent form, and a brief pre-interview questionnaire. Two text and/or email 
reminders were sent to participants one and two weeks’ after sending the study pack. 
Upon receiving the participant’s completed questionnaire and consent form, a one-off 
telephone interview of approximately 30-40 minutes duration was arranged. Informed 
consent was obtained from all individual participants included in the study. 
 
4.3.3. Qualitative data collection 
A semi-structured interview protocol (Appendix E) was purpose-designed and 
informed by widely-cited models of SDM [3, 4, 22], the Ottawa decisional support 
framework [23] and previous qualitative studies of treatment decision-making in 
mental health (e.g., unipolar depression [24]) and medical populations (e.g., cancer 
[25]). To establish the focus on BPII, clinicians were asked at the beginning of their 
interview to describe the range of patients they had treated with BPII as well as the 
course that these patients’ illness has taken over the time in the time they treated 
them. 
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In this paper we report on clinician perceptions of decision-making about BPII 
treatment, including clinician-patient-family involvement, and pre-existing factors 
influencing this process. Other topic results from this qualitative study, such as 
practice challenges and clinician strategies, are to be reported elsewhere ([26], see 
Chapter 5). 
 
4.3.4. Quantitative measures 
Clinician preferences for their own and others’ (i.e., patients and family) involvement 
in treatment decision-making were assessed using an adapted version of the Control 
Preferences Scale (CPS, [20, 27, 28]). This two-item, self-report scale measured 
involvement preferences both in dyadic (clinician-patient) and triadic scenarios 
(clinician-patient-family). The CPS has been used to assess physician perceptions of 
patient involvement in decision-making about cancer treatment [20], and in 
outpatients including those with bipolar disorder [29-31]. 
 
Demographic, clinical and professional characteristics (e.g., age, gender, years in 
clinical practice, typical patient presentation and treatment types) were collected using 
a purpose-designed self-report questionnaire. Participants also indicated whether, 
which, and how often family members attended consultations.  
 
4.3.5. Data analysis 
Descriptive and frequency analyses of questionnaire data were conducted using SPSS 
version 22. Interviews were audio-recorded and professionally transcribed, and then 
thematically analysed [32] using framework methods [33]. Analysis followed five 
main steps [34]:  
1) Familiarisation with the data: AF conducted all interviews, cross-checked each 
transcript against the audio-recording for accuracy, and read each transcript a number 
of times.  
2) Creating a thematic framework: based on independent analyses of 20% of 
transcripts by AF and RL-P, a preliminary thematic framework was developed. Data 
were organised according to themes and sub-themes. Working collaboratively with IJ 
and RL-P, different interpretations of the data were discussed collaboratively until 
consensus was reached on the main themes.  
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3) Indexing: using NVivo11, all transcripts were coded by AF according to the 
framework. Any new themes arising during this stage and revisions were discussed 
with IJ.  
4) Charting: At this stage, AF used MS Excel as a computerised qualitative data 
analysis tool [35], such that themes and supporting quotes from each transcript were 
transferred to a framework matrix with participants as rows and themes as columns.  
5) Mapping and Interpretation: to identify patterns and relationships, the framework 
was examined within and across themes and participants. 
 
To ensure methodological rigour, a proportion of the transcripts (20%) were cross-
coded and discrepancies discussed and resolved before proceeding with coding the 
entire dataset. Secondly, the thematic map was developed in consultation with two co-
authors, IJ and RL-P, who have expertise in treatment decision-making and 
qualitative analysis. All authors certify responsibility for study conduct, data analysis 
and interpretation, and reporting.  
 
4.4. Results  
 
4.4.1. Participant characteristics 
Demographic and clinical characteristics are presented in Table 4.1. Twenty of the 30 
clinicians who agreed to participate completed both the questionnaire and interview 
(67% response rate). Recruitment was balanced across medical practitioners 
(psychiatrists: n=4, GPs: n=6) and clinical psychologists, n=10). Interviews lasted on 
average 34 minutes (Range: 21-51 minutes).  
 
All clinician subgroups were highly experienced (Ms= 13.70-19.25 years, range: 3-
30). Half of psychiatrists (50%) and a majority of clinical psychologists (70%) 
indicated they specialised in the assessment/treatment of bipolar and other mood 
disorders. Most GPs (83%) indicated no mental health speciality. All clinicians 
reported that both medication and psychological-based interventions were typically 
part of their patients’ treatment. All except one psychiatrist preferred patient(/family)-
led or shared decision-making in both dyadic (clinician-patient) and triadic (clinician-
patient-family) scenarios (Table 4.1).  
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Table 4.1. Clinician demographic/ professional characteristics and patient characteristics. 
  Psychiatrists 
(n=4) 
GPs 
(n=6) 
Clinical 
Psychologists 
(n=10) 
Age M(SD) 53.25 (11.44) 55.83 (11.0) 50.50 (10.46) 
Gender (female) n(%) 2 (50.0) 4 (66.7) 7 (70.0) 
Mental health speciality n(%)    
   Bipolar and other mood disorders  2 (50.0) -- 7 (70.0) 
   Other (e.g., Trauma, Psychosis)  2 (50.0) 1 (16.7) 2 (30.0) 
   None  -- 5 (83.3) 1 (10.0) 
Years in speciality M(min-max) 19.25 (8.0-28.0) 16.83 (4.0-30.0) 13.70 (3.0-30.0) 
Hours direct patient contact p/w M(min-max) 22.50 (16.0-30.0) 24.83 (12.0-50.0) 18.90 (10.0-30.0) 
Hours direct contact with BPII patients p/w M(min-max) 7.25 (4.0-12.0) 3.67 (1.0-8.0) 4.15 (0.5-12.0) 
Most common BPII patient presentation n(%)    
   Depressed  2 (50.0) 5 (83.3) 5 (50.0) 
   Mixed state  1 (25.0) -- 1 (10.0) 
   Euthymic/ subsyndromal  -- 1 (16.7) 3 (30.0) 
   Other (e.g., heterogenous)  1 (25.0) -- 1 (10.0) 
Most common medication in BPII n(%)    
   Mood-stabiliser only (Lithium, 
anticonvulsants) 
 1 (25.0) 2 (33.3) 3 (30.0) 
   Antidepressant only  -- -- 1 (10.0) 
   Mood-stabiliser and antidepressant  1 (25.0) 2 (33.3) 4 (40.0) 
   Mood-stabiliser and atypical antipsychotic  -- -- 1 (10.0) 
   Other (e.g., polypharmacy of above)  2 (50.0) 2 (33.3) 1 (10.0) 
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Psychological interventions  n(%)    
   Yes (e.g., CBT, Mindfulness, Wellbeing 
plans) 
 4 (100.0) 6 (100.0) 10 (100.0) 
% BPII patients attending with family (1 +) M(min-max) 32.50 (0.0-60.0) 8.67 (0.0-20.0) 7.50 (0.0-15.0) 
Most common attending family a     
   Spouse/ Partner  2 (50.0) 3 (50.0) 6 (60.0) 
   Parent  1 (25.0) 2 (33.3) 1 (10.0) 
Preferences for patient involvement 
(triadic, clinician-patient-family) a 
n(%)    
   Patient-led with family/clinician  1 (25.0) 3 (50.0) 5 (50.0) 
   Patient/family-led with clinician  1 (25.0) -- 2 (20.0) 
   Patient/family/clinician shared  1 (25.0) 3 (50.0) 1 (10.0) 
   Clinician-led with patient/family  1 (25.0) -- -- 
Preferences for patient involvement 
(dyadic, clinician-patient) 
n(%)  -- -- 
   Patient-led alone   1 (16.7) -- 
   Patient-led with clinician  3 (75.0) 2 (33.3) 8 (80.0) 
   Patient/ clinician shared  -- 3 (50.0) 2 (20.0) 
   Clinician-led with patient  1 (25.0) -- -- 
Notes a = For clinicians reporting family attendance. 
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4.4.2. Qualitative findings 
Qualitative analyses yielded four themes, each comprising several subthemes: 1) Non-
acceptance of diagnosis and treatment; 2) Types of decisions; 3) Treatment 
uncertainty and balancing act; and 4) Decision-making in consultations. As can be 
seen in Figure 4.1, these themes appeared to be inter-related in both an overlapping 
and cyclical manner. According to clinicians, patient acceptance of diagnosis and 
treatment (Theme 1) influenced patient willingness to engage in treatment decision-
making and accept different treatment options (Theme 2). Uncertainty in treatment 
options, and need to balance treatment benefits/side-effects (Theme 3) also influenced 
clinician thoughts about how decision-making occurred in consultations, including 
patient involvement and incorporation of treatment preferences (Theme 4). Illustrative 
patient and family quotes are presented in Tables 4.2 – 4.5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Schematic illustrating main themes.  
 
4.4.3. Theme 1: (Non-)Acceptance of diagnosis and treatment 
Theme 1 (see Table 4.2) captured clinician perceptions of the link between patients 
accepting their BPII diagnosis and accepting treatment, especially medication. This 
theme is positioned at the top of Figure 4.1 because it is an antecedent to treatment 
decision-making from point of diagnosis and continues to exert influence overtime. 
Decision- 
making 
in 
consultations 
(Non-) 
Acceptance of 
diagnosis & 
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Types of 
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uncertainty  
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Whether the diagnosis and treatment are accepted or not affected the types of 
decisions (e.g., discussions around medication), how decisions occurred in 
consultations (e.g., patient involvement), and the relative value given to benefits 
versus side-effects. Clinicians-identified strategies for facilitating diagnosis/treatment 
acceptance by their patients/clients are also encompassed within this theme. 
 
Link between diagnosis and treatment acceptance 
For many clinicians, patient acceptance of diagnosis was considered to be a pre-
requisite for treatment acceptance, especially the need to take medication (GP 324, 
Table 4.2). This said, acceptance of diagnosis by itself was reportedly not sufficient 
for treatment acceptance.  
 
Several clinicians attributed the link between accepting diagnosis and accepting 
treatment to the life-long, prophylactic nature of medication-based treatment for BPII. 
As such, patients generally needed to first accept that BPII was a chronic and 
relapsing disorder before they could accept the need for treatment, which is primarily 
prophylactic and usually involves long-term mood-stabilising medication (Clinical 
psychologist 318, Table 4.2). By contrast, one psychiatrist felt that a positive response 
to medication legitimised BPII diagnosis and encouraged acceptance. 
 
Facilitating treatment acceptance 
The most commonly cited strategy for facilitating patient acceptance of 
diagnosis/treatment was patient education and understanding, namely the nature of 
BPII illness (chronic, relapsing) and the “need for ongoing management” (long-term, 
prophylactic) (GP 326, Table 4.2). Two clinicians also felt that family involvement 
facilitated patient acceptance by helping patients to recognise that they are “not like 
this all the time”, and to disassociate their illness from their "well" self (psychiatrist 
307, Table 4.2). 
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Table 4.2. Illustrative clinician quotations for Theme 1: (Non-)Acceptance of diagnosis and treatment 
Subtheme Illustrative clinician quotations 
1.1. Link between diagnosis and treatment acceptance 
 
 
“The first one is accepting and understanding their condition. You can't even 
move into explaining treatments or getting adherence to treatment without people 
understanding the nature of things.” (GP 324) 
 
“....until the diagnosis is accepted it's very hard to get them [patients] to accept 
the fact that they're probably going to need this medication for the rest of their 
life..... so without acceptance treatment adherence is very difficult.” (Clinical 
psychologist 318) 
 
1.2. Facilitating treatment acceptance 
 
 
“They (patients) need help to understand why they need ongoing management.... 
helping to correct people's knowledge and false information about the 
medication. Trying to help her to understand the value of taking something long 
term to prevent being in such a bad place again.” (GP 326) 
 
“Some people [patients] can feel quite strongly that this is them and this is their 
personality and I think that's when family can be so important for them… if they 
know actually you're not like this all the time.” (Psychiatrist 307) 
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4.4.4. Theme 2: Types of decisions 
Theme 2 (Table 4.3) highlighted the decisions that clinician reported that they, 
patients, and patients’ family encounter within the BPII treatment setting. These 
decisions were described as multifactorial, difficult, and sensitive to patient values. 
This theme focused on treatment decisions, i.e., what clinicians and patients are 
deciding on, and therefore appear within the body of Figure 4.1. 
 
“It's not just about medication” – multifactorial decisions 
Many clinicians spoke about the multifactorial nature of treatment decisions, which 
included medication together with psychosocial and lifestyle approaches. Clinicians, 
especially psychologists, reported engaging patients in a range of different treatment 
decisions; with medical practitioners more commonly discussing medication 
decisions only (Table 4.3). There was an ebb and flow to decision-making such that 
decisions were seldom “final” but were rather iterative and could be revisited at a 
later time point. Medication options were more actively discussed at certain points in 
the illness trajectory (e.g., post-diagnosis, when patient more symptomatic, or non 
responding to current treatment) whereas psychological options were more actively 
discussed at other points (e.g., during maintenance, when patient well-stabilised 
with/out medication).  
 
Several clinicians also alluded to a multidisciplinary approach to patient care, and 
supported patients to seek treatment from other specialists, usually psychiatrists or 
psychologists. This view was more prevalent among clinicians without a bipolar 
specialty, who acknowledged the limits of their own expertise and others’ 
complementary expertise.  
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Table 4.3. Illustrative clinician quotations for Theme 2: Types of decisions 
Subtheme Illustrative clinician quotations 
2.1. “It's not just about medication” – 
non-medication related decisions 
 
 
“I guess helping them navigate the treatment decision around medicine but also more broadly 
helping people in terms of looking at what's going on in their life, in their work life, in their 
personal relationships and within themselves, including adapting to illness and treatment.” 
(Psychiatrist 328) 
2.2. Clinician considerations 
 
 
“…if somebody has, has very low depressive and hypomanic symptoms.... there'd be more of a 
choice of whether they do want to go down the medication pathway.” (Clinical psychologist 308) 
 
 “....more perfectionistic or some people have higher levels of anxiety so you want to tread very 
carefully when you're talking about decisions because too much uncertainty that's actually quite 
anxiety provoking. So you've got to kind of limit the options to some extent....” (Clinical 
psychologist 301) 
 
2.3. “Difficult” decisions “The biggest issue is whether or not to start taking mood stabilising medications….The difficulty in 
managing medication…. [And that] many people really do not want to take medications... the main 
problem is the side effects of the medications and the fact that it’s lifelong medication, that’s 
something that people object to.” (GP 332) 
 
 “…(one health professional) he's kind of said this or (another health professional) she's said this 
and then the client is left a little bit unsure about what they want to do. They may be a bit fearful 
around taking medication…” (Clinical psychologist 308) 
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2.4. Decisions as value sensitive “…it's usually a question of what the evidence says in the scientific literature about what are 
effective treatments and there are a number to choose from. But then it's also an important sort of 
question about patient preference often in terms of the side effect profile.” (Psychiatrist 309) 
 
“...the psychotic thinking in other conditions makes the whole thing (around treatment decision-
making) more complex and means that the medication is an almost essential as opposed to a value 
choice. I have met people with bipolar II who manage over time without medication and become 
very good at managing their illness...” (Clinical psychologist 321) 
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Clinician considerations 
Apart from patients’ acceptance of diagnosis, clinicians identified a number of patient 
characteristics that influenced their treatment decision-making. Symptom severity was 
reported as having a significant impact on patient involvement, while the course and 
severity of illness episodes influenced whether pharmacological treatments were 
necessary (clinical psychologist 308, Table 4.3). Other commonly cited patient 
characteristics, included pregnancy (which precluded certain medication options), low 
socio-economic status (limiting their access to services and internet-based information 
content), “more perfectionistic” personality styles with lower tolerance of uncertain 
outcomes or “higher levels of anxiety” (associated with preferences for more or less 
patient involvement in decision-making) (clinical psychologist 301, Table 4.3).  
 
“Difficult” decisions 
All clinician groups identified medication-based decisions as the most difficult for 
patients, because of the: lifelong nature of mood-stabilising medication; potential for 
side-effects, negative associations with mood-stabilisers (“crazy tag”) versus 
antidepressants, and the changing evidence base for medication options (GP 332, 
Table 4.3). Further, two psychologists described aspects of decisional conflict 
amongst their patients. This manifested as “being unsure about what they wanted to 
do”, due to conflicting clinician recommendations and/or negative preconceptions or 
past experiences with medication, and being uncertain and anxious about whether the 
right decision was made (clinical psychologist 308, Table 4.3). 
 
Value-sensitive decisions 
Almost all clinicians felt that ongoing medication was almost always a necessary part 
of BPII treatment, especially for the treatment and prevention of depressive 
symptoms. This said, almost a quarter of clinicians mentioned that decision-making 
was preference-sensitive with regards to deciding between the available medication 
options. In this instance, decision-making needed to consider up-to-date clinical 
evidence alongside “patient preference in terms of the side effect profile” (psychiatrist 
309, Table 4.3). Only clinicians preferring patient-led and/or SDM expressed this 
view.  
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Decision-making was also described as preference-sensitive with regards to the 
treatment of hypomanic symptoms, which lacked psychotic features in BPII. One 
psychologist noted that psychotic features in bipolar I disorder made “the medication 
an almost essential as opposed to a value choice” as in BPII (clinical psychologist 
321, Table 4.3). 
 
4.4.5. Theme 3: Treatment uncertainty and balancing benefits/costs 
Theme 3 (Table 4.4) highlighted the inherent uncertainty in treatment options and 
difficulties balancing treatment benefits and costs. These formed salient 
characteristics of BPII treatment options (Theme 2) that have a significant impact on 
how decision-making occurs in consultations (Theme 4). Thus, this theme is 
positioned between Themes 2 and 4 in Figure 4.1.  
 
Uncertainties of treatment  
Almost half of clinicians acknowledged the uncertainty of (mainly medical) treatment 
options, such as that decision-making was based on “an educated guess”, had “no 
hard and fast rules”, and was “full of intangibles” and “unknowns” rather than 
“absolute knowledge” (psychiatrist 307, Table 4.4). Uncertainty related to whether a 
particular medication would be efficacious for a particular patient and/or result in 
unwanted side-effects (clinical psychologist 318, Table 4.4). Inherent treatment 
uncertainties, together with changing patient attitudes to medication (e.g., reluctance 
to accept the diagnosis and treatment) meant that decision-making was an ongoing 
process that was continually subject to review (clinical psychologist 318, Table 4.4). 
 
Fewer clinicians acknowledged that treatment uncertainties had a negative 
psychological impact on patients, invoking fear, anxiety and worry. All clinician 
groups, but especially psychologists, expressed this view. Some clinicians highlighted 
that the various “unknowns” in decision-making made SDM necessary and “very 
important” (clinical psychologist 301, Table 4.4).   
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Table 4.4. Illustrative clinician quotations for Theme 3: Treatment uncertainty and balancing act 
Subtheme Illustrative clinician quotations 
3.1. Uncertainties of treatment  
 
 
“…I can only make an educated guess on what will best suit them [patients]. But at the end of 
the day it's about you trying things and seeing what best suits the person.” (Psychiatrist 307) 
 
“… the thing that makes it [treatment decision-making] so difficult is that there's so many 
intangibles.....it's not based on absolute knowledge. A decision about if I take Lithium [mood-
stabiliser] or if I take Lamotrigine [anticonvulsant]. Is that going to take away my symptoms? 
It's often not clear….is it better to stay with the one that's not working well but is at least 
working partially or try something else?” (Clinical psychologist 318) 
 
 “So once a decision's made it's not finished. It's continually reviewed and evaluated…” 
(Clinical psychologist 318) 
 
“…. I think the difficulty is that there are lots of unknowns and as psychologists what we do 
try to do is that shared decision making which is obviously is very important.” (Clinical 
psychologist 301) 
 
3.2. Balancing benefits and costs 
 
 
“...most patients would say that getting the right balance of medication for them...can be quite 
a juggle sometimes and can sort of take time to get right and keep right.” (Psychiatrist 309) 
 
“Seroquel [atypical antipsychotic] is a classic example,  they [patients] find that they get 
really dopey from it and so they don't like that component of it because it makes it hard for 
them to function daily….sometimes the side effects are perceived to be too negative in 
comparison to the gains from [that] mood stabiliser.” (Clinical psychologist 305)  
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Balancing benefits and costs  
Several clinicians spoke of having to strike “the right balance of medication”, which 
clinicians felt was acceptable to them and their patients in terms of good treatment 
efficacy and minimal side-effects. The balance was often precarious (“a juggle”), took 
time and required a number of trials with different medications (psychiatrist 309, 
Table 4.4). Most clinicians said that treatment side-effects took precedence over 
efficacy when deciding on the right balance, and mattered more to patients in their 
decision-making. Anticipated and experienced side-effects (e.g., weight gain, fatigue) 
were cited as the main reason for patient reluctance to start or continue certain 
medications (clinical psychologist 305, Table 4.4). These views were more prevalent 
amongst GPs and psychiatrists. Fewer clinicians felt that patient placed a greater 
value on treatment benefits and were happy to “put up with” unpleasant side-effects. 
One clinician expressed a more balanced view, saying that patients took into account 
both treatment efficacy and side-effects.  
 
4.4.6. Theme 4: Decision-making in consultations 
Theme 4 (Table 4.5) outlines clinician perceptions of decision-making in 
consultations. This includes the various stages of decision-making (i.e., information 
exchange, deliberation, and making a final decision), as well as the relative 
involvement of patients, family, and clinicians in this process. According to 
clinicians, the decision-making stages and relative patient-family-clinician 
involvement seem to depend in part on the types of decisions being made (Theme 2) 
and the inherent uncertainty of, and need to balance benefits/side-effects of treatment 
options (Theme 3). Hence, this theme is preceded by and flows on from Themes 2 and 
3 in Figure 4.1.  
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Table 4.5. Illustrative clinician quotations for Theme 4: Decision-making in consultations 
Subtheme Illustrative clinician quotations 
4.1. Decision-making stages 
 
Information exchange 
 
 
 
 
Giving options 
 
 
 
Deliberation 
 
 
“…we were talking about, what I would recommend as a mood stabiliser for her [this 
patient]…..fairly broad terms what mood stabilisers were and, discussion of their strengths 
and weaknesses and, and highlighting some of the potential unwanted or side effects that 
people tend to worry about” (Psychiatrist 309) 
 
“I go through with the patient what I think would be an appropriate mix of treatment….I tend 
to do things to various recipes….So at the end of the day I think I have canvassed all the 
options.” (GP 333) 
 
“…we discuss the pros and cons of taking medication and how they [patient] feel about it, 
why they're hesitant, things like that….just discussing with them how they feel about it, the 
pros and cons…. sometimes putting out there suggestions” (Clinical psychologist 308) 
 
4.2. Patient involvement  
 
 
 
Patients as the decision-maker 
 
 
 
 
 
“When they [patients] make that final decision your job would be to support them in whatever 
that decision is and to actually then encourage them to carry it out. But...really the decision is 
theirs and it's their responsibility.” (Clinical psychologist 301) 
 
“In the end she [a patient] made the decision but she made it very much with my guidance 
and we reached a compromise that we both felt comfortable with and felt willing to explore.” 
(GP 324) 
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Trends and variability in patient involvement 
 
“I do have quite a few clients with bipolar II who are further down the pathway in that they've 
been diagnosed for quite some time and they're capable of doing [decision-making] 
themselves…” (GP 324) 
 
4.3. Family involvement 
 
 
Family involvement in and out of consultations 
 
 
 
 
Family attendance at consultations 
 “I think the family members do lots of talking and I think they often have a preference but I 
must be fair to many of them that often their preference if it isn't chosen, they're okay about 
it.” (Clinical psychologist 321) 
 
“...If I think it would be beneficial to [the patient] and important to have them [the family] 
come in, I ask “would you mind if I ask them [patient’s family] to come in”. I respect their 
[patient’s] right to privacy and I respect their opinion and their judgement” (Psychiatrist 310) 
 
“I like to bring in [family] at some stage in the early stages of seeing a new client….we 
normally have a discussion where I really ask the partner to ask me any questions that they 
have and we talk about things that have come out in our consultations as well” (Clinical 
psychologist 318) 
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Decision-making stages  
In consultations, most clinicians alluded to information exchange/provision to patients 
about medication. Several clinicians also noted that patients supplemented clinician-
provided information with their own information which they gathered pre-/post-
consultations (e.g., online, discussions with other clinicians and friends/family). 
Approximately half of these clinicians, especially GPs and psychiatrists, tailored 
information to the patients' life circumstances or what the patient already knew, or 
responded to patient preferences for information (desiring a lot of information). For 
the other half, information exchange appeared to be clinician-led with minimal or no 
reference to patient involvement at the “information exchange’ stage of decision-
making. These clinicians tended to only give information relating to a particular 
medication option (psychiatrist 309, Table 4.5). 
 
Several clinicians reported outlining options to patients for treatment. Only a couple 
of clinicians reported explicitly offering patients alternative treatments to pursue. 
Another two GPs/psychiatrists appeared to contradict themselves in their accounts. 
Whilst these clinicians felt they “canvassed all the options” for patients, the options 
reportedly offered seemed restricted by the clinician's own preferences (“various 
recipes”), or influenced by the clinician's perceptions of patient competence (e.g., 
reliability and likelihood of treatment adherence) (GP 333, Table 4.5).  
 
Most clinicians spoke about the deliberation stage of decision-making (i.e., discussion 
of treatment preferences); with approximately three quarters of clinicians reporting 
that they employed shared or collaborative approaches. All clinician groups, 
especially psychologists, and clinicians with a bipolar specialty, reported ‘shared’ 
deliberation. This involved an open and frank discussion of patient preferences (“how 
they feel about it, the pros, the cons”), and “putting out suggestions” or 
recommendations (clinical psychologist 308, Table 4.5). To integrate patient 
preferences, clinicians discussed patient’s treatment goals and feelings towards 
treatment pros/cons, and past medication experiences. This discussion then informed 
an acceptable treatment plan.  
 
Fewer GPs and psychiatrists described clinician-led deliberation without reference to 
involving patients in a discussion about their preferences. This clinician-led style of 
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decision-making was more prevalent amongst medical practitioners without a 
specialty in bipolar disorders.  
 
Patient involvement  
A majority of clinicians considered patients as the final decision-maker in treatment 
decisions. Clinicians supported patients’ having the final say because it concerned 
their lives and was their responsibility to implement the decided-upon treatment 
(clinical psychologist 301, Table 4.5).  
 
Most clinicians felt that their role was to provide “guidance”, “support” and 
“assistance” without excessive influence (i.e., “not telling them what to do”) (GP 
324, Table 4.5). Some clinicians alluded to respect patient autonomy and having to 
support any decision that was made, even if they did not agree with it. Two clinicians 
noted that patients desired greater involvement in treatment decision-making than 
they had, particularly with regards to medication. 
 
In enabling patients to make the final decision, clinicians reportedly practised several 
SDM elements. This included: providing expert opinion and treatment information 
within the context of the patient's life, asking questions to check patients’ 
understanding of information and thoughts about treatment, exploring the potential 
impact of treatment on the patient, suggesting or recommending treatments, listening 
to patients’ treatment concerns and preferences, and trying to accommodate these into 
a mutually-acceptable course of action. 
 
Several clinicians noted variability in patient involvement in treatment decision-
making, and identified factors influencing this. Patients reportedly tended to be more 
involved when they had a longstanding diagnosis and had achieved mood stability, 
viewed themselves as more proactive/independent, and saw their clinician as a 
“human” with inherent limits to their knowledge (GP 324, Table 4.5). By contrast, 
patients were reportedly less involved and more likely to defer decision-making to the 
clinician when they were newly-diagnosed, yet to reach mood stability, viewed 
themselves as passive, held paternalistic attitudes towards the clinician, were younger, 
and were making treatment decisions about medications.  
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Family involvement 
Approximately two thirds of clinicians reported on limited family involvement in 
treatment decision-making. Family involvement almost exclusively occurred outside 
consultations and clinicians reportedly seldom inquired about family involvement or 
patient preferences for this. Several psychologists with a preference for patient/family 
involvement in decision-making noted that family were involved but respected patient 
autonomy, “their [treatment] preference isn't chosen, they're okay about it.” (clinical 
psychologist 321, Table 4.5). 
 
For the most part, clinicians reported that family did not attend consultations. By 
contrast, clinicians with a preference for triadic SDM always reported at least some 
family attendance at consultations. Family attendance was mostly patient-initiated 
(bringing the family member along) and occurred in line with patient stated 
preferences, “their opinion and their judgement” (Psychiatrist 310, Table 4.5). 
Clinician-initiated family attendance usually occurred shortly after diagnosis, or when 
the clinician wanted to give the family an opportunity to ask questions and have their 
concerns addressed (clinical psychologist 318, Table 4.5).  
 
4.5. Discussion 
This is the first known study to explore how clinicians view and experience treatment 
decision-making in BPII. These findings provide insights into the nature of treatment 
decisions, and how decision-making unfolds within consultations, as well as factors 
that seem to influence this process. As seen in Figure 4.1, the themes derived from the 
data are both interrelated and cyclical (e.g., relationship between balancing uncertain 
benefits/side-effects of treatment and patient involvement in consultations flowing 
into acceptance of treatment) and conform to a hierarchy (acceptance of diagnosis and 
treatment contribute to patient engagement in decision-making). Discussion of 
noteworthy findings is provided below.  
 
Clinicians identified a number of patient-related characteristics that they considered 
important in treatment decision-making in BPII. Firstly, according to clinicians, 
patients who accepted their BPII diagnosis were more likely to accept medication and 
engage in decision-making about medication. Secondly, clinicians felt that the 
presence of severe symptoms (either depressive or hypomanic) impeded effective 
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patient engagement in decision-making. Thirdly, clinicians reported that some 
patients were more or less inclined to defer decision-making to clinicians based on 
their personality styles (e.g., independent versus dependent). Of note, these patient-
related characteristics were perceived to have a significant impact on BPII patients’ 
ability and motivation to engage in treatment decision-making. Most research on 
patient involvement in treatment and management decisions in bipolar disorder has 
not considered these patient-related characteristics, apart from symptom severity (e.g., 
[36]). This is likely because global assessments of patient involvement using patient-
report (e.g., [17]) and consultation ratings (e.g., [37]) seldom capture broader factors 
influencing patient involvement. “Optimal” patient involvement is likely to vary over 
the illness trajectory and in response to changing patient symptoms and increasing 
acceptance [38]. By implication, clinicians need to be flexible in their approach to 
decision-making, and ensure that patients are involved as much as preferred at the 
time. To do this, clinicians need to explicitly obtain patient preferences for the type 
and level of decision-making involvement, which was not reported by clinicians in 
this study or other research [12]. Continuously revisiting patient involvement 
preferences seems especially pertinent to BPII, which is characterised by fluctuating 
symptom severity and associated disability, and which relies heavily on patient self-
management to prevent illness episodes (prophylaxis).  
 
In addition, facts about treatment choices also influenced clinician approaches to 
decision-making. According to clinicians, the inherent uncertainty and varying 
benefit/side-effect profiles of BPII medications made medication-based decisions 
particularly difficult. Of note, relatively few clinicians reported that the uncertainty 
inherent in treatments had a negative psychological impact on some patients (e.g., 
distress, fear, concern), and necessitated SDM. These findings contrast with literature 
endorsing SDM when mental health treatment options have uncertain and potentially 
burdensome outcomes [5]. These findings also suggest that clinicians may 
underestimate the negative psychological impact of clinical uncertainty on patients. 
When faced with uncertain treatment outcomes, patients may require additional 
psychosocial support [39], and SDM may help patients to better tolerate uncertainty 
[40]. Clinician recognition of patients’ emotions and responses to treatment options 
may also increase patient satisfaction with decision-making [41]. Education on these 
issues appears warranted, especially as clinician expertise in communicating complex 
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information and coping with patients’ emotional and personal reactions has not been 
found to improve with time and experience [42]. 
 
Further, clinicians expressed discrepant views regarding other aspects of treatment: 
what they perceived patients valued more in treatment options, treatment efficacy 
versus side-effect burden. While some clinicians felt that patients attributed greater 
importance to side-effect burden than treatment efficacy, others expressed opposite 
views. Given that clinicians reported side-effect burden as a major barrier to treatment 
uptake and adherence, consistent with other research [43], it is important that 
clinicians openly discuss patient attitudes towards the different features of treatment 
options. This is especially important considering that clinicians may assume that side-
effects are of lesser importance to patients than patients actually perceive them to be 
[44].  
 
Clinicians almost uniformly supported patient involvement and autonomy in BPII 
treatment decision-making. The patient was seen as the final decision-maker and, 
accordingly, most clinicians reported that they practised elements of SDM (e.g., 
offering options, and checking patient thoughts about treatment). When clinicians 
described their behaviours during past consultations, however, a more mixed picture 
of actual patient involvement emerged (as per [45]), with regards to key SDM steps of 
eliciting patient preferences for involvement and treatment, providing information 
about and deliberating on available treatment options. Indeed, the extent to which 
patients were actually involved seemed to commonly depend on the clinician’s own 
preferences for treatment and patient involvement, judgements about patient 
competence, and health professional background. For example, some clinicians 
appeared to offer a limited number of treatment options based on their own treatment 
preferences and beliefs about the patient (e.g., believing the patient to be too 
unreliable to commit to ongoing medical check-ups for lithium). Further, 
GPs/psychiatrists and clinicians without a speciality in bipolar disorders appeared less 
likely to involve patients in deliberation about treatment options compared to clinical 
psychologists and clinicians with a speciality in bipolar disorders. It may be that 
specialised clinicians are more proficient at involving these patients in treatment 
deliberation. System-related factors (e.g., short consultation times) may also reduce 
shared deliberation with medical practitioners (GPs/psychiatrists) [44] compared to 
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psychologists in the mental health setting. Alternatively, the apparent disconnect 
between clinician endorsement of patient involvement and actual patient involvement 
may be explained by clinician misconceptions that they “are already doing SDM” 
[45], or the distinction that clinicians make between the process of decision-making 
(e.g., sharing of information by clinician) and who makes the final decision (patient) 
[15]. According to this view, patients may be recognised as the final decision-maker 
but have had limited input in the earlier stages of decision-making. Therefore, it is 
important that clinicians have access to interventions designed to encourage them to 
reflect on, and improve their own clinical communication skills. Communication 
skills training, widely tested within the medical setting, is one such intervention 
leading to enduring improvements in clinicians’ clinical communication skills [46, 
47]. Future research comparing clinician-reported steps of SDM with their clinical 
practice could elucidate specific challenges and define the areas of improvement for 
targeted training programs.  
 
As well as influencing patient involvement, clinician preferences also appeared to 
influence family involvement in treatment decision-making. Clinicians were generally 
unaware of family involvement in treatment decision-making outside consultations, 
and did not ask patients their preferences for family involvement. These findings align 
with other consultation studies in mental health showing clinicians rarely ask patient 
preferences for others’ input [48]. Further, family attendance at consultations 
appeared to be mostly initiated by the patient rather than encouraged by the clinician. 
By contrast, when clinicians themselves preferred family involvement in decision-
making, they were more likely to recognise the influence of family on treatment 
decisions, appreciate family involvement, and report family attending consultations. 
Thus, clinician attitudes and behaviours appear to influence whether, and to what 
extent family are involved in treatment decision-making, which accords with findings 
from the medical setting [49]. As family involvement, even “behind-the-scenes”, 
influences and benefits patient involvement and treatment decision-making [50-52], it 
is important that clinicians establish patient preferences for family involvement [49] 
and identify any barriers to involving family to the extent patients prefer.  
 
The present study has several limitations. Firstly, due to the “opt-in” nature of 
clinician recruitment and potential for self-selection bias, it is possible that these 
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findings reflect the views of clinicians who are more interested in treatment decision-
making in BPII. Secondly, although attempts were made to recruit clinicians from 
different health professional backgrounds, the present study included fewer GPs and 
psychiatrists than clinical psychologists. However, medical practitioners’ and clinical 
psychologists’ views were equally represented and data saturation was reached in 
each of the subgroups. Thirdly, the present clinician sample comprised mostly 
experienced clinicians. Whilst this limitation may be less pertinent to specialist 
clinicians, the views and experiences of clinicians in this study may not represent 
those of less experienced or generalist clinicians, who may be less knowledgeable 
about and less confident in treating BPII. For example, the GPs included the study 
may be more knowledgeable about bipolar disorder and the BPII subtype compared to 
other primary care physicians. 
 
In conclusion, this study provides the first known examination of clinician views and 
experiences of treatment decision-making in BPII. Findings demonstrate how 
clinician-related factors (e.g., attitudes towards treatment options) may shape the 
treatment decision-making process. Findings also suggest potential challenges in 
treatment decision-making, such as low patient involvement and failure to assess 
patient attitudes towards treatment options and others’ involvement. These 
shortcomings provide opportunities for clinical practice interventions, such as 
communication skills training in the mental health setting. However, to fully address 
these potential shortcomings, clinician-perceived barriers and facilitators to treatment 
decision-making should be explored in greater depth.   
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Chapter 5: Identifying and addressing barriers to treatment decision-making in 
bipolar II disorder: Clinicians’ perspective. 
 
This chapter is reformatted from the published manuscript:  
Fisher A, Manicavasagar V, Sharpe L, Laidsaar-Powell R, Juraskova I. Identifying 
and addressing barriers to treatment decision-making in bipolar II disorder: 
Clinicians’ perspective. Australian Psychologist. 2018;53(1):40-51. 
https://doi.org/10.1111/ap.12264 
 
 
This chapter reports on a qualitative study, which sought to investigate the barriers 
that clinicians encounter, and the strategies they use when making treatment decisions 
with patients with bipolar II disorder (BPII) and their families. Based on findings, a 
number of preliminary clinician-endorsed decision-making strategies are proposed. 
These strategies were used to inform the content, format, and delivery of the decision-
aid (DA, see Chapter 6). Ethics approval letters are provided in Appendices B1 and 
B2; supplementary materials related to this study are provided in Appendix E. 
 
Author contributions 
Conception and design: AF, IJ 
Participant recruitment: AF 
Data collection: AF 
Data analysis and interpretation: AF, IJ, RL-P, LS 
Manuscript drafting: AF 
Manuscript critical review: All authors 
Review of final manuscript: All authors 
  157 
5.1. Abstract 
Objective. Treatment decision-making in bipolar II disorder is complex due to limited 
evidence on treatment efficacy and potentially burdensome side-effects of options. 
Thus, involving patients and negotiating treatment options with them is necessary to 
ensure that final treatment decisions balance both clinician and patient preferences. 
This study qualitatively explored clinician views on (a) effective treatment decision-
making, unmet patient needs for (b) decision-support and (c) information. 
 
Method. Qualitative semi-structured interviews with 20 practising clinicians (n=10 
clinical psychologists, n=6 GPs, n=4 psychiatrists) with experience treating adult 
outpatients with bipolar II disorder were conducted. Interviews were audiotaped, 
transcribed verbatim and analysed thematically using framework methods. Self-report 
professional experience, and clinician preferences for patient decision-making 
involvement were also assessed.  
 
Results. Qualitative analyses yielded two inter-related themes: 1) challenges and 
barriers to decision-making and 2) facilitators of clinician decision-making. 
Symptom severity, negative family attitudes, system-based factors and information 
gaps were thought to pose challenges to decision-making. By contrast, decision-
making was supported by patient information, family involvement and patient-
centredness, and a strong therapeutic relationship. Clinician views varied depending 
on their professional background (medical versus clinical psychologist), patient 
involvement preferences and whether the clinician was a bipolar specialist. 
 
Conclusions. Whilst clinicians uniformly recognise the importance of involving 
patients in informed treatment decision-making, active patient participation is 
hampered by unmet informational and decision-support needs. Current findings 
inform a number of bipolar II disorder-specific, clinician-endorsed strategies for 
facilitating patient decision-making, which can inform the development of targeted 
patient decision-support resources for use in this setting.  
 
Keywords. Bipolar II disorder, treatment decision-making, qualitative, clinician 
views, barriers, strategies.   
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5.2. Introduction 
In shared treatment decision-making (SDM), the clinician and patient (and others, e.g. 
family) share their respective knowledge and expertise regarding the different 
treatment options, and deliberate on the benefit-costs of these in relation to the 
patients’ values [1, 2]. Critically, the final decision in SDM would incorporate both 
parties’ preferences. Not only does SDM support patient autonomy and informed 
decision-making, it is consistent with many patients’ preferences for information and 
involvement in their own mental health treatment decisions [3-5]. Thus, SDM has 
attracted increasing attention in the literature and in clinical practice for its 
applicability to many mental health conditions [3, 6-8]. 
 
SDM may particularly benefit patient outcomes in chronic mental illnesses, which 
rely on patients adopting a self-management approach to prevent illness symptoms 
[9]. Bipolar disorder is one such illness where shared approaches to decision-making 
and management have been linked to improved outcomes, such as treatment 
adherence and satisfaction with care [10]. Although SDM has value in both bipolar I 
and II disorders, SDM may be particularly important and challenging in bipolar type 
II (BPII), given that treatment options are more finely balanced between clinician and 
patient preferences. This is due to: the absence of psychosis in BPII [11], lack of 
psychosocial impairment during hypomania [12], and limited published BPII-specific 
treatment guidelines which draw on a relative paucity of research to advise first-line 
mood-stabilising medications (i.e., lithium, lamotrigine, quetiapine) together with 
adjunctive psychological treatment (i.e., cognitive behavioural therapy, group psycho-
education) [13-16]. 
 
Despite the importance of collaborative approaches to decision-making, many 
patients with bipolar disorder continue to experience low levels of involvement in 
shared treatment decision-making despite expressing a preference for it [17, 18]. This 
mismatch between preferred and experienced levels of patient involvement in bipolar 
disorder may not only compromise patient outcomes [19, 20], but also points to 
barriers to achieving SDM in this population. There remains a dearth of research on 
SDM in bipolar disorder [18], especially qualitative investigations of key clinician, 
patient, and family perspectives. In order to maximise patient involvement in 
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treatment decision-making, in line with their preferences, challenges and enablers to 
this process need to be examined. 
 
Only one qualitative study has investigated the facilitators of collaboration between 
clinicians and patients in bipolar disorder specifically [21]. This study identified 
patient-related barriers, such as symptoms, communicative difficulties, as well as 
clinician-related barriers, such as poor empathy and listening, and discounting patient 
concerns. Also identified were several patient-related facilitators, such as open 
communication and family involvement, and clinician-related facilitators, such as 
meaningful discussion of patient problems [21]. However, this study did not ask 
specifically about treatment decision-making, and included only patient perspectives. 
In fact, no existing studies have explored the views and experiences of clinicians on 
the process of treatment decision-making in bipolar disorder [18], in contrast to 
several studies on depression [22, 23] and schizophrenia [24-26]. This represents a 
significant gap in the literature as both patient- and clinician-initiated behaviours 
contribute to overall SDM levels within consultations [27]. Thus, clinicians treating 
BPII have a responsibility to carefully negotiate the various treatment options with 
patients to ensure that the final treatment decision is shared and balances both their 
own and their patient’s preferences and values.  
 
The present study aimed to qualitatively explore clinicians’ views and experiences of 
BPII treatment decision-making with patients in an outpatient setting. Consistent with 
the Ottawa decision support framework [28], which posits the link between decisional 
needs, quality of decision-making, and tailoring of decision-support this study had 
two principal aims. These were to elucidate: i) the challenges clinicians encounter in 
meeting patient needs for decision support and information; ii) the perceived barriers 
and facilitators to effective treatment decision-making.  
 
5.3. Methods 
 
5.3.1. Participants 
Eligible clinicians (N=26) were those who were currently practising, and had 
experience in treating adults diagnosed with bipolar II disorder (BPII) within the 
outpatient setting. This included both medical and non-medical clinicians (i.e., 
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psychiatrists, GPs, and clinical psychologists) working across general practice and 
specialist care. Three recruitment methods were utilised: 1) Clinicians affiliated with 
the Black Dog Institute (BDI, a clinical service specialising in the assessment and 
treatment of mood and bipolar disorders); 2) Clinicians attending BDI-organised 
professional development workshops; 3) Clinicians signed up to receive BDI e-
newsletters. Purposive sampling was used to obtain maximum variation on clinician 
characteristics such as years of clinical practice and professional specialty. 
 
Recruitment continued until data saturation (three consecutive interviews revealing no 
new information) was achieved [29]. All aspects of the study received ethics approval 
from The University of Sydney Human Research Ethics Committee (USYD HREC) 
and the BDI Research Advisory Committee, and complied with the Code of Ethics of 
the World Medical Association (Declaration of Helsinki)[30]. 
 
5.3.2. Procedure 
Expression-of-interest flyers were made available at BDI staff meetings, professional 
development workshops, and disseminated via clinician emailing-lists. Interested 
clinicians contacted the researcher at USYD (AF) via details provided on the 
expression-of-interest flyer. The researcher then explained the study rationale to 
clinicians and obtained verbal consent to post/email a study pack to them, which 
contained an information sheet and consent form, and pre-interview questionnaire. 
Participants were sent two reminders, one and two weeks’ after the study pack was 
sent to them. Once the completed questionnaire and consent form were received, a 
one-off telephone interview was arranged. 
 
5.3.3. Qualitative data collection 
A purpose-designed, semi-structured interview protocol (Appendix E) was based on: 
widely-cited models of SDM [1, 2, 31], the Ottawa decisional support framework [28, 
32, 33], and previous qualitative studies of treatment decision-making in the mental 
health (e.g., unipolar depression [34]) and medical settings (e.g., cancer [35]).  
 
In this paper we report on clinician-perceived challenges to decision-making about 
BPII treatment, as well as strategies for improving this process. Other results from 
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this qualitative study, such as clinician-patient-family involvement and the nature of 
treatment decisions in this setting, will be reported elsewhere.  
 
5.3.4. Statement of reflexivity 
The first author (AF), who conducted all interviews, is a female PhD student with a 
background in clinical health psychology and shared decision-making, and experience 
in conducting qualitative interviews across a number of patient populations (e.g., 
bipolar disorder, cancer, traumatic brain injury). Although not trained as a clinical 
psychologist, AF has developed specialised clinical knowledge in mood and bipolar-
related disorders through an Honours degree in Psychology and attendance at 
professional development workshops for clinical psychologists, GPs and allied health 
professionals. During and immediately after each interview, AF wrote memos on any 
initial impressions and noteworthy remarks in order to maintain reflexivity and an 
awareness of potential personal biases throughout the interview process. 
 
5.3.5. Quantitative measures 
Clinician preferences for their own and others’ (i.e., patients/family) decision-making 
involvement were assessed using an adapted version of the Control Preferences Scale 
(CPS, [36-38]). This self-report, two-item scale measured involvement preferences 
both in dyadic (clinician-patient) and triadic scenarios (clinician-patient-family). For 
both dyadic and triadic scenarios, participant preferences can be categorised as active 
(fully patient-led, or patient-led with clinician[/family] involvement), shared (equal 
clinician-patient[-family] involvement), or passive (fully clinician-led or clinician-led 
with patient[/family] involvement). The CPS has been used to evaluate physician 
perceptions of patient involvement in treatment decision-making [38], and in 
outpatient samples including bipolar disorder [20, 39, 40]. 
 
Demographic, clinical and professional characteristics (e.g., age, gender, years in 
clinical practice, typical patient presentation and treatment types) were collected via a 
purpose-designed self-report questionnaire. Participants also indicated whether, and 
how often family members attended consultations.  
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5.3.6. Data analysis 
Descriptive and frequency analyses of questionnaire data were conducted using SPSS 
version 22. Interviews were audio-recorded and professionally transcribed. The 
interviews were then thematically analysed [41] using framework methods as outlined 
by [42]. To ensure methodological rigour, a proportion of the transcripts (20%) were 
cross-coded by a second co-author (RL-P) and discrepancies discussed and resolved 
before proceeding with coding the entire dataset. Secondly, the thematic map was 
developed in consultation with two co-authors, who have expertise in treatment 
decision-making and qualitative analysis.  
 
5.4. Results  
 
5.4.1. Participant characteristics 
Table 5.1 summarises clinicians’ demographic and clinical characteristics. Of the 26 
clinicians who were approached and agreed to participate, 20 completed both the 
questionnaire and interview (76.9% response rate). Recruitment was balanced across 
clinical psychologists (n=10) and medical clinicians (psychiatrists, GPs; n=10). 
Interviews ranged from 21-51 minutes in length (M=34 minutes).  
 
All clinician groups reported extensive professional experience (Ms=13.70-19.25 
years, Range: 3-30); almost all clinicians (90%) practised in metropolitan areas. Half 
of psychiatrists (50%) and most clinical psychologists (70%) reported specialisation 
in the assessment/treatment of bipolar and other mood disorders; most GPs (83%) 
reported no mental health speciality. All clinicians indicated that medication and 
adjunctive psychological-based interventions typically made up their patients’ 
treatment. Regarding preferred patient involvement, all except one clinician preferred 
patient (or family)-led or shared decision-making in both dyadic (clinician-patient) 
and triadic (clinician-patient-family) consultations (Table 5.1).  
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Table 5.1. Clinician demographic/ professional characteristics and patient characteristics. 
  Psychiatrists 
(n=4) 
GPs 
(n=6) 
Clinical 
psychologists 
(n=10) 
Age M(SD) 53.25(11.44) 55.83(11.0) 50.50(10.46) 
Gender (female) n(%) 2(50.0) 4(66.7) 7(70.0) 
Mental health speciality n(%)    
   Bipolar and other mood disorders  2(50.0) -- 7(70.0) 
   Other (e.g.,trauma,psychosis)  2(50.0) 1(16.7) 2(30.0) 
   None  -- 5(83.3) 1(10.0) 
Years in speciality M(min-max) 19.25(8.0-28.0) 16.83(4.0-30.0) 13.70(3.0-30.0) 
Hours direct patient contact p/w M(min-max) 22.50(16.0-30.0) 24.83(12.0-50.0) 18.90(10.0-30.0) 
Hours direct contact with BPII patients p/w M(min-max) 7.25(4.0-12.0) 3.67(1.0-8.0) 4.15(0.5-12.0) 
Most common BPII patient presentation n(%)    
   Depressed  2(50.0) 5(83.3) 5(50.0) 
   Mixed state  1(25.0) -- 1(10.0) 
   Euthymic/subsyndromal  -- 1(16.7) 3(30.0) 
   Other (e.g.,heterogenous)  1(25.0) -- 1(10.0) 
Most common medication in BPII n(%)    
   Mood-stabiliser only 
(lithium,anticonvulsants) 
 1(25.0) 2(33.3) 3(30.0) 
   Antidepressant only  -- -- 1(10.0) 
   Mood-stabiliser and antidepressant  1(25.0) 2(33.3) 4(40.0) 
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   Mood-stabiliser and atypical antipsychotic  -- -- 1(10.0) 
   Other (e.g.,polypharmacy of above)  2(50.0) 2(33.3) 1(10.0) 
Psychological interventions  n(%)    
   Yes (e.g., CBT, Mindfulness, Wellbeing 
plans) 
 4(100.0) 6(100.0) 10(100.0) 
% BPII patients attending with family (1+) M(min-max) 32.50(0.0-60.0) 8.67(0.0-20.0) 7.50(0.0-15.0) 
Most common attending family †     
   Spouse/ Partner  2(50.0) 3(50.0) 6(60.0) 
   Parent  1(25.0) 2(33.3) 1(10.0) 
Preferences for patient involvement 
(triadic) † 
n(%)    
   Patient-led with family/clinician  1(25.0) 3(50.0) 5(50.0) 
   Patient/family-led with clinician  1(25.0) -- 2(20.0) 
   Patient/family/clinician shared  1(25.0) 3(50.0) 1(10.0) 
   Clinician-led with patient/family  1(25.0) -- -- 
Preferences for patient involvement 
(dyadic) 
n(%)    
   Patient-led alone   1(16.7) -- 
   Patient-led with clinician  3(75.0) 2(33.3) 8(80.0) 
   Patient/ clinician shared  -- 3(50.0) 2(20.0) 
   Clinician-led with patient  1(25.0) -- -- 
† = For clinicians reporting family attendance.  
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5.4.2. Qualitative findings 
Qualitative analyses yielded two inter-related themes, each comprising several 
subthemes: 1) Challenges and barriers to decision-making and 2) facilitators of 
clinician decision-making. Illustrative patient and family quotes are presented in 
Tables 5.2 and 5.3.  
 
5.4.3. Theme 1: Challenges and barriers to decision-making 
Theme 1 (Table 5.2) encompassed clinician perceived challenges to decision-making 
about BPII treatment. Challenges were diverse, spanning patient-related, clinician-
related and family-related factors as well as shortcomings of the healthcare system 
and available patient information.  
 
Patient-related 
A large proportion of clinicians referred to the negative impact of BPII symptoms on 
treatment decision-making. Both hypomanic and depressive symptoms were 
associated with limited “chances of making correct decisions”, a skewed “frame of 
reference” (insight), “regret [about] decisions”, and poor “concentration to make 
decisions” (clinical psychologist 318, Table 5.2).  
 
Several clinicians noted that some patients held a priori treatment preferences, based 
on “preconceived ideas and stigma attached to taking medication” (GP 332, Table 
5.2). Clinicians reported that these presented an obstacle to decision-making because 
patients with preconceptions about medications (e.g., lithium, sodium valproate) were 
often reluctant to commence them, or made “decisions in favour of psychological 
support” over pharmacological approaches (GP 332, Table 5.2).  
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Table 5.2. Illustrative clinician quotations for Theme 1: Challenges and barriers to decision-making 
Subtheme Illustrative clinician quotations 
1.1. Patient-related 
 
Impact of symptoms and comorbidities 
 
 
A priori treatment preferences 
 
 
“In that depression you get with bipolar II people don't have the concentration to actually make 
decisions. …..you may regret those decisions. If you are hypomanic….your chances of making 
correct decisions are much more limited.” (clinical psychologist 318) 
 
“Sometimes decisions in favour of psychological support are made because of preconceived 
ideas and stigma attached to taking medication.” (GP 332) 
 
1.2. Clinician-related  
Unhelpful clinician behaviours 
 
“He [one patient] was trying to make a decision about […] medication….His GP was very 
directive…That was an unhelpful way of trying to encourage someone.” (clinical psychologist 
319) 
 
1.3. Negative family influences 
 
“Unhelpful…..family members are more often than not extremely reluctant to accept the 
diagnosis and that the medication is required in this instance.” (GP 332) 
 
 “…over-involved family members…..not allowing the individual to make their own 
decisions….in trying to support are also disempowering the individual.” (psychiatrist 307) 
 
1.4. System-based  
 
“….with bipolar, you want more than just ten [Medicare] sessions…but some people can't 
afford to continue seeing the psychologist beyond those ten.” (clinical psychologist 308) 
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“...when it's a 10 or maybe 15 minute consultation they [patients] can feel that they've just been 
given the next script…that tends to be less satisfying for them.” (clinical psychologist 304) 
 
1.5. Inadequacies in available patient 
information 
 
 “…when really they [patients] still only have a small amount of information…people do 
struggle with that and tend to want my opinion…” (psychiatrist 328) 
 
 “...trying to communicate information around medication into a digestible form….information 
about medication for someone who doesn’t have a medical or pharmacology background is 
really difficult to absorb” (psychiatrist 328) 
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Clinician-related  
Almost half of clinicians noted potentially unhelpful clinician behaviours that 
impeded decision-making. These included: a lack of open and honest communication 
(about medication options/outcomes), inadequate expertise, a lack of rapport or 
patient trust, and being “very directive” with limited patient input (clinical 
psychologist 319, Table 5.2). An overly directive (paternalistic) approach was linked 
to a power imbalance between the patient and their clinician. Inadequate rapport or 
trust, and poor communication were associated with limited time with the patient, and 
clinicians being over-familiar with medications (due to highly specialised 
knowledge), respectively. 
 
Negative family influences 
Over half of clinicians, especially psychologists, reported family behaviours or 
attitudes that were detrimental to decision-making. The most commonly expressed 
attitude was the family’s reluctance “to accept the diagnosis and…that the medication 
is required” (GP 332, Table 5.2). These family attitudes/behaviours resulted in 
patients being reluctant to commence treatment, prematurely discontinue medication, 
or be less successful at implementing psychological strategies. Specifically, some 
family (especially parents) were reported to undermine the patient's autonomy, by 
becoming “overly-involved” or “taking on too much” in a patient's treatment 
decision-making (psychiatrist 307, Table 5.2). 
 
System-based challenges/barriers 
Almost half of clinicians noted system-related barriers to decision-making. These 
included: poor access and affordability of specialist services 
(psychologists/psychiatrists), time constraints during consultations, and a lack of 
multidisciplinary communication or coordination between clinicians with different 
professional training. A lack of accessibility and affordability reportedly led to 
patients prematurely discontinuing psychological treatment, or limiting available 
options (clinical psychologist 308, Table 5.2). Consultations perceived as excessively 
short reportedly led to lower patient satisfaction due to reduced continuity of care and 
more prescriptive decision-making where “they’ve just been given the next script” 
without any meaningful discussion with the patient (clinical psychologist 304, Table 
5.2). 
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Inadequacies in available patient information 
Almost half of clinicians, especially those preferring patient-led decision-making, 
noted gaps in current BPII patient information (both patient-sourced/clinician-
provided information). A few clinicians, mainly psychologists, noted a general lack of 
written/online information and patient understanding of BPII illness and medication 
effects (especially long-term benefits/prognosis). Two GPs/psychiatrists also noted 
that where medication information is available (either online or via patient factsheets), 
it was often “difficult to absorb” and too complicated for patients to understand 
(psychiatrist 328, Table 5.2). The lack of information or availability of highly 
technical information reportedly compromised decision-making because patients 
came to consultations insufficiently informed to make decisions or more likely to 
defer to the clinician (psychiatrist 328, Table 5.2). 
 
5.4.4. Theme 2: Facilitators of clinician decision-making.  
Theme 2 (Table 5.3) highlighted clinician strategies for facilitating decision-making, 
such as patient information and education, encouraging family involvement and 
patient involvement, and fostering a strong therapeutic relationship. These facilitators 
mapped onto similar domains (e.g., patient-/clinician-related, informational and 
systemic) to those discussed in Theme 1.  
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Table 5.3. Illustrative clinician quotations for Theme 2: Facilitators of clinician decision-making 
Subtheme Illustrative clinician quotations 
2.1. Making time – Structuring 
consultations 
 
 
“… almost 100% of the time I don't prescribe on the first session.....it's much better for people to go 
away, think about that [treatment options], reflect on what we've talked about, talk to family, talk to 
partners and come back. I try and get people back within a week…this is a big decision. And by 
doing that there's a much better compliance.” (psychiatrist 307) 
 
2.2. Patient information and education 
facilitating decision-making 
 
Patient information needs and 
preferences 
 
 
 
 
 
Supporting role of information 
 
 
 
 
Value of others’ lived experience 
 
 “When you put a patient on medication they want to know what are the risks and side effects of 
medication. Having clear information about what they can expect…being able to answer their 
questions is important.” (GP 325) 
“…all the evidence-based treatments and look how they fit into the recovery….it would be very 
good to have a spectrum of treatment options.” (clinical psychologist 313) 
 
 
“….information...is really helpful [for] people to come to a decision…ask more appropriate 
questions about treatment….a lot more knowledgeable about the medication that I was 
recommending....and weighing the options.” (psychiatrist 309) 
 
 “....reading other people's stories are really helpful...it's always just so much more credible when 
you hear it from someone who's in that position.” (clinical psychologist 303) 
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2.3. Clinician perceptions of family as 
a resource 
 
Encouraging and facilitating family 
involvement 
 
 
 
 
 
 
 
Family engagement for patient  
treatment engagement 
 
  
 
 
“I certainly like to involve [family]. If there is a significant other I encourage them to be involved 
and encourage the patient to see me…..I need to educate them about the illness as well as to 
educate the patient.” (GP 327) 
 
 “...the contribution from family members can be really valuable because….they known them 
[patients] quite well [and] what they're normally like....that person can often provide a bit of a 
different perspective for the patient.....bring a trusted person with you then it's not such an uneven 
sort of setting....” (psychiatrist 309) 
 
“The more they [family] can get involved in the understanding….and know, the more they are 
likely to make informed decisions. If they're not onside they have a much more powerful effect than 
any therapist has.” (clinical psychologist 318) 
 
2.4. Patient-centredness and 
involvement 
 
“…it's such an important part of clinical practice that the patient really feels like they've made 
choices about their treatment.” (psychiatrist 309) 
 
“I think an individual autonomy and right to make decisions around their treatment is a really 
important part of recovery. That people feel empowered and in a sense guided but being able to 
make the final decision themselves.” (psychiatrist 328) 
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2.5. Therapeutic relationship 
 
“…it does seem to be a bit of a question of trust. But also the trust goes the other way as you get to 
know a patient, I often say to patients that the aim of all of this is for you to become the expert.” 
(psychiatrist 309) 
 
“If a client knows that you know what you're talking about, and they've got a good relationship 
with you I think fundamentally you enlist the relationship and just say now trust me on this one.” 
(clinical psychologist 318) 
 
2.6. Inter-professionalism and 
continuity of care 
 
“...When their initial diagnosis is made I always arrange a psychiatric referral...it gives them 
[patient] a chance to raise questions with someone different, to hear the information from someone 
who's an expert and get a different point of view…” (GP 324) 
 
“I monitor very frequently which means there's not this sense of being sent off to oblivion with 
some new medication and…no sense of someone watching it and monitoring it.” (GP 324) 
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Making time – Structuring consultations 
Over half of clinicians, mainly GPs/psychiatrists and clinicians with a speciality in 
bipolar disorders, felt that making time (e.g., scheduling longer consultations) and 
structuring decision-making over multiple consultations facilitated the treatment 
decision-making process. Usually, in the first consultation (which sometimes involved 
patient diagnosis), treatment options would be presented. Patients would then be 
encouraged to find out more about these options (via clinician-provided information 
or independent information gathering) and deliberate them with family/friends. In a 
second follow-up appointment, the patient and clinician would discuss these options 
further and then make final treatment decisions.  
 
According to clinicians, structuring decision-making over more than one consultation 
engendered several patient benefits. Patients were reportedly more informed, asked 
more questions, had options explained more comprehensively, were more satisfied 
with decision-making (through feeling more involved), and had better treatment 
adherence (psychiatrist 307, Table 5.3). Two psychiatrists pointed out that this style 
of decision-making was more an option in BPII because the need to bring the illness 
under control quickly is not as pressing (as sometimes the case in bipolar I disorder). 
 
Patient information and education facilitating decision-making  
Several clinicians (n=5) made reference to patient information needs and preferences 
(GP 325, Table 5.3). Two clinicians reported that their patients with BPII had 
particularly strong information preferences (e.g., “hungry” for information). 
In order to support the development of a patient decision-making resource, clinicians 
were asked their preferences/recommendations. All three clinician groups made 
recommendations; almost three quarters of clinicians made recommendations relating 
to content and features, and recommendations mostly came from clinicians who 
preferred patient-led decision-making. Clinicians uniformly felt that the optimal time 
of delivery for a patient decision-making resource was shortly after diagnosis, as this 
coincided with when patients were frequently considering their treatment options.  
Regarding content, clinicians felt that information should cover a broad “spectrum of 
treatment options” including medication and psychological treatments. Information 
on treatment benefits/side-effects, rationale for medication use, and longer-term 
prognosis were all perceived as helpful (clinical psychologist 313, Table 5.3). 
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Although a few clinicians placed greater importance on side-effect and safety 
information, one clinician felt that more information on treatment benefits and 
prognosis was needed. Another two clinicians indicated that including some 
background information on the illness (symptoms, course) was necessary, especially 
as treatment decisions were made in the knowledge that BPII was a life-long, 
remitting illness.  
 
In terms of proposed features of decision-making resources, clinicians felt that 
information should be specific, easy-to-read and free of medical jargon. Clinicians 
also valued evidence-based, reliable information with an Australian focus. Several 
clinicians endorsed including exercises to help patients consider which features of the 
different treatment options mattered most to them (i.e., values-clarification methods) 
alongside clinically-based information about options. This is because clinicians felt 
that values motivated decision-making, reflected the varied presentations of BPII and 
its treatment, and the resource would be more engaging for patients.  
 
Several clinicians, especially those with a bipolar speciality, alluded to the supporting 
role of information in facilitating treatment decision-making. Clinician-provided 
psycho-education during consultations was valued and often supplemented patient 
resources providing written information. Both these forms of information reportedly 
enabled patients to be “more knowledgeable” about their illness and treatment 
options, “ask more appropriate questions about treatment”, more actively “weighing 
up options”, and have greater autonomy (psychiatrist 309, Table 5.3). One clinician 
also noted that such resources, when used in consultations could serve as a prompt for 
discussing treatment options in a structured way.  
 
Clinician-provided psycho-education and written information resources was also 
thought to facilitate treatment decision-making in a number of ways. Firstly, written 
information and the resulting knowledge potentially increases patient empowerment 
and optimism towards treatment (knowing that it is a treatable illness with various 
treatment options). Secondly, the provision of such information is important in 
dispelling common myths and misconceptions around medication (e.g., that it is 
addictive).  
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Almost half of clinicians reported benefits of patients hearing others’ lived experience 
with BPII. Reported benefits included: greater credibility than clinician-provided 
information, providing realistic treatment goals for patients, reduced feelings of 
patient isolation, and acknowledging the variable presentations of BPII (clinical 
psychologist 303, Table 5.3).  
 
Clinician perceptions of family as a resource 
Many clinicians were unaware of the extent of family involvement that their patients 
used in making decisions, which is consistent with self-report questionnaires 
indicating family rarely attended consultations (M=13% of consultations had family 
attend). Despite this, over half of clinicians felt that family involvement benefited 
treatment decision-making. Further, a third of clinicians, all of whom specialised in 
bipolar disorders, actively encouraged family involvement in decision-making (e.g., 
inviting family/significant others to attend appointments where important treatment 
decisions were likely to be made).  
 
Most-commonly, family who attended consultations were perceived to provide 
valuable informational support to both clinicians and patients. Informational support 
included providing additional information about the patient's illness history and 
symptoms, identifying problem areas and treatment targets that mattered to them and 
the patient, and communicating information between different clinicians if patients 
were unable to (e.g., due to symptoms). Family also purportedly helped to equalise 
potential power imbalances between the patient and clinician and provided 
reassurance for the patient (psychiatrist 309, Table 5.3).  
 
Several clinicians viewed family engagement as playing an important role in 
facilitating patient treatment engagement. Patients were perceived as more engaged 
with treatment when family were involved, informed, and “on-side” with treatments. 
When family were not involved (and by implication, likely to be uninformed about) a 
patient’s treatment decision-making they reportedly often challenged the validity of 
treatment decisions, which could lead to patient non-adherence to treatment (clinical 
psychologist 318, Table 5.3). Of note, the benefits of family involvement were noted 
more frequently by clinicians preferring patient/family-led and/or triadic (clinician-
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patient-family) SDM than those preferring patient-led or clinician-led decision-
making.  
 
Patient-centredness and involvement  
Half of clinicians reported that involving patients was critically important to treatment 
decision-making, and was aligned with most patient involvement preferences 
(psychiatrist 309, Table 5.3). According to clinicians, the need to involve patients was 
well-justified. Patients were seen as bringing recognised expertise to treatment 
decision-making due to their lived experience and treatment-relevant values. By 
involving patients and incorporating patient values into treatment decisions, patients 
reportedly were more informed about treatment choices, had increased feelings of 
decisional control and greater satisfaction, and better treatment adherence (both 
psychological strategies and medication) (clinical psychologist 318, Table 5.3).  
 
A few clinicians noted instances where they took a more directive approach in 
decision-making. These instances included patient preferences for minimal 
participation in decisions, or when patients had reduced decisional capacity (i.e., due 
to symptoms). Similarly, when clinicians felt that their patients’ preferred option was 
“not good”, they also saw the need to be more directive in their advice. However, 
most clinicians still tried to involve patients in decision-making as much as possible. 
 
Therapeutic relationship  
Half of the clinicians, irrespective of patient involvement preferences, reported that a 
strong, collaborative therapeutic relationship founded on mutual trust was imperative 
to good treatment decision-making (psychiatrist 309, Table 5.3). Medical 
practitioners, in particular, felt that mutual trust facilitated the discussion of treatment 
options, more open and honest patient communication, and clinician-led decision-
making when patient capacity was compromised (clinical psychologist 318, Table 
5.3).  
 
Other qualities which clinicians felt they needed to achieve for a “good” therapeutic 
relationship conducive to effective decision-making included being welcoming and 
open, non-judgemental, and non-authoritarian. Clinicians emphasised the 
collaborative aspects of the therapeutic relationship, describing it as a “partnership” 
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or “shared journey” between the patient and clinician. Collaboration was considered 
by one psychologist as a buffer against clinician-patient disagreement in treatment 
decisions.  
 
Inter-professionalism and continuity of care 
Over half of clinicians endorsed engaging different clinicians in treatment decision-
making for a number of reasons. Both psychiatrists and GPs acknowledged that 
psychiatrists had more specialist knowledge and served as a good back-up for GP’s 
ongoing management of medication. Clinicians reports that many patients preferred a 
multidisciplinary team approach, and that clinician consensus reassured patients that 
treatment recommendations were sound (GP 324, Table 5.3).  
 
Despite this notion of multidisciplinary teams managing patient care, clinicians 
highlighted the importance of a “leading” clinician to ensure continuity of care for the 
patient and their family. Several clinicians perceived good continuity of care, in the 
form of regular appointments with the same clinician, as critical to treatment and 
ongoing treatment decision-making. Two clinicians reported practising good 
continuity of care by arranging frequent follow-up appointments, which allowed them 
to monitor the patient and encourage patients to reflect on their treatment decisions 
(GP 324, Table 5.3).  
 
5.5. Discussion  
This is the first known study to investigate clinician-perceived barriers and facilitators 
to BPII treatment decision-making. Further, clinicians gave insightful suggestions as 
to ways that patient decision-making could be improved. These strategies were often 
targeted directly to changing the discussed barriers. These findings form the basis of 
preliminary clinician-endorsed strategies for effective decision-making in BPII, 
outlined below and in Table 5.4. 
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Table 5.4. Preliminary clinician-endorsed strategies to address challenges in 
treatment decision-making in BPII. 
Challenges  Strategies 
Patient-related 
 
Impact of symptoms and 
comorbidities 
 
 
 
 
 
A priori treatment preferences 
 
 
Structuring consultations–Making time 
- Allowing greater deliberation of options, less 
impulsive, hasty decisions affected by mood. 
Therapeutic relationship  
- Enlist when patient symptomatic  
- Buffers against clinician-patient disagreement about 
treatment choice 
Patient-centredness and involvement  
- Moderate patient involvement 
- Incorporate patient values into decision-making 
Structuring consultations–Making time 
- Giving patients time to deliberate options between 
consultations and access information about options to 
make more involved, informed decisions  
Patient information and education supporting decision-making  
- Meeting patient information needs and preferences 
Supporting role of information 
- More actively weigh up treatment options, be more 
informed about options and illness. 
Clinician-related  
 
 
 
 
 
Non-supportive clinician input 
Interprofessionalism 
- Involving different health professionals with 
complementary expertise to address gaps in 
clinician’s own expertise 
Patient-centredness and involvement 
- Incorporating patient values into treatment decisions, 
coming to mutual agreement  
Encouraging and facilitating family involvement. 
- Reduce clinician-patient power imbalance 
- Provide personalised knowledge of patient 
Therapeutic relationship 
- Non-directive, non-authoritarian 
- More open and honest communication 
- Fosters mutual trust and rapport  
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Negative family influences 
 
Structuring consultations–Making time 
- Encouraging patients to deliberate/discussion options 
with family between consultations, prior to coming to 
treatment decision 
Facilitating family engagement for treatment engagement 
- Encouraging family attendance in line with patient 
preferences 
- Identifying treatment targets that matter to them and 
the patient 
- Ensuring involved and informed about treatment 
System-based  
 
Structuring consultations-Making time 
- Scheduling longer appointments with regular follow-
ups  
Inter-professionalism and continuity of care 
- Regular appointments with ‘leading’ clinician  
- Engaging clinicians with different health professional 
backgrounds 
- Team approach to patient care and management 
Supporting role of information 
- Prepare patients to ask more appropriate questions 
- Serves as prompt for discussing treatments in more 
structured, efficient way 
- Greater independence and autonomy in decision-
making; discouraging prescriptiveness/script-pad 
approach to decision-making 
Inadequacies in available patient 
information 
 
Meeting patient information needs and preferences 
- Comprehensive, evidence-based and easy-to-
understand information on range of treatment options 
- Values clarification exercises to make more readable 
Supporting role of information 
- Encourages patients to be more informed and 
knowledgeable about illness and treatment options 
- Mobilises patient involvement in decision-making; 
more active question-asking and more active 
weighing-up/ deliberation of options.  
Value of others' lived experience and personal stories 
- Useful supplement to clinical information 
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5.5.1. Structuring consultations 
More than half of clinicians, mainly GPs and psychiatrists, reportedly structured their 
consultations in order to facilitate more informed and active patient involvement in 
treatment decision-making. “Splitting” decision-making over at least two 
consultations reportedly encouraged patients to be more informed about, and clearer 
on their preferences for treatment decision-making. Of note, this strategy maps onto 
Elwyn and colleagues’ [31] three key steps of SDM for clinical practice: choice talk, 
option talk, and decision talk, which are linked by ongoing deliberation occurring 
outside clinical consultations via discussion with others and information/decision-
support resources. Importantly, this strategy, which has previously been advocated as 
an effective strategy in the medical setting, potentially addresses a number of 
decision-making challenges also identified by the sample (see Table 5.4). Structuring 
consultations allows patients the time to process information before reaching a 
decision, and helps clinicians more optimally schedule when final treatment decisions 
are made. In this way, clinicians can balance the need to act promptly to restore 
positive mental health and need to have a well thought out and accepted decision. 
Thus, impulsive and/or reactive decisions and decisional regret might be avoided.   
 
5.5.2. Allowing deliberation of treatment options outside consultations 
Encouraging patients to deliberate on treatment options between consultations 
reportedly increased the likelihood of involving family involvement in information 
gathering and treatment discussions. Given that family rarely attend consultations 
[43], involving family during post-consultation discussions gives them the 
opportunity to contribute to treatment preferences prior to reaching a final treatment 
decision. Indeed, patients appreciate when family act as a sounding board for 
treatment discussions outside consultations [5], whilst engaging family helps to 
mobilise them as effective supports and partners in illness management and to 
facilitate patient autonomy [35]. Finally, structuring decision-making over multiple 
consultations may compensate for short consultation times, a common systemic 
barrier [23, 44] that was associated with poorer decision quality in this study (i.e. 
more clinician-led, “prescriptive” decision-making and potentially/reportedly lower 
patient satisfaction with decision-making).  
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5.5.3. Supplementing clinician psycho-education with patient information resources  
Providing patients with information about their illness and treatment options emerged 
as a key decision-support strategy. Both clinician-provided psycho-education and 
written patient information resources (e.g., factsheets, recommended websites) 
reportedly facilitated the decision-making process by addressing a number of 
clinician-reported barriers (see Table 5.4). Specifically, written patient information 
resources were perceived as helping patients to: reconsider preconceived treatment 
preferences, make more efficient use of short consultations, and better understand 
their treatment options/preferences rather than deferring to clinician expertise. As 
patients were able to consult these resources outside consultations, patients arrived 
better prepared to initiate treatment discussions, which results in greater integration of 
patient preferences into treatment decisions in mental health [45]. Additionally, 
written patient information resources may benefit clinicians in-consultation, by 
facilitating clearer and more structured treatment discussions with patients, and by 
identifying gaps in patient knowledge about treatment options, which are seldom 
assessed [46].  
 
5.5.4. Improving patient information resources  
Acknowledging that many patients still lacked a comprehensive understanding of 
treatment options, effects, and longer-term outcomes, clinicians identified priorities 
for future decision-support resources. These included: comprehensive and easy-to-
understand, evidence-based information that is specific to BPII, and covers a broad 
spectrum of treatments (medication and psychological-based) options and outcomes. 
These priorities align with well-established recommendations in the literature for 
patient information resources [47]. Clinicians also endorsed the inclusion of values-
clarification exercises, which are a key component of patient decision-aids (DAs) and 
may facilitate better alignment between patient preferences and treatment choice, as 
in depression and schizophrenia [48]. 
 
5.5.5. Fostering the therapeutic relationship  
Consistent with clinicians placing a high value of patient-centredness and 
involvement, many endorsed the therapeutic relationship as integral to effective 
treatment decision-making. This supports other findings that successful adaptation of 
SDM to chronic care [49] and mental health [8, 50] settings requires greater emphasis 
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on partnership-building and the therapeutic relationship. Critically, a therapeutic 
relationship founded on mutual trust reportedly alleviated patient-clinician 
disagreement over treatment and made patients with acute symptoms more 
comfortable deferring decision-making responsibility to clinicians. Indeed, patient 
trust is seen by psychiatrists as a “prerequisite” for SDM [24]. Thus, fostering the 
therapeutic relationship in BPII may counteract unsupportive clinician behaviours 
(e.g., being overly directive/coercive, authoritarian), and support better continuity of 
care through better treatment engagement [10].  
 
5.5.6. Facilitating family involvement 
In addition to patient involvement, several clinicians also acknowledged the 
importance of family involvement in treatment decision-making. Encouraging and 
facilitating family involvement, especially within consultations, may overcome a 
number of barriers to treatment decision-making (see Table 5.4). Firstly, family 
provision of informational support within consultations may be of particular benefit 
when patients are symptomatic and cannot communicate their treatment preferences 
as effectively [51]. Secondly, having family attend consultations and serve as “a 
second pair of ears” [35, 52] may foster better continuity of care through improved 
communication of information between clinicians. Lastly, involving family within 
consultations may strengthen their support of treatment decisions by permitting 
clinicians to educate family about BPII illness and the rationale for treatment options, 
and for family to express their treatment preferences and clarify any concerns [43]. 
Given that clinicians linked family involvement to BPII patient outcomes, both 
positive (e.g., improved treatment adherence) and negative (e.g., premature 
discontinuation of medication), ensuring family are informed and involved, to the 
extent desired by patients, is important.  
 
Although clinicians uniformly endorsed some views of treatment decision-making, it 
was evident that clinician views varied depending on their professional background 
(medical versus clinical psychologist), preferences for patient involvement in 
decision-making and level of expertise/specialty treating BPII patients. For example, 
clinicians with a preference for patient-led decision-making were more likely to 
identify inadequacies in available patient information, and endorse a patient decision-
making resource. Further, clinicians specialised in bipolar disorders were more likely 
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to structure their consultations in order to optimise decision-making, and actively 
encourage family involvement in decision-making. These clinician-related factors 
have not been systematically explored within other qualitative studies of clinician 
views in unipolar depression [22, 23] and schizophrenia [25, 26]. These findings 
highlight the importance of inter-professionalism in mental health [44], where 
clinicians from different backgrounds collaborate to deliver integrated patient care 
based on complementary expertise. 
 
In considering the present findings, a number of clinician-endorsed strategies may 
also be applicable to treatment decision-making in bipolar I disorder. For example, 
fostering the therapeutic relationship and providing patients with supplementary 
information resources in order to facilitate i) greater patient involvement and ii) 
treatment decisions that are consistent with patient treatment preferences are both 
reasonable goals, as bipolar I disorder is also a life-long remitting illness which relies 
on patient education and patient self-management. Other strategies, however, may be 
less applicable to bipolar I disorder, such as structuring decision-making over 
multiple consultations to permit deliberation outside consultations. This is because 
bipolar I disorder may require clinicians to act more promptly to restore mood 
stability, especially if a current or impending manic episode involves psychotic 
features. An interesting avenue for future research would be to elucidate differences 
between bipolar I and II disorders in terms of how clinicians approach and involve 
patients in treatment decision-making. 
 
Despite the present study strengths, such as including both medical professionals and 
clinical psychologists, there are some limitations. Firstly, the present clinician sample 
was biased towards mostly experienced clinicians, many of whom specialised in 
bipolar and other mood disorders. Thus, the views and experiences of clinicians in 
this study may not represent those of less experienced clinicians, who may be less 
knowledgeable about and confident in treating BPII. Secondly, the “opt-in” nature of 
clinician recruitment creates the potential for self-selection bias. Thus, the present 
findings may reflect the views of clinicians who are more interested in treatment 
decision-making in BPII. However, it is likely that those with this expertise and a 
preference for SDM are best placed to advise on ways to minimise the barriers 
towards effective decision-making in patients with BPII.  
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This sample of experienced, practising clinicians acknowledged that treatment 
decision-making in BPII is hampered by numerous barriers, which span patient-
related, clinician-related, relational, systemic, and informational domains. These 
clinicians also proposed a number of complementary facilitators and strategies for 
optimising treatment decision-making in BPII, which they described within their own 
and others’ clinical practice, and which serve to address various barriers and 
challenges. Whilst clinicians uniformly recognised the importance of involving 
patients in informed treatment decision-making, they also identified a number of 
challenges to active patient participation. These findings can inform the development 
of BPII-specific decision-support resources, designed to educate and involve these 
patients in, values-congruent decision-making about their own treatment.  
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Chapter 6: Rationale for and development of the decision-aid (DA) 
 
This chapter firstly summarises the qualitative study findings presented in Chapters 3, 
4, and 5, and provides a rationale for developing a treatment decision-aid (DA) to 
assist patients with bipolar II disorder (BPII) and their families. Secondly, this chapter 
presents a step-by-step outline of the DA development and planned evaluation process 
(Chapter 7, and Appendix G), in accordance with International Patient Decision Aid 
Standards (IPDAS) and other literature recommendations. The final DA is presented 
in PDF format in Appendix H.  
 
6.1. Rationale for a DA 
The initial qualitative phase of this PhD research program (see Chapters 3, 4, 5) 
elucidated key priorities for information and decision-support in the BPII treatment 
setting. Importantly, these qualitative findings provided a comprehensive, “360-
degree” view of the treatment decision-making process from the patient, family and 
clinician perspectives. All participant groups endorsed similar barriers and facilitators 
to effective decision-making; namely, decision-making that involves patients (and 
family) to the extent preferred (by the patient), and results in evidence-informed 
treatment decisions that incorporate patient values and life circumstances. The 
development of patient decision-aid (DA) was well-endorsed by both patients and 
family, as well as all clinician groups. Importantly, a DA stands out as an 
appropriate intervention for improving treatment decision-making and as an 
effective strategy to address a number of unmet needs for information and decision-
support in this setting. 
 
Patients with BPII, their families, and clinicians placed a high value on patient 
involvement in treatment decision-making and uniformly felt that patients should 
retain authority in the final decision. Despite this, it was evident in many participant 
accounts that real world clinical practice fell short of the stated ideal for patient 
involvement. The shared decision-making (SDM) stages of information exchange and 
deliberation, as described by participants, were often clinician-led with limited 
discussion of alternative treatment options and patient preferences for treatment. As a 
result, a substantial proportion of patients, especially those who were recently 
diagnosed or who preferred patient-led/SDM, did not experience their preferred level 
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of involvement in consultations regarding treatment. Although uncommon, when 
patient did not experience their preferred level of decision-making involvement, nor 
preferred choice of treatment, they appear more likely to have negative outcomes, 
such as treatment non-adherence. By contrast, when clinicians employed more 
collaborative decision-making styles and actively involved patients (e.g., asked 
questions, elicited treatment preferences) this led to more positive patient outcomes, 
such as improved knowledge, satisfaction with care and decision-making, treatment 
adherence, engagement and continuity-of-care. Taken together, these results suggest 
that patients, especially those with a recent BPII diagnosis and/or stronger preferences 
for involvement, have unmet treatment preferences and involvement needs. A patient 
DA is well-placed to address these unmet needs by encouraging more active patient 
involvement and better alignment between patient treatment preferences and final 
treatment choice. 
 
Patient knowledge and understanding of treatment options emerged as a key 
contributor to effective decision-making in this setting. According to patients, 
families and clinicians, well-informed treatment decisions relied on having 
comprehensive, unbiased and easy-to-understand information about a broad range of 
evidence-based treatments [1-3]. Many clinicians reportedly provided patients with 
information resources with the aim of informing patients about, and encouraging them 
to deliberate on treatment options. However, all participant groups acknowledged that 
existing treatment information resources were inadequate for supporting informed 
treatment decisions. In addressing this unmet need, a strong evidence base [4] 
supports the use of DAs in helping patients to: i) be more knowledgeable about 
treatment options, ii) have more accurate benefit/risk perceptions, iii) take a more 
active role in decision-making, and iv) make informed treatment choices that are 
based on their values and preferences. By providing these patients with a consolidated 
source of information to take away and read, such as a DA, it is likely that patients 
will come to their follow-up consultation better informed about options. Moreover, by 
presenting a balanced summary of treatment option benefits and side-effects along 
with values clarification exercises, patients will be able to more actively consider 
option pros and cons with respect to their personal values, and be better prepared to 
state their treatment preferences to clinicians.  
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When comparing clinician interviews to those with patients and family, it was evident 
that clinicians were largely unaware of family involvement in treatment decision-
making. Indeed, family involvement was mostly limited to outside consultations, with 
patients appreciating the decision support family provided and acknowledging that 
family views were taken into account in their decision-making. Given the potential for 
family to support or derail the treatment decision-making process, an intervention that 
effectively engages family in these decision-support roles is warranted. One aspect of 
family involvement that patients perceived as beneficial was the family acting as a 
sounding board, which involved family encouraging patients to reflect on their 
treatment preferences and concerns and weigh up options in a way that fitted with the 
patient’s perspective. Families acting as a sounding board generally occurred during 
post-consultation deliberations, so providing patients with a DA for use outside 
consultations is likely to enhance family involvement at a point when family are 
already most likely to be involved. The inclusion of a comprehensive, evidence-based 
information resource negates the need for family to rely on patient recall. It also 
ensures family can be sufficiently informed about available options even if they have 
not attended consultations, which was cited as a barrier to their involvement in post-
consultation deliberations. Further, the inclusion of values clarification exercises in 
the DA helps to formalise the use of the family as a sounding board and makes 
patients’ reasons for leaning towards one option over another more transparent. In 
sum, a patient DA encourages patients to involve their family in conversations and 
deliberations that they identify as beneficial. 
 
6.2. Development and evaluation of the DA 
The content and formatting of the treatment decision-aid (DA) booklet was guided by: 
the International Patient Decision Aid Standards (IPDAS) [5]; best available clinical 
evidence [6-9]; in-depth qualitative interviews with key stakeholders (i.e., 28 patients, 
13 family members, and 20 treating clinicians) [1-3] (see Chapters 3, 4, and 5); and 
iterative review by an expert advisory group comprising senior-level researchers with 
expertise in DA development and evaluation, patients with bipolar II disorder (BPII), 
their family and treating clinicians. The steps in the development of the DA are 
outlined in the following sections.  
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6.2.1. A systematic approach to DA development and evaluation 
To ensure a systematic approach to developing and evaluating the current DA, the DA 
development team followed the steps outlined in O’Connor and Jacobsen [10]:  
 
1) Assess need 
The need for a DA stemmed from the unmet decision-making needs identified in key 
informant interviews with patients with BPII, and their families who were facing or 
had faced a decision about treatment as well as treating clinicians (see section 6.1. and 
Chapters 3, 4, 5). Decisions about medication for prophylaxis (relapse prevention) 
were regarded as especially important and difficult for all stakeholder groups given 
the high levels of uncertainty inherent in treatment options, the need to make value 
trade-offs between treatment benefits and costs, as well as patient variability in 
preferences for outcomes. Moreover, patients reported a lack of knowledge 
about/understanding of the full range of medication and psychological treatment 
options, less-than-preferred involvement in decision-making, and treatment choices 
that were inconsistent with their preferences [2]. 
 
Systematic reviews of the literature further underscored the need for a treatment DA 
in the BPII setting. The most recent Cochrane review of randomised controlled trials 
(RCT) of DAs for treatment and screening decisions identified only two DAs for 
mental health conditions, one for schizophrenia and one for depression [11]. Since 
this review was published, another two DAs have been developed for depression [12, 
13]. Our own systematic review of communication and decision-making about 
treatment in mental health conditions including bipolar disorder [14] (see Chapter 2), 
found that minimum shared decision-making requirements were achieved in less than 
half of immediate and/or complex decisions, according to established criteria [15]. 
Immediate or complex decisions were defined as having a moderate-to-extensive 
impact on the patient (e.g., side effects and/or risk), involving some degree of medical 
uncertainty, and potentially posing a risk to patients. These decisions have attributes 
(i.e., uncertainty, side-effects) which characterise medication decisions in BPII. Taken 
together, the need for a treatment DA in BPII is well justified. 
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2) Assess feasibility 
The feasibility of the current DA was determined in a number of ways. Firstly, 
sufficient evidence was available on the benefits and risks of treatment options to 
incorporate into the DA (see section 1 above). Secondly, the development team 
comprised researchers with expertise in DA development and evaluation, as well as 
practising clinicians with expertise in the treatment and assessment of BPII who were 
able to provide access to relevant dissemination networks. More broadly, the DA 
development and evaluation project formed part of established and successful 
partnerships with the Black Dog Institute (BDI), a tertiary outpatient clinical service, 
and BeyondBlue, a national mental health awareness agency. Collaboration with 
recognised leaders in the awareness, assessment and treatment of mood and bipolar-
related disorders was thought to enhance the DA’s exposure among patients and 
treating clinicians, thus expediting dissemination of this decision-making resource 
into broader clinical practice. Thirdly, the development team engaged stakeholders in 
all aspects of the DA development (qualitative interviews to assess needs, expert 
working party review, pilot/usability testing) which was key to promoting the DAs 
relevance, feasibility and usefulness among potential end users [16]. Moreover, the 
timing of DA delivery, i.e., shortly after patient diagnosis, is consistent with the usual 
delivery of care, when clinicians commonly introduce treatment options and 
encourage patients to become more informed about, and consider, their preferences 
for treatment options. Such timing will allow for the DA (if successful) to be readily 
integrated into current mental health services in a timely, accessible and acceptable 
manner.  
 
3) Define the objectives of the DA 
The objectives of the DA were designed to address unmet decision-making needs as 
well as incorporate priorities for decision-support in the BPII treatment setting.  
 
Specific objectives related to quality in decision-making regarding treatment for 
relapse prevention in BPII were to improve patients’:  
i) Certainty and comfort in decision-making (i.e., reduce decisional conflict); 
ii) Knowledge and understanding of available treatment options and their 
outcomes;  
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iii) Involvement in decision-making, so that patients experience their preferred 
level of involvement;  
iv) Informed treatment choices, which are consistent with patient preferences 
and values; 
v) Preparedness to make a treatment decision.  
 
Specific objectives related to quality of decision outcomes regarding treatment for 
relapse prevention in BPII were to:  
vi) Reduce patient regret about treatment decision; 
vii) Increase patient uptake of effective medical and psychological 
interventions. 
 
4) Identify the framework of decision support 
 The Ottawa framework of decision support was chosen to guide the DA development 
[17],  as it recognises and addresses several problems that patients, families and 
clinicians reported during patient decision-making about treatment options for their 
bipolar disorder (see Chapters 3, 4, and 5) [1-3]. These included inadequate 
knowledge about treatment options and outcomes, unrealistic expectations of 
benefits/costs, unclear values regarding treatment, high uncertainty and decisional 
conflict, and limited perceived support and skills in shared decision-making.  
 
5) Select the methods of decision support to be used in the DA 
The DA incorporated a number of methods to support decision-making and address 
decision-making problems (see section 4) above). To address inadequate knowledge, 
the DA provided information on BPII illness as well as treatment options and 
outcomes. To address unrealistic expectations of benefits/costs of treatment options, 
the DA provided probabilistic information about the likelihood of benefits/costs, 
using numerical and graphic illustrations (100 person dot diagrams with shading in a 
row rather than randomly, together with absolute risk information describing 
respective proportions of people/occurrences in the diagram) [18]. The DA also 
encouraged more realistic expectations of the benefits/costs by providing balanced 
‘bona-fide’ patient and family quotes to exemplify the key benefits and costs of each 
treatment option. To promote clarification of values and address decisional conflict, 
the DA included explicit values clarification (“weight scale”) exercises, which asked 
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patients to consider the personal importance of benefits/costs of each treatment 
option. These exercises sought to clarify for patients (and their families) treatment 
values/preferences and integrate these into their treatment choice. To illustrate the 
values clarification process, patients (and their families) were also provided with three 
example exercises showing patients who held different values, and thus different 
preferences for a treatment option. Finally, to address perceptions of limited support 
and skills in shared decision-making, the DA provided structured guidance in the 
form of step-by-step decision-making guides and question prompt lists.  
 
6) Select the designs and measures to evaluate the DA 
As with development, the evaluation of the DA involved an effective and ongoing 
stakeholder-engagement approach. Engaging stakeholders during the DA’s 
development and evaluation is key to ensuring the DA’s relevance and usefulness 
among potential ender-users, patients with BPII and their family [16]. With these 
considerations in mind, a pilot/usability study (see Chapter 7) was conducted, which 
involved potential end users (patients with BPII and their family) who were either: 
actively considering treatment options (the DA target population); or have already 
made a BPII treatment decision and are therefore experienced in the decision-making 
to provide informed feedback.  
 
The measures selected for the pilot study were designed to identify any preliminary 
trends in the DA’s usefulness, and included a combination of validated and purpose-
designed questionnaires (see Chapter 7 section 7.3.4. for specific measures). The 
validated measures have been widely used to assess the effectiveness of DAs in 
improving decision-making quality (quality of the decision-making process) and 
decision quality (quality of decision outcomes) [18]. Based on conceptual and 
empirical grounds, the primary outcome chosen to evaluate the DA’s potential 
usefulness was decisional conflict. Conceptually, lower levels of decisional conflict 
reflect patients feeling well-informed about the available treatment options and 
outcomes, clear about their values for treatment, and well-supported to make an 
effective decision. These attributes align with the overarching goal of DAs – to help 
patients to make informed, preference-sensitive decisions, especially in situations 
where there is no clinically superior treatment option and treatment choices may be 
more influenced by patient preference (see [19]). Indeed, decisional conflict is 
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arguably more appropriate than treatment-related knowledge as a primary outcome 
measure. Knowledgeable patients may still lack the support needed to integrate their 
knowledge of treatment options and outcomes with their values and come to an 
effective decision [20]. In addition, empirical reasons supported the use of decisional 
conflict as a primary outcome measure, including: high-quality evidence to support 
DA-related reductions in decisional conflict [11], and review findings demonstrating 
that the Decisional Conflict Scale [21] is superior to most other primary outcome 
measures used in DA trials with respect to its psychometric properties, clinical 
sensibility, and appropriateness or consistency with IPDAS decision process criteria 
[5, 22]. Secondary outcomes using validated measures, include: i) congruence 
between preferred/experienced levels of patient involvement in decision-making (via 
two administrations of an adapted version of the Control Preferences Scale [23]; ii) 
preparation for decision-making scale [24]; iii) informed, values-based choice 
measure [25]; and iv) decisional regret [26]. As with decisional conflict, these 
secondary outcomes have all been identified as key indicators of DA effectiveness 
[18]. 
 
In addition to the validated measures, a purpose-designed knowledge measure was 
developed based on: i) current NHMRC guidelines for providing information to 
patients about medical treatment/intervention(s) [27, 28], ii) relevant IPDAS criteria 
for information (1, 3, 4, 5, 6) and probabilities (1, 3, 4, 6, 7) [5], iii) knowledge 
measures used in previous DA development/evaluation studies [29], and iv) theory-
informed, competency-based approaches to assessing knowledge [30]. Both gist 
(conceptual) and verbatim (numerical) knowledge were assessed because they 
represent two independent systems of processing and recalling information, that is, 
extracting the core meaning versus precise detail [30]. Secondly, gist and verbatim 
knowledge appear do differentially impact on decision-making. Specifically, gist 
knowledge appears to be more enduring and more strongly influences decision-
making compared to verbatim knowledge, likely because it is less affected by stress 
and anxiety which impair comprehension of information [31, 32]. Also included in 
the pilot/usability study were semi-structured interview questions to elicit 
acceptability information and supplement the questionnaires with more in-depth 
qualitative feedback on the DA during the pilot/usability testing. The interview guide 
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was adapted from previous DA pilot studies [33] and the Ottawa Acceptability 
measure [34].  
 
7) Plan dissemination 
The DA was developed and evaluated in collaboration with the BDI. As a recognised 
world-leader in this area, the BDI will greatly enhance the DA’s dissemination into 
broader clinical practice. Once evaluated (and if successful), the DA will be 
disseminated in hard-copy (booklet) form through the BDI clinics and professional 
development workshops for GPs and allied health professionals. The DA will also be 
made widely available as a free download in electronic format (PDF) through the 
BDI’s existing webpages for patients/family and clinicians on bipolar disorder 
treatments. Postcards containing introductory information and web-access details will 
be disseminated to GP practices Australia-wide, so that treating GPs can make 
patients with BPII aware of this resource. The DA’s combined offline and online 
delivery will: i) promote its rapid and widespread dissemination, ii) ensure the 
information remains in step with best available clinical evidence, and iii) promote the 
DA’s ongoing uptake among Australian adults, who are increasingly “Internet-
connected” (~ 83% in 2012-2013) [35] and tend to seek their health information 
online [36]. 
 
6.2.2. Qualitative interviews with key stakeholders/informants 
In line with a stakeholder-engagement approach to DA development [12, 16], the DA 
prototype was informed by the unmet decision-making needs reported by patients, 
their family, and clinicians, with the aim of facilitating more active and informed 
patient role in their treatment decision-making. Through a series of large, in depth 
qualitative studies (outlined in Chapters 3, 4 and 5), the DA development group were 
able to assess and contextualise the nature of these needs, and identify informational 
and decisional-support priorities among patients with BPII and their family. 
Qualitative findings relevant to the DA development were tabulated and summarised 
for patient/family and clinician groups according to three areas: content, 
formatting/presentation, and delivery (see Table 6.1).  
 
By and large, patient/family and clinician groups identified similar priorities for these 
areas, however, priorities were also included even if they were only identified by one 
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stakeholder group. In terms of content, patients/family and clinicians all wanted the 
DA to present a broad range of BPII-specific medication and adjunctive psychological 
treatment options, with a focus on options for relapse prevention (see Chapters 3 and 
4). All stakeholder groups also felt that it was necessary for the DA to acknowledge 
the preference-sensitivity of treatment choice/s and include values clarification 
methods for deliberating options. In terms of formatting, patients/family and 
clinicians all prioritised unbiased, evidence-based information using plain language 
[2, 3]. Although patients/family and clinicians tended to prefer hardcopy information 
(e.g., booklet, factsheet) clinicians pointed out the DA could also be made available 
online. In addition, patients/family groups felt that information should be organised 
into sections for ease of navigation. In terms of delivery, all stakeholder groups stated 
a preference for delivering the DA shortly after patient diagnosis, as this is when 
patients are first presented with, and are considering treatment options. This said, the 
iterative and ongoing nature of decision-making in BPII (see Chapters 3 and 4) would 
permit the DA to be used by patients who have a longer-standing diagnosis and are 
re/considering treatment options in response to unpleasant side-effects or treatment 
which has not been highly effective. Moreover, all stakeholder groups agreed that the 
DA would be best provided to patients as a supplementary information resource 
during consultations with their clinician, but that the DA’s primary intended use 
would be prior to or between consultations involving discussion and decision-making 
about treatment options. Additionally, clinicians stated that the DA could be also used 
within consultations as a prompt for discussing different aspects of treatment options 
in a more structured, systematic way [1].   
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Table 6.1. Summary of BPII treatment DA priorities based on interviews with 
patients (n=28), families (n=13) and clinicians (n=20) 
 Patients/families 
 
Clinicians 
Content - Specific to bipolar II disorder.  
- Some background information on 
the illness (symptoms, course, 
chronic, remitting nature of illness). 
- Broad range of medication and non-
medication-based options (incl. 
psychological interventions, lifestyle 
and/or complementary options). 
- Focus on options for relapse 
prevention (prophylaxis). 
- Medication effects and rationale for 
use.  
- Expected benefits/efficacy and side-
effects (both short and long-term), 
along with rationale for 
recommending one type of 
medication over another. 
- List of available additional 
resources and psychosocial 
support services.  
- Patient/ personal stories/others' lived 
experience of illness and 
medication, acknowledges the 
individualised nature of BPII 
illness (as opposed to population-
based descriptions). 
- Values clarification exercises 
alongside clinically-based 
information:  
- Acknowledgement that treatment 
choice is sensitive to patient values 
and life circumstances. 
- Encourage active reflection on, and 
understanding of option pros and 
cons within context of life 
circumstances and values. 
- Separate information for family 
members on (e.g., how to support 
someone with BPII, illness 
symptoms and course). 
- A question prompt list outlining 
patient questions for their 
clinician. 
 
- Specific to bipolar II disorder.  
- Some background information on the 
illness (symptoms, course, chronic, 
remitting nature of illness). 
- Broad range of medication and non-
medication-based options (incl. 
psychological interventions, lifestyle 
and/or complementary options). 
- Focus on options for relapse 
prevention (prophylaxis). 
- Medication effects and rationale for 
use.  
- Expected benefits/efficacy and side-
effects (both short and long-term), 
along with rationale for 
recommending one type of 
medication over another. 
- Safety aspects.  
- Longer-term prognosis (probably 
course and outcome of illness) 
- Patient/ personal stories/others' lived 
experience of illness and medication, 
present treatment goals/decisions 
for patients to consider for 
themselves. 
 
- Values clarification exercises 
alongside clinically-based 
information:  
- Acknowledgement that treatment 
choice is sensitive to patient values 
and life circumstances. 
- Encourage active reflection on, and 
understanding of option pros and 
cons within context of life 
circumstances and values. 
- Separate information for family 
members on (e.g., how to support 
someone with BPII, illness 
symptoms and course). 
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Formatting/ 
presentation 
- Written information. 
- Hardcopy information (e.g., a 
booklet, factsheet or brochure). 
- Clearly-worded and easy-to-
understand 
- Use of plain language.  
- Evidence-based, unbiased, reliable 
- Produced by a reputable 
organisation. 
- Balanced presentation of benefits 
and side-effects.  
- Easy-to-understand graphics 
depicting the level of evidence 
supporting particular treatment 
options (e.g., “thumbs up” icon). 
- Organised into separate sections 
starting from more general to 
more specific information. 
 
- Written information 
- Hardcopy, or available online via 
referred website. 
- Clearly-worded and easy-to-
understand 
- Use of plain language.   
- Evidence-based, unbiased, reliable 
- Australian focus. 
 
- Balanced presentation of benefits and 
side-effects.  
- Optimistic and hopeful tone. 
 
Delivery  - Shortly after diagnosis when 
presented with/considering treatment 
options. 
- Used prior to, or between 
consultations involving treatment 
discussions. 
- Clinician provided and/or made 
available at the clinic they 
attended. 
 
 
 
- Supplement clinician in-consultation 
provided information/education. 
- Given after consultation in which 
treatment options presented. Read 
prior to follow-up consultation 
involving further deliberation and 
final decision-making. 
 
- Shortly after diagnosis when 
presented with/considering treatment 
options. 
- Used prior to, or between 
consultations involving treatment 
discussions. 
- Clinician provided during 
consultations. 
- Also in-consultation as a prompt 
for discussing the different aspects 
of treatment options in a 
structured way. 
- Supplement clinician in-consultation 
provided information/education. 
- Given after consultation in which 
treatment options presented. Read 
prior to follow-up consultation 
involving further deliberation and 
final decision-making. 
 
Note = bolded items indicate items identified by that stakeholder group only.  
 
On the basis of these informational and decision-support priorities, the DA 
development team derived a table of contents for the DA prototype (Table 6.2). The 
table of contents sought to integrate all of the content areas identified by stakeholder 
groups as important (see Table 6.1). These included a description of a range of 
available medical and psychological treatment options together with a rationale for 
their use, inclusion of text-based and graphical representations of information, 
separate information section for family members, an in-consultation question prompt 
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list and values clarification exercises. For completeness, the table of contents was also 
cross-checked against IPDAS criteria [5].  
 
Table 6.2. DA prototype content list 
1.  Explanation of the booklet’s rationale and aim including: 
- Focus on treatment options for prophylaxis in patients with recent BPII diagnosis 
- Acknowledgement of incomplete evidence base, potential for adverse effects, and 
that treatment choice is sensitive to patient values and life circumstances.  
- Encourage active reflection on, and understanding of option pros and cons within 
context of life circumstances and values. 
2.  Background to BPII illness (symptoms, course, chronic and remitting nature, need for 
prophylactic treatment approach). 
3.  Description of medication options and rationale for use (incl. different medication classes 
mood-stabilisers, antipsychotics, anticonvulsants, adjunctive antidepressants) including 
potential benefits as well as potential risks/safety aspects and side-effects (short and long 
term). 
4.  Description of (adjunctive) psychological interventions and rationale for use (CBT, 
mindfulness, wellbeing strategies) including potential benefits as well as potential adverse 
effects/ “costs” (short and long term). 
5.  Description of other (evidence-based) complementary options and rationale for use 
including potential benefits as well as potential adverse effects/ “costs” (short and log term). 
6.  100 dot diagrams depicting treatment efficacy outcomes (mood stability/episode 
prevention) for options 
7.  100 dot diagrams depicting side-effects (weight gain, fatigue, “cognitive dulling/fogginess”, 
sexual dysfunction) for options 
8.  Tabulated summary of medication options pros/ cons 
9.  Tabulated summary of psychological interventions pros/ cons 
10.  Information for family members – how to support someone with BPII and decision-making 
about treatment.  
11.  Step-by-step decision-making guide for making a decision regarding treatment in BPII 
12.  Question prompt list – questions to ask clinician and space to write additional 
comments/notes/questions 
13.  Personalised worksheets (value clarification exercises) to help patients/family  
(i) weigh up the ‘pros’ and ‘cons’ of treatment options by rating the importance of 
related concerns and benefits;  
(ii) indicate their treatment choice.  
14.  List of “further contacts” detailing reliable websites for additional information (BDI, 
Beyond Blue, Bipolar carers) and local psychosocial services (BPII wellbeing program, 
REACH programs, Medicare information for accessing psychologists & psychiatrists) 
15.  Acknowledgments and Reference list and developer details/ year last updated 
16.  Glossary of clinical/medical terms 
 
 
6.2.3. Review of best available clinical evidence 
The IPDAS stipulate that DAs present information based on syntheses of scientific 
evidence that are comprehensive and up-to-date, and subject to critical appraisal [5, 
37]. To provide the best available clinical evidence on treatment options and 
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outcomes for the prevention of relapse in bipolar disorder, the DA development team 
consulted recent meta-analytic reviews of medical [9] and psychological treatment 
options [38]. Most of the studies included in these meta-analytic reviews involved 
mixed-samples of patients with BPI and BPII; there were no published meta-analytic 
reviews of studies involving samples of patients with BPII only. This said, the DA 
development team only consulted the meta-analytic data for treatments recommended 
as first-line/level 1 evidence-supported options for relapse prevention in BPII [6, 7]. 
These meta-analytic reviews were chosen because they included comprehensive 
search methods, were specific to relapse prevention in bipolar disorder, reported odd 
ratios for overall relapse and specific depressive versus hypo/manic relapse, included 
studies of patients with BPII cited in up-to-date clinical guidelines [6, 7], and included 
only randomised or quasi-randomised trials with follow-ups of at least 3 months to 
assist with comparability across medication and psychological treatment options in 
the DA.  
 
The selection of treatment options to include in the DA was primarily guided by up-
to-date clinical guidelines for relapse prevention in bipolar disorder, in consultation 
with clinician experts. At the time of DA development, the medication treatment 
options (lithium, lamotrigine, and quetiapine) were all first-line treatments for relapse 
prevention in bipolar II disorder according to current CANMAT guidelines [6], which 
are the only clinical guidelines to include a separate section specific to relapse 
prevention in BPII. Meanwhile, the psychological treatment options (cognitive 
behavioural therapy and group psycho-education) were the only bipolar disorder-
specific psychological interventions to be supported by level 1 evidence according to 
current guidelines for Australia and New Zealand [7]. Finally, information on the 
potential side-effects or risks of medication options was mainly sourced from double-
blinded randomised placebo-controlled trials (where available). Information relating 
to long-term adverse effects (i.e., 5-20 years) or very rare risks (e.g., Stevens-Johnson 
Syndrome) was sourced from large-scale naturalistic (population-based) studies or 
open-label clinical studies. All information relating to adverse effects was consistent 
with that presented in current international consensus-based guidelines for the safety 
monitoring of treatments for bipolar disorders [39].  
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6.2.4. Iterative working party review 
Once an initial DA prototype was drafted by the PhD candidate it was subject to 
iterative review by an expert advisory panel comprising: 
 clinical academics/research psychologists with expertise in DA development 
and evaluation (n=2),  
 practising psychiatrists (n=2) and clinical psychologists (n=2) with expertise 
in the assessment and treatment of bipolar-related disorders,  
 practising primary care physicians (i.e., general practitioners, GPs) with (n=1) 
and without (n=1) expertise in mental health,  
 patients with BPII (n=3), and their families (n=2) who had previously 
made/helped make a decision about treatment for relapse prevention.  
 
In line with IPDAS [5], and in order to minimise potential biases, the content/format 
review comprised both members of the development team who were involved in 
producing DA (n=4) as well as others (n=8) who were not involved in producing the 
DA. The working party included members with complementary areas of expertise; for 
example, those with expertise in DA development and evaluation had limited 
expertise in the assessment and treatment of bipolar-related disorders and vice versa. 
This “360-degree” approach ensured a comprehensive review of potential problems 
with the DA (e.g., comprehensibility, safety issues) as well as suggested 
modifications to the DA. 
 
The DA underwent a total of 14 iterative “cycles”. A cycle was defined as one 
prototype/version of the DA; each new cycle involved showing a previous version to 
a member of the working party and making at least one change to create a new 
prototype. Cycles were organised such that members of the development team were 
collectively consulted at the beginning and end of prototype development. In the 
interim, clinicians, patients and family were individually consulted; the order in which 
each member of the working party was approached ensured that the DA was 
iteratively reviewed by clinicians and patients/family on an alternating basis, rather 
than consecutively reviewed first by clinicians and then by patients/family, or vice-
versa.  
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To carry out the DA content/format review, a two-step process was used. As a first 
step, a member of the working party was emailed a PDF copy of the DA and asked to 
read it through in order to familiarise themselves with content/format. Secondly, the 
PhD candidate arranged a one-off face-to-face or Skype meeting (as needed) with the 
working party member to go through the DA together and elicit their thoughts and 
opinions on content/format. Open-ended questions focused on areas such as: i) 
comprehensibility and completeness of written information and graphics; ii) 
acceptability, i.e., anything that clinicians/patients/their family anticipated that would 
present as problematic or that patients would like/dislike or present; usability; and iii) 
any suggested improvements or modifications. Working party members were also 
asked to give their thoughts and opinions on any other areas they felt were relevant 
and not covered by questions asked.  
 
Major revisions to the DA prototype based on working party feedback included:  
Content 
- Inclusion of section introducing the different clinicians (psychiatrists, 
psychologists, primary care physicians/GPs) who may play a role in BPII 
treatment/management, and the key differences between them. 
- Reiterating for patients that the treatment options presented in the DA are not 
exhaustive and that other medication and psychological treatment options may be 
recommended based on patient needs (feedback given by: 1 x psychiatrist, 1 x 
clinical psychologist).  
- Inclusion of “real world” probabilities to familiarise patients/family with the 
likelihood of events occurring (1 x family).  
- Retaining only bipolar-specific psychological treatment options supported by 
Level 1 evidence (i.e., cognitive behavioural therapy and group psychoeducation) 
(1 x clinical psychologist).  
- Inclusion of complementary treatment options (e.g., Omega 3 fish oils) and 
comment on the current state of evidence in BPII relapse prevention (1 x GP).  
- Inclusion of directions for “Involving your clinician” in the values clarification 
exercises (1 x GP).  
- Inclusion of additional advantages and disadvantages for cognitive behavioural 
therapy (1 x patient, 2 x family), and group psycho-education (1 x patient, 1 x 
family). 
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Format 
- Presenting 100-person icon arrays for overall relapse prevention (depression, 
hypo/mania, mixed episode, other) and specific relapse prevention (depression 
and hypomania) separately (1 x DA expert, 1 x patient). 
- Replacing relative estimates of treatment efficacy (based on meta-analytic risk 
ratios) with absolute estimates pooled across the studies included in meta-analyses 
(i.e., 50 in 100 people).  
- Inclusion of text boxes below 100 person icon arrays to reiterate the main 
message/s about treatment efficacy for each treatment option (1 x DA expert, 1 x 
patient).  
- Adjusting colours in 100 person icon arrays to enhance contrast (1 x DA expert, 1 
x patient, 1 x family).  
- Inclusion of separate pros/cons rating scale within values clarification exercises 
for family to complete (1 x GP, 1 x family).  
- Redesigning second values clarification exercise for psychological treatment 
options (2 x patients).  
 
When deciding whether to make a suggested revision to the DA, the development 
team leader (the PhD student AF) checked that the suggested revision was consistent 
with i) IPDAS criteria ([5], see Table 6.3), and ii) the informational and decision-
support priorities identified by stakeholders (see Table 6.1). In situations where a 
decision was not clear, the student consulted with other members of the development 
team until agreement was reached. Once a final DA draft was approved by members 
of the working party, the DA content/format was reviewed by a professional copy-
editor for low health literacy and designed/formatted by a professional graphic/visual 
designer. Low health literacy copy-editing is an important yet often overlooked step 
in the development of SDM interventions [40], and ensured that those patients/family 
with lower health literacy can understand and effectively use the DA information. 
This is a necessary consideration as ~60% of Australian adults lack basic health 
literacy [41]. Changes to the DA based on the healthy literacy review, mostly 
included: i) simplifying some terminology/vocabulary; ii) simplifying sentence 
structure/word order; and iii) reordering some subsections within the DA to make 
more logical flow of information. A subsequent independent assessment of the DA’s 
health literacy levels, using the Patient Education Materials Assessment Tool 
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(PEMAT; [42]), yielded “understandability” scores of 76%, placing the DA in the 
“superior” range for easy to understand and use patient education materials [43]. 
Secondly, professional graphic design/formatting was a necessary development 
considerations as both visual features (i.e., text appearance, visuals, layout and 
design) and content features (i.e., message content, text appearance, visuals, layout 
and design, and language complexity) of written health communication materials may 
impair or enhance reader comprehension [44].  
 
6.2.5. Evaluation of quality and rigor 
To ensure quality and rigor, the DA development was guided by IPDAS [5]. These 
widely-used and supported consensus-based criteria comprise 47 items to assess the 
quality of decision-support technologies across nine dimensions (ten dimensions for 
test/screening decisions), such as: information which includes sufficient details about 
treatment options to make a specific decision; values as in describing the positive and 
negative features of options and outcomes and asking patients to consider the 
importance of these); and development processes which include in/formal needs 
assessment of potential end users, involvement of potential end users in expert review 
and pilot/usability testing. These criteria were used to firstly guide DA development, 
and then assess the DA prototype in order to identify areas of lower quality (e.g., use 
of jargon-based rather than plain language) and make improvements to subsequent 
versions. The IPDAS checklist, as applied to the final DA prototype (see Appendix 
H), appears in Table 6.3.  
 
In addition, an independent, experienced rater, who was external to the DA 
development team, assessed the quality of the DA content, presentation of 
information, and development process using the IPDASi v.4 [45]. Based on the rater’s 
assessment, the booklet qualified as a DA (met all six qualifying criteria, see Table 
6.3). Thus, the booklet clearly described the target health condition (BPII), the index 
decision to be made (i.e., to decide between first-line medication options and whether 
or not to have adjunctive psychological treatment to prevent relapse), the available 
treatment options and their associated positive features, negative features, and 
potential consequences.  
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In its final version, the booklet could also be certified as a DA because it scored 3 or 
more on all certifying criteria (Table 6.3). A review on the feasibility and application 
of these IPDAS criteria to a sample of 30 DAs included in the 2014 Cochrane Review 
[11] found that only ~10% of the reviewed DAs met all these certifying criteria [46]. 
On this basis, the current DA is set apart from many other existing DAs, most which 
would require minor modifications in order to be certified. 
 
In terms of quality criteria, the DA booklet met all but two relevant criteria (scored 3 
or more, see Table 6.3) and scored 80 out of a possible score of 92. This quality rating 
suggests that this DA booklet is superior to many other existing DAs (Med = 54.79 
[46]). This said, the quality of the DA could be further enhanced by: i) conducting 
field-testing with clinicians/practitioners who counsel patients who face this decision; 
and ii) reporting on readability levels or justifying why these may not be an 
appropriate index of patients’ comprehension of the content. Moreover, at this stage, 
some quality criteria relating to the evaluation of the DA were only supported by 
preliminary evidence (see pilot study, Chapter 7), and would need to be re-applied 
pending results from the future planned RCT phase. 
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Table 6.3. Quality assessment of the final DA (see Appendix H) according to IPDAS criteria* [5] 
Dimension 
 
Item Yes/No and explanation 
Information  
 
Providing information about options in 
sufficient detail for making a specific 
decision 
1. The decision support technology describes the health condition or problem 
(intervention, procedure or investigation) for which the index decision is 
required.a 
Yes, pages 6-7. 
 2. The decision support technology describes the decision that needs to be 
considered (the index decision).a 
Yes, page 6. 
 3. The decision support technology describes the options available for the index 
decision.a 
Yes, pages 16, 43. 
 4. The decision support technology describes the natural course of the health 
condition or problem, if no action is taken.c 
Yes, page 13. 
 5. The decision support technology describes the positive features (benefits or 
advantages) of each option.a 
Yes, pages 23, 30, 37, 50, 57. 
 6. The decision aid describes negative features (harms, side effects or 
disadvantages) of each option.a 
Yes, pages 24-25, 30-32, 51, 58. 
 7. The decision support technology makes it possible to compare the positive 
and negative features of the available options.c 
Yes, pages 40-41, 60-61 (Summary tables). 
 8. The decision support technology shows the negative and positive features of 
options with equal detail (for example using similar fonts, order, and display of 
statistical information).b 
Yes.  
Same typeface and size, similar order of 
information, and combined use of statistical and 
text-based information.  
Probabilities 
 
Presenting outcome probabilities 
 
1. The decision support technology provides information about outcome 
probabilities associated with the options (i.e. the likely consequences of 
decisions).c 
Yes, pages 20-22, 27-29, 34-36, 47-49, 54-56. 
 2. The decision support technology specifies the defined group (reference class) 
of patients for which the outcome probabilities apply.c 
Yes.  
Control/reference group defined as placebo 
(medication options) or medication plus 
treatment-as-usual (psychological options).  
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Treatment group defined by medication-type 
(medication options) or medication plus 
adjunctive psychological treatment-type 
(psychological options).  
 3. The decision support technology specifies the event rates for the outcome 
probabilities (in natural frequencies).c 
Yes, pages 20-22, 27-29, 34-36, 47-49, 54-56.. 
 4. The decision support technology specifies the time period over which the 
outcome probabilities apply.c 
Yes, pages 20-22, 27-29, 34-36, 47-49, 54-56. 
 5. The decision support technology allows the user to compare outcome 
probabilities across options using the same denominator and time period.c 
Yes.  
Treatment efficacy data based on meta-analyses 
of studies all with follow-ups of at least 3 
months (up to 3 years).  
 6. The decision support technology provides information about the levels of 
uncertainty around event or outcome probabilities (e.g. by giving a range or by 
using phrases such as ‘‘our best estimate is…’’)b 
Yes.  
Graphical and statistical ranges presented for 
some outcomes (e.g., “20-25 in 100 people”, 
“10-30 in 100 people”; pages 24, 42). 
Qualitative ranges presented for some outcomes 
(e.g., “Estimates… vary…”, “It is unclear…”; 
pages 14, 30)  
 7. The decision support technology provides more than one way of viewing the 
probabilities (e.g. words, numbers, and diagrams).c 
Yes, pages 20-22, 27-29, 34-36, 47-49, 54-56. 
Words, numbers and 100 person diagrams all 
used for all options.  
 8. The decision support technology provides balanced information about event 
or outcome probabilities to limit framing biases.b 
 
Yes, pages 20-22, 27-29, 34-36, 47-49, 54-56. 
Consistent presentation of outcome probabilities 
across all treatment options.  
Values 
 
Clarifying and expressing values 
1. The decision support technology describes the features of options to help 
patients imagine what it is like to experience the physical effects.a 
Yes, pages 19, 26, 33.  
Inclusion of illustrative patient/family quotes to 
describe features of each treatment option.  
(e.g., “it [quetiapine] made me put on a 
significant amount of weight...”)  
 2. The decision support technology describes the features of options to help 
patients imagine what it is like to experience the psychological effects.a 
Yes, pages 45, 52.  
Inclusion of illustrative patient/family quotes to 
describe features of each treatment option. 
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(e.g., “CBT is quite useful because it's not just 
medication, it's changing your way of 
thinking…”) 
 3. The decision support technology describes the features of options to help 
patients imagine what it is like to experience the social effects.a 
Yes, page 19.  
Inclusion of illustrative patient/family quotes to 
describe features of each treatment option.  
(e.g., “Lithium kind of has bad associations... 
‘doped up’ people in mental wards that sort 
thing”). 
 4. The decision support technology asks patients to think about which positive 
and negative features of the options matter most to them.c 
Yes, pages 77-83.  
Via values clarification exercises  
Decision guidance 
 
Structured guidance in deliberation and  
communication 
1. The decision support technology provides a step-by-step way to make a 
decision.c 
Yes, page 66.  
 2. The decision support technology includes tools like worksheets or lists of 
questions to use when discussing options with a practitioner.c 
Yes, pages 68-70, 77-83.  
Via question prompt list and values clarification 
exercises 
Development 
 
Using a systematic development process 
 
1. The development process included finding out what clients or patients need to 
prepare them to discuss a specific decision.c 
Yes.  
In depth qualitative interviews conducted with 
patients and family. Interview guides based on 
Ottawa decisional support framework [17].  
 2. The development process included finding out what health professionals need 
to prepare them to discuss a specific decision with patients.c 
Yes.  
In depth qualitative interviews conducted with 
psychiatrists, GPs, and clinical psychologists. 
Interview guides based on Ottawa decisional 
support framework [17]. 
 3. The development process included expert review by clients/patients not 
involved in producing the decision support technology.c 
Yes.  
Content/format review included 3 patients, 2 
family members not involved in producing DA.  
 4. The development process included expert review by health professionals not 
involved in producing the decision aid.c 
Yes. 
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Content/format review included 1 psychiatrist, 2 
GPs, 1 clinical psychologist not involved in 
producing DA. 
 5. The decision support technology was field tested with patients who were 
facing the decision.c 
Yes.  
Phase I pilot/usability testing conducted in 
patients/family who were currently facing 
decision (as well as patients/family who had 
already faced decision).  
 6. The decision support technology was field tested with practitioners who 
counsel patients who face the decision.c 
 
No.  
Field testing with health professionals was not 
deemed necessary as: i) this group was not the 
intended target group of potential users; ii) DA 
intended for use in the home or other private 
setting, primarily before/after clinical 
encounters. 
Evidence 
 
Using a systematic development process 
1. The decision support technology (or associated documentation) provides 
citations to the studies selected.c 
Yes, pages 97-99. 
 2. The decision support technology (or associated documentation) describes how 
research evidence was selected or synthesised.c 
Yes, page 96. 
Treatment efficacy data based on best available 
clinical evidence, i.e., meta-analytic reviews of 
medication and psychological options.  
Side-effect/risk data based on well-designed 
placebo-controlled trials and/or large scale 
naturalistic studies (long-term lithium 
outcomes). 
 3. The decision support technology (or associated documentation) provides a 
production or publication date.b 
Yes, page 94. 
 4. The decision support technology (or associated documentation) provides 
information about the proposed update policy.b 
Yes, page 94. 
Next proposed update in 2 years from 
production date, i.e., January 2019.  
 5. The decision support technology (or associated documentation) describes the 
quality of the research evidence used.b 
Yes, pages page 96.  
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Treatment efficacy data based on best available 
clinical evidence, i.e., meta-analytic reviews of 
medication and psychological options. 
Side-effect/risk data based on well-designed 
placebo-controlled trials and/or large scale 
naturalistic studies (long-term lithium 
outcomes).  
Disclosure 
 
Disclosure and transparency 
1. The decision support technology (or associated technical documentation) 
provides information about the funding used for development.b 
Yes, page 94. 
 2. The decision support technology includes author/developer credentials or 
qualifications.c 
Yes, page 94. 
Plain language 
 
 
1. The decision support technology (or associated documentation) reports 
readability levels (using one or more available scales).c  
No  
Noted that the DA was professionally copy-
edited for low health literacy levels. A health 
literacy review using the Patient Education 
Materials Assessment Tool (PEMAT; 
Shoemaker [42]) yielded “understandability” 
scores of 76%, placing the DA in the “superior” 
range for easy to understand and use patient 
education materials [43].    
DST evaluation 1. There is evidence that the decision support technology improves the match 
between the features that matter most to the informed patient and the option that 
is chosen.  
Yes, preliminary evidence based on pilot 
evaluation.  
As evidenced by high proportion of patients 
indicating values-based informed choice (see 
Chapter 7).  
 2. There is evidence that the patient decision support technology helps patients 
improve their knowledge about options’ features.  
Yes, preliminary evidence based on pilot 
evaluation.  
As evidenced by patients’ high-levels of 
subjective/objective knowledge of treatment 
options and outcomes (see Chapter 7) 
Notes.  
*Test criteria excluded (pertain to decision support technologies directed at investigations or screening tests).  
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a = qualifying criteria 
b = certifying criteria 
c = quality criteria  
  216 
6.3. Summary 
This chapter described the comprehensive development and planned pilot testing of 
the treatment DA for patients with BPII and their families. A systematic approach to 
DA development and evaluation was undertaken, which included ongoing 
engagement of key stakeholders and potential end users. Quality and rigor in the DA 
development were ascertained via established international criteria, which are 
currently considered to be “gold standard”. This development process ensures that the 
final DA is a relevant, evidence-based resource for the target population. The use of 
well-developed outcome measures ensures rigorous evaluation of the DA’s potential 
efficacy at improving decision-making and relevant patient outcomes.  
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Chapter 7: Development and pilot of a decision-aid for patients with bipolar II 
disorder and their families making decisions about treatment options to prevent 
relapse. 
 
This chapter is reformatted from the published manuscript:  
Fisher A, Sharpe L, Anderson J, Manicavasagar V, Juraskova I. Development and 
pilot of a decision-aid for patients with bipolar II disorder and their families making 
decisions about treatment options to prevent relapse. PLoS ONE. 2018;13(7): 
e0200490. https://doi.org/10.1371/journal.pone.0200490 
 
 
This chapter reports on the development and piloting of a decision-aid booklet (DA) 
for patients diagnosed with bipolar II disorder (BPII) and their families who are 
deciding on medication and psychological treatment options for relapse prevention. 
The DA content, format and delivery was informed by the unmet informational and 
decision-support needs of these patients and their families (Chapter 3, 4) as well as 
the clinician-perceived strategies for addressing decision-making barriers (Chapter 5, 
see Chapter 6 for full outline of the development process). Pilot findings revealed that 
the DA was highly acceptable, feasible, and safe to use amongst this sample of 
potential end-users, and potentially useful at improving treatment decision-making in 
this setting. Findings also guided the design of a future planned randomised controlled 
trial of the DA (Appendix G). Ethics approval letters are provided in Appendices B3 
and B4; supplementary materials related to this study are provided in Appendices F1 
– F3. A copy of the final DA booklet is provided in Appendix H.  
 
Author contributions 
Conception and design: AF, IJ 
Participant recruitment: AF 
Data collection: AF 
Data analysis and interpretation: AF, IJ 
Manuscript drafting: AF 
Manuscript critical review: All authors 
Review of final manuscript: All authors 
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7.1. Abstract 
Introduction. Treatment decisions in bipolar II disorder (BPII) are finely-balanced and 
sensitive to patient preferences. This pilot study evaluated a decision-aid booklet 
(DA) for patients with BPII (and their family) to obtain evidence on its acceptability, 
feasibility, safety, and usefulness in potential end-users. 
 
Methods. The DA booklet was developed according to International Patient Decision-
Aid Standards. Thirty-one patients diagnosed with BPII and their families (n=11), 
who were currently making or had previously made treatment decisions, participated. 
Participants read the DA and completed validated and purpose-designed 
questionnaires. A follow-up semi-structured telephone interview elicited more in-
depth DA feedback (n=40). 
 
Results. Patients and family endorsed the DA booklet as: easy-to-use (100% agree), 
useful in treatment decision-making (100%), presenting balanced (patients = 96.8%, 
family = 100%), up-to-date (93.5%, 100%) and trustworthy information (93.5%, 
100%) that did not provoke anxiety (93.5%, 90.9%). All participants stated that they 
would recommend the DA to others. Following DA use, all except one participant 
(97.6%) demonstrated adequate treatment knowledge (>50% score). Patients reported 
low decisional conflict (M=18.90/100) following DA use and felt well-prepared to 
make treatment decisions (M=4.28/5). Most patients (90.3%) indicated uptake of 
treatments consistent with the best available clinical evidence. Additionally, a large 
proportion of patients made an informed choice about medication (65.5%) with 
adjunctive psychological treatment (50.0%), based on adequate knowledge and their 
treatment values. Interview findings further supported the DA’s acceptability among 
participants.  
 
Discussion. Pilot findings indicate that patients with BPII and their family consider 
this DA booklet highly acceptable and useful in making evidence-based treatment 
decisions that align with their treatment preferences. 
 
Keywords: bipolar II disorder; decision aid; treatment; shared decision-making; 
knowledge; decisional conflict.   
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7.2. Introduction 
A diagnosis of bipolar II disorder (BPII) is commonly accompanied by a need to 
make complex treatment decisions about mood-stabilising medications and adjunctive 
psychological therapies, often for lifetime prophylactic use. These decisions are 
challenging, both from a clinical and a patient perspective. Firstly, there are limited 
BPII-specific clinical guidelines [1, 2], which reflect limited evidence to support 
available treatment options in individuals with BPII [3, 4]. Next, there are a number 
of viable medical and adjunctive psychological treatment options available with 
varying benefit/cost profiles. Some medication options can have significant potential 
side-effects, for example, cognitive dulling and weight gain [5, 6], which some 
patients may perceive as outweighing any immediate therapeutic benefits. Thus, these 
“preference-sensitive” treatment decisions need to incorporate the best available 
clinical evidence, clinician judgement, and patient preferences [7].  
 
To date, no known resources have been developed to facilitate more informed and 
active patient (and family) involvement in BPII treatment decision-making. Patient 
decision-aids (DAs) are evidence-based interventions for potentially improving 
shared treatment decision-making (SDM) in BPII. DAs are designed to help patients 
make specific and deliberative healthcare choices, by weighing up the pros 
(‘benefits’) and cons (‘costs’) of all available options whilst considering their personal 
values/preferences. Emerging evidence from randomised controlled trials (RCT) 
supports the effectiveness of six known mental health treatment DAs, for unipolar 
depression [8-10], post-traumatic stress disorder [11, 12], and schizophrenia [13]. In 
light of these promising findings, and in the absence of any BPII-specific DAs, this 
pilot study aimed to: 
1)  obtain preliminary evidence on the acceptability, safety, feasibility and 
potential usefulness of a newly-developed DA booklet for patients with BPII 
and their family making decisions about prophylactic treatment (for relapse 
prevention); and 
2)  establish the feasibility, relevance and acceptability of the procedures and 
measures used, to inform the design of a RCT evaluation of the DA.  
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7.3. Methods 
 
7.3.1. Participants 
Patients: Adults with a clinical diagnosis of bipolar II disorder (BPII) who were 
currently making or had previously made decisions about their treatment (medical or 
non-medical) were eligible to participate.  
 
Family members: Adults whose family member had: i) an adult BPII diagnosis (18+ 
years), and who had ii) attended at least one consultation involving treatment 
decision-making, and/or had iii) experience helping their family member make 
treatment decisions outside consultations were also invited to participate. Patient 
participation was not a pre-requisite for family member participation. 
 
Exclusion criteria for both samples were: i) insufficient English proficiency; ii) 
inability to provide informed consent; ii) (comorbid) substance abuse disorder; iv) 
other major psychiatry/neurological disorder or cognitive impairment.  
 
Ethics approval was obtained from the University of Sydney (USYD) Human 
Research Committee and the Black Dog Institute (BDI) Research Advisory 
Committee; the study was carried out according to the principles outlined in the 
Declaration of Helsinki [14].  
 
Participants were recruited through the following pathways: A. patient referrals to 
BDI (with family members identified through patients) an outpatient clinical service 
specialising in the assessment and treatment of mood disorders; B. patient/family 
attendees at the BDI’s BPII support groups; C. purposively-sampled participants from 
previous research [15] who had agreed to be contacted regarding future research 
participation; D. members of Australia-based online community forums/social-media 
platforms for people affected by mood disorders (patients and family) (BeyondBlue, 
SANE and LIVIN’).  
 
The use of multiple recruitment pathways ensured a mix of participants who were 
actively considering treatment options - the DA target population (i.e. pathway A); or 
who had already made a BPII treatment decision (i.e. pathways B-D). 
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For patients recruited through pathways A-C, BPII diagnosis was based on a 
“consensus diagnostic decision” between at least two assessing psychiatrists with 
expertise in mood and bipolar disorders [16]. To establish BPII diagnosis, all patients 
were clinically assessed by an intake psychiatrist who made a lifetime clinical 
diagnosis of BPII applying clinician-judged criteria. These criteria took into account 
DSM-5 symptom criteria [17] but did not impose the minimum duration criterion for 
hypomania (4 days). This criterion is largely arbitrary and not of clinical significance 
[16, 18]. Approximately a third of these patients were also assessed by a second 
independent psychiatrist. Prior to clinical assessment, patients also completed the 27-
item Mood Swings Questionnaire [19], which has sensitivities and specificities of 70-
82% and 78-98% in tertiary patient referral samples [20, 21]. For patients recruited 
through pathway D, BPII diagnosis was based on self-report. We required, however, 
that these patients had been diagnosed with BPII by a mental health specialist (i.e., 
psychiatrist) as opposed to general physician (GP) (i.e., primary care provider).  
 
7.3.2. Procedure 
For the patient referral sample (pathway A) a clinic research assistant introduced the 
study to eligible patients following their clinical assessment, and gave the contact 
details of interested patients to the study coordinator at USYD (AF). Purposely-
sampled participants (pathway C) were contacted directly by AF via their provided 
contact details to introduce the study and ascertain their interest in participating. All 
other participants responded to an expression-of-interest flyer, which was 
disseminated via the support group meetings and online forums (pathways B and D, 
respectively).  
 
AF telephoned interested participants to explain the nature and purpose of the study 
and obtain verbal consent to post/email a study pack containing: an information sheet 
and consent form, a copy of the DA booklet and a study questionnaire. Upon 
receiving the completed questionnaires and written consent form, a one-off telephone 
interview was arranged. 
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7.3.3. Materials 
 
The BPII decision-aid (DA)  
The BPII DA booklet was informed by the International Patient Decision-Aid 
Standards (IPDAS) [22] and the Ottawa decisional support framework [23]. Content, 
formatting and design were based on: a systematic review [24], the best available 
evidence (e.g., clinical guidelines [1, 2, 25], meta-analyses [26, 27] and well-
designed, placebo-controlled RCTs [28-34]); in-depth qualitative interviews with 
patients (n=28), family (n=13), and clinicians (n=20) [15, 35, 36]; and iterative review 
by an expert working party. The BPII DA was a 100 page A5 booklet, with 
information divided into three main sections (via dividing tabs): Medication Options, 
Psychological Options, and Making Decisions. Throughout, the DA provides 
evidence-based, lay information using text and graphics on the known efficacy and 
benefits/costs of the current first-line medications (e.g., lithium, lamotrigine, 
quetiapine) [1, 2] and Level-1 evidence-supported psychological treatments (e.g., 
individual cognitive behavioural therapy [CBT], group psycho-education) [25] for 
relapse prevention in BPII specifically. Values clarification exercises (VCE’s) help 
patients/family consider their preferences and deliberate on the benefits/costs of the 
different treatment options. Other (i.e., second-line and/or adjunctive) medications 
and psychological treatment options were excluded due to limited data supporting 
their efficacy specifically for patients with BPII. Including these other options was 
deemed superfluous to the main purpose of a DA, which is to support patients facing 
‘preference-sensitive’ decisions. That is, deciding between treatment options that are 
supported by similar evidence, and thus clinical uncertainty remains with regards to 
which option is superior (i.e., equipoise) [37]. 
 
The DA’s readability levels were not assessed, as readability may not be an 
appropriate index of comprehensibility when patient information materials contain 
multisyllabic medical terminology [38]. This terminology was necessary to include 
and were defined in simple, descriptive terms in the DA’s glossary. As a more 
appropriate alternative to assessing readability levels, the DA was professionally 
copy-edited for low health literacy levels. In addition, health literacy review using the 
Patient Education Materials Assessment Tool (PEMAT; Shoemaker [39]) yielded 
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“understandability” scores of 76%, placing the DA in the “superior” range for easy to 
understand and use patient education materials [40]. 
 
The DA is designed for patients/family to use before and/or after clinical 
consultations in which treatment options for relapse prevention/maintaining mood 
stability are discussed. Thus, the DA is not intended to replace treatment discussions 
with their managing clinician, but rather support and prepare patients to have these 
discussions. See Appendix F1 for a full summary of the DA booklet content. 
 
Interview guide 
The purpose-designed, semi-structured interview guide (see Appendix F2) was 
informed by the Ottawa Acceptability measure [41]. Open-ended questions elicited 
feedback on the DA’s acceptability and suggested improvements. 
 
7.3.4. Measures 
Purpose-designed and validated measures evaluated the DA’s acceptability and 
potential usefulness in terms of key decision quality constructs [42]. Asterixed 
measures (*) were completed by patients only. 
 
Participant DA feedback was assessed using an adapted measure from previous 
acceptability studies of mental health decision-support [43]. Participants indicated 
their agreement on the DA’s perceived ease of use (8 items), perceived usefulness (9 
items), attitudes towards using (3 items), and perceived trustworthiness/bias (4 
items). Four agreement categories were collapsed into agree (agree/somewhat agree) 
and disagree (disagree/somewhat disagree).  
 
Measures of decision-making quality 
Perceived difficulties with decision-making* were assessed using the 16-item 
validated Decisional Conflict Scale (DCS; α’s=0.78-0.92) [44]. Five subscales 
measured patients’ feelings of being: i) uncertain about the treatment options, ii) 
uninformed, iii) unsupported, iv) unclear about values in decision-making, and v) 
unable to make an effective decision (scores 0-100). A total score (0-100) indicated 
overall decision-making difficulties. Lower scores denoted less decision-making 
difficulty.  
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Objective knowledge of treatment options and outcomes employed a competency-
based approach [45], whereby 14 forced-choice items assessed conceptual/gist (9 
items yielding possible total scores 0-18; “true”, “false”, “don’t know”) and 
numerical/verbatim (5 items yielding possible total scores 0-20; A-E responses) 
knowledge of information contained in the DA. Assessed domains were based on 
current NHMRC guidelines for medical practitioners on giving information to 
patients for informed consent purposes [46]. Based on Smith et al. [45], responses 
were scored according to an a priori marking scheme, with the threshold for adequate 
knowledge for informed choice (yes/no) set at > 50% of total possible score (i.e., 
score of 20 or more out of 38) (Appendix F3).  
 
Subjective/perceived knowledge of treatment options and outcomes was assessed via a 
15-item purpose-designed measure, whereby participants indicated how well they had 
understood (1=didn’t understand at all to 5=understood very well) information 
contained in the DA. Again assessed knowledge domains were based on current 
NHMRC guidelines [46]. 
 
Informed, values-based choice* was determined via a composite measure of objective 
knowledge (see above), attitudes, and treatment choice. Attitudes towards medication 
and psychological options were assessed using two Likert-type scales, which each 
contained four items. Each item was anchored by opposing positive/negative 
adjectives (e.g., 1=Beneficial, 7=Harmful) [47]. Patients also indicated their 
(hypothetical) treatment choice after reading the DA (e.g., medication/s with/out 
adjunctive psychological treatment versus no medication/treatment). Patients were 
defined as making an informed choice if they had adequate objective knowledge (i.e., 
> 50%) [45] and made a treatment choice that was consistent with their values (e.g., 
positive attitudes towards medication/s plus indicating intentions to take up 
medication/s) [47]. A median split categorised patients with positive attitudes 
(≥median) or negative attitudes (<median) [47]. 
 
Preparation for decision-making scale* assessed via 10 items patient perceptions of 
the DA’s usefulness in preparing them to make treatment decisions (α’s=0.92-0.96) 
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[48]. Each item was rated from not at all=1 to a great deal=5 yielding a mean 
possible score of 1-5.  
  
Measures of sample characteristics 
Anxiety levels were assessed using the 6-item short form of the State Trait Anxiety 
Inventory (STAI-Y-SF) [49].  
 
Symptom severity/mood state* within the past 24 hours was self-reported using the 
17-item Internal States Scale (ISS) [50]. Each item was rated from 0 (rarely/not at all) 
to 100 (very much so/most of the time). The combination of total scores on the 
Activation (<155 or ≥155) and Wellbeing (<125 or ≥125) subscales indicated the 
patient’s current mood state.  
 
Stage of decision-making scale categorised patient’s (lack of) readiness to engage in 
decision-making, from not thinking about treatment choices (item 1) to actively 
deliberating on options (item 3) to having already made a treatment decision (item 5) 
[51].  
 
Preferred and experienced levels of patient involvement in decision-making were 
assessed via two administrations of the single-item adapted Control Preferences Scale 
(CPS) [52, 53]. Concordance/discordance was indexed via (dis)agreement between 
the two ratings [54, 55].  
 
Information preferences were assessed using an adapted version of the Cassileth 
Information Styles questionnaire [56]. Items elicited preferences regarding the 
amount (1-5) and type (enough to care for self; only good; all information, good and 
bad) of medical information. 
 
Health literacy was measured via the Single Item Literacy Screener (SILS) [57]: 
“How often do you need to have someone help you read instructions, pamphlets, or 
other written material from your doctor or pharmacy?”. (never=1 to always=5). 
Scores of >2 reflect some difficulties understanding written health materials. To 
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control for mood symptoms as a potential confound, the item was reworded for 
patients to include: “When not experiencing symptoms of depression or 
hypomania…” 
 
Demographic, clinical and family involvement information was obtained via a 
purpose-designed self-report questionnaire.  
 
7.3.5. Data analyses 
Descriptive and frequency analysis of the quantitative questionnaire data used IBM 
SPSS version 23. Qualitative analyses of participants’ interview responses used a 
thematic approach [58] to inform the relevant quantitative findings.  
 
7.4. Results 
 
7.4.1. Sample demographics 
Of the 49 patients and 20 family members who agreed to participate, 30 patients and 
10 family members completed both the questionnaire and follow-up interview lasting 
approximately 30 minutes on average (response rates: 61.2% and 50%, respectively). 
An additional one patient and one family member completed the questionnaire only. 
Due to the way in which participants were approached for this study (e.g., patient 
referrals from a private clinic), limited information is available for those patients and 
family who agreed to participate but did not go on to complete study procedures. Of 
those participants who were able to be contacted, reasons for non-participation 
included: lack of interest and time/other competing commitments (n=2), significant 
change in personal circumstances (moving overseas, undergoing divorce, n=2), not 
receiving the study package in the post (n=2), and hospitalisation for mood symptoms 
(n=1).  
 
Sample demographics are summarised in Table 7.1. Patients were aged on average 
36.67 years, (SD=12.63), and family on average 46.64 years (SD=15.87). Both 
samples comprised mostly women (77.4% patients, 81.8% family), the majority were 
Australian-born (80.6%, 72.7%) with university level education (58.1%, 63.7%) and 
engaged in part-time/full-time work (70.9%, 72.8%).  
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Table 7.1. Demographic characteristics of patient (n=31) and family (n=11) samples 
 Patients Family 
 M (SD)  M (SD) 
Age 36.87 (12.63) 46.64 (15.87) 
 n (%) n (%) 
Gender    
   Female 24 (77.4) 9 (81.8) 
Relationship to patient   
   Parent -- 5 (45.5) 
   Spouse/partner -- 3 (27.3) 
   Sibling -- 2 (18.2) 
   Child -- 1 (9.1) 
Highest qualification    
   Year 12/ HSC or below 7 (22.6) 2 (18.2) 
   TAFE certificate/diploma 6 (19.4) 2 (18.2) 
   University degree 14 (45.2) 4 (36.4) 
   Postgraduate degree 4 (12.9) 3 (27.3) 
Current employment    
   Working full-time 13 (41.9) 4 (36.4) 
   Working part-time 9 (29.0) 4 (36.4) 
    Studying 3 (9.7) -- 
    Not employed/retired/home-duties 5 (16.1) 3 (27.3) 
    Other (e.g., part-time work & study) 2 (6.5) -- 
Country of birth   
   Australia 25 (80.6) 8 (72.7) 
   Other (e.g., UK, Japan) 6 (19.4) 3 (27.3) 
Language spoken at home   
   English 30 (96.8) 11 (100) 
   Other (Turkish) 1 (3.2) -- 
Current relationship status   
   Married/living with partner 17 (54.8) 10 (90.9) 
   Single/dating 10 (32.3) -- 
   Separated or divorced 4 (12.9) 1 (9.1) 
Current living arrangement   
   With partner (with/out children) 16 (51.6) 9 (81.8) 
   By yourself/independently  5 (16.1) 2 (18.2) 
   With other family members 5 (16.1) -- 
   With non-family members 5 (16.1) 1 (9.1) 
Patient/family participant pairs  -- 3 (27.3) 
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7.4.2. Clinical and family involvement characteristics  
As seen in Table 7.2, an equal number of patients reported having a recent (<12 
months, 41.9%) or longer-standing BPII diagnosis (1-5 years ago, 41.9%). 
Meanwhile, over half of family participants had a family member with a longer-
standing BPII diagnosis (54.5%). Both patients and family participants indicated 
slightly elevated anxiety at the time of the study (~one SD above age-matched 
community norms, M=46.56, 44.55, respectively).  
 
Patients and family reported that they/their family member experienced mainly 
depressive or equal depressive/hypomanic episodes (83.9, 81.8%, respectively). 
Almost half of patients (45.2%) and two-thirds of family participants (63.9%) 
reported that they/their family member was currently taking a mood-stabiliser 
medication. Around two-thirds of patients (61.3%) and a third of family (36.4%) 
reported that they/their family member was undertaking psychological treatment. 
Most patients and family nominated relapse prevention as their/their family member’s 
current treatment goal (77.4%, 81.8%, respectively).  
 
Most patients and family participants indicated that family had attended at least one 
consultation regarding BPII treatment (71%, 81.8%, respectively), however, patients 
usually attended consultations alone/unaccompanied (77.4%, 81.8%).  
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Table 7.2. Clinical characteristics of patient (n=31) and family (n=11) samples 
 Patients Family 
 M (SD) M (SD) 
Age diagnosed with BPII 34.16 (11.96) 32.64 (12.96) 
State anxiety (20 - 80) 46.56 (13.23) 44.55 (15.72) 
 n (%) n (%) 
Time since BPII diagnosis   
   <1 month 5 (16.1) -- 
   1 – 12 months 8 (25.8) 4 (36.4) 
   1-5 years 13 (41.9) 6 (54.5) 
   5 + years 5 (16.1) 1 (9.1) 
BPII episodes – (perceived) frequency    
   More than once per month 10 (32.3) 2 (18.2) 
   4 or more times per year 11 (35.5) 3 (27.3) 
   2-3 times per year 5 (16.1) 5 (45.5) 
   About once per year 4 (12.9) -- 
   Less than once per year 1 (3.2) 1 (9.1) 
BPII episodes – (perceived) type    
   Mainly depressive episodes 15 (48.4) 3 (27.3) 
   Equal depression/hypomania 11 (35.5) 6 (54.5) 
   Mainly hypomanic episodes 4 (12.9) 1 (9.1) 
   Mainly euthymic/subsyndromal 1 (3.2) 1 (9.1) 
Current mood state (ISS)   
   Hypomania 13 (41.9) -- 
   Euthymia 7 (22.6) -- 
   Depression 6 (19.4) -- 
   Mixed state 5 (16.1) -- 
Current medication/s   
   Mood stabiliser only (incl. anticonvulsants) 14 (45.2) 7 (63.6) 
   Atypical antipsychotic -- 1 (9.1) 
   Antidepressant 2 (6.5) -- 
   Mood stabiliser plus atypical antipsychotic 2 (6.5) -- 
   Mood stabiliser plus antidepressant 4 (12.9) -- 
   All three types 4 (12.9) 1 (9.1) 
   No medication 5 (16.1) 2 (18.2) 
Current psychological treatment   
   Yes (e.g., CBT, counselling) 19 (61.3) 4 (36.4) 
Current goal of BPII treatment   
   Prevent recurrence/relapse 24 (77.4) 9 (81.8) 
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   Treat current depression 3 (9.7) -- 
   Treat current hypomania -- 1 (9.1) 
   Other (e.g., combination of above) 4 (12.9) -- 
   Don’t know -- 1 (9.1) 
Family attended consultation/s   
   Yes 22 (71) 9 (81.8) 
Usual attendance in consultation/s   
   Usually patient alone 24 (77.4) 9 (81.8) 
   Attends accompanied 3 (9.7) 1 (9.1) 
   Sometimes alone or accompanied 4 (12.9) 1 (9.1) 
 
7.4.3. Pre-existing decision-making characteristics  
 
Information preferences and decision-making stage 
Both patients and family preferred to receive a large amount of information (M=4.82, 
4.91/5, respectively) and most wanted “as much information as possible, good or bad” 
(87.1, 90.9%, respectively) (Table 7.3). In terms of decision-making stage, 77.4% of 
patients and 63.6% of family indicated that they/their family member were either 
currently considering treatment options, or had already made a treatment decision but 
were willing to reconsider these options. No participants indicated health literacy-
related difficulties (scores < 2).  
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Table 7.3. Pre-existing decision-making characteristics of patient (n=31) and family 
(n=11) samples 
 Patients Family 
 M (SD) M (SD) 
Information preferences  - amount (/5) 4.82 (0.42) 4.91 (0.30) 
 n (%) n (%) 
Information preferences – type   
   As much information as possible, good or bad 27 (87.1) 10 (90.9) 
   Only information to take care of myself/my family 4 (12.9) 1 (9.1) 
Involvement in decision-making (dyadic)  Pref Exp Pref Exp 
   Patient-led with/out clinicianb 12 (38.7) 14 (45.2) 8 (72.7) 9 (81.8) 
   Shared/collaborative 12 (38.7) 9 (29.0) 3 (27.3) 1 (9.1) 
   Clinician-led with/out patientc 7 (22.6) 8 (25.9) -- 1 (9.1) 
Involvement in decision-making (triadic)  Pref Exp Pref Exp 
   Patient-led with/out clinician/familyb 22 (71) 22 (71) 11 (100) 10 (90.9) 
   Shared/collaborative 2 (6.5) 2 (6.5) -- -- 
   Clinician-led with/out patient/familyc 7 (22.6) 6 (19.4)  -- -- 
   No family involvement -- 1 (3.2) -- -- 
Experienced preferred level of patient involvement 
(dyadic) 
  
   Yes 19 (61.3) 4 (36.4) 
Experienced preferred level of patient involvement 
(triadic) 
  
   Yes 17 (54.8) 8 (72.7) 
Patient decision-making stage   
   Not begun to think about choices but interested 1 (3.2) -- 
   Considering options now 9 (29.0) -- 
   Already made a decision, willing to reconsider 15 (48.4) 7 (63.6) 
   Already made a decision, unlikely to change mind 6 (19.4) 4 (36.4) 
Read the DA    
   Just briefly 1 (3.2) 1 (9.1) 
   Just parts relevant to me 3 (9.1) 2 (18.2) 
   Quite thoroughly 8 (25.8) 4 (36.4) 
   From cover to cover 19 (61.3) 4 (36.4) 
Notes:  
a Participants indicated perceived/experienced levels of clinician-patient(-family) involvement in the 
most recent consultation involving BPII treatment decision/s. This consultation may have occurred 
prior to/after exposure to the DA. 
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b Combines “fully patient-led decision-making” and “patient-led decision-making with clinician (and 
family) input” 
c Combines “fully clinician-led decision-making” and “clinician-led decision-making with patient (and 
family) input” 
 
Preferred and experienced involvement in decision-making 
As with information, patients and family also indicated strong preferences for patient 
involvement (Table 7.3). Overall, patients and family mostly preferred and 
experienced either patient-led or shared decision-making in consultations involving 
BPII treatment decision/s. A smaller proportion of patients compared to family 
preferred and experienced patient-led decision-making. Further, patients more often 
than family preferred and experienced shared or clinician-led decision-making in 
consultations (Table 7.3).  
 
Regarding concordance, 61.3% of patients (n=19) and 36.4% of family (n=4) 
experienced their preferred level of patient involvement in the most recent dyadic 
(clinician-patient) consultation involving BPII treatment decision/s (Table 7.3). By 
contrast, 54.8% of patients (n=17) and 72.7% of family (n=8) experienced their 
preferred patient level of involvement in the most recent triadic (clinician-patient-
family) consultation involving BPII treatment decision/s (Table 7.3). 
 
Read the DA 
All participants reported reading the DA and most also indicated good engagement; 
87.1% of patients and 72.8% of family participants read the DA “quite thoroughly” or 
“cover to cover” (Table 7.3). Participants were not asked how long it took them to 
read through the DA, however, participants were expected (and encouraged) to review 
the DA over a number of sittings (as opposed to a single sitting). This said, 
participants who volunteered this information during interviews noted that reading 
through the DA took approximately 40 – 45 minutes.  
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7.4.4. Decision-making quality characteristics 
 
Uptake of effective treatment option 
After reading the DA, almost all patients (90.3%) indicated that they would take up an 
effective treatment option: mostly a medication option (48%) or combination of 
medication/s plus an adjunctive psychological treatment (41.9%, Table 7.4). 
Remaining patients (n=3, 9.7%) indicated that they were unsure or chose to delay 
treatment uptake.  
 
Decision-making difficulties and preparation  
With regards to their hypothetical treatment choice, patients indicated low levels of 
decisional conflict on their total score (M=18.90/100) and on each of the subscales 
(M=8.87–30.11/100) (Table 7.4), on average. Only the uncertainty subscale had 
average scores over 25 (30.11/100), indicating that some patients felt unsure/unclear 
about which option was best for them. On average, patients also indicated that the DA 
prepared them well to make treatment decisions (M=4.28/5).  
 
Knowledge and understanding of treatment options 
Patients and family reported good subjective understanding of the DA treatment 
options and outcomes (M=4.45, 4.36/5, respectively, Table 7.4). Objective knowledge 
was similarly high; patients and family were highly knowledgeable in terms of 
average total (M=32.04, 34.41/38, respectively), conceptual and numerical knowledge 
(Table 7.4). Accordingly, all but one patient demonstrated adequate knowledge (i.e., 
>50% of possible total score, Appendix F3). Additional post-hoc analyses were 
conducted on adequate knowledge about treatment options and outcomes. Using a 
cut-off score of >75% instead of >50%, these analyses revealed that, even with the 
more stringent cut-off score, the large majority of both patient (n=24, 77.4%) and 
family (n=9, 81.8%) participants still demonstrated adequate knowledge of treatment 
options and outcomes.  
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Table 7.4. Decision-making quality characteristics of patient (n=31) and family 
(n=11) samples 
 Patient Family 
 n (%) n (%) 
Uptake of effective treatment options (as per DA)a   
   Medication/s only 15 (48.4) -- 
       - Lithium 1 (3.2) -- 
       - Lamotrigine 8 (25.8) -- 
       - Quetiapine 1 (3.2) -- 
       - Combination of above medications 2 (6.5) -- 
  Medication/s plus adjunctive psychological treatment 13 (41.9) -- 
   No treatment uptake/ unsure 3 (9.7) -- 
 M (SD) M (SD) 
Decisional conflict (/100)a   
   Total 18.90 (13.90) -- 
   Uncertainty 30.11 (24.97) -- 
   Informed 13.98 (14.65) -- 
   Values 8.87 (12.16) -- 
   Support 15.32 (14.45) -- 
   Effective decision 24.40 (19.25) -- 
Preparation for decision-making (/5) 4.28 (0.61) -- 
Subjective understanding of treatment options (/5) 4.45 (0.57) 4.36 (0.50) 
Objective knowledge of treatment options   
   Total score (/38) 32.04 (4.43) 34.41 (3.81) 
   Conceptual/gist knowledge (/18) 15.16 (2.72) 16.73 (1.85) 
   Numerical/verbatim knowledge (/20) 16.87 (2.88) 16.32 (5.18) 
 n (%) n (%) 
Adequate level knowledge of treatment options  
(Total score > 50%, see Appendix F3 for scoring)* 
30 (96.8) 11 (100) 
Attitudes medication options (as per DA)*   
   Positive (at or above median) 20 (64.5) 8 (72.7) 
   Negative (below median) 9 (29) 3 (27.3) 
Attitudes adjunctive psychological options (as per DA)*   
   Positive (at or above median) 21 (67.7) 7 (63.6) 
   Negative (below median) 9 (29) 4 (36.4) 
Informed treatment choice (yes)a   
   Medication/s uptake 19 (65.5) -- 
  Medication/s plus adjunctive psychological treatment uptake 15 (50.0) -- 
a = based on hypothetical choice/uptake after reading the DA 
* Note remaining percentage = missing data 
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Attitudes towards treatment options and informed treatment choice 
The majority of patients and family expressed positive attitudes towards the presented 
medications (64.5%, 72.7%, respectively) and adjunctive psychological treatments 
(67.7%, 63.6%, respectively) for BPII relapse prevention (Table 7.4).  
 
Based on congruence between patient’s knowledge and treatment attitudes, 65.5% 
made an informed choice about medication uptake and 50.0% made an informed 
choice about taking-up adjunctive psychological treatment. All remaining patients 
made a treatment choice that was based on adequate knowledge (except n=1) but was 
incongruent with their treatment attitudes (e.g., negative attitudes towards medication, 
yet decided to take-up medication).  
 
7.4.5. Participant feedback on the DA 
Quantitative participant feedback on the booklet was highly positive across all 
acceptability domains (Table 7.5). The qualitative interview data reflected these 
mostly positive attitudes. Differences between patients and family or those 
participants with a recent (<12 months) versus longer-standing (1 year +) diagnosis 
are noted below. These differences were minimal overall, however. For illustrative 
participant quotes, see Table 7.6.  
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Table 7.5. Quantitative participant feedback on the decision-aid (DA) in the patient (n=31) and family (n=11) samples 
 Patients  Family  
 Agree/ 
Somewhat 
Agree 
n (%) 
Disagree/ 
Somewhat 
Disagree 
n (%) 
Agree/ 
Somewhat Agree 
 
n (%) 
Disagree/ 
Somewhat Disagree 
 
n (%) 
Perceived ease of use of DA     
   Font easy-to-read  31 (100) -- 11 (100) -- 
   Easy-to-use 31 (100) -- 11 (100) -- 
   Clearly organised information 30 (96.8) 1 (3.2) 11 (100) -- 
   Design appealing 31 (100) -- 11 (100) -- 
   Easy-to-understand information 31 (100) -- 11 (100) -- 
   Colours pleasant 31 (100) -- 11 (100) -- 
   Pictures relevant 31 (100) -- 11 (100) -- 
   Important information easy-to-find 31 (100) -- 11 (100) -- 
Perceived usefulness of DA     
   Content interesting 31 (100) -- 11 (100) -- 
   Useful in making a treatment decision 31 (100) -- 11 (100) -- 
   Right amount of information included 31 (100) -- 10 (90.9) 1 (9.1) 
   Information I needed included 31 (100) -- 10 (90.9) 1 (9.1) 
   Helped with my concerns 30 (96.8) 1 (3.2) 10 (90.9) 1 (9.1) 
   Found links to information and other resources 28 (90.3) 3 (9.7) 11 (100) -- 
   Learnt something new 29 (93.5) 2 (6.5) 11 (100) -- 
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   Made it easier to discuss treatment options with family 26 (83.9) 4 (12.8) 10 (90.9) 1 (9.1) 
   Made it easier to discuss treatment options with (my) clinician* 28 (90.3) 3 (9.7) 10 (90.9) -- 
Attitudes towards using DA     
   Would recommend to others in my situation 31 (100) -- 11 (100) -- 
   Would go back and re-read sections 30 (96.8) 1 (3.2) 11 (100) -- 
   Information did not make me anxious (safety check) 29 (93.5) 2 (6.5) 10 (90.9) 1 (9.1) 
Perceived trustworthiness and balance of information in DA     
   Information trustworthy* 29 (93.5) 1 (3.2) 11 (100) -- 
   Information up-to-date* 29 (93.5) 1 (3.2) 11 (100) -- 
   Equal emphasis placed on each of the medication options 30 (96.8) 1 (3.2) 11 (100) -- 
   Equal emphasis placed on each of the adjunctive psychological options 31 (100) -- 11 (100) -- 
*Remaining percentage = missing data 
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Perceived ease of use 
All participants except one patient agreed that the DA was easy-to-use, and contained 
information that was easy-to-understand and clearly-organised (Table 7.5). 
Qualitative feedback echoed this, with most participants commenting that the DA was 
well-laid out and provided “plain” “straightforward” information, with balanced use 
of text and graphics (Table 7.6, IDs 143, 107). About half of participants (n=17), in 
particular patients (n=16), felt that it would be helpful to have a clinician go through 
the DA to introduce medications and highlight the different DA sections. 
 
Perceived utility 
All patients and all except one family member agreed that overall, the DA was useful 
for making a treatment decision-making (Table 7.5). Despite this, several participants, 
especially those with a longer-standing diagnosis, indicated that the information in the 
DA did not specifically: help them with their concerns, provide them other resources, 
teach them something new, and/or make it easier to discuss treatment options. 
Participants commented that the DA was a “good starting point” and especially 
useful for those with a recent BPII diagnosis because it clearly summarised the main 
available options in terms of their pros (e.g., efficacy) and cons (e.g., side-effects). 
Participants reported that the visual aids (e.g., colour-coded summary tables, 100-
person dot diagrams) enhanced the DA’s usefulness, because they permitted cross-
comparisons between the different treatment options in a structured and guided way. 
Several participants commented that access to comprehensive and specific benefit/risk 
information helped them to feel more informed, in control, and “active consumers” 
(Table 7.6, IDs 210, 123).  
 
The usefulness of DA section on family member involvement in treatment decision-
making revealed somewhat mixed views. Some patients and family - who had a 
recent diagnosis or were yet to involve family/be involved - found this section 
increased their awareness of the practical ways of involving family and/or served as 
an impetus to involve family. Ten patients and two family participants explained that 
this section had limited relevance to them as family were not involved, or they had 
already involved family. 
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Attitudes towards using the DA 
All participants agreed that they would recommend the DA to others in their situation 
(Table 7.5). Two patients and one family member indicated that reading the DA made 
them feel anxious. During interviews, these participants attributed their anxiety to 
reading about the more “serious” side-effects and incomplete efficacy of medications 
at preventing relapse, yet they endorsed this information as necessary and important 
(Table 7.6, IDs 120, 219). Contrastingly, a few participants noted that reading the DA 
reduced their anxiety because the information provided them with reassurance and a 
sense of “control”. 
 
Perceived trustworthiness and balance 
Participants agreed that the DA provided a trustworthy, unbiased presentation of the 
treatment options (Table 7.5). This positive feedback was reiterated in interviews 
(Table 7.6, IDs 115, 118, 120).  
 
Nine participants, mainly those with a longer-standing diagnosis, suggested that the 
DA includes a clearer rationale for selecting lithium, lamotrigine and quetiapine as 
provided medication options, and emphasise that other options are available; and 
explain that patients may need to supplement these medications or try other 
medications.  
 
Of note, most patients (n=24) and family (n=7) felt that the inclusion of patient/family 
quotes was helpful in giving positive but realistic expectations of treatment outcomes. 
The quotes were endorsed as a valuable “person-based” supplement to the "clinical" 
and "statistical" type information presented.  
 
Other qualitative findings – suggested changes and additions 
Half of patients (n=15) and most family members (n = 6) did not suggest including 
any additional DA content. Suggested additions included: more information on the 
evidence base relating to complementary therapies (e.g., exercise, mindfulness); 
clarification on other commonly-prescribed medications for bipolar (e.g., sodium 
valproate); and the fact that finding the ‘right’ medication offering the most 
therapeutic benefit and fewest side-effects takes time. 
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Table 7.6. Illustrative participant quotes on DA acceptability feedback 
Acceptability domain Illustrative participant quotes 
Perceived ease of use 
 
 “…I liked the tabs, {made the DA…] easy to navigate… [I] liked how it [the DA] is set out, very user 
friendly, clear and well explained and easy to read…” (Patient ID143, female 24 yrs, dx < 1 month) 
 
 “…[I liked the use of…] calming and neutral colours. Subsections useful in helping to 
locate info. Design is good and the text was broken up into small sections; this made a 
good balance between the text and the images, diagrams…” (Patient ID107, male 28 yrs, 
dx > 5 yrs) 
Perceived usefulness 
 
“…[The DA is…] the most solid thing I’ve got in terms of knowing the options and not just relying on the 
psychiatrist and the psychologist and their recommendations. You can tailor the options to you and you can 
decide the side effects that are worth while and give more control.” (Family ID210, wife of 40 yrs male 
patient dx 2 yrs).  
 
“…[The DA was…] really helpful. The information was in-depth and gave you a good 
clear understanding of the options. [It’s a..] useful tool… when you’re first diagnosed you 
don't know where to start and are reliant on medical professionals.” (Patient ID123, 
female 50 yrs, dx 4 yrs) 
Attitudes towards using 
 
“… Seeing some of the negative, side effects can be daunting but I'm someone who likes to know 
everything…” (Patient ID120, female 32 yrs, dx < 1 month) 
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“… Probably the fact that it [the DA] talks about family involvement and helping with the 
decision-making […made me anxious]. We've not really been involved. [But]... after 
reading that I went to see my son’s psychiatrist to see how I can help him manage better.” 
(Family ID219, mother of 28 yrs, male patient dx 3 yrs) 
Perceived trustworthiness and 
balance 
 
“…the information [in the DA was] straight-up, not biased at all” (Patient ID115, female 
23 yrs, dx 2 yrs) 
 
“…[the DA] just gave the evidence as it is…” (Patient ID118, male 46 yrs, dx > 5 yrs) 
 
“…[the DA’s balanced view] helped with making one’s own informed decision…” (Patient 
ID120, female 32 yrs, dx < 1 month) 
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7.5. Discussion 
This paper reports on the development and pilot of the first BPII-specific decision-aid 
(DA) to assist patients and their families to make decisions about treatment options to 
prevent relapse. Quantitative and qualitative feedback provided evidence of the DA’s 
acceptability in terms of its perceived ease of use, usefulness, trustworthiness and 
balance, and attitudes towards using the booklet. Evidence of safety using the DA was 
derived from participant ratings of whether the DA information provoked 
anxiety/stress, along with state anxiety levels. Feasibility evidence was derived from 
the pilot process itself, and identifying any recruitment or procedure-related 
challenges. Evidence of the DA’s potential usefulness in improving BPII treatment 
decision-making was assessed via numerous measures of decision-making quality, 
such as: decisional conflict, knowledge of treatment options and outcomes, perceived 
involvement in decision-making, and (hypothetical) uptake of evidence-based 
treatments which are congruent with patient preferences/values (i.e., informed 
choice). Importantly, the DA appears to be an appropriate resource for its target 
population, given that there were few differences between patients with a recent 
diagnosis (i.e., the target DA population) and those with a longer-standing diagnosis. 
Taken together, these findings are informative for the design of a future planned RCT 
to determine the DA’s potential efficacy at improving BPII treatment decision-
making compared to usual care.  
 
7.5.1. Acceptability 
Both quantitative and qualitative feedback confirmed that the DA had high 
acceptability amongst this sample of potential end-users. High acceptability is not 
surprising given that the DA’s content and format adhered to expert consensus-based 
international criteria (i.e., IPDAS) [22], were informed by the unmet informational 
and decision-support needs of potential end users [15], and were subject to rigorous 
iterative review by key stakeholder groups [59]. Moreover, strong endorsement of the 
DA among potential end-users is likely to support its successful future uptake and 
implementation in clinical settings, which is a challenge many decision-support 
interventions encounter [60].  
 
Although participants uniformly endorsed the DA’s usefulness in treatment decision-
making in general, some patients and family members indicated that the DA did not 
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provide them with any new information nor facilitate treatment discussions with their 
family and/or treating clinician. A possible explanation of these findings is that the 
current high information-seeking, health literate sample had actively sought out 
and/or been provided with most of the DA-based information in the earlier stages of 
diagnosis, when this information is also most relevant. Further, this DA, like others 
[37], was designed to target a specific treatment decision at a specific point in the 
BPII trajectory. It was therefore beyond the DA’s scope to address other potential 
relation-based factors acting as supports or barriers to treatment decision-making, 
such as pre-existing family tensions and the strength of the therapeutic relationship 
[15, 35, 36], which are posited as especially important for shared decision-making 
(SDM) in mental health [61]. Although DAs are tools designed to facilitate SDM, 
they should not be considered synonymous with, nor sufficient for SDM [62]. Thus, 
embedding this DA in the broader care context may enhance its usefulness in 
supporting treatment discussions with clinicians. Indeed, about half of patients and 
family expressed a preference to use the DA in conjunction with their treating 
clinician. Clinicians are also likely to support using the DA in consultations, given 
that it incorporates a number of clinician-endorsed decision-support strategies [35], 
and its development involved substantial input from expert clinicians.  
 
7.5.2. Safety and feasibility 
Participant feedback and self-report suggested that the DA content is not anxiety 
provoking and is therefore safe to use in this setting. State anxiety levels, although 
slightly elevated compared to non-clinical samples, were consistent with clinical 
norms for psychiatric samples [63], and were thus considered not specific to using the 
DA. Reinforcing this, the vast majority of patients and family indicated that reading 
the DA did not make them stressed or anxious. Those who did report experiencing 
some anxiety mostly attributed this to reading about adverse side-effects from 
medication. However, these participants, like other mental health patients [64], valued 
knowing this side-effect information and acknowledged that it was necessary for fully 
informed decision-making [46]. These findings align with those from a recently 
published Cochrane review of DA effectiveness, which indicate that exposure to a DA 
does not result in increased anxiety levels [37].  
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This pilot also demonstrated that the DA’s provision to these patients (and their 
families) is feasible. Firstly, the chosen recruitment strategies resulted in a large 
proportion of patients with a recent BPII diagnosis who were currently considering or 
open to reconsidering their treatment options. These patients are at the decision-
making stage whereby DAs are most useful [51] and thus form the DA’s target 
population. Secondly, response rates for both the patient (61.2%) and family (50%) 
samples were above the weighted average for similar research in counseling and 
clinical psychology, 49.6% [65]. Thirdly, both participant groups also indicated good 
engagement with the DA, with all indicating that they read the DA, with most reading 
it thoroughly. These encouraging response rates and high engagement with the DA 
suggest that the pilot procedure did not present any major barriers to patient/family 
participation, and provide preliminary support for the DA’s delivery within a 
community-based clinical setting.  
 
7.5.3. Potential usefulness 
In addition to participant feedback, the DA’s potential usefulness was also supported 
by well-established measures of DA effectiveness [42]. After reading the DA, both 
patient and family were highly knowledgeable about treatment options and outcomes, 
based on current national guidelines on informed patient consent to medical 
interventions [46]. Namely, increased knowledge is one of the primary outcomes for 
assessing DA effectiveness [37], and has consistently been identified as enabling 
patient participation in decision-making and treatment uptake [66]. A majority of 
patients (65.5%) also made a decision that was congruent with their informed 
treatment values for medication, and half of patients (50%) for adjunctive 
psychological treatments, respectively). This said, the remaining patients made a 
treatment choice that was not consistent with their treatment attitudes. This finding 
was mainly attributable to patients being knowledgeable about treatment options, and 
choosing to take up medication with/out adjunctive psychological treatment despite 
their negative attitudes towards treatment. DAs are designed to target patient 
knowledge not attitudes. Therefore, this finding does not negate the value of this DA; 
i.e., helping patients to make informed, evidence-based choices. Indeed, greater 
knowledge of treatment side-effects and more realistic expectations of treatment 
benefits may indirectly impact on treatment attitudes. Furthermore, these informed 
choice rates compare favorably to RCT findings showing higher rates of informed 
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choice amongst patients exposed to a DA for mammography (24%), [67], and bowel 
cancer screening (34%) [68], compared to usual care. Informed choice also represents 
an important DA outcome in the context of these ‘preference-sensitive’ decisions [37, 
42].  
 
In addition to making an informed choice, over 90% of patients made a treatment 
decision that was concordant with the best-available evidence (as per the DA). These 
high uptake rates closely align with those from a pre-/post- evaluation of an online 
DA for depression in young adults (93%) [69]. Of note too, similar proportion of 
patients chose to take up medication with/without adjunctive psychological treatment, 
which is encouraging as it provides support for the unbiased, non-directional nature of 
DAs [70], and patients’ awareness of choice [71]. These findings also challenge 
possible mental health clinician reluctance to engage patients in SDM, which stems 
from the concern that patients who receive balanced information on the adverse side-
effects, and uncertain efficacy of available treatment options, would be less likely to 
accept evidence-based treatments [60, 72].  
 
Paralleling these positive decision-making outcomes, the quality of the decision-
making process was also high. After reading the DA, patients indicated feeling well-
prepared to make treatment decisions and reported low levels of decisional conflict. 
This indicates that patients felt confident, well-informed and well-supported in 
decision-making, clear about their treatment values, and able to make an effective 
decision. Indeed, low decisional conflict has garnered amongst the most attention and 
support in the empirical literature on DA effectiveness [37], and is regarded as a 
hallmark attribute of decision-making quality [42]. Notably, the obtained decision 
conflict total and subscale means (<25) are associated with patients more successfully 
following through with their treatment decision [44], which also aligns with one of 
the primary rationales for SDM, that SDM improves adherence to treatment [73]. 
These means also compare to those reported in RCTs where outpatients receiving a 
DA reported significantly lower decisional conflict for depression (M=20.3) [9], 
(M=23.85) [10] or PTSD treatments (M=32.5), [12], compared to usual care. By 
contrast, the uncertainty subscale mean (>25) indicated that some patients were 
feeling uncertain about their treatment decision after reading the DA. Other RCTs of 
mental health DAs report higher means or larger ranges on the uncertainty subscale 
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relative to the other decisional conflict subscales [9, 10]. However, elevated levels of 
uncertainty are not necessarily unexpected or undesirable in this context, as they may 
reflect that the DA increased patient’s knowledge and thus afforded them better 
understanding of inherent uncertainty in the treatment options, and greater awareness 
of choice between numerous available options.  
 
Another key outcome of DA effectiveness in decision-making is increased patient 
perceptions of involvement [37]. Consistent with this, only a small proportion of 
participants reported experiencing clinician-led decision-making in both dyadic and 
triadic consultations. However, it was not possible to determine whether patient and 
family reports of experienced involvement referred to consultations they attended 
before or after using the DA. That said, almost half of patients and two thirds of 
family member reported not experiencing their preferred level of patient involvement. 
This lack of concordance, either due to experiencing a more active or passive 
decision-making role than desired, may be especially pronounced in patients with 
bipolar disorder [24] who desire higher levels of involvement compared to other 
psychiatric patients but demonstrate fewer “active” behaviours (e.g., question-asking) 
in consultations [74]. Determining the DA’s effectiveness at improving the 
concordance between patients’ preferred and experienced involvement remains an 
important avenue for future intervention research. Indeed, concordance is associated 
with lower patient unmet needs, which in turn influence outcomes relevant to 
treatment adherence [54] such as the therapeutic relationship and quality-of-life [75].  
 
Of note, pilot findings suggest the selected validated and purpose-designed measures 
were appropriate. Participants did not appear to encounter problems self-
administering these measures (e.g., few missing data), and observed means/standard 
deviations aligned with similar DA RCTs [9, 10]. Other DA evaluation measures, 
such as satisfaction with decision and decisional regret [37], may serve as important 
additions to a future RCT to assess the DA’s longer-term impact on patient outcomes.  
 
Finally, to evaluate the DA’s use in a future RCT using a larger, more representative 
patient sample, it is necessary to consider appropriate design changes to accommodate 
individuals who are more symptomatically-impaired, less health literate, and/or have 
fewer resources than the current pilot sample. Based on the PEMAT assessment [39], 
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recommended changes to further strengthen the DA’s usability and understandability 
for individuals with low health literacy levels, (i.e., items scoring 0 or “disagree”) 
include: removing information or content that distracts from the DA’s purpose; using 
more common everyday language (e.g., replacing the following; pg. 18: 
“circumstances” with “life situation”; pg. 25 “minimise” with “reduce as much as 
possible”); and ensuring that all visual aids have clear titles and/or captions (e.g., 
adding titles and captions to all graphs and diagrams). For lower functioning 
individuals, the DA has the potential to be used during discussions with their 
clinicians and their families. Indeed, some patients and family (n=16 and 1, 
respectively) indicated a preference for in-consultation use in the current pilot study.  
 
7.5.4. Limitations 
Some limitations include the ‘opt-in’ recruitment methods, with the potential for self-
selection bias. Secondly, the current findings may not generalise to patients and 
family with lower education, symptom-related functioning and/or health literacy 
levels. Nor may findings fully capture the preferences and decision-making 
characteristics of patients who are actively considering their treatment options, given 
that the majority of patients had already made a treatment decision by the time they 
reviewed the DA. Of note though, there were no apparent differences between 
participants who were symptomatic and those who were euthymic, nor between 
participants who were currently considering their treatment options and those who 
had made a treatment decision in the past. This lack of differences may be due to the 
fact that patients experiencing acute mood symptoms were excluded from the 
research, and that this self-selecting sample was likely more interested in/engaged 
with the treatment decision-making process regardless of whether or not they had 
already made a treatment decision. This said, as a pilot study, the small sample size 
(30 patients, 10 family members) precluded any formal statistical analyses of 
between-group differences. 
 
Further, the current pilot design was not able to determine whether using the DA led 
to improvements on patient/family outcomes (e.g., high knowledge, low decisional 
conflict) because outcomes were assessed only at post-DA use and it did not include a 
control group. A future RCT phase will clarify any DA-specific improvements. 
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7.5.5. Conclusion 
This innovative DA addresses numerous unmet decisional-support needs identified by 
patients with BPII and their family [15], and adds to the relative paucity of evidence-
based interventions for promoting SDM in mental health [76, 77]. Supporting the 
pilot aims, the DA was highly acceptable among potential end-users, and was feasible 
and safe to deliver to newly-diagnosed patients who are considering their treatment 
options to prevent relapse. Assessed factors related to both quality of the decision-
making process (e.g., decisional conflict) and outcomes (e.g., knowledge and values-
concordant choice) confirmed the DA’s potential usefulness for supporting informed 
treatment choices in the BPII setting.   
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Chapter 8: Final discussion and conclusion 
 
8.1. Overview of thesis 
This thesis comprised a comprehensive, multi-phase program of research, which 
culminated in the development and evaluation of a decision-aid booklet (DA) to assist 
patients with bipolar II disorder (BPII) and their families to make informed decisions 
about treatment options for relapse prevention. This PhD research program took a 
step-wise approach, with each phase informing the aims and scope of the subsequent 
phases. Further, the program involved a range of research methodologies, namely: a 
systematic review of the empirical literature (Chapter 2), qualitative interviews with 
key stakeholders (Chapters 3, 4, 5, 7), consultation and iterative review by an expert 
working party (Chapter 6), and self-report validated and purpose-designed 
questionnaires (Chapters 3, 4, 5, 7).   
 
The systematic review (Chapter 2) provided an introductory overview of the current 
empirical literature in terms of triadic (patient-family-clinician) decision-making 
about treatment in the mental health setting, with a focus on patients with bipolar 
disorder (I and II) disorder. In light of a paucity of empirical studies specific to 
patients with bipolar disorder (Chapter 2), we needed to conduct an in-depth 
qualitative investigation of the treatment decision-making process, to elucidate the 
perceived barriers and facilitators to effective treatment decisions (Chapters 3, 4, 5). 
These qualitative studies explored multiple stakeholder perspectives, which had been 
lacking in the previous literature (Chapter 1), and which offered more in-depth “360-
degree” insights into the views and experiences of all core members of the decision-
making triad (i.e. patients with BPII, their family and expert medical and non-medical 
treating clinicians).  
 
Findings from the qualitative research phase both complemented and built on the 
systematic review findings in the following ways: firstly, qualitative findings 
confirmed some of the results from the systematic review (e.g., that patients with BPII 
desire greater information and involvement, which is sensitive to their current mood 
symptoms). Further, the systematic review led to a number of preliminary clinical 
recommendations, several of which aligned with the clinician-endorsed strategies in 
the subsequent qualitative studies (e.g., importance of a collaborative therapeutic 
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relationship, and need to facilitate family involvement as desired by patients). 
However, in contrast to the systematic review, the qualitative studies more clearly 
delineated and provided novel insights into the decision–making process specific to 
the BPII population and setting (e.g., family perspectives of their own involvement 
the decision-making process, and patient preferences for decision-support resources).  
 
Of note, the need for a patient DA in BPII stemmed from the informational and 
decision-support needs identified during the qualitative research phase (Chapters 3, 4, 
5). The objectives, content, format, and delivery of the final DA were further refined 
and contextualised via a systematic development process guided by consensus-based 
international standards for DAs [1, 2], literature recommendations, and iterative 
review by an expert working party of key stakeholders/informants (Chapter 6). 
Finally, the pilot study (Chapter 7) evaluated the DA’s acceptability, safety and 
potential effectiveness at improving the quality of the decision-making process and 
outcomes (e.g., being well-informed, well-supported, clear about available options 
and making choices that reflect personal values/preferences). Not only are these 
quality measures well-established in the DA literature, they also align with the goals 
that BPII patients, their families, and expert clinicians prioritise when making 
treatment decisions (Chapters 3, 4, 5). Thus, the final evidence-based DA represents a 
strongly endorsed, specific and targeted resource addressing the unmet informational 
and decision-support needs of patients with BPII.   
 
8.2. Summary of principal significant findings 
 
8.2.1. The broader context of shared-decision-making (SDM) 
This program of research provided timely, novel insights into the process of treatment 
decision-making within a mental health population that had previously received little 
empirical attention. The systematic review (Chapter 2) provided an “expanded” view 
of shared decision-making (SDM) in bipolar disorder (I and II), which went beyond 
the three discrete steps of decision-making in Charles et al.’s model [3-5] to include 
decision antecedents (patient characteristics and patient preferences), decision 
process (quality of patient-clinician interactions), and decision outcomes (influence of 
SDM/ patient-centred approach on patient outcomes). The qualitative studies 
(Chapters 3, 4, 5) further demonstrated the importance of the broader context on SDM 
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in the BPII setting. Here, background patient factors (e.g., current symptoms, illness 
chronicity, experience with medications) appeared to “set the scene” for patient 
attitudes and response to treatment, as well as their interactions with clinicians during 
treatment decision-making. These clinician-patient-family interactions then had a 
substantial impact on treatment outcomes. For example, patients who were recently 
diagnosed with BPII were more likely to experience less decision-making 
involvement than they preferred, and be prescribed medications that did not align with 
their treatment values/preferences, which then adversely impacted on their adherence 
to treatment. These findings exemplified how patient experience and perspectives 
influence the decision-making process and outcomes, and thus should guide the 
informational and decision-support priorities in this setting.  
 
8.2.2. Link between decision-making process and outcomes  
The systematic review and qualitative studies yielded themes linking the decision-
making process to decision outcomes. These themes included: “quality of clinician-
patient interactions” and “influence of SDM/patient-centred approach on patient 
outcomes” (see Themes 3 and 4 of systematic review, Chapter 2); “nature and flow of 
decision-making” (see Theme 3 of patient/family interviews, Chapter 3) and 
“decision-making in consultations” (see Theme 4 of clinician interviews, Chapter 4). 
Across all phases of the research, process and outcomes emerged as distinct yet 
interrelated aspects of decision-making in the BPII setting. This is consistent with 
how DA effectiveness has been conceptualised and measured in the literature [6, 7], 
and highlights how a decision-support intervention may mediate improvements in 
both process and outcomes. Specifically, across the systematic review and qualitative 
findings (Chapters 2-5), decision outcomes were improved when the decision-making 
process integrated patient preferences for involvement and treatment choices (i.e., was 
patient-centred) and involved a strong, positive, and collaborative therapeutic 
relationship. Improved decision outcomes were operationalised as: higher patient 
satisfaction with the treatment decision and better uptake and implementation of 
chosen treatments.  
 
These findings suggest that enhancing the decision-making process – via the 
provision of targeted and specific decision-support tools – is a pre-cursor to 
improving decision-making outcomes. This suggestion was supported by the DA pilot 
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(Chapter 7), where positive findings on process-related measures (e.g., low decisional 
conflict, high preparation for decision-making) were accompanied by positive 
findings on outcome-related measures (e.g., high proportion of patients choosing 
treatments consistent with clinical guidelines, and making informed choices based on 
their treatment values). It was also important to target decision support to the 
decision-making process given that patients (and family) reported valuing the 
“process of involvement” (being informed about, and deliberating on available 
treatment options) (Chapters 2, 3), which often contrasted with clinician-reported 
behaviour (Chapter 4). In other words, clinicians tended to focus more on the decision 
outcome than process, placing greater emphasis on patients making the final decision 
(i.e., “actual decisional responsibility”, see Chapter 4) [8].  
 
8.2.3. Need for values clarification regarding treatment options 
With the aim of enhancing the decision-making process, qualitative findings also 
signalled the need for a decision-support tool to include values clarification methods 
or exercises (VCEs). These are exercises designed to guide patients through a 
deliberative process of weighing up the positive (‘pros’) and negative (‘cons’) 
features of each treatment option against their preferences, values and life 
circumstances. Patients, family and clinicians all spoke about the “preference-
sensitive” nature of BPII treatment decisions; they recognised the uncertainty inherent 
in the available treatment options and felt that final treatment choices should be 
guided by patient values for treatment (Chapters 3, 4, 5). Interviews with patients and 
their families (Chapter 3) further clarified that patients differ in how much value they 
ascribed to the benefits (e.g., treatment efficacy) versus the costs (e.g., side-effects) of 
available treatment options. This “values trade-off” in turn determined patient 
preferences for, and willingness to start/adhere to treatment options. Similarly, 
clinicians held differing opinions with regards to the importance patients placed on 
the benefits relative to the costs of treatment options (Chapter 4). Thus, VCEs were 
deemed necessary, both as a method for: i) patients to consider their treatment values 
in a structured and deliberate way; and ii) making explicit and transparent the 
discussion of treatment values between patients, their families, and treating clinicians. 
Of note, VCEs form a core component of DAs [9-11], and distinguish DAs from 
standard patient psycho-education materials [1, 2], as well as simpler SDM 
interventions to increase patient involvement in treatment discussions (e.g., question 
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prompt lists [12]; Option Grids [13], AskShareKnow questions [14]). The need to 
include VCEs therefore strengthened the rationale for a DA specifically, in favour of 
other interventions to encourage SDM.  
 
8.2.4. Incorporating clinician strategies into decision support 
The final DA incorporates a number of the preliminary clinician-endorsed strategies 
to address challenges in BPII treatment decision-making (Chapter 5). Firstly, the DA 
is timed to be delivered to patients during/after a consultation where treatment options 
are introduced, and before consultation/s where treatment options are decided on. This 
timing is therefore in keeping with the clinician-recommended approach of 
“Structuring consultations – Making time” and allowing deliberation of options 
outside consultations (see clinician strategies Table 5.4, Chapter 5). This approach of 
“splitting” the decision-making stages across initial and follow-up consultations, 
reportedly encourages patients to: i) more carefully deliberate on treatment options, ii) 
have the opportunity to involve family members/significant others in treatment 
discussions, and iii) make more efficient use of short consultation times by arriving 
better informed and prepared to make treatment decisions that are less affected by 
current mood symptoms (Chapter 5). Supporting this, pilot findings (Chapter 7) 
revealed that after using this DA, patients were highly knowledgeable about the 
available treatment options and felt well-prepared to make treatment decisions.  
 
In addition, the final DA has scope to facilitate other key clinician-endorsed strategies 
(Chapter 5). For example in the pilot study, the DA’s content and format were highly 
acceptable amongst patients and their families, which lends support to “meeting 
patient information needs and preferences” (see Table 5.4, Chapter 5). Next, the DA 
appears to support “patient-centredness and involvement” (see Table 5.4, Chapter 5), 
through its inclusion of VCEs to assist patients to incorporate their treatment values 
into treatment decision-making. This is evidenced by the fact that a large proportion 
of pilot study patients reported experiencing patient-led/shared decision-making 
(SDM), and made informed, values-based treatment choices (Chapter 7). Moreover, 
the DA represents a practical resource for “encouraging and facilitating family 
involvement” (see Table 5.4, Chapter 5) by including a separate section that outlines 
for patients (and their families) the roles (and benefits) that family members can 
assume during the treatment decision-making process in/out of consultations. Finally, 
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pilot findings suggested that patients’ families engaged well with the information in 
the DA, and were highly knowledgeable about treatment options and outcomes after 
reviewing the DA (Chapter 7), which addresses two patient-/family-reported barriers 
to family involvement in BPII treatment decision-making (i.e., family’s lack of 
engagement with, and understanding of treatment information, see Chapter 3).  
 
However, some clinician-endorsed strategies were beyond the scope of the current 
DA. These include strategies relating to the therapeutic relationship, inter-
professionalism, and continuity-of-care (see Table 5.4, Chapter 7). By not 
incorporating these strategies, some patient-related, clinician-related and system-
based challenges to treatment decision-making remain. For example, the DA cannot 
address existing shortcomings in the patient’s therapeutic relationship with their 
clinician (e.g., lack of mutual trust, clinician’s authoritative behaviour), nor their 
clinician’s lack of specialised knowledge/expertise in BPII treatment. The DA may, 
however, standardise the decision-making process, and thus help to mitigate the 
effects of a poor therapeutic relationship (Chapters 2, 3, 4, 5) and/or limited clinician 
speciality (Chapters 4, 5) on the decision-making process and outcomes. Irrespective 
of the therapeutic relationship or clinician speciality, the DA informs patients about 
the available treatment options, and assists them to deliberate on their values towards 
options in a way that is non-directional, evidence-based and promotes patient 
autonomy. In addition, DA provision may “indirectly” address other prevailing 
system-based challenges, such as short consultation times [15, 16], by making 
patients more informed about, and better prepared to discuss their treatment options at 
follow-up consultations.  
 
8.3. Implications and future directions 
This program of research, which explored the BPII treatment decision-making process 
and produced a DA to address unmet informational and decision-support needs, has 
several implications for future research and clinical practice.  
 
8.3.1. Implementing the DA in clinical practice 
In developing the current BPII DA, this thesis included a comprehensive development 
and evaluation process (see Chapters 6, 7). It was, however, beyond the scope of the 
current thesis to include a DA implementation phase. Indeed, the implementation of 
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DAs in clinical practice is a relatively neglected area of research and warrants 
increased empirical attention. Despite a substantial body of research supporting the 
efficacy of DAs [17], it is acknowledged that the use of DAs in clinical practice is 
variable, and typically low [18]. Sub-optimal DA use may reflect the paucity of 
formal implementation studies of DAs. In addition, most reviews have focused on 
identifying the general barriers and facilitators to SDM, and offer few practical 
strategies to overcoming implementation challenges [16, 18, 19]. This research gap 
may be especially pertinent to the mental health setting, where there may be 
additional cultural and attitude-based challenges (e.g., patient self-stigma, clinician 
judgments about patient competence) to the routine use of DAs in clinical practice, 
and implementing SDM more broadly [19]. Although practical implementation 
strategies are lacking, the literature offers some directions for future DA research. 
Namely, future DA efficacy studies need to expand their current focus on assessing 
the short-term cognitive and affective impact on patients (i.e., decisional conflict and 
knowledge), to include other factors that impact on long-term and sustainable clinical 
practice change, such as cost-effectiveness and efficiency [20].  
 
Nonetheless, the current DA development process included methods aimed at 
optimising the DA’s future implementation in clinical practice. These included: i) 
systematically investigating clinician, patient, and family views and experiences of 
decision-making, along with associated challenges, and enablers for change; ii) 
assessing the unmet informational and decision-support needs and preferences of 
potential end-users (Chapters, 3, 4, 5), and using these to guide the DA content, 
format/design, and delivery mode/timing (Chapter 6); iii) integrating the DA into the 
clinician’s usual delivery of care and staging of decision-making, i.e., provide the DA 
at a time when clinicians usually provide patients/their families with information 
resources to consider treatment options (Chapter 5); iv) ongoing stakeholder 
engagement during the DA review process to ensure their agreement with the DA 
content/format (Chapter 6); and v) assessing the acceptability and feasibility of the 
DA within a sample of potential end-users (Chapter 7). In hindsight, several of these 
methods were consistent with the PARiHS framework (Promoting Action on 
Research Implementation in Health Services) [21, 22], which posits that three 
elements, evidence, context, and facilitation, guide the successful implementation of 
research into evidence-based practice. With regards to optimising the evidence, key 
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decisions in the DA development process were based on evidence that combined 
multiple sources of knowledge and information, namely: research evidence, clinical 
experience, and patient experience. With regards to optimising the context, the timing 
and mode of DA delivery were sensitive to the culture of clinical practice, including 
its prevailing values, practices, and available resources. Also relevant to optimising 
the context, the DA was evaluated using multiple methods and sources of information, 
such as subjective and objective measures of decision quality, and semi-structured 
interviews about patient-family experiences of using the DA to make decisions. 
According to the PARiHS framework, these data on evidence and context can then be 
used to determine the most appropriate facilitation method, in order to enable the 
DA’s implementation into practice [23]. 
 
Rates of patient participation in the pilot study (Chapter 7) may also guide the DA’s 
future implementation into practice. Thirty patients participated in the DA pilot study, 
which corresponds to 35.7% of the 84 patients diagnosed with BPII at the BDI during 
the same eight-month recruitment period (February – October 2017; personal 
communication M. Hoeschen 16/02/2018). This participation rate is similar to (37%) 
[24] or markedly higher than (~10%) [25] in other studies of DA use within 
community-based primary care settings, where use has been either elective (opt-in) 
and/or without any financial incentive. This participation rate suggests modest 
‘Reach’ within the eligible patient population (i.e., individuals affected by BPII), as 
per the RE-AIM framework [26]. Although comparable to rates reported elsewhere in 
the literature, this rate provides impetus for investigating potential barriers to DA 
uptake. Admittedly, the pilot study did not include a clinician sample, however, the 
DA content was reviewed by experienced treating clinicians (Chapter 6), and 
incorporated several clinician-endorsed strategies for addressing challenges to 
treatment decision-making (see section 8.2 and Chapter 5). Thus, it is likely that 
clinicians working in the BPII setting would find the DA acceptable, which is a major 
barrier to implementing DAs [18]. A future pilot study is needed to confirm the DA’s 
acceptability and feasibility amongst clinicians, and to investigate the potential 
barriers and/or facilitators to the DA’s use in routine clinical practice.  
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8.3.2. Clinician-targeted interventions to support SDM 
In its current form, the DA facilitates a self-directed or ‘guidance’-based approach to 
treatment decision-making of patients with BPII and their families [27]. Thus, future 
research could supplement current DA provision with concurrent training and 
resources for clinicians who treat patients with BPII. A 2014 Cochrane Systematic 
Review found that interventions were most effective at promoting SDM (e.g., 
observed and patient-perceived involvement in decision-making), when they targeted 
both patients and clinicians rather than one group or the other [28]. In this context, 
clinician-targeted interventions might include training seminars to educate clinicians 
about the DA, its purpose and potential usefulness, and to increase clinician’s self-
efficacy with using the DA in their clinical practice.  
 
In addition, the current DA content could be adapted to create supplementary “in-
consultation” resources for clinicians. One simple adaptation would be to print out 
key pages of the DA (e.g., the treatment option summary tables) and use these during 
the consultations when discussing the pros and cons of the treatment options. Indeed, 
the “ShareD-BD” RCT protocol [29] – published since the DA pilot study (Chapter 
7) – describes a SDM intervention for bipolar disorder (types I and II), which 
comprises an in-consultation DA, standardised decision-making process using SDM 
components, and clinician training. This “multi-component” approach to SDM 
interventions is in keeping with the aforementioned recommendations, and may 
enhance SDM uptake and related outcomes in bipolar disorder. This intervention may, 
however, may overlook the specific decision-making needs and preferences of 
patients with BPII (versus BPI), whose treatment decisions are supported by relatively 
limited evidence and may be more finely-balanced in terms of treatment benefits and 
costs [30]. Another potential resource is an Option Grid, which help clinicians – 
especially less experienced clinicians – to standardise their information provision and 
encourage patients to visualise (and compare) the available treatment options [13]. 
One recently published example is an Option Grid for deciding on anti-psychotic 
medications [31]. In user-testing, patients with long-term psychosis perceived the 
Option Grid as potentially useful and feasible in routine psychiatric care, and 
especially valued its use within consultations [31]. As a standalone (rather than 
supplementary) intervention, however, an Option Grid may not meet the high 
information needs of patients with BPII, and fact that key decision-making stages 
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occur outside/between consultations for these patients (e.g., deliberation with their 
families, see Chapter 3).  
 
Greater targeting of clinicians also aligns with patient/family preferences; about half 
of the pilot participants reported wanting the clinician’s assistance with using the DA 
(Chapter 7). Future research is needed to confirm whether combining the current 
patient DA with clinician-targeted interventions increases its efficacy and uptake in 
clinical practice [28]. To this end, the PhD student (AF) has already been in 
discussions with the Black Dog Institute (BDI), where most of the participating 
patients were recruited. The BDI’s education program coordinators have expressed 
interest in presenting the DA at their clinician education workshops, and in producing 
a manual/resources for general practitioners (GPs). This said, a more systematic 
research program into the acceptability and potential uptake of such training / 
interventions by clinicians is needed. 
 
8.3.3. Future iterations of the DA 
Other potential avenues for research include the development and evaluation of other 
DA iterations for BPII. Future DA iterations include a DA for difficult to engage, at-
risk populations (e.g., young adults and their families) and/or an online 
adaptation/website. A recently published systematic review of SDM interventions in 
patients with mood disorders highlights that such iterations are needed [32]. This 
review identified 10 interventions for specific MDD populations with potentially 
higher unmet needs (e.g., adolescents and the elderly), but none for bipolar disorder 
[32]. Indeed, the unmet informational and decision-support needs reported by patients 
with BPII and their families may be more prominent among young adults, who are 
more likely to be newly-diagnosed, and prefer more active decision-making 
involvement than they currently experience in clinical practice (Chapter 3). An online 
DA offers several benefits that distinguish it from the current booklet version. These 
benefits may also be especially pertinent to young adults. For example, an online DA 
would: i) promote the DA’s rapid and widespread dissemination at a national and 
international level; ii) reach patients who reside in remote and rural areas and do not 
have ready access to specialised mental health clinics (like the BDI); iii) ensure the 
information remains in step with the best available clinical evidence, and iv) promote 
the DA’s uptake among young adults, who are among the most “Internet-connected” 
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Australians (~ 98%) [33] and tend to seek their health information online [34]. 
Additionally, findings from a recent uncontrolled trial showed that, after using an 
online DA, young adults with unipolar depression felt involved in their treatment 
decision-making, and made evidence-based treatment decisions they were satisfied 
with [35]. These findings provide preliminary empirical support for the potential 
usefulness of an online DA for young adults with BPII. For more detail on this 
planned future research see Appendix G, which includes a protocol paper describing a 
parallel Phase II randomised control trial (RCT) to evaluate a novel decision-aid 
website (DA) to support young adults with BPII (under review). The DA pilot study 
provided directions for the RCT (Chapter 7), such as assessing decision outcomes at 
follow-up to determine the longer-term effects on receiving the DA, and whether any 
short-term positive effects are maintained over time. Although not undertaken as part 
of the PhD candidature, this research phase was informed by, and builds on the 
program of research undertaken by the PhD student.  
 
8.4. Limitations of the current research  
 
Whilst the current research program posits many strengths (see following section 8.4), 
there are a number of limitations that warrant attention. Firstly, the empirical 
components of this research program (Chapters 3-5, 7) employed “opt-in” recruitment 
strategies for patients with BPII, their families, and clinicians. Both the qualitative 
studies and the pilot study used a multifaceted recruitment approach and purposive 
sampling in order to increase heterogeneity within the samples and ensure a 
representative range of views and experiences. However, the possibility of self-
selection bias remains, such that the recruited participants may be more interested in 
the treatment decision-making process and more likely to hold positive views towards 
decision-support provisions. In light of this, it is not known whether the current 
findings are generalisable to others in the BPII population; a larger scale RCT will 
help to confirm this (see Appendix G).  
 
Secondly, the large majority of patients and clinicians were recruited through the 
BDI, a tertiary outpatient clinical service that specialises in the assessment and 
treatment of mood and bipolar-related disorders. Thus, the clinician-patient(-family) 
interactions that most patients and clinicians described may not be typical in the 
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community, but relate to a highly specialised treatment setting. To address this issue 
and capture a greater cross-section of experiences, studies recruited patients with 
recent and with longer-standing BPII diagnoses (Chapters 3, 7), and clinicians with 
varying levels of professional experience and specialisation (Chapters 4, 5). 
Moreover, all participants were encouraged to reflect on their experiences of 
treatment decision-making across a range of clinical settings (e.g., community mental 
health services, primary care settings) and health providers/patients.  
 
In addition to the specialised clinical setting in which most participants were 
recruited, it is important to also consider patient characteristics. In both the qualitative 
and pilot studies (Chapters 3, 7), the vast majority of patients and family members 
were native English speakers and of Western cultural backgrounds (92.9 – 96.8%). By 
contrast, 2016 Census results reveal that over 28% of Australian residents were born 
overseas, with the largest growth coming from neighbouring Asian countries [36]. 
Thus, culturally and linguistically diverse (CALD) individuals were underrepresented 
in this research. This limitation is common in the SDM research, yet there is a 
pressing need to adapt SDM interventions (such as DAs) to patients from CALD 
backgrounds [37]. This is because these patients may have lower self-efficacy with 
regards to communication with clinicians, be more likely to defer decision-making to 
the clinician, and have different preferences for family involvement in decision-
making compared to patients of Western cultural backgrounds [38, 39].  
 
Due to the small number of GPs (n=4) and psychiatrists (n=6) recruited in the 
clinician qualitative studies (Chapter 4, 5), it was not possible to compare these two 
clinician groups since within-group theoretical saturation was not reached [40] (see 
also Chapters 4, 5). Qualitatively comparing these two groups may have provided 
interesting novel insights into the BPII treatment decision-making process, especially 
given that some qualitative differences were noted between these medically-trained  
clinicians and clinical psychologists. A more in-depth comparison of the decision-
making attitudes and practices of GPs and psychiatrists could also inform 
recommendations for increasing inter-professionalism in this setting. Indeed, many 
clinician participants endorsed inter-professionalism as a BPII decision-making 
strategy. More broadly, inter-professional approaches to SDM expand the clinician-
patient dyad to address both individual-level factors (clinician-patient-family) and 
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system-level factors (professional organisations, health care policies, workplace 
culture) [41]. These factors are widely acknowledged as facilitators or barriers to 
adopting SDM [16], and addressing both levels may be especially relevant to 
decision-making about medication in mental health [42]. 
 
Another potential limitation to this research program is that it did not include 
independent observer perspectives of clinician-patient (-family) interactions and 
treatment decision-making. The decision to not include observer perspectives, via 
coding of video/audio-recording of consultations to obtain an objective account of 
decision-making behaviours, and instead focus on the views and subjective 
experiences of patients, their families and clinicians was deliberate, and consistent 
with the overarching research aims. First, the systematic review (Chapter 2) and 
qualitative studies (Chapters 3, 4, 5) revealed that both patient- and clinician-related 
factors influenced the decision-making process, and patients did not define their 
decision-making involvement in terms of a discrete set of observable SDM 
behaviours (Chapters 2, 3). Instead, patients valued less tangible, interpersonal 
aspects of “feeling” involved [43], which is consistent with more recent research on 
patient perspectives of patient-centred care in bipolar disorder [44]. These aspects 
could not be captured by commonly-used measures assessing clinician SDM 
behaviours in consultations (e.g., the OPTION to measure the extent to which 
clinicians involve patients in decision-making, [45]). Next, it was critical that the end-
users themselves defined the unmet decision-making needs, in order to inform the DA 
content and format and ensure that they viewed it as acceptable and potentially useful. 
Using observer measures to identify unmet needs was not appropriate for this 
purpose, given that they are not sensitive to patient preferences and priorities for 
information and decision-support.  
 
8.5.  Strengths of the current research  
 
Limitations notwithstanding, this program of research has a number of strengths that 
distinguish it from previous research and add to its significance. Firstly, this research 
program employed both qualitative and quantitative methods, and benefitted from the 
complementary strengths of each approach. For example, the use of a quantitative 
self-report measure, the Control Preferences Scale (CPS, [46], see Chapters 2-5, 7), 
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allowed us to: i) characterise and compare the participant samples in terms of their 
decision-making involvement preferences, ii) compare our samples to other mental 
health-based samples in the literature, and iii) determine whether stated involvement 
preferences influenced qualitatively described attitudes and experiences of treatment 
decision-making. On the other hand, qualitative methods such as semi-structured 
interviews were useful in: i) exploring complex phenomena which had previously 
received scant empirical attention (e.g., family perspectives of their involvement, 
Chapter 3), and ii) clarifying and giving greater context and nuance to participant 
responses on the quantitative measures (e.g., the dynamic and fluid nature of patient 
involvement preferences according to the stage of decision-making, and severity of 
illness symptoms (Chapters 3, 4). 
 
Next, the initial step in this research program was a systematic review, which 
identified key literature gaps and priorities for research in the BPII setting. One key 
literature gap was a limited number of qualitative studies and absence of multiple 
stakeholder perspectives of the decision-making process. Both these limitations were 
then addressed in the qualitative phase, which afforded an in-depth exploration and 
comparison of patient, family, and clinician views and experiences of BPII treatment 
decision-making. In this way, findings from the systematic review directly guided the 
aims and scope of the subsequent studies, and ensured that these studies provided 
novel and informative additions to the existing literature.  
 
Furthermore, the DA content and format was guided by theory (i.e., the Ottawa 
decisional support framework [47]), international standards [1, 2], and literature 
recommendations for the development and evaluation of DAs [48]. As testament to 
this rigorous and systematic development process, the final DA satisfied all except 
two IPDAS quality criteria (field testing DA with clinicians, and providing readability 
scores), which were argued to be not applicable in the current context (see Table 6.3, 
Chapter 6). Further, pilot study findings (Chapter 7) supported IPDAS-endorsed 
criteria for establishing that a DA is effective, namely: decision quality (e.g., patients 
making informed, values-based choices) and decision processes leading to decision 
quality (e.g., patients reporting low decisional conflict). By adhering to “gold 
standard” IPDAS criteria, we ensured that the current DA presented high quality 
information and: i) used a systematic development process, with ongoing and 
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meaningful engagement of potential end-users; ii) used up-to-date scientific evidence, 
via extensive searching of systematic reviews, RCTs, official clinical guidelines, and 
any additional clinical evidence; iii) addresses usability issues, via health literacy 
review and revisions by patients/their families; iv) has a clear dissemination plan. In 
this way, the current DA overcame many of the common shortcomings of patient 
health information materials, which vary widely in terms of the quality of their 
information content and quality of their development process [49].  
 
A final strength of this research program was the DA pilot study (Chapter 7), which 
considered both the feasibility and the future implementation of research findings into 
clinical practice. The pilot study served an important dual purpose in the DA’s 
development and evaluation: first, it obtained evidence on the acceptability, 
feasibility, safety and potential usefulness of the DA; and second, it informed the 
design of a planned Phase II RCT study (Appendix G). A Phase II RCT is a necessary 
though frequently overlooked step in the evaluation of psychosocial interventions 
[50]. In addition, the pilot study made use of well-established, validated measures of 
DA effectiveness (e.g., decisional conflict, informed choice) as well as purpose-
designed measures (e.g., subjective/objective knowledge), which were rigorously 
developed and informed by theory and clinical practice guidelines [51, 52]. These 
considerations ensure that the final DA represents a resource that can be readily 
integrated into routine patient care (i.e., via acceptability, feasibility) to foster a more 
active and informed role in treatment decisions (i.e., via potential usefulness) for 
patients with BPII and their families.  
 
8.6. Conclusion 
 
In summary, this thesis presents a multi-phase program of research, which included 
an in-depth qualitative exploration of patient, family, and clinician views and 
experiences to inform the development of an innovative treatment DA for patients 
with BPII and their families. The DA’s development followed “gold standard” 
international criteria, and involved ongoing engagement of all core members of the 
decision-making triad. The pilot study confirmed the DA’s potential usefulness at 
addressing the numerous unmet informational, involvement, and decision-support 
needs identified by patients with BPII and their families. The substantive involvement 
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of key stakeholders throughout the DA development and evaluation mirrors a broader 
shift towards greater involvement of consumers in SDM research [37], and also 
recognises the potential benefits of consumer involvement, such as increased 
relevance to community needs and more effective translation of research findings to 
deliver improved health outcomes [53].  
 
The final DA (see Appendix H) is the first for the BPII population, and helps to 
bridge the gap between mental health and physical health conditions in the provision 
of evidence-based patient/family-centred SDM interventions. Mental health services 
have been slow to enact SDM, even though this approach is widely endorsed [54], 
and is already commonplace in medical settings, such as oncology. This is somewhat 
paradoxical, as patients with chronic mental illnesses, such as BPII, often need to play 
a much more active role in their own self-management than patients with cancer, for 
example, because patient education, medication adherence and lifestyle changes are 
key to reducing long-term relapse risk and functional impairment. This said, recent 
years have seen increased momentum in the development and evaluation of evidence-
based tools to support SDM in the mental health setting; Cochrane reviews published 
in 2010 [55] and 2014 [56] identified the same two RCTs of DAs for mental health 
conditions, whereas the current 2017 update identified an additional two [17].  
 
Finally, the current DA not only integrates a number of BPII clinician-endorsed 
decision-making strategies, it also aligns with drafted Australian standards “Standard 
Two: Partnering with Consumers”, which encourage clinicians and patients to partner 
together “…to plan, communicate, set goals and make decisions about the current 
and future care’’ (see [37] p. 18). Thus, the final DA not only has implications for 
greater adoption of SDM within the BPII setting, it also provides a model resource for 
supporting patients with other mental health conditions to make informed treatment 
decisions, which are consistent with patient values and preferences.    
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Appendix C – Checklist for assessing the quality of quantitative and qualitative 
studies.  
 
Criteria for quantitative studies (2 = fully met, 1 = partially met, 0 = not met)  
1 Question/objective sufficiently described? 
2 Study design evident and appropriate? 
3 Method of subject/comparison group selection or source of information/input 
variables described and appropriate? 
4 Subject (and comparison group, if applicable) characteristics sufficiently 
described? 
5 If interventional and random allocation was possible, was it described? 
6 If interventional and blinding of investigators was possible, was it reported? 
7 If interventional and blinding of subjects was possible, was it reported? 
8 Outcome and (if applicable) exposure measure(s) well defined and robust to 
measurement/misclassification bias? Means of assessment reported? 
9 Sample size appropriate? 
10 Analytic methods described/justified and appropriate? 
11 Some estimate of variance is reported for the main results? 
12 Controlled for confounding? 
13 Results reported in sufficient detail? 
14 Conclusions supported by results? 
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Criteria for qualitative studies (2 = fully met, 1 = partially met, 0 = not met) 
1 Question/objective sufficiently described? 
2 Study design evident and appropriate? 
3 Context for the study clear? 
4 Connection to a theoretical framework/wider body of knowledge? 
5 Sampling strategy described, relevant and justified? 
6 Data collection methods clearly described and systematic? 
7 Data analysis clearly described and systematic? 
8 Use of verification procedure(s) to establish credibility? 
9 Conclusions supported by the results? 
10 Reflexivity of the account? 
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Appendix D – Overview of patient [family] interview guide 
 
General discussion:  
1) Types of decisions 
a) What are the kinds of decisions you have (had)[/ has your family had] to make 
when it comes to managing your bipolar II disorder? 
b) What kinds of treatment decisions have you [has your family] discussed with 
your [their] clinician? 
 
2) Decisional conflict 
c) Which decisions have been the most difficult [for your family] to make when 
managing your [their] bipolar II disorder? 
d) What has made these decisions difficult? 
e) What is needed to make deciding between different options less difficult? 
 
3) Decision support (barriers and facilitators) 
f) How have you [has your family] felt when making these decisions? 
g) Has your [their] clinician supported you [them] when making decisions about 
treatment? If so, how? How about your family and friends?  
 
4) Suggestions for support and resources 
h) Is there anything else, for example information booklets or online exercises 
that would help better support you [your family] when making decisions about 
treatment?  
i) What would you like these to look like?  
 
5) Patient/ family involvement 
j) Who has been involved when making decisions about your [family’s] 
treatment?  
k) What do you think about your [your family’s] level of involvement in 
decisions? How about others’ level of involvement? 
l) Have there been any challenges, or things that have made it difficult for you 
[your family] to be as involved as they’d like in making decisions about 
treatment? 
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Focused discussion:  
6) Decision-making stages 
Thinking about a specific decision- we are now going to try to break down the steps of 
when decisions are made. Can you give me one example of a decision that needed to 
be made about your bipolar II disorder while in consultation with a health 
professional. Now keep that example in mind....... 
 
Information gathering 
a) Outside this consultation, did you [your family] seek any information about 
your [their] illness and treatment?  
 
Information exchange 
b) Can you tell me about how the information about different options was 
discussed in the consultation? 
 
Deliberation (process of expressing/discussing treatment preferences) 
c) Once the information had been discussed, how did you [your family] weigh up 
the pros and cons before coming to a decision? 
d) Did you (and your family member, if present) think or talk more about options 
once you left the consultation? What happened? 
 
Decision  
e) When it came down to making the decision, how involved were you (was your 
family member, if present)? What was your role/their role? 
f) When it came down to actually making the decision, who do you think had the 
most influence?  
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Decisional monitoring 
g) Have you thought any more about the decision you [your family] made?  
 
Reflecting on decision making process 
h) Do you feel anything was missing (or left out) in the decision-making 
process? If so, what? 
i) Did anything about making your decision that not meet your expectations? If 
so, what?  
 
Decision-aid 
j) We are looking to develop a decision-support resource to help patients and 
family make decisions about their treatment. What sort of information would 
be helpful to include?  
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Appendix E - Clinician interview guide 
 
General discussion:  
7) Types of decisions 
a) What are the kinds of decisions you have (had) to make with patients 
managing their bipolar II disorder? 
b) What kinds of treatment decisions do you spend time discussing with 
patients? 
 
8) Decisional conflict 
c) Which decisions have been the most difficult to make with patients managing 
their bipolar II disorder? 
d) What has made these decisions difficult? 
e) What is needed to make decision-making less difficult? 
 
9) Decision support (barriers and facilitators) 
f) How do you usually make decisions about treatment for bipolar II disorder? 
g) How do you support your patients’ decision-making about treatment? How 
about their family and friends?  
 
10) Suggestions for support and resources  
h) Is there anything else, for example information booklets or online exercises, 
which would help better support you in your decision-making about 
treatment?  
i) What would you like these to look like?  
 
11) Patient/ family involvement 
j) Who is involved in the decision-making process about patients’ treatment?  
k) What do you think about patients participating in decisions? Others’ 
involvement?  
l) Are there any challenges to involving patients in decision-making about 
treatment?   
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Focused discussion: 
12) Decision-making stages 
Can you give me a couple of examples of a decision that needed to be made about a 
patient’s bipolar II disorder while in consultation with them. Keep those examples in 
mind....... 
 
k) Who aside from you and the patient is generally present during these 
consultations?  
 
Information gathering 
l) Outside these consultations, are you aware of patients seeking information 
about their illness and treatment?  
 
Information exchange 
m) Can you tell me about how the information about different options is 
discussed in the consultation? 
 
Deliberation (process of expressing/discussing treatment preferences) 
n) Once the information has been discussed, what happens when the different 
options are being weighed up within consultations? 
o) Do you and the patient (and their family member) talk or think more about 
options after this consultation? What happens generally? 
 
Decision 
p) When it comes down to making the decision, how involved are you (is the 
patient/ their family)?  
q) When it comes down to actually making the decision, who do you think has 
the most influence?  
 
Decisional monitoring 
r) Have you reflected any more about the decisions made in these consultations?  
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Reflecting on decision making process 
s) Do you feel anything was missing (or left out) in the decision-making 
process? If so, what? 
t) Did anything about the decision-making process not meet your expectations? 
If so, what? 
 
Decision-aid 
u) We are looking to develop a decision-support resource to help patients and 
family make decisions about their treatment. What sort of information would 
be helpful to include?  
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Appendix F1 – Summary of the decision-aid (DA) contents 
 
DA section Outline of included content 
General introduction  Outlined the purpose of DA, intended use/patient group, available treatment option 
Bipolar II disorder background  
 
Outlined types and prevalence of bipolar disorder, describing mood cycles, and types of treating 
clinicians 
Introduction to medication options  
 
Introduced the three first-line medication options (lithium, lamotrigine, quetiapine) in text and 
via flowchart, their effectiveness and ongoing, iterative nature of treatment decision-making 
Medication option 1: Lithium  
 
Introduced lithium, when lithium is recommended, its effectiveness at preventing different types 
of relapse via text and 100 person dot diagrams; outlined possible advantages (benefits) and 
disadvantages (side-effects/risks) of lithium over short, medium, long-term; included bona-fide 
patient/family member quotes relating to perceived pros and cons of lithium 
Medication option 2: Lamotrigine  See above for lithium, with rewording as appropriate 
Medication option 3: Quetiapine  See above for lithium, with rewording as appropriate 
Summary table of advantages/disadvantages of medication options  Tabulated summary using traffic light info-graphic and colour-coding to denote advantages and 
disadvantages of lithium, lamotrigine, and quetiapine 
Introduction to add-on (adjunctive) psychological options  Introduced the two level-1 evidence adjunctive psychological options (CBT and group psycho-
education) in text and via flowchart, the rationale for having psychological treatment in addition 
to medication for relapse prevention, their key/overlapping components.  
Psychological option 1: Cognitive Behavioural Therapy (CBT)  Introduced CBT, when CBT is recommended, its effectiveness at preventing different types of 
relapse via text and 100 person dot diagrams; outlined possible advantages (benefits) and 
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disadvantages (side-effects/risks) of CBT; included bona-fide patient/family member quotes 
relating to perceived pros and cons of CBT 
Psychological option 2: Group Psycho-education  See above for CBT, with rewording as appropriate 
Summary table of advantages and disadvantages of add-on 
psychological options  
 
Tabulated summary using traffic light info-graphic and colour-coding to denote advantages and 
disadvantages of CBT and group psycho-education 
What is the role of complementary therapy? Defined complementary therapy; introduced Omega-3 fatty acids and outlined current state of 
evidence in terms of relapse prevention 
How can family members be involved in decision-making? Outlined the potential roles and benefits of family involvement in decision-making both within 
and outside consultations with clinicians 
Making treatment decisions that are right for you  Step-by-step guide on things to do/consider when making a treatment decision 
Making the most of your time with your clinician  Gave examples of and addressed common patient barriers to asking clinicians questions; 
included “Ask-Share-Know” questions and question prompt list 
Worksheets: What is important to you about your treatment? Included values clarification exercises (with weight scale visual aids) for each medication and 
psychological treatment option, patient examples, and suggestions for involving family 
members and clinicians in completing these exercises 
Further resources  Provided list of links to Australian-based websites/online resources 
Glossary of key terms  Defined in lay language all medical/clinical terminology in the DA 
Acknowledgments  Named and acknowledged development team, members of expert working party; indicated 
month/year that information is current, month/year of next planned update 
Reference list and further research  Outlined the type of research/evidence used to base included treatment options and inform 
treatment efficacy data, list of key empirical studies/reviews 
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Appendix F2 – Telephone interview guide 
 
Question 1: Initial Response 
a) In your words what do you think is the purpose of this booklet? 
b) What were your first impressions of this booklet? 
c) What did you like about it? What was the best part? 
d) What did you dislike about it? How can we improve on it? 
e) Was there anything in the booklet that made you stressed or anxious? 
f) Overall do you think a booklet like this is useful for a person to use when 
they are trying to decide about medication and psychological options to 
prevent relapse in bipolar II? 
 
Question 2: Design 
Do you have any comments about the ‘look’ or ‘design’ of the booklet, e.g., 
the colours; the images; the size of the writing; anything about the way it is 
presented? 
 
Question 3: General length and content 
a) What did you think about the length of the decision aid? Was it: 
  Too long 
  The right length 
  Too short  
   
b) Was there:   
  Too much information  
  The right amount of information 
  Not enough information 
  
Question 4: Assistance with booklet   
Would it have been helpful if a clinician went through some of the pages with 
you before you looked through the booklet?  If so, which ones? 
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Question 5: Wording   
Were there any sentences or sections in the booklet that could have been 
clearer? 
 
Question 6: Now we will go over specific sections  
a) Turn to pages 16-17: Was the explanation of the different medication 
options clear? 
b) On pages 42-43: Was the explanation of the different add-on psychological 
options clear? 
c) Did you like that we included other people’s comments (in grey italics) on 
the pros and cons of each option? 
d) Turn to pages 16 and 42: Are you clear about the options available?  
  Yes 
  No 
e) In your own words, what are the options available (tick if mention option):   
 Medications (lithium, lamotrigine, quetiapine) 
 Adjunctive psychological treatments (CBT, group psycho-education) 
 
f) What did you think of the 100 person dot diagrams (showing how effective 
options are at preventing relapse)? On pages 27 – 29: As an example, can you 
go through with me what each of these diagrams mean? 
g) Do you have any comments about the description of the advantages/ 
benefits of each treatment option? How about in the summary tables? 
h) Do you have any comments about the description of the disadvantages/ 
side-effects of each treatment option? How about in the summary tables on 
pages 40-41 and pages 60-61? 
i) In terms of the presentation of the options, would you say that it favoured 
any particular option or did it provide a balanced view: 
  Taking a particular medication over others  
(State which: ____________________)  
  Having a particular adjunctive psychological treatment over another  
(State which: ____________________) 
  Balanced view 
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j) On pages 63 - 65, titled Information for family members: was this section 
useful? 
k) Page 71: Worksheets: 
i) Were the instructions on how to use the worksheets clear? 
ii) Do you think the worksheets are a good idea?  Did you find them useful? 
l) Page 84: Further resources:  
i) Would you access any of these websites? 
ii) Would you recommend any other websites? 
 
Question 7 - Comprehensiveness  
a) Are there any topics or questions that you feel were not covered in the 
booklet that should be included? 
 Yes  (i) If yes, please tell us what you think should be added) 
 No  
b) Are there any topics or information that you think should not have been 
included in the booklet? 
 Yes (ii) If yes, please tell us what you think should be removed?) 
 No  
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Appendix F3 – Summary of purpose-designed knowledge items and scoring rubric 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NHMRC guidelines on 
information to be given for 
informed consent [1]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DA-related Conceptual (gist) knowledge – 9 
questions x 2 marks (/18) 
 
DA-related Numerical (verbatim) knowledge – 5 questions x 4 marks (/20) 
 
1) The possible of likely 
nature of the illness or disease 
 
 1) Over the long term, how much of the time will the average person with BPII spend 
WITHOUT ANY SYMPTOMS?  
 
ANSWER: 24 weeks per year (46% of the time) without any symptoms.  
“Adequate knowledge” is defined as a pass mark of > 50% (i.e., at least 20 out 
of 38 marks) 
To have adequate knowledge, participants must either:  
- Get correct all conceptual/gist knowledge items (18 marks) plus at least 
2 marks on numerical/verbatim knowledge items (2 marks) 
ALTERNATIVELY 
- Get correct all numerical/verbatim knowledge items (20 marks).  
 
In this way, participants cannot have “adequate knowledge” on the basis of 
conceptual/gist knowledge alone, instead they either need to have a combination 
of conceptual/gist and numerical/verbatim knowledge, or numerical/verbatim 
knowledge alone [2, 3].  
 
Note that each applicable NHMRC guideline was assessed with a conceptual 
and/or numerical question. 
  319 
 
Almost one half of the time (~ 24 weeks per year) = 4 marks 
Just over one third of the time (~ 19 weeks per year) = 3 marks  
Less than one fifth of the time (~ 8 weeks per year) = 2 marks 
Almost never (1 - 2 weeks per year) = 1 mark 
Almost all the time (45 -50 weeks per year) = 0 marks  
2) The proposed approach to 
treatment: 
 
i) what the proposed 
approach entails 
 
 
 
 
 
 
 
ii) the expected benefits 
 
 
 
 
 
 
 
2) i) Taking medication together with 
psychological treatments is more effective than 
medication only for preventing relapse in BPII. 
 
True (correct) = 2 marks 
False/Don’t know = 0 marks 
 
 
 
2) ii) Lithium, lamotrigine, and quetiapine differ 
in terms of how effective they are at preventing 
hypomania.  
 
True (correct) = 2 marks 
 
 
 
 
 
 
 
 
 
 
 
 
2) ii) Imagine a group of 100 people taking quetiapine. About how many people taking 
quetiapine will RELAPSE in general?  
 
ANSWER: 23 in 100 people will experience relapse in general. 
 
  320 
 
 
 
 
 
 
 
iii) common side effects and 
material risks of any 
intervention 
 
 
 
 
 
 
 
 
 
iv) whether the intervention 
is conventional or 
experimental  
 
False/Don’t know = 0 marks 
 
 
 
 
 
 
2) iii) Lamotrigine is associated with sedation, 
weight gain, and sleepiness/drowsiness. 
 
True/Don’t know = 0 marks 
False (correct) = 2 marks 
 
 
 
 
 
 
 
2) iv) N/A 
 
 
 
About one quarter (~25 in 100 people) = 4 marks 
About one third (30-40 in 100 people) = 3 marks  
Almost one half (45-50 in 100 people) = 2 marks 
Less than fifth (10-15 in 100 people) = 1 marks  
Almost everyone (~90 in 100 people) = 0 marks  
 
 
2) iii) Imagine a group of 100 people starting lamotrigine.  
About how many in 100 people will experience non-serious (benign) rash within the 
first 2 months? 
 
ANSWER: 8-9 in 100 people 
 
Almost one tenth (5-10 in 100 people) = 4 marks 
About one quarter (~25 in 100 people) = 3 marks 
About one third (30-40 in 100 people) = 2 marks 
About one half (~50 in 100 people) = 1 mark 
More than three quarters (75+ in 100 people) = 0 marks 
 
2) iv) N/A 
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v) who will undertake the 
intervention 
 
2) v) In Australia, clinical psychologists have 
training to provide cognitive behavioural 
therapy (CBT).  
 
True (correct) = 2 marks 
False/Don’t know = 0 marks 
3) Other options for 
treatment  
 
3) Lithium, lamotrigine, and quetiapine are the 
only available medication options that your 
clinician will recommend to you.  
 
True/Don’t know = 0 marks 
False (correct) = 2 marks 
 
4) The degree of uncertainty 
of any diagnosis arrived at  
 
N/A (DA not related to diagnosis) N/A (DA not related to diagnosis) 
5) The degree of uncertainty 
about the therapeutic 
outcome 
 
5) We still do NOT know which out of lithium, 
lamotrigine, and quetiapine is the most effective 
at preventing relapse in BPII.  
 
True (correct) = 2 marks. 
False/Don’t know = 0 marks. 
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6) The likely consequences of 
not choosing the proposed 
treatment, or of not having 
any treatment at all. 
 
6) A person with BPII who does NOT take any 
medication is at greater risk of relapse compared 
to a person with BPII who DOES take 
medication.  
 
True (correct) = 2 marks. 
False/Don’t know = 0 marks. 
 
6) Imagine a group of 100 people treated with medication but WITHOUT any add-on 
or adjunctive psychological treatment.  
About how many in 100 people will relapse within 2 years? 
 
 
ANSWER: 50 in 100 
 
About half (~50 in 100 people) (i.e., 50 > 10%)= 4 marks 
About one third (30-40 in 100 people) (i.e., 50 +/- 25%) = 3 marks 
About one quarter (~25 in 100 people) (i.e., 50 +/- 50%) = 2 marks 
More than three quarters (~80 in 100 people) (i.e., 50 +/ - 75%) = 1 mark. 
Almost everyone (~99 in 100 people) (i.e., 50 +/- 100% +) = 0 marks. 
7) Any significant long term 
physical, emotional, mental, 
social, sexual or other 
outcome that may be 
associated with a proposed 
intervention. 
 
  7) Imagine a group of 1000 people taking lithium over the long-term.  
How common is it for these people to experience complete kidney (renal) failure? 
 
ANSWER: 5 in 1000 
 
Uncommon (1-9 in 1000 people) = 4 marks 
Rare (Less than 1 in 1000 people) = 3 marks 
Common (50-100 in 1000 people) = 2 marks 
Very common (~500 in 1000 people) = 1 mark 
Experienced by almost everyone (~900-990 in 1000 people) = 0 marks. 
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8) The time involved. 
 
8) The actual number of sessions in 
psychological therapies (cognitive behaviour 
therapy and group psycho-education) varies 
from one person to another or from one group to 
another.  
 
True (correct) = 2 marks. 
False/Don’t know = 0 marks.  
 
9) The costs involved, 
including out of pocket 
expenses. 
 
9) Lithium, lamotrigine, and quetiapine are all 
subsidised by the PBS, and so cost a similar 
amount.  
 
True/Don’t know = 0 marks.  
False (correct) = 2 marks.  
 
 
1. Australian Government National Health and Medical Research Council. General guidelines for medical practitioners on providing 
information to patients2004 1 August 2016. Available from: https://www.nhmrc.gov.au/guidelines-publications/e57. 
2. Smith SK, Barratt A, Trevena L, Simpson JM, Jansen J, McCaffery KJ. A theoretical framework for measuring knowledge in screening 
decision aid trials. Patient education and counseling. 2012;89(2):330-6. 
3. Smith SK, Trevena L, Simpson JM, Barratt A, Nutbeam D, McCaffery KJ. A decision aid to support informed choices about bowel 
cancer screening among adults with low education: randomised controlled trial. BMJ. 2010;341:c5370.
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Phase II Randomised Controlled Trial of a patient decision-aid website to 
improve treatment decision-making for young adults with bipolar II disorder: a 
feasibility study protocol  
 
Fisher, Alana.1,2, Sharpe, Louise.1 , Costa, Daniel. 3, Anderson, Josephine.4, 
Manicavasagar, Vijaya. 4, Juraskova, Ilona.1,2.  
 
1. School of Psychology, Brennan MacCallum Building (A18), The University 
of Sydney, NSW, 2006, Australia. 
2. Centre for Medical and Evidence-based Decision-making (CeMPED), Level 
6, Chris O'Brien Lifehouse (C39Z), The University of Sydney, NSW, 2006, 
Australia 
3. Sydney Medical School, Edward Ford Building (A27), The University of 
Sydney, NSW, 2006, Australia 
4. The Black Dog Institute, Hospital Road, Prince of Wales Hospital, Randwick, 
NSW, 2031, Australia.  
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Abstract 
 
Background/Aims: This paper describes the protocol for a feasibility study for a 
parallel Phase II randomised control trial (RCT) aiming to evaluate a novel decision-
aid website (e-DA) to support young adults with bipolar II disorder (BPII), and their 
families.  
 
Material and methods: The e-DA was developed according to the International 
Patient Decision-Aid Standards (IPDAS). Participants will be 40 young adults (18-30 
years) referred to a specialist outpatient clinical facility, who have a confirmed 
clinical diagnosis of BPII. Participants will be randomised (1:1) to receive access to 
the clinic’s online factsheets/website with (Intervention) or without (Control) the e-
DA. A series of validated and purpose-designed questionnaires will be administered 
at baseline (T0), immediately post-decision (T1), and 3 months post-decision (T2). 
Questionnaires assess key decision-making constructs related to decision-making 
quality, including: decisional conflict, subjective and objective treatment knowledge, 
values-based informed choice, concordance between preferred/actual decision-making 
involvement, preparation for decision-making, and decisional regret. Self-report 
symptom severity and anxiety will ascertain the safety of e-DA use. The focus of 
analyses will be to assess effect sizes, in order to guide a future RCT. 
 
Discussion: This feasibility study will evaluate a world first, evidence-based online 
decision-support resource, a DA website, for young adults with BPII and their 
families who are deciding on treatment options for relapse prevention. Findings will 
determine the e-DA’s feasibility in RCT procedures (i.e., outpatient clinical setting) 
and provide estimates of effect sizes on outcomes related to improving treatment 
decision-making and patient outcomes in a sample of potential end-users, compared 
to usual care. 
 
Trial Registration: This trial is registered with the Australian New Zealand Clinical 
Trials Registry (ANZCTR) - ACTRN12617000840381 
 
Keywords: Bipolar II disorder; treatment decision-aid; decisional conflict; informed 
choice; randomised controlled trial; young adults.   
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Introduction  
Young adults (18-30 years) have the highest prevalence of mental illness relative to 
any other age group [1]. In particular, affective disorders (including mood and 
bipolar-related disorders) are both more prevalent [1] and more burdensome [2] 
amongst young adults. Although bipolar II disorder (BPII) is around twice as common 
as bipolar I disorder (BPI) in community (5% vs. 2.4% of samples; [3]), BPII remains 
largely understudied, with few high quality research studies on treatment efficacy [4, 
5]. Young adulthood is a critical time period for onset of BPII, with an average age of 
onset estimated at 20 years [6]. As a chronic, relapsing, and burdensome psychiatric 
condition with a focus on long-term adherence to prophylactic treatment, BPII relies 
heavily on patient education and self-management to prevent future episodes. It is 
therefore essential that targeted, patient-centred interventions are developed to 
address the treatment needs of young adults newly diagnosed with BPII.  
 
Decision-making about treatment in BPII represents one area in pressing need of 
targeted, patient-centred interventions. Shared treatment decision-making (SDM) is 
increasingly advocated in serious mental illnesses [7]. SDM involves the clinician and 
the patient partnering together to share their understanding of available treatment 
options, and their views about the advantages and disadvantages of these. There are 
ongoing barriers to achieving SDM in BPII, with patients and their families 
expressing numerous unmet informational and decisional-support needs [8-10]. As a 
result of suboptimal involvement, patients and families often felt that treatment 
decisions were not made in line with their treatment preferences [8-10]. Moreover, 
these unmet needs are likely to be greater among young adults, who tend to prefer 
greater decision-making involvement compared to older cohorts [11]. In order to 
better support treatment decision-making in BPII, young adults would benefit from 
interventions that are designed to encourage their active and informed participation in 
treatment decision-making that is both evidence-based and concordant with their 
values.  
 
SDM interventions, such as patient decision-aids (DA), represent a key step in 
facilitating young people’s informed uptake of and effective adherence to evidence-
based medication and adjunctive psychological treatment options, which, in turn, are 
likely to reduce their risk of relapse. DAs are interventions (e.g., booklets, brochures, 
  328 
websites), which present patients with unbiased, evidence-based information on all 
available healthcare options, and then guide patients through a deliberative process of 
actively weighing-up the benefits/costs of available treatment options. This enables 
decision-making that is both evidence-based and considerate of patient preferences 
and life circumstances. The effectiveness of DAs across an array of 
treatment/screening decisions in physical health (e.g., cancer, diabetes) is well-
established [12], and similar DA effectiveness is also emerging for mental health 
conditions, such as schizophrenia [13] and depression in adults [14-16] and in young 
people [17]. Compared to usual care, DA interventions significantly improve patient 
knowledge of available treatment options and outcomes, increase patient feelings of 
involvement, and reduce patient feelings of regret, uncertainty, being uninformed, 
unsupported and unclear about their values towards treatment choices [13]. Despite 
these promising findings, no known treatment DAs have been developed specifically 
for BPII.   
 
Aims 
This DA will be the first of its kind, and aims to address the gap between initial 
advances made in treatment decision-making in other serious psychiatric illnesses, 
such as depression and schizophrenia, and BPII.  
 
This protocol paper describes the proposed evaluation of a novel DA website (e-DA) 
to support young adults with BPII and their families. The e-DA is adapted from a DA 
booklet, which was piloted in a sample of potential end-users [18]. A website 
adaptation was warranted for this young adult population, in order to integrate tailored 
content together with more advanced interactive features and navigation capabilities.  
 
This study employs a parallel-group randomised design in order to determine the e-
DA’s acceptability and feasibility in an outpatient clinical setting. As a feasibility 
study, we do not propose any specific hypotheses. Instead the focus of analyses will 
be to assess DA-related effect sizes on an established battery of outcome variables, in 
order to guide a future RCT phase. The battery of outcome variables relate to the 
quality of the decision-making process and decision quality (i.e., quality of the choice 
made. Variables are drawn from previous RCTs of DAs for mental health [13-16], 
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and medical conditions [12], the Ottawa decision-support framework [19, 20], and 
international consensus-based standards on establishing the effectiveness of DAs [21]: 
 
The quality of the decision-making process 
i) Feeling well-informed, certain, and well-supported in the treatment decision,   
and clear about values/preferences (i.e., low levels of decisional conflict);  
ii) Good (subjective) understanding of treatment options and outcomes 
iii) Concordance between preferred and actual levels of decision-making 
involvement 
iv) Good preparation for decision-making  
v) Low levels of regret about the treatment decision 
 
Decision quality – Quality of the choice that is made 
vi) Good (objective) knowledge about treatment options and outcomes;  
vii) Informed treatment choices, in line with patient preferences/values (i.e., 
values-based, informed choice). 
viii) Higher uptake of effective medical and psychological interventions. 
 
Further, we do not expect that e-DA use will be associated with harm. That is, it is not 
anticipated that receiving the DA will lead to:  
ix) Higher depression or hypomania symptomatology 
x) Higher state anxiety;  
xi) Medication non-adherence. 
 
Materials and Methods 
 
Design 
This study is a feasibility study with 1:1 parallel randomisation to either the 
intervention (DA website) or active control (BDI webpage/online factsheets on 
bipolar disorder treatments). Assessment occurs at three time points: i) baseline (T0); 
ii) post-treatment decision (T1); and iii) three months follow-up (T2).  
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Participants and setting 
Participants will be recruited through the Black Dog Institute (BDI), a specialist 
outpatient clinical and research facility, which specialises in the assessment and 
treatment of mood and bipolar-related disorders.  
 
Inclusion criteria 
To be eligible, participants will be young adult patients aged 18-30 years old, who: i) 
have a confirmed clinical diagnosis of BPII; ii) have recovered from an acute mood 
episode (as determined by an assessing psychiatrist), and iii) are considering 
treatment options for maintaining mood-stability/relapse prevention. The selected 30 
year age cut-off for patient inclusion brings the current protocol into line with other 
research on self-management strategies for young adults with bipolar disorder [22], 
acknowledges the common delay between onset of BPII symptoms and diagnosis, and 
captures the full peak onset period for BPII (15-30 years, [23]). To ensure that 
patients are at the stage of making a treatment decision, they will be consecutively 
recruited immediately following their consultation with a psychiatrist in which 
treatment options are presented and discussed.  
 
Exclusion criteria  
These include: i) lack of English proficiency; ii) lack of capacity to provide informed 
consent; iii) experiencing acute/severe hypomanic, depressive or mixed mood 
symptoms (as determined by assessing psychiatrist); iv) a concurrent neurocognitive 
or psychiatric condition; and v) no computer/internet access. In addition, patients 
participating in the BDI’s concurrent RCT comparing the efficacy of lithium versus 
lamotrigine for BPII treatment (ANZCTR; ACTRN12616001702404) will not be 
eligible to participate in this trial.  
 
Ethical approval to conduct this study was obtained from the University of Sydney 
Human Research Ethics Committee (USYD HREC, 2016/763) and the Black Dog 
Institute Research Advisory Group (2016011 Fisher). The RCT protocol is registered 
with the Australian and New Zealand Clinical Trials Registry 
(ACTRN12617000840381). Any important modifications to the study protocol (e.g., 
change to eligibility criteria) will be communicated to relevant parties (e.g., USYD, 
BDI, ANZCTR) in advance via their respective online portals. 
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Procedure 
The study procedure is illustrated in Figure 1. Recruitment flow and procedure will 
follow CONSORT guidelines [24] including independent randomisation of 
participants, use of standardised measures to ensure rigorous, controlled testing of 
outcomes, and consideration of real-world implementation factors such BDI’s 
existing service delivery model.  
 
Following their diagnostic/treatment review consultation with a psychiatrist at the 
BDI, clinic staff will ask eligible patients for their permission to have their details 
passed onto the USYD research team. A researcher (AF) will then contact the 
potential participant to explain the study, answer any questions, and obtain verbal 
agreement to participate. Participants will be emailed a link and individual login 
details to the DA website (www.bipolardecisionaid.com.au). Upon logging into the 
website and indicating their consent to participate, participants will be asked to 
complete baseline questionnaires (T0). Once baseline measures are completed, 
participants will be randomised (1:1) via an inbuilt site-generated random sequence to 
receive usual care either with (Intervention) or without access to the DA website 
(Control). Only participants in the Intervention group will be provided access the full 
DA website; Control participants will be provided restricted access to the login-page 
and questionnaires only. Usual care/attention control will comprise: access to the 
existing BDI webpage and downloadable factsheets on treatments for bipolar disorder 
(https://www.blackdoginstitute.org.au/clinical-resources/bipolar-disorder/treatment), 
as well as any information materials that BPII patients are routinely provided with, or 
advised to consult at their BDI appointment. Neither participants nor the trial 
researchers will be blinded to participants’ group assignment.  
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Participant                                                                                                                    * 
enrolment  
(at BDI) 
 
 
 
 
 
 
 
 
 
 
 
 
Consults 
assigned 
materials 
 
 
 
 
Continues 
to  
consult  
assigned 
materials 
 
 
 
Figure 1. Flow-chart illustrating RCT procedure. 
T0: BASELINE (n=40) 
Post-diagnosis/initial treatment review 
by assessing psychiatrist at BDI 
Randomisation (1:1) 
Intervention 
(n=20)  
DA website + BDI online factsheets/website 
Usual care 
(n=20)  
BDI online factsheets/website only 
T2: 3 months post-treatment decision 
(Follow-up treatment review by BDI psychiatrist) 
Treatment decision w/ managing GP/psychiatrist in community 
T1: Post-treatment decision 
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Four weeks after completing baseline measures (T0), during which time participants 
have unlimited access to the BDI and DA websites, participants will complete another 
set of questionnaires post-treatment decision (T1, ~ 3 weeks post-T0) and again at 
three months’ follow-up (T2, ~ 3 months post T1) [43]. To ensure fidelity to the 
protocol and promote retention, participants will be sent email/text prompts and up to 
three weekly reminders (as needed) to complete the questionnaires. The proposed 
assessment times were chosen to coincide with important time points in patients’ 
decision-making to ensure that they receive the intervention when most useful to 
them: i.e. when patients are first presented with treatment options by BDI psychiatrist 
(T0), shortly after they decide on the most appropriate treatment option/s with their 
managing GP/psychiatrist (T1), and review selected treatment with BDI psychiatrist 
(T2). In line with ethics requirements, any study participant may request to withdraw 
from the study at any time and without reason. 
 
Materials and Measures 
The DA 
The DA explains the main available medication and adjunctive psychological 
treatment options for relapse prevention in BPII, based on current guidelines for first-
line maintenance treatment in BPII [25] with specific sections for young adult patients 
and their families. It provides evidence-based, unbiased information, reviewed and 
professionally copy-edited for low health literacy levels. Lay information is presented 
using text and graphics on the rationale for and efficacy/known benefits/costs of each 
treatment option. Interactive values clarification exercises are included to assist 
patients/family to consider their preferences and deliberate on the benefits/costs of the 
different treatment options.  
 
The content and format of the BPII DA was developed by the research team, and was 
informed by: best available clinical evidence and systematic review [26]; extensive 
qualitative interviews with key stakeholders (28 patients, 13 family, and 20 clinicians) 
[8-10]; and International Patient Decision Aid Standards (IPDAS) [27]. Initial drafts 
of the DA underwent iterative review by an expert advisory group, comprising DA 
experts (academic/research, n=2), patients with BPII (n=3) and their families (n=2) 
who had previously made or were making a treatment decision, and practising 
psychiatrists (n=2), clinical psychologists (n=2) and GPs (n=2) with at least 10 years’ 
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experience in treating mood and bipolar-related disorders in an outpatient setting. 
Moreover, proposed additions and modifications to the DA’s young adult website 
content (e.g., self-management strategies for young adults with BPII [22], impact of 
alcohol/recreational drug use on BPII symptoms and medication) and design (e.g., 
additional images of young adults) were endorsed (75-100% agreement) via 
structured interviews with young adults with BPII (n=12) and their family (n=7). A 
final version of the DA was reviewed and approved by the expert advisory group.  
 
The e-DA: Website design and development 
The e-DA content was developed into a custom-designed interactive website by 
professional web-designers and developers experienced with developing evidence-
based health resources. Web design/development included a systematic co-
development process involving: prototyping and iterations to the user-interface and 
key features of the site, focus testing and usability/acceptability testing with potential 
end-users. Usability/acceptability testing with potential end users (2 patients, 2 
family, 6 clinicians) identified and addressed suggested changes pertinent to the 
website content (additional information, clarifications, typographical errors, wording), 
format (improvements, errors) and usability (additional features, navigation issues) 
prior to commencing the RCT evaluation.  
 
The final e-DA interactive website (www.bipolardecisionaid.com.au) contains a series 
of drop-down menus listing the information sections and respective subsections. After 
logging in and viewing the orientation page/dashboard, participants are free to access 
the information sections in whichever order they wish, to afford maximum flexibility. 
However, participants are required to first access/view all sections marked as 
containing essential information, before proceeding to the values clarification 
exercises (Figure 2), and then the questionnaires. These exercises are highly 
interactive and visually respond to participant input in real-time; for example, the 
weight-scale leans in one direction or the other as the participant rates the importance 
of treatment features. Patient preferences can then be saved and reviewed at a later 
date if desired. To ensure fidelity during the RCT evaluation and monitor adherence, 
participants’ individual use of the website (page views, time spent on page etc.) will 
be tracked via the website’s inbuilt analytics software. Additional information on 
participants’ general use of the DA website (e.g., bounce rate; defined as the 
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percentage of site users who navigate away from the site after viewing only one page) 
will be tracked using Google Analytics (analytics.google.com; ID: 103244832).  
 
 
 
Questionnaire measures 
Participants will complete a series of validated and purpose-designed questionnaires 
at each time-point (T0, T1 and/or T2). For the time-point/s at which questionnaires 
will be administered see Table 1. Selected measures are drawn from previous RCTs 
of DAs in mental health conditions (depression: [14-16]; schizophrenia: [13]) and the 
broader DA literature [28].  
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Table 1. Administration of participant outcome measures 
 
Measure Baseline  
(T0) 
Post-
treatment 
decision (T1) 
3 months’ 
follow-up 
(T2) 
   Demographics/ Clinical 
information* 
X   
   Technology Acceptance Measure*  X  
Quality of the decision-making 
process 
   
   Decisional Conflict Scale  X  
   Subjective understanding of 
treatment* 
 X X 
   Control Preferences Scale a  X  
   Preparation for Decision-making 
Scale 
 X  
   Decisional Regret Scale   X 
Decision quality     
   Objective knowledge of treatment*  X X 
   Informed Choice Measure b *  X X 
   Attitudes towards treatment*  X X 
   Treatment choice/uptake*  X  
Safety     
   Internal State Scale   X X 
   Morisky Medication Adherence  X X 
   State-Trait Anxiety Inventory  X X 
 
* Purpose-designed or adapted for use in study 
a T0 and T1 administrations combined to assess concordance between preferred (T0) and actual (T1) 
involvement in treatment decision-making. 
b Composite of objective knowledge of treatment (adequate levels, >50% possible total score), attitudes 
towards treatment, and treatment choice/uptake. 
 
 
Quality of the decision-making process measures 
Decisional conflict referring to participant perceptions of uncertainty, being 
uninformed, unsupported and having unclear values in decision-making will be 
assessed using the 16-item validated Decisional Conflict Scale (DCS; α’s=0.78-0.92) 
[29].The DCS is considered superior to most other primary outcome measures used in 
DA trials with respect to its psychometric properties, face validity, and 
appropriateness or consistency with IPDAS decision process criteria [30, 31]. 
 
(Subjective) Understanding of treatment options and outcomes will be assessed via a 
purpose-designed questionnaire containing 15 Likert-type scale items. Items cover 
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domains stipulated by NHMRC guidelines for medical practitioners on providing 
information to patients [32].  
 
Concordance between preferred and actual levels of decision-making involvement 
will be assessed via discrepancies between ratings on two administrations (pre-/post-
decision) of the single-item adapted Control Preferences Scale [33, 34], as per [35].  
 
Preparation for Decision-making Scale (10 items) will assess participants’ 
perceptions of the DA’s usefulness in helping them recognise that a decision needs to 
be made, and preparing them to make treatment decisions (α’s=0.92-0.96) [36].  
 
Regret or remorse associated with treatment decision will be assessed via the 5-item 
validated Decisional Regret Scale (α’s=0.81-0.92) [37]. 
 
Decision quality measures 
 (Objective) Knowledge of treatment options and outcomes will be assessed via a 
purpose-designed questionnaire containing 14 forced-choice items, which relate to 
conceptual (gist; 9 items) and numerical (verbatim; 5 items) knowledge. As above, 
items are based on NHMRC guidelines [32].  
 
Values-based, Informed-choice will be a purpose-designed composite measure 
adapted from Marteau et al.’s informed choice measure [38]. Values-based, informed-
choice will indexed by participants who have adequate knowledge (>50% on 
Objective Knowledge, as per [39]) and who indicate a clear treatment 
preference/choice (e.g., take a certain medication or not) that aligns with their self-
report attitudes to medication and psychological treatments [38]. To assess treatment 
attitudes, participants will rate their level of agreement on eight items, each of which 
contain a pair of opposing adjectives to describe either medication or psychological 
treatment (e.g., medication is ‘important’/ ‘unimportant’), as per [38].  
 
Uptake of effective treatment options will be assessed by having participants indicate 
which treatment option they chose (e.g., medication with or without psychological 
treatment versus no medication +/- psychological treatment or unsure/delayed 
decision-making). 
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Other measures 
Participant feedback on e-DA’s acceptability (i.e., perceived ease of use, usefulness, 
attitudes towards using/user acceptance, and trustworthiness and balance of 
information) will be assessed via a 24-item questionnaire adapted from the 
Technology Acceptance Measure [40]. This measure also asks about the extent to 
which participants actually accessed the DA website. 
 
Demographics and clinical information will be elicited at baseline via a purpose-
designed self-report questionnaire which includes items on age, education, time of 
BPII diagnosis, current medication/psychological treatment/s (if any), and pattern of 
BPII symptoms (e.g., frequency and predominant mood episode type). 
 
To determine that DA use is not associated with any harm/safety issues, participants 
will also complete additional validated self-report measures of symptom severity (16-
item Internal State Scale, [41]), state anxiety (6-item short-form of the State-Trait 
Anxiety Inventory state scale, [42]) and medication adherence (8-item Morisky 
Medication Adherence Measure, [43].  
 
Sample size and feasibility 
Because the purpose of this study is not to test hypotheses about efficacy but to 
examine feasibility and acceptability, and to estimate efficacy parameters (e.g., effect 
size) to inform a future RCT, formal sample size calculation is inappropriate. Using 
guidelines provided by Hertzog [44], and based on the observation that decisions aid 
interventions typically produce large effects, we determined that a sample of 20 per 
group is sufficient. In 2014, 380 patients presented to the BDI with BPII. Of these 
patients, 61% who were approached to take part in research agreed to participate. It is 
estimated that 40% of BPII patients will be eligible to take part in this study (i.e., 
young adults out of acute episode), which equates to 152 eligible patients per year. To 
maximise recruitment and study feasibility, there are also provisions to expand 
recruitment to additional sites as needed. Estimating a 61% uptake rate (~ n=92), the 
research team envisages no difficulty in achieving the target of 40 participants within 
the planned 12-month active recruitment timeframe.  
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Planned statistical analyses 
The focus of the analysis will be on description of the acceptability and feasibility 
outcomes, comparing the e-DA intervention group to the control (usual care) group.  
In addition to descriptive statistics (means and standard deviations for variables that 
are approximately continuous, medians and inter-quartile ranges for ordinal variables, 
and frequencies for categorical variables), we will also examine standardised mean 
differences. Group differences on all other outcomes will also be examined using 
standardised mean differences. These standardised mean differences will be used to 
partially inform sample size for the main RCT, although we will use them in 
conjunction with estimates of effect size from other research given the limitations of 
interpreting effect sizes in small studies [45]. 
 
Discussion  
Most people who develop bipolar disorder in their lifetime will have experienced 
symptoms by age 25 [46]. As a chronic, relapsing and highly burdensome illness, 
BPII relies heavily on patients implementing a self-management approach of taking 
prophylactic medications, monitoring symptoms and making behavioural changes in 
response to symptoms to reduce relapse risk [47]. As such, it is crucial that young 
adults with BPII are encouraged to adopt an active role in their illness management as 
early as possible, preferably from the point of diagnosis. Indeed, most patients with 
BPII, especially young adults and those with a recent diagnosis, prefer a more active 
role in their treatment decisions than they currently report experiencing in clinical 
practice. Further, a lack of knowledge and involvement in one’s own treatment has 
been found to compromise optimal BPII management, resulting in poorer patient 
outcomes [8-10, 26, 48-50].  
 
Of note, the current e-DA recognises that people with BPII are faced with unique and 
more complicated treatment decision-making challenges. For example, in comparison 
to depression, schizophrenia and BPI disorder, the evidence base for treatment 
efficacy in BPII is considerably more limited [25]. Much of the evidence for 
medication and psychological treatment efficacy in BPII is derived from studies 
predominantly with BPI. In BPI, the benefits of mood stabilisers are clear because 
they prevent psychotic, manic episodes which interfere with patients’ psychosocial 
functioning. However, in BPII, there is an absence of psychotic symptoms [51][[52], 
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and patients typically feel that hypomanic episodes help rather than impair perceived 
psychosocial functioning [53]. As such, the trade off with high potential side-effects 
of mood-stabilisers is less clear in BPII. With greater ambiguities in the benefits of 
prophylactic medications in BPII, patients are more likely to discontinue treatment, 
placing them at heightened risk for relapse. 
 
To address these clinically important and persistent unmet decision-making needs 
among young adults, this feasibility study will evaluate a world first, evidence-based 
online decision-support resource, a DA website, for young adults with BPII who are 
deciding on treatment options for relapse prevention. The e-DA targets both the 
quality of the decision-making process and quality of the decision made, two distinct 
yet related constructs of decision-making quality [28]. In terms of decision-making 
quality, it is expected that the e-DA will be associated with effects indicating that 
young adults: i) feel well-informed, certain and supported, and clear about their 
values in treatment decision-making, ii) achieve their preferred level of involvement 
in treatment decision-making, and iii) feel prepared to make treatment decisions. In 
terms of decision quality, it is expected that the e-DA will assist young adults to: i) be 
knowledgeable about treatment options and outcomes, and ii) make informed 
treatment decisions that are in line with the best available clinical evidence, as well as 
their preferences for treatment.  
 
Both the feasibility and implementation of research findings into clinical practice 
have been considered from the inception of this study. Firstly, the proposed feasibility 
study is a necessary though frequently overlooked step in the evaluation of 
psychosocial interventions [54]. This study will identify any potential feasibility and 
acceptability issues with implementing the DA into practice and provide the 
opportunity to rectify these prior to conducting a future RCT in a larger, multi-site 
study. Further, once efficacy is established, the DA’s online delivery will: i) promote 
its rapid and widespread dissemination, ii) ensure the information remains in step with 
best available clinical evidence, and iii) promote the DA’s uptake among young 
adults, who are among the most “Internet-connected” Australians (~98%) [55] and 
tend to seek their health information online [56].  
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Also relevant to implementation, is the effective and ongoing engagement of key 
stakeholders, which has been integral to the development and evaluation of this DA 
website. An effective and ongoing stakeholder-engagement approach to DA 
development is critical to ensuring the DA’s relevance and usefulness among young 
adults with BPII [57]. The initial need for an online DA derives from the unmet 
decision-support needs identified by patients, their families, and clinicians for patients 
to take a more active and informed role in their BPII management. A series of 
qualitative studies contextualised the nature of these needs and identified 
informational priorities among young adults with BPII [8-10], as did consultation 
with key stakeholders as part of an expert advisory group.  
 
Finally, the timing of DA delivery, i.e., shortly after patient diagnosis, is consistent 
not only with patient preferences but also with the usual delivery of care, when 
clinicians commonly introduce treatment options and encourage patients to become 
more informed about, and consider, their preferences for treatment options. If found 
to be efficacious, such timing will facilitate the DA’s successful implementation into 
current mental health services.  
 
The e-DA website represents a resource that can be readily integrated into routine 
patient care to foster a more active and informed role in treatment decisions for young 
adults with BPII. Mental health services have been slow to enact SDM, even though 
this approach is widely endorsed [7], and is already commonplace in medical settings, 
such as oncology. This is somewhat paradoxical, as patients with chronic mental 
illnesses, such as BPII, often need and want to play a more active role in their own 
self-management than patients with cancer, for example, because patient education, 
medication adherence and lifestyle changes are strongly related to long-term relapse 
risk and functional impairments. Therefore, the proposed e-DA would not only have 
important implications for BPII treatment, it could also be adapted to other chronic 
mental illnesses commonly affecting young adults where self-management and 
decision-making involvement are also important, such as anxiety. Greater adoption of 
SDM via dissemination of decision-making resources in mental health settings has the 
potential to significantly enhance the management and outcomes of many psychiatric 
illnesses. 
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Active recruitment (First participant recruited 07/12/2017).  
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How can this booklet help you 
to make decisions about your 
treatment?
What is the purpose of this booklet? 
The purpose of this booklet is to help people with bipolar II 
disorder (BPII) who are in partial or full remission to make an 
informed decision about treatment. The information may help 
people to decide:
 • between available medication options 
 • whether or not to have add-on (adjunctive) psychological 
treatment. 
What information does this booklet include?
There is information about:
 • BPII and its symptoms
 • the treatments available
 • pros (benefits) and cons (risks/side effects) of each option
 • questions that you may like to ask your clinician
 • advice on how to make a decision that will best suit your 
values and goals
 • examples of how other people in similar situations have 
approached treatment decisions. 
This booklet is designed to add to, but not replace, discussions that 
you will have with your psychiatrist, GP or psychologist and your 
family about the options available to you. 
Depending on your life situation, your clinician may not discuss 
all the options that appear in this booklet, or might discuss other 
options. This booklet is another resource you can use to ensure that 
you are making a decision that is right for you.
What is bipolar II disorder?
This booklet is about BPII, which is a type of mental health 
condition that affects a person’s mood, energy, thoughts and 
behaviour. A person who has BPII experiences mood “cycles”, 
involving “lows” (depression) and “highs” (hypomania). These 
“cycles”, especially lows, usually occur a number of times in a 
person’s lifetime.
For more information about BPII, including the clinicians who are 
involved in BPII treatment, see page 10.
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What treatment options are available? 
Mental health professionals can recommend long-term treatment for 
BPII. The goals of long-term treatment are to:
 • keep the person well 
 • prevent “cycles” 
 • reduce the impact of “cycles”, to improve quality of life. 
There are many available treatment options to prevent relapse 
in BPII. For most people, medication is the main treatment and 
psychological treatment is an add-on (also called an adjunct/
adjunctive treatment). Psychological treatment is not meant to 
replace medication.
There are different types of medication and psychological treatments 
to choose from depending on your situation. Each treatment option 
has its own possible benefits, side effects and risks.
Your decisions about medication and psychological treatments are 
not “final”. You will probably check in with your clinician about how 
treatment is working and revisit your decisions a number of times.
Who is this booklet for?
This booklet is for people who: 
 • have recently been diagnosed with BPII
 • are showing few, mild symptoms or no symptoms of BPII 
(known as being in partial or full remission from depression 
and/or hypomania)
 • are seeing a doctor and considering treatment options to 
maintain wellness and prevent relapse. 
You may or may not already be on medication, for example, 
antidepressants. 
The information may also be helpful to a family member or 
other support person who is helping you make a decision about 
treatment.
This booklet is not meant for people who aren’t seeing a clinician 
to discuss treatment options, and it is less helpful for people who 
are currently experiencing severe or intense (acute) symptoms of 
depression and/or hypomania. 
* The following sections contain a lot of clinical information and new terms. If you are 
finding it difficult to read all at once, it may helpful to come back and re-read it at another 
time. There is also a glossary of all bolded terms on page 87. 
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Bipolar II disorder
What are the types of bipolar disorder?
Bipolar disorder is a mental health condition that affects a person’s 
mood, energy, thoughts and behaviour. 
There are two main types: bipolar I disorder (BPI) and bipolar 
II disorder (BPII). They are both lifelong conditions that involve 
mood cycles or mood swings, where a person experiences ‘lows’ 
(depression) and ‘highs’ (hypomania/mania). 
These mood swings can last a number of days (four or more days 
for hypomania) to a number of weeks (two or more weeks for 
depression).
A person with BPI or BPII can also experience mixed states, 
meaning they have symptoms of both depression and hypomania 
at the same time. 
For more information on ‘lows’ and ‘highs’, see page 12.
How is bipolar II disorder different from bipolar I 
disorder?
People with BPI and BPII disorder both experience a combination 
of depressive and hypomanic episodes. However, people 
diagnosed with BPI disorder experience full manic episodes, 
which are longer and more severe ‘highs’. People diagnosed with 
BPII disorder do not experience full manic episodes.
Diagram shows the types of 'low' and 'high' episodes in BPI and BPII.
Mania (BPI only)
Hypomania (BPI and BPII)
Depression (BPI and BPII)
Bipolar I disorder 
(BPI)
Bipolar II disorder 
(BPII)
‘Lows’  • Similar in both. May 
include psychotic 
experiences.
 • Similar in both. 
Unlikely to include 
psychotic experiences.
‘Highs’  • Longer, more 
severe; includes 
mania
 • Difficulties 
carrying out work, 
social, and family 
commitments as 
normal
 • May require 
hospitalisation
 • May include 
psychotic 
experiences
 • Shorter, milder
 • Can usually carry 
out work, social, and 
family commitments as 
normal or with minimal 
disruption
 • Does not usually 
require hospitalisation. 
 • No psychotic 
experiences
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People with BPII disorder tend to experience more depressive 
episodes and have shorter recovery time between episodes, 
compared to BPI disorder. Although the highs are shorter and 
milder in BPII disorder, it is still a serious condition and can affect a 
person’s life. 
What do ‘lows’ and ‘highs’ look like?
‘Lows’ or depression usually lasts from a couple of weeks to a 
couple of months. During this time, you may experience low mood 
(sadness or flatness) and a loss of interest or pleasure in most things, 
as well as: 
 • changes in appetite, such as having no appetite or eating too 
much and losing or gaining weight
 • getting too little sleep or sleeping too much
 • feeling physically slowed down, tired or having little energy
 • feeling troubled or nervous (agitated)
 • feeling hopeless and helpless
 • having difficulties concentrating
 • having thoughts of suicide.
‘Highs’ or hypomania usually lasts from a few days to a few weeks. 
During this time, you may feel excessively happy, elevated or irritable 
or more ‘wired’ and ‘hyper’ than normal, as well as: 
 • feeling more confident
 • needing less sleep but still feeling rested
 • being more talkative 
 • having racing thoughts and ideas which flit from topic to topic
 • having difficulties concentrating
 • feeling physically agitated or overly driven to pursue goals
 • being overly involved in activities that feel good or are 
pleasurable (such as sex or taking drugs) despite possible 
negative outcomes. 
What are the mood cycles like in bipolar II disorder?
 In 2003, Judd and colleagues found that over a 20 year period the 
average person with BPII disorder experiences 2-3 cycles per year 
(both with and without treatment). Over the long term, ‘lows’ are 
much more common than ‘highs’.
The average person with BPII disorder spends:
 • around 24 weeks of the year (46%) without any symptoms. 
 • around 19 weeks of the year (36%) experiencing symptoms  
of depression.
 • around 1 week of the year (1-2%) experiencing symptoms  
of hypomania.
 • around 8 weeks of the year (17%) experiencing mixed or  
mild symptoms. 
It is important to note that these symptoms are averages and do 
not reflect a person's individual experience.
Diagram shows the percentages of weeks per year that the average person 
with BPII spends with symptoms.
No symptoms
Symptoms of 
depression
Symptoms of 
hypomania
Mixed or mild 
symptoms
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For most people diagnosed with BPII disorder, mood cycles are 
recurrent, meaning they happen repeatedly over time. Between 
episodes, you may be mostly well and/or symptom free (euthymic), 
or you may experience mild symptoms (subsyndromal symptoms).
However, some people experience one cycle after another, which is a 
more long-term (chronic) pattern of illness. People who relapse four 
or more times in a year have what is known as rapid cycling bipolar 
disorder. 
How common is bipolar II disorder?
There may be different criteria used to diagnose BPII disorder, so 
estimates on how common BPII is vary.
People can be diagnosed at different ages. Most people experience 
their first episode in their early 20s, but might not be diagnosed until 
much later.
Evidence suggests that between 4 in 1000 and 50 in 1000 people 
will be diagnosed with BPII at some stage in their lifetime.
Which clinicians are involved in treating bipolar II 
disorder?
It is likely treatment for BPII will involve three main health 
professionals: a psychiatrist, a GP, and a psychologist. There are 
important differences between these clinicians. 
A psychiatrist is a medical doctor who has done extra training 
to specialise in mental health. They can prescribe medicines and 
can help a GP to manage medications. In the treatment of BPII, 
psychiatrists often confirm diagnosis.
A GP, like a psychiatrist, is a medical doctor but usually has limited 
training in mental health. GPs can also prescribe medicines and 
Between 4 in 1000 and 50 in 1000 
people will be diagnosed with BPII 
at some stage in their lifetime.
Between 950 in 1000 and 
996 in 1000 people will NOT.
are usually involved in the general, day-to-day management of 
medications. In the treatment of BPII, GPs often coordinate care 
and provide referrals to other clinicians or services.
A psychologist has qualifications in psychology and is not a 
medical doctor. Like psychiatrists, psychologists have also done 
training to specialise in mental health, but cannot prescribe 
medications. In the treatment of BPII, psychologists often help 
people to develop strategies to stay well and reduce the impact of 
mood episodes when they occur.
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MEDICATION OPTIONS
For most people with a diagnosis of bipolar II disorder (BPII), 
long-term medication is the main treatment for staying well and 
preventing relapse. 
This section will help you to understand the different medication 
options recommended for Bipolar II disorder.
Which medications are recommended in bipolar II 
disorder? 
Most available guidelines only give recommendations on treating 
bipolar I (BPI) disorder. This is because most high-quality research 
on treatments has been done in patients with BPI.  
Only one set of up-to-date guidelines includes recommendations 
about medication to prevent relapse of BPII. There is evidence for 
three types of common medications: 
MEDICATION OPTIONS
OPTION 2 
Lamotrigine 
Lamactil
OPTION 1 
Lithium 
Lithicarb/Quilonum SR
OPTION 3 
Quetiapine 
Seroquel
These three options are presented in detail in the following 
sections. For a summary of the advantages and disadvantages of 
these medication options, see pages 40-41. 
There is a similar amount of evidence for the three medication 
options described in this booklet. Because only very few studies 
have looked at medication in BPII separately, recommendations 
about medication are based on a combination of research and 
what most clinicians agree are the most appropriate treatment 
options (clinical consensus).
However, these are not your only medication options. Your 
clinician may also recommend:
 • a combination of these medications
 • another mood-stabilising medication (e.g. sodium valproate 
or olanzapine) 
 • antidepressant medication (e.g. fluoxetine or sertraline). 
The medication option your clinician recommends to you
will depend on your individual needs and life situation.
How effective will medication be for me?
The following sections explain some of the possible benefits and 
risks of the medication options. 
18 19
Before trying any particular medication, it is impossible to know 
if it will be effective at preventing relapse for you as an individual. 
Instead, your clinician may talk to you about the general chances 
(or likelihood) of a certain outcome. To give you an idea about how 
this might be expressed, here are some familiar examples: 
 • About 92 in 100 trains will run on time in Sydney. 
 • About 80 in 100 people will lodge their tax returns to the 
Australian Tax Office on time.
 • About 60 in 100 overseas trips made by Australians are for 
holidays. 
 • About 25 in 100 babies born in Australia today will live to be 
100 years old. 
 • In 40 years time, less than 11 in 100 people will live in areas 
outside the four major capital cities in Australia. 
 • About 1-2 in 100 pregnant women in Australia will give birth 
to twins in any year. 
Statistics information is about a group of people, not you as an 
individual. You may be asked consider the statistics about a certain 
medication and the information about it before deciding to try it 
or not.
Finding the right medication
It may take some time to find the ‘right’ medication option for you. 
You will probably check in with your clinician about how treatment 
is working and revisit your decision a number of times.
If you decide to take medication, it is important that you take 
it consistently as that it can be effective and prevent relapse as 
much as possible. Staying on medication long-term (adherence) 
can be challenging, but it can help to set habits about taking the 
medication, develop a good relationship with your clinician and 
consider some psychological treatments (see pages 42-43). 
 MEDICATION OPTION 1 
LITHIUM
“My wife was put on lithium and things progressed very 
quickly into the very positive ... She’s been stable…”
“To me, lithium kind of has bad associations ... ‘doped up’ 
people in mental wards, that sort thing.”
What is lithium?
 • Lithium is also known as Lithicarb or Quilonum SR. It is one of 
the most widely-used and studied medications for treating 
bipolar disorder. 
 • Research shows that lithium helps strengthen nerve cell 
connections in parts of the brain involved in regulating mood, 
thinking and behaviour. 
 • The dose prescribed is based on your blood levels. There is a 
working (therapeutic) range, which is 0.6-0.8 mmol/litre.
 • Lithium is the oldest mood-stabiliser. New medications are 
often compared or measured against it.
 • It acts on a person’s central nervous system (brain and spinal 
cord) to “stabilise” mood.
When is lithium recommended? 
Lithium may be better suited to people who experience:
 • clearly defined episodes of hypomania and depression
 • long periods of wellness
 • normal levels of functioning between episodes
 • more severe or more frequent highs than lows 
 • a tendency towards suicidal thoughts or behaviours. 
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How effective is lithium at preventing relapse?1
1) One group of studies looked at how effective lithium is at 
preventing any type of relapse. 
When comparing people taking lithium versus people taking no 
medication, these studies show that:
1 Meta-analysis based on randomised controlled trials (RCTs) of relapse in people with bipolar I and II 
disorders from 3 months up to 3 years. (Lithium dose: to achieve 0.5-1.5 mEq/l).
2) Another group of studies looked at how effective lithium is 
at preventing relapse into depression. 
When comparing people taking lithium versus people taking no 
medication, these studies show that:
ANY TYPE OF RELAPSE
LITHIUM NO MEDICATION
67in100
in100
in100
in100
43
33 57
people will NOT RELAPSE people will NOT RELAPSE
people taking lithium will  
RELAPSE within 3 months up to 2 years
people taking no medication will 
RELAPSE within 3 months up to 2 years
RELAPSE INTO DEPRESSION
LITHIUM NO MEDICATION
70in100
in100
in100
in100
66
30 34
people will NOT RELAPSE  
into depression
people will NOT RELAPSE  
into depression
people taking lithium will  
RELAPSE into depression  
within 3 months up to 2 years
people taking no medication will 
RELAPSE into depression  
within 3 months up to 2 years
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3) Another group of studies has looked at how effective 
lithium is at preventing relapse into hypomania. 
When comparing people taking lithium versus people taking no 
medication, these studies show that…
What are the possible ADVANTAGES of taking 
lithium?
 • Lithium is effective at preventing both depressive and 
hypomanic/mixed relapse. 
 • Lithium can reduce the risk of suicidal thoughts and 
behaviours. These anti-suicidal properties are unique to 
lithium.
 • There is less weight gain associated with lithium than other 
medications (for example, quetiapine and olanzapine).
 • Most people are able to continue taking lithium even if they 
do experience some side-effects. Around 84 in 100 people 
continued taking lithium in a study lasting 18 months.
 • Lithium is subsidised by the PBS (Pharmaceutical Benefits 
Scheme), meaning that the Australian government covers 
part of the cost of this medication to make it more affordable. 
Check your eligibility for this scheme via:  
www.pbs.gov.au/info/general/faq#Whoiseligibletoreceivebe
nefitsunderthePBS
RELAPSE INTO HYPOMANIA
LITHIUM NO MEDICATION
84 in100
in100
in100
in100
73
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people will NOT RELAPSE  
into hypomania
people will NOT RELAPSE  
into hypomania
people taking lithium will  
RELAPSE into hypomania  
within 3 months up to 2 years
people taking no medication will 
RELAPSE into hypomania  
within 3 months up to 2 years
Studies show that lithium is better than no medication at preventing all 
types of relapse. It appears to be good at preventing both depression and 
hypomania, but it may be better at preventing hypomania than depression.
24 25
For most people, these symptoms are mild to moderate in intensity and 
do not stop them taking lithium.
Long-term 
 • Regular, ongoing monitoring is needed for:
 •  blood serum levels, to ensure they remain in the 
therapeutic range and avoid lithium toxicity. 
 • kidney function, 
 • thyroid function and 
 • weight gain.
This usually involves urine and blood tests, and body weight 
measurement every 3-6 months.
 • Over the long-term (5+ years on average) approximately 
13-14 in 100 people taking lithium will experience clinical 
hypothyroidism. This means the thyroid gland is under-
active. This condition can be treated with thyroid hormone 
replacement medication.
 • Over the long-term (20+ years on average) about 1-2 in 
100 people taking lithium will experience chronic kidney 
disease. 
 • About 5 in 1000 people taking lithium will experience 
complete kidney (renal) failure. This is uncommon.
With regular, ongoing monitoring you can greatly reduce the risk of 
possible long-term side effects.
What are the possible DISADVANTAGES of taking 
lithium?
Short-term
 • Lithium may take longer to take effect (2-4 weeks) compared 
to other medications for BPII.
 • Within the first 4 months of starting/increasing lithium, 
people commonly experience: 
Dry mouth 53 in 100 people (53%)
Increased thirst 49 in 100 people (49%)
Nausea/vomiting 47 in 100 people (47%)
Upset stomach 43 in 100 people (43%)
Increased need to urinate (pee) 33 in 100 people (33%)
Cognitive ‘dulling’ (i.e., 
difficulties remembering, 
slowed down thinking)
20-25 in 100 people (20-25%)
In general, these side effects tend to pass. 
Mid-term
 • Within the first 18 months of taking lithium to prevent 
relapse, people also may experience:
Headache 19 in 100 people (19%)
Tremor 17 in 100 people (17%)
Sleepiness/drowsiness or 
fatigue
13 in 100 people (13%)
Weight gain of ≥ 7% of body 
weight *
10-12 in 100 people (10-12%)
*For a person weighing 70kg = ~ 5kg gain
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 MEDICATION OPTION 2 
LAMOTRIGINE
“Lamotrigine is a relatively new drug, it has a good evidence 
base. We felt very relieved and positive about it.”
“The thing that bothers me about lamotrigine ... is a very 
serious skin condition and I think: what sort of chemical  
am I putting into my body?”
What is lamotrigine?
 • Lamotrigine is also known by its brandname Lamictal. It is a 
type of anticonvulsant or antiepileptic medication. 
 • Originally, studies found that lamotrigine controlled seizures 
in epilepsy but studies also found that it is effective at 
stabilising mood in bipolar disorder. 
 • Research shows that lamotrigine changes brain chemicals 
associated with mood. 
 • To help prevent relapse, the usual dose for lamotrigine is 50-
200 mg/day.
When is lamotrigine recommended?
Lamotrigine is best suited to people with BPII who experience:
 • more severe and more frequent lows than highs
 • episodes of depression and hypomania that are not clearly 
defined (non-distinct)
 • mixed symptoms of depression and hypomania at the same 
time (mixed episode)
 • at least four episodes of depression and/or hypomania in a 
year (rapid cycling). 
How effective lamotrigine at preventing relapse?2
1) One group of studies looked at how effective lamotrigine is 
at preventing any type of relapse. 
When comparing people taking lamotrigine versus people taking no 
medication, these studies show that:
2 A meta-analysis based on studies of relapse in people with bipolar I and II disorders from 3 months up to 3 
years (Lamotrigine dose: 100-500mg/day).
ANY TYPE OF RELAPSE
LAMOTRIGINE NO MEDICATION
52in100
in100
in100
in100
40
48 60
people will NOT RELAPSE people will NOT RELAPSE
people taking lamotrigine  
will RELAPSE  
within 6 months up to 1.5 years
people taking no medication  
will RELAPSE  
within 6 months up to 1.5 years
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2) Another group of studies looked at how effective 
lamotrigine is at preventing relapse into depression. 
When comparing people taking lamotrigine versus people taking no 
medication, these studies show that:
3) Another group of studies looked at how effective 
lamotrigine is at preventing relapse into hypomania. 
When comparing people taking lamotrigine versus people taking no 
medication, these studies show that:
RELAPSE INTO DEPRESSION
LAMOTRIGINE NO MEDICATION
71in100
in100
in100
in100
62
29 38
people will NOT RELAPSE  
into depression
people will NOT RELAPSE  
into depression
people taking lamotrigine will 
RELAPSE into depression  
within 6 months up to 1.5 years
people taking no medication will 
RELAPSE into depression  
within 6 months up to 1.5 years
Studies show that lamotrigine is better than no medication at 
preventing all types of relapse. It appears to be better at preventing 
depression than hypomania.
RELAPSE INTO HYPOMANIA
LAMOTRIGINE NO MEDICATION
81 in100
in100
in100
in100
77
19 23
people will NOT RELAPSE  
into hypomania
people will NOT RELAPSE  
into hypomania
people taking lamotrigine will 
RELAPSE into hypomania  
within 6 months up to 1.5 years
people taking no medication will 
RELAPSE into hypomania  
within 6 months up to 1.5 years
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 • Within the first 2 months of starting lamotrigine, people may 
experience:
Benign (or non-serious) rash 8-9 in 100 people (8-9%)
Serious (Steven-Johnson’s like) 
rash. 
1 in 10,000 to 1 in 1000 
people (0.01-0.1%)
Rash requiring hospitalisation and stopping medication. This rash 
is rare but can cause death (<5 in 100 people who develop it and 
do not stop medication or receive proper treatment). 
 • When starting lamotrigine, it may take 2-3 months to reach 
the working (therapeutic) dose. Dose increases need to be 
done slowly to avoid developing rash.
 • Within the first 4 months of taking lamotrigine, people may 
experience side effects, such as headache, nausea/vomiting, 
infection and dizziness.
In the first 2 months of starting lamotrigine, it is important to remain 
alert as most rashes develop during this time.
If you notice any signs of a rash, don’t take your next dose of 
lamotrigine and immediately contact your GP or psychiatrist 
for consultation. This may help you to avoid the complications 
associated with serious rash. 
What are the possible ADVANTAGES of taking 
lamotrigine?
 • Lamotrigine is effective for preventing depressive relapse, 
which is the most common mood state in BPII.
 • Lamotrigine has few side effects compared to other 
medications for BPII. It does NOT cause: 
 •   weight changes – lamotrigine is considered a ‘weight 
neutral drug’
 •   cognitive ‘dulling’ – people do not tend to have trouble 
concentrating, focussing or remembering things
 •   sleepiness/drowsiness – people taking lamotrigine may 
feel more energetic
 •   problems with sexual functioning – this is reported by less 
than 1 in 100 people taking lamotrigine.
 • Most people are able to continue taking lamotrigine even if 
they do experience side effects. In a study lasting 18 months, 
around 91 in 100 people continued taking lamotrigine for the 
duration of the study.
 • Lamotrigine does not require regular ongoing monitoring 
over the long-term. 
What are the possible DISADVANTAGES of taking 
lamotrigine?
 • Lamotrigine is not currently subsidised by the PBS 
(Pharmaceutical Benefits Scheme) for BPII, meaning that this 
medication costs more than some others available.
Short-term
 • It is unclear if lamotrigine is effective at preventing 
hypomanic/mixed episodes, meaning that you may need to 
take add-on medication/s to deal with these symptoms.
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Mid-term
 • Within the first 18 months of taking lamotrigine to prevent 
relapse, people can commonly also experience: 
Headache 18 in 100 people (18%)
Nausea/vomiting 17 in 100 people (17%)
Infection 12 in 100 people (12%)
Dizziness 8 in 100 people (8%)
For most people, side effects in the medium term are mild to moderate 
in intensity and do not stop them taking lamotrigine.
 MEDICATION OPTION 3 
QUETIAPINE
“For me, quetiapine has less scary side effects … I was more 
inclined to trust it.”
“With quetiapine, I found it really successful [in stabilising 
mood], but it made me put on a significant amount of 
weight.”
What is quetiapine?
 • Quetiapine is also known by its brand name Seroquel. It is a 
newer (second generation) type of antipsychotic medication. 
 • Even though quetiapine is an ‘antipsychotic’ it can stabilise 
mood and prevent relapse in conditions like BPII, where the 
person does not experience psychotic episodes.
 • Quetiapine helps to stabilise mood by restoring the balance 
of natural substances (neurotransmitters) in the brain. 
 • To help prevent relapse, the usual dose for quetiapine is 10-
25 mg daily.
When is quetiapine recommended?
Quetiapine may be a good ‘all-rounder’ medication for people with 
BPII disorder who experience:
 • a similar number of ‘lows’ and ‘highs’
 • depressive and hypomanic symptoms at the same time 
(mixed episodes)
 • at least four episodes of depression and/or hypomania in a 
year (rapid cycling)
 • are not sleeping enough
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How effective quetiapine at preventing relapse?3
1) One group of studies looked at how effective quetiapine is 
at preventing any type of relapse. 
When comparing people taking quetiapine versus people taking no 
medication, these studies show that:
3 A meta-analysis based on RCT studies of relapse in people with bipolar I and II disorders from 3 months up 
to 3 years (Quetiapine doses 300-800mg/day).
2) Another group of studies looked at how effective quetiapine 
is at preventing relapse into depression. 
When comparing people taking quetiapine versus people taking no 
medication, these studies show that:
ANY TYPE OF RELAPSE
QUETIAPINE NO MEDICATION
77in100
in100
in100
in100
53
23 47
people will NOT RELAPSE people will NOT RELAPSE
people taking quetiapine will 
RELAPSE within 1 up to 2 years
people taking no medication will 
RELAPSE within 1 up to 2 years
RELAPSE INTO DEPRESSION
QUETIAPINE NO MEDICATION
89in100
in100
in100
in100
75
11 25
people will NOT RELAPSE  
into depression
people will NOT RELAPSE  
into depression
people taking quetiapine will 
RELAPSE into depression  
within 1 up to 2 years
people taking no medication will 
RELAPSE into depression  
within 1 up to 2 years
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3) Another group of studies looked at how effective quetiapine 
is at preventing relapse into hypomania. 
When comparing people taking quetiapine versus people taking no 
medication, these studies show that:
What are the possible ADVANTAGES of taking 
quetiapine?
 • Quetiapine is effective at preventing both depressive and 
hypomanic/mixed relapse. 
 • It is possible to reach the working (therapeutic) dose of 
quetiapine more quickly than with other medications for BPII, 
such as lamotrigine. 
 • Most people are able to continue taking quetiapine even if 
they experience side effects. In a study lasting one year, about 
92-94 in 100 people continued taking quetiapine. However, 
the side effects of quetiapine depend on the dose taken.
What are the possible DISADVANTAGES of taking 
quetiapine?
 • Quetiapine is not currently subsidised by the PBS 
(Pharmaceutical Benefits Scheme) for BPII, meaning that this 
medication costs more than some others available.
Short-term
 • Within the first 2-3 months of taking quetiapine, people 
experience the following side effects: 
Sleepiness/drowsiness 17-19 in 100 people (17-19%)
Cognitive ‘dulling’ (i.e., 
difficulties remembering, 
slowed down thinking)
5-16 in 100 people (5-16%)
Weight gain ≥ 7% of body 
weight*. 
3-12 in 100 people (3-12%)
*For a person weighing 70kg = ~ 5kg gain. 
Studies show that quetiapine is better than no medication at preventing 
all types of relapse. It appears to be good at preventing both depression 
and hypomania relapse.
RELAPSE INTO HYPOMANIA
QUETIAPINE NO MEDICATION
88 in100
in100
in100
in100
78
12 22
people will NOT RELAPSE  
into hypomania
people will NOT RELAPSE  
into hypomania
people taking quetiapine will 
RELAPSE into hypomania  
within 1 up to 2 years
people taking no medication will 
RELAPSE into hypomania  
within 1 up to 2 years
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Weight gain is more common when taking higher doses of 
quetiapine and generally plateaus within first 10 weeks of 
treatment.
Mid-term
Within the first year of starting quetiapine, people may experience 
the following side effects: 
Changes to their metabolism  
(e.g. blood sugar and cholesterol 
levels)*. 
*  It is unclear if these changes 
put people at higher risk of 
type II diabetes.
7-15 in 100 people (7-15%)
Weight gain ≥ 7% of body 
weight*. 
*  For a person weighing 70kg = 
~ 5kg gain.
6-10 in 100 people (6-10%)
Headache 11-14 in 100 people (11-14%)
Sleepiness/drowsiness 6-7 in 100 people (6-7%)
Dry mouth 3-6 in 100 people (3-6%)
Movement and muscle control 
problems
2-3 in 100 people (2-3%)
In most patients, these side effects are mild to moderate in intensity and 
become less severe over 1-4 months of treatment.
Long-term
 • Regular, ongoing monitoring of blood sugar levels, 
cholesterol and weight gain is required. This usually involves 
urine and blood tests, and body weight measurement every 
3-6 months.
Note many of the possible side effects of quetiapine depend 
on the dose taken. 
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Summary table of ADVANTAGES and  
DISADVANTAGES of medication options
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ADD-ON (ADJUNCTIVE)  
PSYCHOLOGICAL OPTIONS
This section will help you to understand the different add-on 
psychological options recommended for bipolar II disorder (BPII).
Why are psychological treatments recommended in 
bipolar II disorder?
Although medication forms the main treatment for most people 
with BPII, people may still relapse into depression or hypomania 
even when they are taking medication. ‘Real-world’ studies of 
people with bipolar I and II disorders suggest that on average, for 
any type of episode (depression or hypomania):
Because medication does not offer complete protection against 
relapse in BPII, adjunctive psychological interventions or ’talking 
therapies’ are added to help prevent relapse. 
Studies show that when used together with medication, two 
bipolar-specific psychological treatments are effective in 
preventing relapse:
These two psychological treatments are presented in detail in 
the following sections. For a summary of the advantages and 
disadvantages, see pages 60-61.
There are other psychological treatments available which may also 
be helpful to you. 
For more information about other psychological treatments, such 
as family-focussed therapy (FFT) and interpersonal and social 
PSYCHOLOGICAL 
OPTIONS
MEDICATION 
OPTION 2 
Group  
psycho-education
OPTION 1 
Cognitive 
behavioural therapy 
WITHIN 2 YEARS WITHIN 5 YEARS
50 in100
in100
in100
in100
10-30
50 70-90
people will NOT RELAPSE people will NOT RELAPSE
people treated with medication will 
RELAPSE within 2 years
people treated with medication will 
RELAPSE within 2 years
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 PSYCHOLOGICAL OPTION 1  
COGNITIVE BEHAVIOURAL 
THERAPY (CBT)
“CBT is quite useful because it’s not just medication, it’s 
changing your way of thinking…”
“I’ve done a bit of CBT, but I don’t think it does anything for 
me…”
What is cognitive behavioural therapy?
Cognitive behavioural therapy (CBT) is a type of psychological 
treatment that focuses on how people can change themselves. As 
seen in the diagram on page 46, this treatment:
 • focuses on the idea that any situation can be taken in a 
number of ways. How a person thinks about or interprets a 
situation can influence their feelings about it (emotions) and 
their reaction to it (behaviour). 
 • explains that if a person thinks about a situation in a negative 
way, this can lead to feelings and reactions that are unhelpful 
and unwanted. 
 • helps the person with BPII to develop strategies to challenge 
and change wrong or unhelpful thinking, emotions and 
behaviours. Some examples of these types of thoughts are: “I 
am a hopeless failure” or “No one is interested in what I have to 
say.” 
 • aims to decrease symptoms and relapse risk. 
 • CBT includes 6-20 hour-long weekly sessions for up to six 
months. The actual number of sessions will vary from one 
person to another based on individual needs. It is usually 
recommended to attend CBT sessions over the longer-term.
rhythm therapy (IPSRT), talk to your clinician (see Australian 
Psychological Society – “Find a psychologist” under Further 
Resources on page 86.)
All of these psychological treatments appear to:
 • be more effective at preventing relapse than medication only 
and usual care
 • be similar in terms of effectiveness, suggesting that any of 
these treatments will help
 • have a number of common core strategies, such as ways you 
can prevent relapse and stay on medication.
Because of this, it is up to you to consider which psychological treatment 
fits in best with your life and preferences. As with medication, the option 
your clinician recommends will depend on your individual needs and life 
situation. Your clinician may also combine elements of these psychological 
treatments with others to help you in the most effective way.
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How effective is CBT at preventing relapse?4
1) One group of studies looked at how effective add-on CBT is 
at preventing any type of relapse. 
When comparing people doing add-on CBT versus people having 
usual care these studies show that:
4 Meta-analyses based on randomised controlled trials (RCTs) of relapse in people with bipolar I and II 
disorders with follow-ups of at least 3 months.
THOUGHT
the situation is 
interpreted
EMOTION
a feeling occurs as a  
result of the thought
BEHAVIOUR
an action in response  
to the emotion
SITUATION
something happens
A model showing the main parts of cognitive  
behavioural therapy (CBT)
ANY TYPE OF RELAPSE
MEDICATION + CBT MEDICATION + USUAL CARE
51 in100
in100
in100
in100
35
49 65
people will NOT RELAPSE people will NOT RELAPSE
people doing add-on CBT  
will RELAPSE  
within 6 months up to 2 years
people having usual care  
will RELAPSE  
within 6 months up to 2 years
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2) Another group of studies looked at how effective add-on 
CBT is at preventing relapse into depression.
When comparing people doing add-on CBT versus people having 
usual care, these studies show that:
3) Another group of studies looked at how effective add-on 
CBT is at preventing relapse into hypomania. 
When comparing people doing add-on CBT versus people having 
usual care, these studies show that:
RELAPSE INTO DEPRESSION
MEDICATION + CBT MEDICATION + USUAL CARE
70 in100
in100
in100
in100
55
30 45
people will NOT RELAPSE  
into depression
people will NOT RELAPSE  
into depression
people doing add-on CBT will 
RELAPSE into depression  
within 6 months up to 2 years
people having usual care will  
RELAPSE into depression  
within 6 months up to 2 years
Studies show that taking medication AND doing add-on CBT is better 
than medication and usual care at preventing all types of relapse.
It appears better at preventing depression than hypomania.
RELAPSE INTO HYPOMANIA
MEDICATION + CBT MEDICATION + USUAL CARE
72 in100
in100
in100
in100
66
28 34
people will NOT RELAPSE  
into hypomania
people will NOT RELAPSE  
into hypomania
people doing add-on CBT will 
RELAPSE into hypomania  
within 6 months up to 2 years
people having usual care will  
RELAPSE into hypomania  
within 6 months up to 2 years
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What are the possible ADVANTAGES of CBT?
 • Up to 10 CBT sessions with a psychologist are covered by 
Medicare rebate with a GP referral under the Australian 
Government’s Better Access Initiative. 
 • CBT is a highly accessible treatment. Most clinical 
psychologists in Australia have training in this approach. 
To find someone in your area, see Australian Psychological 
Society – “Find a psychologist” under Further Resources on 
page 86. 
 • Treatment is individually-tailored to your patterns of thinking, 
emotions and behaviours. 
 • Skills learnt in CBT are useful, practical and helpful strategies 
that can be incorporated in everyday life to help coping even 
after treatment has finished. 
 • CBT sessions can be arranged at a time/day that fits into your 
schedule. 
 • Includes education about BPII (psycho-education).
 • May help you to stay on prescribed medication. This is 
called adherence. More people report good adherence to 
medication when doing add-on CBT (89 in 100 people) versus 
people only taking medication and not receiving CBT (67 in 
100 people).
 • Most people are able to continue with and complete therapy. 
About 84 into 100 people were able to continue therapy 
sessions in a study lasting one year.
What are the possible DISADVANTAGES of CBT?
 • CBT often requires more than 10 sessions per calendar year, 
the maximum number covered by Medicare rebate. At this 
point, people wanting to continue therapy will probably need 
to pay full fees, unless their private health insurance covers 
part of the fee. 
 • To gain access to the Medicare rebate, the person needs to 
first make an appointment with their GP to get a referral. 
 • Some people find it emotionally demanding/distressing to 
talk about thoughts, feelings or experiences. 
 • You may be asked to complete home-based practice tasks 
between therapy sessions, which requires dedication and 
motivation. 
 • If there are broader issues (e.g. family conflict, workplace 
stresses), other therapies may be more helpful. 
 • Not everyone likes the structure of CBT. 
 • The one-on-one format means you don’t have direct support 
from other people who have BPII (peer support).
 • It may take time to find a psychologist whom you feel is a 
good match and ‘right’ for you. You might have to meet with 
a couple of psychologists before finding one you want to 
work with. 
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 PSYCHOLOGICAL OPTION 2 
GROUP PSYCHO-EDUCATION
 “It was really good getting all the ‘ins and outs’ from both 
medical personnel and also from people who were diagnosed 
with bipolar and told us how to deal with it.”
“At an early stage, I’d go to some group sessions but I found 
them not very helpful, and I didn’t really want to continue 
doing those.”
What is group psycho-education?
Psycho-education is a type of specialised education for people 
with a particular illness. This helps people learn about a condition, 
such as bipolar II disorder (BPII).
However, group psycho-education also refers to formal programs 
led by a clinician or other health professional that aim to help 
people become ‘experts’ at managing their BPII. The programs 
focus on:
 • overall awareness of BPII, including triggers and early warning 
signs
 • the importance of taking medication as prescribed (adhering 
to medication)
 • keeping moods stable.
There are a variety of group psycho-education programs available, 
both face-to-face and online. Because the focus is on learning, it 
is not really considered ‘therapy’. However, it is not clear if many 
available group psycho-education programs help to prevent 
relapse in BPII. More research is also needed to evaluate shorter 
face-to-face and online programs.
Research has mostly been done on face-to-face programs. Some 
studies looked at about 21 weekly sessions of 90 minutes over six 
months. These programs used step-by-step guides (manuals) and 
showed psycho-education was effective. 
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How effective is group psycho-education  
at preventing relapse?5
1) One group of studies looked at how effective add-on group 
psycho-education is at preventing any type of relapse. 
When comparing people participating in add-on group psycho-
education versus people having usual care, these studies show that:
5 Meta-analyses based on RCT studies of relapse in people with bipolar I and II disorders with follow-ups of 
at least 3 months.
2) Another group of studies looked at how effective add-
on group psycho-education is at preventing relapse into 
depression. 
When comparing people participating in add-on group psycho-
education versus people having usual care, these studies show that:
ANY TYPE OF RELAPSE
MEDICATION +  
GROUP PSYCHO-EDUCATION
MEDICATION + USUAL CARE
41in100
in100
in100
in100
16
59 84
people will NOT RELAPSE people will NOT RELAPSE
people participating in add-on 
group psycho-education will 
RELAPSE  
within 6 months up to 2 years
people having usual care  
will RELAPSE  
within 6 months up to 2 years
RELAPSE INTO DEPRESSION
MEDICATION +  
GROUP PSYCHO-EDUCATION
MEDICATION + USUAL CARE
71in100
in100
in100
in100
41
29 59
people will NOT RELAPSE  
into depression
people will NOT RELAPSE  
into depression
people participating in add-on 
group psycho-education will 
RELAPSE into depression  
within 6 months up to 2 years
people having usual care will  
RELAPSE into depression  
within 6 months up to 2 years
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3) Another group of studies looked at how effective add-
on group psycho-education is at preventing relapse into 
hypomania. 
When comparing people participating in add-on group psycho-
education versus people having usual care, these studies show that:
What are the possible ADVANTAGES of group 
psycho-education?
 • Group psycho-education can be a good starting point for 
people reluctant to do ‘therapy’. Different individual therapies 
can be tried later.
 • Group meetings can give members the opportunity to:
 • support one another
 • share common experiences
 • reduce feelings of isolation
 • help confirm the individual’s experience of illness.
 • Psycho-education can help with acceptance of a BPII 
diagnosis, making the illness seem more ‘normal’ or less 
frightening.
 • It can increase knowledge about BPII and managing relapse 
and provide practical skills for daily life. 
 • Most people are able to continue with and complete psycho-
education. Around 73 in 100 people were able to continue 
psycho-education sessions over a six-month period.
 • Many group psycho-education programs are affordable. 
Some are covered by Medicare with or without having to 
pay a one-off fee. Other groups require members to pay for 
workbooks and make a weekly gold coin donation.
 • There are a variety of programs available. These include 
shorter face-to-face and online programs. For more 
information, see “The REACH program” and “Moodswings” 
under Further Resources on page 86. 
Studies show that taking medication AND doing add-on group  
psycho-education is better than medication and usual care at preventing 
all types of relapse. This also appears to be good at preventing both 
depression and hypomania. 
RELAPSE INTO HYPOMANIA
MEDICATION +  
GROUP PSYCHO-EDUCATION
MEDICATION + USUAL CARE
57in100
in100
in100
in100
38
43 62
people will NOT RELAPSE  
into hypomania
people will NOT RELAPSE  
into hypomania
people participating in add-on 
group psycho-education will 
RELAPSE into hypomania  
within 6 months up to 2 years
people having usual care will 
RELAPSE into hypomania  
within 6 months up to 2 years
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What are the possible DISADVANTAGES of group 
psycho-education?
 • The program is not flexible to individual schedules. Given the 
group format, there is usually a set meeting time and place, 
and you may have to travel to attend.
 • Information and activities are general enough to meet the 
needs of the group, but may not fit in with your individual 
needs and preferences. 
 • You may not be comfortable in a group setting, which 
involves speaking in front of others and sharing personal 
information.
 • You may not be able to identify with others’ experiences and/
or find these discouraging. 
 • If you share information that you want to keep private, you 
can’t guarantee that it won’t be shared outside the group. 
However, it is strongly encouraged that group members are 
respectful and don’t break each others’ trust.
 • Sessions can be long (90 minutes) over six months so requires 
ongoing commitment and motivation to attend. However, 
the actual number of sessions offered varies. 
 • Group psycho-education may help you to stay on 
medications (adherence). However, research shows that 
people participating in group psycho-education appear to 
stay on some but not all medications more consistently than 
people having usual care.
"For me... it's this holistic 
approach to managing 
my illness... it's about 
the medication working 
together with the 
psychological options."
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Summary table of ADVANTAGES and  
DISADVANTAGES of add-on  
psychological options
Cognitive 
behavioural  
therapy (CBT)
Group  
psycho-education
Accessibility 
(Is the therapy 
widely available?)
Highly accessible 
treatment.
Limited number of 
meeting venues.
Cost/
affordability
Up to 10 sessions 
covered by Medicare 
rebate, then full fees.
Mostly affordable.
Engagement
(Number of 
people who 
continue with and 
complete therapy)
84 in 100 people 73 in 100 people
Flexible for your 
schedule
Flexible for your 
schedule.
Not flexible 
for individual 
schedules.
Focus on 
problem areas
May not focus enough 
on broader issues 
May not focus 
enough on 
individual issues
Cognitive 
behavioural  
therapy (CBT)
Group  
psycho-education
Medication 
adherence (Will it 
help you stay on 
your prescribed 
medication?)
Better adherence to 
medication.
Better adherence 
to some 
medications only.
Privacy/
confidentiality
Safeguarded by 
clinician-patient 
confidentiality.
May be more 
limited due to 
group setting.
Tailored to 
individual’s 
needs
Individually-tailored. May not fit 
individual needs 
and life situation.
Time 
commitment
6–20 sessions of 1 
hour over about 6 
months.
Up to 21 weekly 
sessions of about 
1.5 hours over 6 
months.
= Possible disadvantage that is serious and may involve stopping treatment.
= Possible disadvantage that can be managed/tolerated.
= Possible advantage.
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What is the role of 
complementary treatment?
Many people with bipolar II disorder (BPII) express an interest in 
complementary treatment options to help to prevent relapse into 
either depression or hypomania. 
Complementary treatments are treatments that are used together 
with conventional or mainstream medicine, such as medications 
and psychological treatments. By being used as add-on (adjunctive) 
treatments, complementary treatments may help lessen symptoms. 
There are a number of complementary treatment options available, 
but there is little evidence for them in BPII apart from omega-3 fatty 
acids.
Can omega-3 fatty acids help to prevent relapse in 
bipolar II disorder?
In bipolar disorder, one complementary treatment that has received 
a lot of interest is omega-3 fatty acids or fish oils. These are found 
naturally in plant and marine life but fish oil supplements can also be 
purchased in capsule form over-the-counter (without prescription) 
from the pharmacy or some supermarkets. 
The latest Australian guidelines for bipolar disorders (I and II) 
mention evidence showing that omega-3 fatty acids help to reduce 
symptoms of depression when used with medication. However, 
omega-3 fatty acids do not appear to help reduce symptoms of 
hypomania. 
When it comes to preventing relapse, there is still not enough 
evidence to know if adding omega-3 fatty acids to medication helps 
to prevent relapse in BPII.
Current guidelines do not make recommendations about omega-3 
fatty acids as a treatment option for preventing relapse in BPII or 
complementary treatment. If you are taking omega-3 fatty acids 
or are interested in taking them, discuss this with your GP or 
psychiatrist. 
How can family members be 
involved in decision-making?
Bipolar II disorder (BPII) can affect not only you, but also those 
close to you, including family members6. For this reason, involving 
family in preventing relapse can be important, because family 
members are often the first to notice the early warning signs of 
relapse. Family members can also help when you are starting or 
continuing treatment.
Your family can also be involved or contribute to decision-making 
about treatment. There are different ways that they can be 
involved. 
At appointments with clinicians (consultations)
Family members can help give the clinician helpful information 
about:
 • your illness history and symptoms
 • what is ‘normal’ and what is ‘not normal’ or out of character 
for you
 • what matters most to you (e.g. your values, goals and 
preferred treatment options)
 • how well you are responding to treatment and coping with 
side effects.
During consultations, family can give your clinician helpful information.
 
6 Family members may also include other support people, such as friends, colleagues or neighbours.
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Attending consultations can also be helpful for family members, as 
they can:
 • ask questions
 • discuss any concerns about recommended treatment options
 • better understand the treatment options
 • discuss options with you after the consultation before coming 
to a final decision. 
Outside consultations with clinicians
At home, your family members can help you to: 
 • reflect on what is important to you and what matters to you 
about the different treatment options, so you have a clearer 
idea of your preferences
 • weigh up the pros (i.e. benefits) and cons (i.e. side effects or 
risks) of all of the treatment options available, and how they 
would impact you
 • get more information about the recommended treatment 
option
 • have more realistic expectations about treatment benefits (for 
example, there may be delayed effects)
 • work through any concerns, uncertainties or reluctance you 
have about starting or continuing treatment. 
Your family may also encourage you to continue seeing your 
clinician, especially if your side effects or symptoms worsen. 
Outside consultations, family can help gather information and consider 
the available treatment options.
Many people with BPII appreciate the support of family members 
and wish to involve family members when making decisions about 
treatment. Clinicians usually also appreciate family involvement.
People with BPII may wish to involve family in a small way or in a 
large way, or at different stages of decision-making (for example, 
before or after discussing treatment options with their clinician, 
before or after making a decision). 
As long you are well enough, it is ultimately your choice how and 
how much to involve your family in decisions. Keeping this in 
mind, it is important that your family talks to you about how much 
they would like to be involved and if they would like to attend a 
consultation.
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Making decisions - treatment 
decisions that are right for you
The previous sections have outlined the main options for people 
with bipolar II disorder (BPII). 
Not everyone will feel the same about what to do next. The 
following seven steps may help you to make decisions about 
which medication and psychological treatment options you wish 
to take up:
1. Decide on the level of involvement that you want from your 
clinician and tell them your preferences.
2. Decide on the level of involvement that you want from your 
family and tell them your preferences.
3. Understand your current options.
4. Review the pros (benefits) and cons (side effects/risks) of 
each option.
5. Assess how important the pros and cons of each option are 
to you.
6. Get more information and clarify any uncertain areas by 
asking questions.
7. Work out which option/s you are leaning towards.
Making the most of time  
with your clinician
“Even just having questions you can ask your doctor about is 
helpful …. when you go to the appointments, you know what 
you want to talk about.”
It is important to feel informed about bipolar II disorder (BPII) and 
your treatment options. Having the answers you want may help 
you to feel more confident about your choice and more in control 
of your treatment. 
When you have an appointment or consultation with your 
clinician, you should have time to ask questions. Some people are 
afraid to ask questions, but it is your right to do so.
It is completely acceptable and important to ask
your clinicians questions and raise options 
when discussing your treatment.
Five key points about  
question-asking in consulations: 
1. Many clinicians like to be asked questions
2. Question-asking does NOT challenge the professional 
expertise of the clinician
3. Question-asking does NOT mean that patients do not trust the 
clinician
4. Question-asking does NOT show that patients lack respect for 
the clinician
5. Clinicians do NOT think that patients who ask questions are 
"more difficult" or "worse" to deal with. 
During the consultation, your clinician will not know if you are 
confused about something or need more information unless you 
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ask about it. You might need to ask the same questions more than 
once if you don’t understand. Don’t be afraid to ask your clinicians 
the same questions again.
You also might have more questions after you have had a chance to 
think things over, so you can also ask how you can get information 
outside of the consultations. It is important to know a good, 
reliable source of facts about BPII treatment. 
What are some questions to ask your clinician?
Below are three quick questions that may be useful in getting key 
information about your condition from your clinician:
What are my 
options?
What are the 
possible benefits 
and risks of those 
options?
How likely are the 
benefits and risks 
of each option to 
happen to me?
ASK
SHARE
KNOW
For more information see: www.askshareknow.com.au 
Other questions 
Your clinician may not be able to answer all your questions at 
the time, but they can help direct you to where to find answers.
 Below is a list of some other questions you may find helpful to 
discuss with your clinician after you have received a diagnosis of 
BPII and are discussing treatment options.
  What is going on with my illness?
  What is the best way to manage it now?
  Do you recommend starting treatment?
  What treatment options do you recommend?
  What would be the aim of these treatment options?
  How likely it is that each treatment option will help me?
  How likely is that my symptoms will respond?
   How likely is it that I will remain stable with this treatment and for 
how long?
  What side effects could I expect from treatment?
  Is there anything that can be done to treat these side effects?
   What has been the experience of other patients when on this 
treatment?
  How often will I need to come for treatment reviews?
  How long until the treatment starts working? 
   How will I be monitored? Would would make me need to change 
treatment? 
If treatment does not seem to be working, when would we stop/
consider other options?
  How do my other existing health conditions affect my treatment?
  How much will treatment cost?
   How could my lifestyle be affected (e.g. daily activities, sexual life)? 
Tick ( ) the questions you want to ask.
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   Can you recommend any other sources of information about the 
treatment options?
  What happens if I choose not to have treatment at this time?
  Who will organise/manage my care?
  Who else will be available to support me?
  Do you recommend any complementary treatments?
  Can you give me any advice on how to cope better?
   Is there someone I can talk to who has been through this 
treatment?
  Is there anything else I should do at this time?
  When will my next follow-up appointment be?
  Is there support available to help my partner/family?
……………………………………………………………………
……………………………………………………………………
……………………………………………………………………
……………………………………………………………………
……………………………………………………………………
……………………………………………………………………
……………………………………………………………………
……………………………………………………………………
Worksheets: What is important 
to you about your treatment?
“I’m an individual and what works for one person wouldn’t 
work for another.”
“It’s helpful having ideas of what I need to consider 
in making treatment decisions … [such as] fitting my 
medication in with my lifestyle.”
Any treatment decision involves weighing up the likely benefits of 
the treatment (pros) with the side effects, risks and other possible 
negative impacts of the treatment (cons). 
To help you make your own decision, we have provided the 
following blank worksheets where you can go through the pros 
and cons of the options and rate how important these are to you 
(pages 77–80). There are also examples of how some other people 
with BPII viewed the pros and cons of the options available. 
Before completing the worksheets it is a good idea that you 
think about your pattern of highs and lows. Reread page 12 
which describes what highs and lows look like and decide 
which signs you experience more and which signs cause you 
the most problems. 
Each pro or con statement has three options describing how 
important you consider the issue to be. By circling one of the 
options you can indicate how important each issue is to you. 
Circling “Very important”
Means that the issue is a 
very big concern to you.
Circling
“Somewhat 
important”
Means that the issue is a 
small concern to you.
Write down any other questions you would like to ask
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Circling “Not important” 
Means that the issue is not 
a concern to you.
Patient examples: Overall, are the pros or cons more 
important to you?
For example: One of the cons of quetiapine (Seroquel) is that it can 
cause sleepiness and drowsiness. If a person feels that they will be 
able to handle this (i.e. this issue is of no concern), they circle that it 
is “Not important” for them. 
It can be hard to deal with sleepiness and drowsiness during 
the day. 
“This is not really an issue for me.” 
Not important
Somewhat  
important
Very important
After rating how important you consider each statement to be, look at 
whether you have rated more of the pros as somewhat/very important 
OR more of the cons as somewhat/very important. This will help you 
to understand how you feel overall. At the bottom of the worksheet, 
you can then indicate which way you are leaning in your decision by 
circling one of the five diamonds. See some examples over the page.
Overall, are the pros or the cons more important to 
you? 
 
Example 1: 
Taking LITHIUM Not taking LITHIUM
PROS CONS
Lithium may help prevent 
relapse into both depression 
and hypomania.
Lithium may make me  
put on weight.
There’s a lot of research about the 
long term outcomes of lithium.
I might develop problems with 
my kidney or thyroid function.
Other: Other:
Lithium is more affordable than 
other medications.
I may get tired/drowsy and feel 
as though I can’t think properly.
Lithium can help reduce 
thoughts of harming myself.
I will have to commit to regular, 
ongoing monitoring.
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Pros more 
important
Cons more 
important
By circling the third diamond in the middle, this person is 
indicating they are still unsure (50/50) about choosing this 
treatment option. In this situation, it may be a good idea to discuss 
the options more with their clinician. 
Overall, I’m not sure whether the 
pros or cons are more important  
for me…
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Example 2: 
PROS
CONS
Taking LITHIUM
Lithium may help prevent relapse into 
both depression and hypomania.
There’s a lot of research about the 
long term outcomes of lithium.
Other:
Lithium is more affordable than 
other medications.
Lithium can help reduce thoughts of 
harming myself.
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not taking LITHIUM
Lithium may make me  
put on weight.
I might develop problems with my 
kidney or thyroid function.
Other:
I may get tired/drowsy and feel as 
though I can’t think properly.
I will have to commit to regular, 
ongoing monitoring.
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Pros more 
important
Cons more 
important
By circling the first diamond to the left, this person is indicating 
they are leaning towards choosing this treatment option. 
 
Example 3: 
PROS
CONS
Taking LITHIUM
Lithium may help prevent relapse into 
both depression and hypomania.
There’s a lot of research about the 
long term outcomes of lithium.
Other:
Lithium is more affordable than 
other medications.
Lithium can help reduce thoughts of 
harming myself.
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not taking LITHIUM
Lithium may make me  
put on weight.
I might develop problems with my 
kidney or thyroid function.
Other:
I may get tired/drowsy and feel as 
though I can’t think properly.
I will have to commit to regular, 
ongoing monitoring.
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Pros more 
important
Cons more 
important
By circling the fourth diamond to the right, this person is indicating 
they are leaning towards not choosing this treatment option. 
Overall, the pros are more much 
important to me than the cons…
Overall, the cons are slightly more 
important to me than the pros…
76 77
Involving a family member
“My partner will often ask me questions about the decisions 
I’m making, to clarify in my own head what’s going on. She 
wants to know that I’m clear about why I’m doing what I 
want to do.”
If you would like to involve your family member/support person 
in your decision about how to manage your BPII, you may also like 
to give that person worksheets. If the person uses the worksheets, 
you may like to discuss each of your answers together. 
This can help a family member/support person to share in the 
choice about treatment option/s to manage your BPII, so you can 
make the decision together. 
Involving your clinician
“I told my clinician exactly how I felt about gaining weight 
… He listened to that and he told me why he suggested the 
medication he did. It was basically looking at the pros and 
the cons and seeing what you can do.”
You may also like to go through these worksheets with your 
clinician. Once you have completed all the sections of the 
worksheet, you can discuss your answers with the clinician. This 
can be a helpful conversation starter and way for you to share 
what is important to you and what matters to you with each of the 
treatment options. 
After you discuss the pros and cons of options further, your 
clinician may make a recommendation that suits your values and 
preferences.
PATIENT WORKSHEET 
Medication option 1: LITHIUM
Taking LITHIUM Not taking LITHIUM
PROS CONS
Lithium may help prevent 
relapse into both depression 
and hypomania.
Lithium may make me  
put on weight.
There’s a lot of research about 
the long term outcomes of 
lithium.
I might develop problems 
with my kidney or thyroid 
function.
Other: Other:
Lithium is more affordable 
than other medications.
I may get tired/drowsy and 
feel as though I can’t think 
properly.
Lithium can help reduce 
thoughts of harming myself.
I will have to commit to 
regular, ongoing monitoring.
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
How important are the pros and cons to you overall?
PATIENT RATING
Pros more 
important
Cons more 
important
FAMILY RATING (optional)
Pros more 
important
Cons more 
important
Leaning towards 
taking LITHIUM
Leaning towards
NOT taking LITHIUM
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PATIENT WORKSHEET 
Medication option 2: LAMOTRIGINE
PROS CONS
Taking LAMOTRIGINE
Lamotrigine will especially 
help to prevent depression.
I won’t feel tired/drowsy and 
will be able to think properly.
Other:
I won’t need to undergo 
regular, ongoing monitoring.
Lamotrigine won’t make me 
put on weight.
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not taking LAMOTRIGINE
Lamotrigine might not help to 
prevent hypomania.
I will have to increase my dose 
slowly and it takes time to 
reach the therapeutic dose.
Other:
I may develop a rash, which 
could be serious and involve 
hospitalisation.
Lamotrigine costs more than 
some other medications.
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
How important are the pros and cons to you overall?
PATIENT RATING
Pros more 
important
Cons more 
important
FAMILY RATING (optional)
Pros more 
important
Cons more 
important
Leaning towards 
taking LAMOTRIGINE
Leaning towards
NOT taking LAMOTRIGINE
PATIENT WORKSHEET 
Medication option 3: QUETIAPINE
PROS CONS
Taking QUETIAPINE
Quetiapine may help prevent 
both depression and 
hypomania.
I will probably stop gaining 
weight after a couple of 
months.
Other:
I can probably reach the 
working therapeutic dose 
quite quickly.
Most side effects become 
less severe over the first few 
months of treatment.
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not taking QUETIAPINE
I might gain weight taking 
quetiapine.
Quetiapine might cause 
changes to my blood sugar 
and cholesterol levels.
Other:
I may get tired/drowsy and 
feel as though I can’t think 
properly.
I will have to commit to 
regular, ongoing monitoring.
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
How important are the pros and cons to you overall?
PATIENT RATING
Pros more 
important
Cons more 
important
FAMILY RATING (optional)
Pros more 
important
Cons more 
important
Leaning towards 
taking QUETIAPINE
Leaning towards
NOT taking QUETIAPINE
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PATIENT WORKSHEET 
ADD-ON PSYCHOLOGICAL OPTIONS
PROS CONS
Having  
PSYCHOLOGICAL treatment
I want to learn about BPII and 
understand what triggers my 
relapses.
I want support and 
encouragement to take my 
medication consistently.
Other:
I want to develop strategies 
for keeping my moods stable 
and preventing relapses.
I want more than medication 
only to keep my moods stable 
and prevent relapses.
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not having  
PSYCHOLOGICAL treatment
I will need to commit to 
sessions over several months.
I will need to find a 
psychologist I can afford for 
long-term treatment.
Other:
I will need to find the time to 
attend therapy.
I’m not comfortable 
discussing my thoughts, 
feelings and how I behave.
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
Not 
important
Somehow 
important
Very 
important
How important are the pros and cons to you overall?
PATIENT RATING
Pros more 
important
Cons more 
important
FAMILY RATING (optional)
Pros more 
important
Cons more 
important
Having PSYCHOLOGICAL 
treatment
Not having PSYCHOLOGICAL 
treatment
If you thought pros were more important than cons, then you are 
leaning towards medication plus psychological treatment. Some 
people may want to access the different benefits of both Cognitive 
behavioural therapy (CBT) and group psycho-education, but if 
you prefer to pursue one psychological option over the page is a 
strategy for making your choice.
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PATIENT WORKSHEET – Choosing between 
psychological options:
CBT versus group psycho-education
This section helps you to work out which features of the add-on 
psychological treatments are most important to you. To start, 
choose with a tick ( ) from the list which features of treatment are 
most important to you. By following the instructions below you’ll 
be able to see which psychological treatment option is better for you: 
CBT or group psycho-education.
Is this 
important 
to you?
(  if yes)
1)  Individual-tailored treatment that is fitted to my 
personal needs.
2)  Group-based treatment that will allow me to meet 
other people with BPII.
3)  Treatment is one-on-one, involving only my 
clinician and me.
4)  Treatment focuses on reducing the thoughts 
emotions and behaviours which cause me 
problems. 
5)  Treatment focuses on becoming educated about 
my illness, triggers and early warning signs.
6)  Gives me a simple starting point for treatment; I can 
move onto other treatments later.
7) Treatment is flexible to my individual schedule.
8)  Treatment sessions may be led by clinicians other 
than a psychologist (e.g. social worker or mental 
health nurse).
Now count how many blue items you ticked
Now count how many green items you ticked 
 • If you ticked more of the blue items, you are leaning more 
towards CBT. 
 • If you ticked more of the green items, you are leaning more 
towards group psycho-education.
It is possible that you value features of both CBT and group 
psycho-education. The psychological treatment option/s with 
more ticks fits in more with your values and preferences. When 
seeing a psychologist or other clinician they will assess your main 
concerns and help you decide which parts of psychological treatments 
are likely to be most helpful to you. 
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Further resources
“Getting information helps me to feel more in control … it 
just puts me in a better position to be decisive.”
Many people seek information on the Internet about treatments, 
research and support services for bipolar II disorder (BPII). Not all 
information is accurate or reliable, so make sure you discuss any 
questions, ideas or concerns with your clinician first. 
Listed below are Australian-based websites of leading mental 
health organisations and other information resources, which can 
be trusted. The information on these sites is general (not specific 
to your situation), so it is important to discuss your situation with 
your clinician. Your clinician can also recommend other reliable 
websites.
INFORMATION AND SUPPORT 
Black Dog Institute  
www.blackdoginstitute.org.au
Info line: (02) 9382 4530
The Black Dog Institute offers specialist mood disorders 
assessment, treatment and information. It contributes to research 
in the area and offers education programs. 
Beyondblue  
www.beyondblue.org.au 
Info line: 1300 22 4636
Beyondblue is dedicated to improving understanding and 
acceptance of depression, anxiety, bipolar disorder and postnatal 
depression. You can access free online or printed information on 
these disorders and their treatment. The site also has symptom 
checklists, advice on how to find a GP or psychologist in your area 
and a directory of mental health internet services.
SANE Australia  
www.sane.org 
Helpline: 1800 18 SANE  
(9am-5pm and messages can be left after hours)
SANE offers helpful information and support for people with 
bipolar disorder, their families and friends. It also focuses on 
improving the overall health of people with mental illness. SANE 
campaigns for better services and attitudes towards people with 
mental illness. Through its online helpline, SANE will try to answer 
any questions you have about mental illness.
Bipolar Caregivers  
www.bipolarcaregivers.org
Provides guidance and information for caregivers (closer family, 
friends, carers, support people) about bipolar disorder diagnosis, 
treatment and management; how to support a person with bipolar 
disorder; ways caregivers can take care of themselves; and dealing 
with bipolar disorder and the personal impact on caregivers. 
Information is also available as a printable PDF. 
86 87
Headspace  
www.headspace.org.au
Info line: (02) 8624 1348
Headspace offers support, information and health services for 
young people (age 12-25) with mental health problems and their 
families at 30 centres throughout Australia.
Moodswings 
www.moodswings.net.au
This is a comprehensive online psycho-education based program 
for people with bipolar disorder, which has been developed and 
evaluated by the University of Melbourne.
The REACH program  
http://www.blackdoginstitute.org.au/public/gettinghelp/
blackdogsupportgroups.cfm
REACH is a 9-week psycho-educational wellbeing group for 
people with bipolar disorder or depression. The website provides 
information about topics covered, eligibility criteria, and details on 
upcoming groups. 
Australian Psychological Society – “Find a psychologist” 
https://www.psychology.org.au/FindaPsychologist 
This is an online search engine providing information and contact 
details for over 2,400 practising psychologists Australia-wide. It 
allows users to search for a psychologist based on area/location, 
client issue, services offered, therapeutic approaches and Medicare 
billing status. 
Glossary of key terms
Term Definition
acute symptoms Symptoms that are short lasting but require 
urgent treatment because they tend to be 
more intense or severe. The opposite of 
acute is chronic.
adjunct/
adjunctive 
treatments
Treatments that supplement or are added on 
to the main treatment. 
bipolar disorder A type of mental health condition that 
affects a person’s mood, energy, thoughts 
and behaviour. There are two types of bipolar 
disorder: bipolar I disorder and bipolar II 
disorder.
chronic 
symptoms
Symptoms that are long-lasting and have 
long-term effects. The opposite of chronic is 
acute.
circadian 
rhythms
Changes to your body, behaviour and 
thinking that follow a roughly 24-hour 
(daily) cycle. These changes occur mainly in 
response to light and darkness in a person’s 
environment. 
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Term Definition
clinical 
consensus
When a group of experts agree on a 
particular area of clinical knowledge, for 
example the use of a particular treatment in 
BPII. These experts agree that this knowledge 
is based on the latest evidence. 
clinician A health professional who sees patients.
complementary 
treatment 
A type of treatment that gets used together 
with conventional or mainstream treatment, 
such as medications and psychological 
treatments. An example of a complementary 
treatment is taking fish oil supplements 
in addition to medication to help lessen 
symptoms of depression.
cons The disadvantages of a particular option. 
Cons of a type of treatment might include 
the risks, side effects, safety concerns or 
harms, or other negative features. 
cycle Experiencing an episode of depression, 
mania or hypomania followed by a period 
of wellness or by another episode. This may 
be called a mood swing and can happen 
periodically over time.
Term Definition
delayed effects When there is a period of time or ‘delay’ 
between starting to take a new medication 
and that medication starting to produce 
results or ‘work’. 
depression A ‘low’ mood lasting two weeks or more, 
characterised by sadness or flatness as well 
as a loss of interest or pleasure in most 
things.
episode/mood 
episode
An instance or period of time when a person 
experiences symptoms of depression, mania 
or hypomania.
euthymic/
euthymia
A ‘normal’ non-depressed and reasonably 
positive mood. When euthymic, a person 
is not experiencing symptoms of either 
depression or hypomania and is feeling well 
or recovered. 
family-focussed 
therapy
A type of psychological treatment and is a 
therapy that involves both the person with 
BPII and their family; they are considered 
a “unit”. It is based on evidence that stress 
and interactions in the family have an 
influence on relapse, and aims to improve 
communication and problem-solving skills in 
the family to avoid relapse. 
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Term Definition
hypomania A ‘high’ mood characterised by feeling 
excessively happy, elevated or irritable 
or more wired and hyper than usual. 
Hypomania is shorter and less severe than 
mania, and does not include psychotic 
experiences. It occurs in BPII, but may also 
occur in bipolar I disorder. 
interpersonal 
and social 
rhythm therapy 
(IPSRT)
A type of psychological therapy based 
on the idea that stressful life events and 
unstable or disrupted daily routines can 
interfere with circadian rhythms in people 
with BPII. Unstable circadian rhythms are 
linked to poor wake/sleep cycles which can 
trigger hypomania or depression. IPSRT aims 
to manage illness symptoms and prevent 
relapse by introducing routines aimed at 
stabilising circadian rhythms via stabilising 
social rhythms (e.g., fixing wake time across 7 
days of the week, keeping regular job hours). 
mania/ full 
manic episode
A ‘high’ mood which is characterised by 
feeling excessively happy, elevated or 
irritable or more ‘wired’ and ‘hyper’ than 
usual. Mania is longer and more severe than 
hypomania, and may include psychotic 
experiences or require hospitalisation. Mania 
does not occur in BPII, it only occurs in 
bipolar I (BPI) disorder. 
Term Definition
mixed states/
mixed episode
When a person experiences symptoms of 
depression or hypomania at the same time. 
omega-3 fatty 
acids
A type of polyunsaturated fatty acids that 
occur naturally in certain fish (e.g. salmon, 
swordfish, tuna) and plants (e.g. flaxseed, 
walnuts, canola oil). 
pharmacological Treatment options that involve medication. 
pros The advantages of a particular option. Pros of 
treatment might include the benefits, safety, 
or other positive aspects of a treatment. 
psychological 
treatments
Treatments that help a person to understand 
and work through problems by identifying 
and changing patterns of thinking and 
behaviour. These treatments also help 
people to learn skills so they can cope with 
challenges in their life as they arise. These 
are also called psychotherapies or talking 
therapies.
psychotic 
(experiences) or 
psychosis
When a person perceives or interprets things 
(hallucinations or delusions) so differently 
from other people around them that they are 
said to be disconnected from reality.
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Term Definition
rapid cycling When a person experiences four or more 
episodes of depression or hypomania in a 
year. 
recurrent 
symptoms
When symptoms return or happen time-
after-time.  
remission When symptoms have improved or subsided 
so that they can be managed and are not 
getting any worse. 
Stevens-Johnson 
syndrome
A rare, serious disorder of the skin and mucus 
membranes. It appears as a red or purplish 
rash that spreads and blisters. It is associated 
with high fever and a general sense of feeling 
unwell. The rash usually begins on the upper 
torso, upper extremities and/or face. 
subsyndromal 
(symptoms)
Milder symptoms that are not severe 
enough to be diagnosed as a full episode of 
depression or hypomania. 
Term Definition
talking therapies A general term for psychological treatments 
that involve talking to someone (e.g. a 
psychologist) who is trained to help address 
difficulties or problems in your life and 
manage them better through developing 
strategies. 
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